Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15301728,Tmax,"In the homo EMs and the PMs groups, the main kinetic parameters were as follows: Tmax (2.44+/-0.85) and (2.33+/-0.94) h, Cmax(1.10+/-0.34) and (1.73+/-0.56) mg/L, Cl/F (16.55+/-0.38) and (3.58+/-1) L/h, T1/2ke (1.96+/-0.51) and (4.21+/-0.53) h, AUC were (3.23+/-0.08) and (11.05+/-0.23) mg.L(-1).",Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301728/),h,2.44,227,DB00338,Omeprazole
,15301728,Tmax,"In the homo EMs and the PMs groups, the main kinetic parameters were as follows: Tmax (2.44+/-0.85) and (2.33+/-0.94) h, Cmax(1.10+/-0.34) and (1.73+/-0.56) mg/L, Cl/F (16.55+/-0.38) and (3.58+/-1) L/h, T1/2ke (1.96+/-0.51) and (4.21+/-0.53) h, AUC were (3.23+/-0.08) and (11.05+/-0.23) mg.L(-1).",Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301728/),h,2.33,228,DB00338,Omeprazole
,15301728,Cmax,"In the homo EMs and the PMs groups, the main kinetic parameters were as follows: Tmax (2.44+/-0.85) and (2.33+/-0.94) h, Cmax(1.10+/-0.34) and (1.73+/-0.56) mg/L, Cl/F (16.55+/-0.38) and (3.58+/-1) L/h, T1/2ke (1.96+/-0.51) and (4.21+/-0.53) h, AUC were (3.23+/-0.08) and (11.05+/-0.23) mg.L(-1).",Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301728/),[mg] / [l],1.10,229,DB00338,Omeprazole
,15301728,Cmax,"In the homo EMs and the PMs groups, the main kinetic parameters were as follows: Tmax (2.44+/-0.85) and (2.33+/-0.94) h, Cmax(1.10+/-0.34) and (1.73+/-0.56) mg/L, Cl/F (16.55+/-0.38) and (3.58+/-1) L/h, T1/2ke (1.96+/-0.51) and (4.21+/-0.53) h, AUC were (3.23+/-0.08) and (11.05+/-0.23) mg.L(-1).",Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301728/),[mg] / [l],1.73,230,DB00338,Omeprazole
,15301728,Cl/F,"In the homo EMs and the PMs groups, the main kinetic parameters were as follows: Tmax (2.44+/-0.85) and (2.33+/-0.94) h, Cmax(1.10+/-0.34) and (1.73+/-0.56) mg/L, Cl/F (16.55+/-0.38) and (3.58+/-1) L/h, T1/2ke (1.96+/-0.51) and (4.21+/-0.53) h, AUC were (3.23+/-0.08) and (11.05+/-0.23) mg.L(-1).",Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301728/),[l] / [h],16.55,231,DB00338,Omeprazole
,15301728,Cl/F,"In the homo EMs and the PMs groups, the main kinetic parameters were as follows: Tmax (2.44+/-0.85) and (2.33+/-0.94) h, Cmax(1.10+/-0.34) and (1.73+/-0.56) mg/L, Cl/F (16.55+/-0.38) and (3.58+/-1) L/h, T1/2ke (1.96+/-0.51) and (4.21+/-0.53) h, AUC were (3.23+/-0.08) and (11.05+/-0.23) mg.L(-1).",Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301728/),[l] / [h],3.58,232,DB00338,Omeprazole
,15301728,T1/2ke,"In the homo EMs and the PMs groups, the main kinetic parameters were as follows: Tmax (2.44+/-0.85) and (2.33+/-0.94) h, Cmax(1.10+/-0.34) and (1.73+/-0.56) mg/L, Cl/F (16.55+/-0.38) and (3.58+/-1) L/h, T1/2ke (1.96+/-0.51) and (4.21+/-0.53) h, AUC were (3.23+/-0.08) and (11.05+/-0.23) mg.L(-1).",Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301728/),h,1.96,233,DB00338,Omeprazole
,15301728,T1/2ke,"In the homo EMs and the PMs groups, the main kinetic parameters were as follows: Tmax (2.44+/-0.85) and (2.33+/-0.94) h, Cmax(1.10+/-0.34) and (1.73+/-0.56) mg/L, Cl/F (16.55+/-0.38) and (3.58+/-1) L/h, T1/2ke (1.96+/-0.51) and (4.21+/-0.53) h, AUC were (3.23+/-0.08) and (11.05+/-0.23) mg.L(-1).",Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301728/),h,4.21,234,DB00338,Omeprazole
,15301728,AUC,"In the homo EMs and the PMs groups, the main kinetic parameters were as follows: Tmax (2.44+/-0.85) and (2.33+/-0.94) h, Cmax(1.10+/-0.34) and (1.73+/-0.56) mg/L, Cl/F (16.55+/-0.38) and (3.58+/-1) L/h, T1/2ke (1.96+/-0.51) and (4.21+/-0.53) h, AUC were (3.23+/-0.08) and (11.05+/-0.23) mg.L(-1).",Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301728/),[mg] / [l],3.23,235,DB00338,Omeprazole
,15301728,AUC,"In the homo EMs and the PMs groups, the main kinetic parameters were as follows: Tmax (2.44+/-0.85) and (2.33+/-0.94) h, Cmax(1.10+/-0.34) and (1.73+/-0.56) mg/L, Cl/F (16.55+/-0.38) and (3.58+/-1) L/h, T1/2ke (1.96+/-0.51) and (4.21+/-0.53) h, AUC were (3.23+/-0.08) and (11.05+/-0.23) mg.L(-1).",Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301728/),[mg] / [l],11.05,236,DB00338,Omeprazole
,1458764,bioavailability,"This was reflected in an increase in bioavailability from 56 to 76%, a reduction in mean systemic clearance by approximately 50% (0.25 L/min) and a prolongation of the mean elimination half-life from 0.7 to 1.0h compared with the young.",Pharmacokinetic study of omeprazole in elderly healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458764/),%,56,761,DB00338,Omeprazole
,1458764,systemic clearance,"This was reflected in an increase in bioavailability from 56 to 76%, a reduction in mean systemic clearance by approximately 50% (0.25 L/min) and a prolongation of the mean elimination half-life from 0.7 to 1.0h compared with the young.",Pharmacokinetic study of omeprazole in elderly healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458764/),[l] / [min],0.25,762,DB00338,Omeprazole
,1458764,elimination half-life,"This was reflected in an increase in bioavailability from 56 to 76%, a reduction in mean systemic clearance by approximately 50% (0.25 L/min) and a prolongation of the mean elimination half-life from 0.7 to 1.0h compared with the young.",Pharmacokinetic study of omeprazole in elderly healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458764/),h,0.7,763,DB00338,Omeprazole
,1458764,elimination half-life,"This was reflected in an increase in bioavailability from 56 to 76%, a reduction in mean systemic clearance by approximately 50% (0.25 L/min) and a prolongation of the mean elimination half-life from 0.7 to 1.0h compared with the young.",Pharmacokinetic study of omeprazole in elderly healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458764/),h,1.0,764,DB00338,Omeprazole
,25707517,oral clearance,"Typical mean value of MPA oral clearance, estimated by base model (without covariates) was 0.741 L h(-1).",Variability of mycophenolic acid elimination in the renal transplant recipients – population pharmacokinetic approach. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25707517/),[l] / [h],0.741,1786,DB00338,Omeprazole
,3689634,area under the curve (0 to 72 h),2. Omeprazole significantly increased the area under the curve (0 to 72 h) of phenytoin (mean +/- s.e. mean) from 121.6 +/- 14.0 to 151.4 +/- 13.6 micrograms ml-1 h) (P less than 0.01).,Oral phenytoin pharmacokinetics during omeprazole therapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689634/),[h·μg] / [ml],121.6,3467,DB00338,Omeprazole
,3689634,area under the curve (0 to 72 h),2. Omeprazole significantly increased the area under the curve (0 to 72 h) of phenytoin (mean +/- s.e. mean) from 121.6 +/- 14.0 to 151.4 +/- 13.6 micrograms ml-1 h) (P less than 0.01).,Oral phenytoin pharmacokinetics during omeprazole therapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689634/),[h·μg] / [ml],151.4,3468,DB00338,Omeprazole
,7587960,total body clearance,Elimination was rapid with total body clearance of 57.6 ml/min/kg for OPZ and 58.6 ml/min/kg for LPZ.,"Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587960/),[ml] / [kg·min],57.6,5162,DB00338,Omeprazole
,7587960,total body clearance,Elimination was rapid with total body clearance of 57.6 ml/min/kg for OPZ and 58.6 ml/min/kg for LPZ.,"Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587960/),[ml] / [kg·min],58.6,5163,DB00338,Omeprazole
,7587960,volumes of distribution at steady-state,"The volumes of distribution at steady-state were 0.66 liter/kg for OPZ and 1.04 liter/kg for LPZ, and the plasma unbound fractions were 0.105 and 0.069.","Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587960/),[l] / [kg],0.66,5164,DB00338,Omeprazole
,7587960,volumes of distribution at steady-state,"The volumes of distribution at steady-state were 0.66 liter/kg for OPZ and 1.04 liter/kg for LPZ, and the plasma unbound fractions were 0.105 and 0.069.","Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587960/),[l] / [kg],1.04,5165,DB00338,Omeprazole
,7587960,plasma unbound fractions,"The volumes of distribution at steady-state were 0.66 liter/kg for OPZ and 1.04 liter/kg for LPZ, and the plasma unbound fractions were 0.105 and 0.069.","Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587960/),,0.105,5166,DB00338,Omeprazole
,7587960,plasma unbound fractions,"The volumes of distribution at steady-state were 0.66 liter/kg for OPZ and 1.04 liter/kg for LPZ, and the plasma unbound fractions were 0.105 and 0.069.","Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587960/),,0.069,5167,DB00338,Omeprazole
,7587960,Second-order rate constants,"Second-order rate constants for association of OPZ or LPZ and H+,K+-ATPase based on a PK/PD model were 72.5 +/- 30.0 (estimated value +/- SD) and 124 +/- 58 ml/micrograms/hr respectively.","Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587960/),[ml] / [h·μg],72.5,5168,DB00338,Omeprazole
,7587960,Second-order rate constants,"Second-order rate constants for association of OPZ or LPZ and H+,K+-ATPase based on a PK/PD model were 72.5 +/- 30.0 (estimated value +/- SD) and 124 +/- 58 ml/micrograms/hr respectively.","Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587960/),[ml] / [h·μg],124,5169,DB00338,Omeprazole
,7587960,Apparent turnover rate,"Apparent turnover rate of H+,K+-ATPase was 8.8 hr as half-life, assuming the same value for both drugs.","Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587960/),h,8.8,5170,DB00338,Omeprazole
,8104793,bioavailability,Food intake did not significantly influence the bioavailability of CdA (42% after food intake vs 46% while fasting) but it did reduce the maximum plasma concentration (Cmax) by 40%; 83 compared to 116 nM while fasting.,On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104793/),%,42,5513,DB00338,Omeprazole
,8104793,bioavailability,Food intake did not significantly influence the bioavailability of CdA (42% after food intake vs 46% while fasting) but it did reduce the maximum plasma concentration (Cmax) by 40%; 83 compared to 116 nM while fasting.,On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104793/),%,46,5514,DB00338,Omeprazole
,8104793,maximum plasma concentration (Cmax),Food intake did not significantly influence the bioavailability of CdA (42% after food intake vs 46% while fasting) but it did reduce the maximum plasma concentration (Cmax) by 40%; 83 compared to 116 nM while fasting.,On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104793/),nM,83,5515,DB00338,Omeprazole
,8104793,maximum plasma concentration (Cmax),Food intake did not significantly influence the bioavailability of CdA (42% after food intake vs 46% while fasting) but it did reduce the maximum plasma concentration (Cmax) by 40%; 83 compared to 116 nM while fasting.,On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104793/),nM,116,5516,DB00338,Omeprazole
,8104793,time to reach maximum concentration (tmax),The time to reach maximum concentration (tmax) was delayed about 0.8 h after food intake.,On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104793/),h,0.8,5517,DB00338,Omeprazole
,8104793,bioavailability,"Pretreatment with omeprazole did not significantly influence the bioavailability of CdA (51% vs 46% without), or the interindividual variability in bioavailability in the fasting state (C. V. 0.26 with and C. V. 0.27 without).",On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104793/),%,51,5518,DB00338,Omeprazole
,8104793,bioavailability,"Pretreatment with omeprazole did not significantly influence the bioavailability of CdA (51% vs 46% without), or the interindividual variability in bioavailability in the fasting state (C. V. 0.26 with and C. V. 0.27 without).",On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104793/),%,46,5519,DB00338,Omeprazole
,24688155,Cmax,"In the 2 periods of treatment, the mean Cmax of omeprazole was 730.8 ng/mL (omeprazole monotherapy) and 1725.5 ng/mL (combination treatment with fluoxetine).",Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),[ng] / [ml],730.8,5615,DB00338,Omeprazole
,24688155,Cmax,"In the 2 periods of treatment, the mean Cmax of omeprazole was 730.8 ng/mL (omeprazole monotherapy) and 1725.5 ng/mL (combination treatment with fluoxetine).",Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),[ng] / [ml],1725.5,5616,DB00338,Omeprazole
,24688155,AUC0-∞,"The observed AUC0-∞ was 1453.3 and 5072.5 ng/mL/h and AUC0-t was 1465.0 and 5185.3 ng/mL/h, respectively.",Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),[ng] / [h·ml],1453.3,5617,DB00338,Omeprazole
,24688155,AUC0-∞,"The observed AUC0-∞ was 1453.3 and 5072.5 ng/mL/h and AUC0-t was 1465.0 and 5185.3 ng/mL/h, respectively.",Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),[ng] / [h·ml],5072.5,5618,DB00338,Omeprazole
,24688155,AUC0-t,"The observed AUC0-∞ was 1453.3 and 5072.5 ng/mL/h and AUC0-t was 1465.0 and 5185.3 ng/mL/h, respectively.",Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),[ng] / [h·ml],1465.0,5619,DB00338,Omeprazole
,24688155,AUC0-t,"The observed AUC0-∞ was 1453.3 and 5072.5 ng/mL/h and AUC0-t was 1465.0 and 5185.3 ng/mL/h, respectively.",Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),[ng] / [h·ml],5185.3,5620,DB00338,Omeprazole
,24688155,Tmax,The Tmax was 1.30 and 1.63 hours and the elimination rate constant was 0.753 and 0.482 hr(-1).,Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),h,1.30,5621,DB00338,Omeprazole
,24688155,Tmax,The Tmax was 1.30 and 1.63 hours and the elimination rate constant was 0.753 and 0.482 hr(-1).,Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),h,1.63,5622,DB00338,Omeprazole
,24688155,elimination rate constant,The Tmax was 1.30 and 1.63 hours and the elimination rate constant was 0.753 and 0.482 hr(-1).,Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),1/[hr],0.753,5623,DB00338,Omeprazole
,24688155,elimination rate constant,The Tmax was 1.30 and 1.63 hours and the elimination rate constant was 0.753 and 0.482 hr(-1).,Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),1/[hr],0.482,5624,DB00338,Omeprazole
,24688155,t½,"The t½ was 0.96 and 1.47 hours, whereas the mean residence time was 2.33 and 3.35 hours, respectively.",Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),h,0.96,5625,DB00338,Omeprazole
,24688155,t½,"The t½ was 0.96 and 1.47 hours, whereas the mean residence time was 2.33 and 3.35 hours, respectively.",Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),h,1.47,5626,DB00338,Omeprazole
,24688155,mean residence time,"The t½ was 0.96 and 1.47 hours, whereas the mean residence time was 2.33 and 3.35 hours, respectively.",Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),h,2.33,5627,DB00338,Omeprazole
,24688155,mean residence time,"The t½ was 0.96 and 1.47 hours, whereas the mean residence time was 2.33 and 3.35 hours, respectively.",Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),h,3.35,5628,DB00338,Omeprazole
,16128938,pH,"At presumed steady-state (day 7), median 24-h pH values were 5.02 and 4.79 for tenatoprazole and esomeprazole, respectively.",Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16128938/),,5.02,5792,DB00338,Omeprazole
,16128938,pH,"At presumed steady-state (day 7), median 24-h pH values were 5.02 and 4.79 for tenatoprazole and esomeprazole, respectively.",Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16128938/),,4.79,5793,DB00338,Omeprazole
,16503713,AUC(0-24),The mean +/- SD AUC(0-24) for phase A was 16.3 +/- 9.0 microM x hour versus 0.95 +/- 1.8 microM x hour for phase B (p<0.01).,Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16503713/),h·μM,16.3,5810,DB00338,Omeprazole
,16503713,AUC(0-24),The mean +/- SD AUC(0-24) for phase A was 16.3 +/- 9.0 microM x hour versus 0.95 +/- 1.8 microM x hour for phase B (p<0.01).,Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16503713/),h·μM,0.95,5811,DB00338,Omeprazole
,16503713,maximum concentration,The mean +/- SD maximum concentration of atazanavir was 3.2 +/- 1.7 microM for phase A and 0.13 +/- 0.19 microM for phase B (p<0.01).,Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16503713/),μM,3.2,5812,DB00338,Omeprazole
,16503713,maximum concentration,The mean +/- SD maximum concentration of atazanavir was 3.2 +/- 1.7 microM for phase A and 0.13 +/- 0.19 microM for phase B (p<0.01).,Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16503713/),μM,0.13,5813,DB00338,Omeprazole
,15906422,AUC(0-inf),"The median AUC(0-inf) was 784.86 +/- 1182.88 (ng.h/ml), and the median C(max) was 521 +/- 354 (ng/ml) (median +/- SD).",Variable omeprazole kinetics in healthy Jordanian adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15906422/),[h·ng] / [ml],784.86,5925,DB00338,Omeprazole
,15906422,C(max),"The median AUC(0-inf) was 784.86 +/- 1182.88 (ng.h/ml), and the median C(max) was 521 +/- 354 (ng/ml) (median +/- SD).",Variable omeprazole kinetics in healthy Jordanian adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15906422/),[ng] / [ml],521,5926,DB00338,Omeprazole
,18520598,AUC[0-infinity],"During the placebo phase, area under the plasma concentration-time curve (AUC) and elimination half-life (t1/2) of R-warfarin in PMs was significantly greater than those in hmEMs (AUC[0-infinity], 42,938/34,613 ng h/mL [PM/hmEM], P = 0.004; t1/2, 48.8/40.8 hours [PM/hmEM], P = 0.013).",The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520598/),[h·ng] / [ml],"42,938",6842,DB00338,Omeprazole
,18520598,AUC[0-infinity],"During the placebo phase, area under the plasma concentration-time curve (AUC) and elimination half-life (t1/2) of R-warfarin in PMs was significantly greater than those in hmEMs (AUC[0-infinity], 42,938/34,613 ng h/mL [PM/hmEM], P = 0.004; t1/2, 48.8/40.8 hours [PM/hmEM], P = 0.013).",The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520598/),[h·ng] / [ml],"34,613",6843,DB00338,Omeprazole
,18520598,t1/2,"During the placebo phase, area under the plasma concentration-time curve (AUC) and elimination half-life (t1/2) of R-warfarin in PMs was significantly greater than those in hmEMs (AUC[0-infinity], 42,938/34,613 ng h/mL [PM/hmEM], P = 0.004; t1/2, 48.8/40.8 hours [PM/hmEM], P = 0.013).",The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520598/),h,48.8,6844,DB00338,Omeprazole
,18520598,t1/2,"During the placebo phase, area under the plasma concentration-time curve (AUC) and elimination half-life (t1/2) of R-warfarin in PMs was significantly greater than those in hmEMs (AUC[0-infinity], 42,938/34,613 ng h/mL [PM/hmEM], P = 0.004; t1/2, 48.8/40.8 hours [PM/hmEM], P = 0.013).",The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520598/),h,40.8,6845,DB00338,Omeprazole
,18520598,AUC(0-infinity),"Omeprazole treatment significantly increased the AUC(0-infinity) (41,387 ng h/mL, P = 0.004) and t1/2 (46.4 hours, P = 0.017) of R-warfarin in hmEMs to levels comparable to those in the PMs.",The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520598/),[h·ng] / [ml],"41,387",6846,DB00338,Omeprazole
,18520598,t1/2,"Omeprazole treatment significantly increased the AUC(0-infinity) (41,387 ng h/mL, P = 0.004) and t1/2 (46.4 hours, P = 0.017) of R-warfarin in hmEMs to levels comparable to those in the PMs.",The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520598/),h,46.4,6847,DB00338,Omeprazole
,18520598,AUC[0-infinity],"There were no differences in S-warfarin pharmacokinetics between the CYP2C19 genotypes (AUC[0-infinity], 15,851/16,968 ng*h/mL [PM/hmEM]; t1/2, 22.7/25.4 h [PM/hmEM]), or between the two treatment phases (AUC[0-infinity], 14,756/18,166 ng h/mL [PM/hmEM]; t1/2, 27.0/25.4 hours [PM/hmEM] in the omeprazole phase) as well as anticoagulant effects.",The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520598/),[h·ng] / [ml],"15,851",6848,DB00338,Omeprazole
,18520598,AUC[0-infinity],"There were no differences in S-warfarin pharmacokinetics between the CYP2C19 genotypes (AUC[0-infinity], 15,851/16,968 ng*h/mL [PM/hmEM]; t1/2, 22.7/25.4 h [PM/hmEM]), or between the two treatment phases (AUC[0-infinity], 14,756/18,166 ng h/mL [PM/hmEM]; t1/2, 27.0/25.4 hours [PM/hmEM] in the omeprazole phase) as well as anticoagulant effects.",The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520598/),[h·ng] / [ml],"16,968",6849,DB00338,Omeprazole
,18520598,t1/2,"There were no differences in S-warfarin pharmacokinetics between the CYP2C19 genotypes (AUC[0-infinity], 15,851/16,968 ng*h/mL [PM/hmEM]; t1/2, 22.7/25.4 h [PM/hmEM]), or between the two treatment phases (AUC[0-infinity], 14,756/18,166 ng h/mL [PM/hmEM]; t1/2, 27.0/25.4 hours [PM/hmEM] in the omeprazole phase) as well as anticoagulant effects.",The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520598/),h,22.7,6850,DB00338,Omeprazole
,18520598,AUC[0-infinity],"There were no differences in S-warfarin pharmacokinetics between the CYP2C19 genotypes (AUC[0-infinity], 15,851/16,968 ng*h/mL [PM/hmEM]; t1/2, 22.7/25.4 h [PM/hmEM]), or between the two treatment phases (AUC[0-infinity], 14,756/18,166 ng h/mL [PM/hmEM]; t1/2, 27.0/25.4 hours [PM/hmEM] in the omeprazole phase) as well as anticoagulant effects.",The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520598/),[h·ng] / [ml],"14,756",6851,DB00338,Omeprazole
,18520598,t1/2,"There were no differences in S-warfarin pharmacokinetics between the CYP2C19 genotypes (AUC[0-infinity], 15,851/16,968 ng*h/mL [PM/hmEM]; t1/2, 22.7/25.4 h [PM/hmEM]), or between the two treatment phases (AUC[0-infinity], 14,756/18,166 ng h/mL [PM/hmEM]; t1/2, 27.0/25.4 hours [PM/hmEM] in the omeprazole phase) as well as anticoagulant effects.",The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520598/),h,27.0,6852,DB00338,Omeprazole
,25332052,ζ-potential,"Particularly one formulation, which was designed to be mucus penetrative by addition of a high quantity of TPGS 400 and a ζ-potential close to 0 mV, showed a very strong mucus association in the duodenum and jejunum.",Improved oral bioavailability of human growth hormone by a combination of liposomes containing bio-enhancers and tetraether lipids and omeprazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25332052/),m,0,7677,DB00338,Omeprazole
,25332052,bioavailability,"Vesicles with CpCl 33% (mol/mol) led to a relative hGH bioavailability of 3.4% compared with s.c. control, whereas free hGH administered orally showed a bioavailability of only 0.01%.",Improved oral bioavailability of human growth hormone by a combination of liposomes containing bio-enhancers and tetraether lipids and omeprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25332052/),%,3.4,7678,DB00338,Omeprazole
,25332052,bioavailability,"Vesicles with CpCl 33% (mol/mol) led to a relative hGH bioavailability of 3.4% compared with s.c. control, whereas free hGH administered orally showed a bioavailability of only 0.01%.",Improved oral bioavailability of human growth hormone by a combination of liposomes containing bio-enhancers and tetraether lipids and omeprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25332052/),%,0.01,7679,DB00338,Omeprazole
,16364049,Cmax,"It was demonstrated that increasing the rate of intravenous infusion of esomeprazole 40 mg resulted in higher Cmax values (geometric means; 5.2-7.6 micromol/l), but the AUC values remained relatively constant (7.1-7.2 micromor/l).",Pharmacokinetics of esomeprazole following varying intravenous administration rates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16364049/),[μM] / [l],5.2-7.6,8213,DB00338,Omeprazole
,16364049,AUC,"It was demonstrated that increasing the rate of intravenous infusion of esomeprazole 40 mg resulted in higher Cmax values (geometric means; 5.2-7.6 micromol/l), but the AUC values remained relatively constant (7.1-7.2 micromor/l).",Pharmacokinetics of esomeprazole following varying intravenous administration rates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16364049/),[μmor] / [l],7.1-7.2,8214,DB00338,Omeprazole
,16364049,Cmax,intravenous injection had lower Cmax (3.6 micromol/l) and AUC (2.9 micromol.r/l) values than any of the infusions of esomeprazole 40 mg.,Pharmacokinetics of esomeprazole following varying intravenous administration rates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16364049/),[μM] / [l],3.6,8215,DB00338,Omeprazole
,16364049,AUC,intravenous injection had lower Cmax (3.6 micromol/l) and AUC (2.9 micromol.r/l) values than any of the infusions of esomeprazole 40 mg.,Pharmacokinetics of esomeprazole following varying intravenous administration rates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16364049/),[r·μM] / [l],2.9,8216,DB00338,Omeprazole
>,10071967,Recoveries,Recoveries of the analytes and internal standard were >75.48%.,Advanced method for determination of omeprazole in plasma by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071967/),%,75.48,9803,DB00338,Omeprazole
,10071967,detection limit,The detection limit in plasma was 2 ng/ml.,Advanced method for determination of omeprazole in plasma by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071967/),[ng] / [ml],2,9804,DB00338,Omeprazole
,7625786,peak concentrations in plasma (Cmax),"The mean peak concentrations in plasma (Cmax) and the areas under the curves (AUC), respectively, of lomefloxacin and ciprofloxacin, respectively, after prior treatment with placebo were 2.88 +/- 0.73 (mean +/- standard deviation) as against 2.60 +/- 0.76 micrograms/ml and 24.9 +/- 3.13 as against 11.9 +/- 1.89 micrograms.h/ml, and 72.4% +/- 5.10% as against 36.1% +/- 7.50% of the doses of lomefloxacin and ciprofloxacin, respectively, were recovered from the urine.",Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625786/),[μg] / [ml],2.88,10775,DB00338,Omeprazole
,7625786,peak concentrations in plasma (Cmax),"The mean peak concentrations in plasma (Cmax) and the areas under the curves (AUC), respectively, of lomefloxacin and ciprofloxacin, respectively, after prior treatment with placebo were 2.88 +/- 0.73 (mean +/- standard deviation) as against 2.60 +/- 0.76 micrograms/ml and 24.9 +/- 3.13 as against 11.9 +/- 1.89 micrograms.h/ml, and 72.4% +/- 5.10% as against 36.1% +/- 7.50% of the doses of lomefloxacin and ciprofloxacin, respectively, were recovered from the urine.",Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625786/),[μg] / [ml],2.60,10776,DB00338,Omeprazole
,7625786,areas under the curves (AUC),"The mean peak concentrations in plasma (Cmax) and the areas under the curves (AUC), respectively, of lomefloxacin and ciprofloxacin, respectively, after prior treatment with placebo were 2.88 +/- 0.73 (mean +/- standard deviation) as against 2.60 +/- 0.76 micrograms/ml and 24.9 +/- 3.13 as against 11.9 +/- 1.89 micrograms.h/ml, and 72.4% +/- 5.10% as against 36.1% +/- 7.50% of the doses of lomefloxacin and ciprofloxacin, respectively, were recovered from the urine.",Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625786/),[μg] / [ml],2.60,10777,DB00338,Omeprazole
,7625786,areas under the curves (AUC),"The mean peak concentrations in plasma (Cmax) and the areas under the curves (AUC), respectively, of lomefloxacin and ciprofloxacin, respectively, after prior treatment with placebo were 2.88 +/- 0.73 (mean +/- standard deviation) as against 2.60 +/- 0.76 micrograms/ml and 24.9 +/- 3.13 as against 11.9 +/- 1.89 micrograms.h/ml, and 72.4% +/- 5.10% as against 36.1% +/- 7.50% of the doses of lomefloxacin and ciprofloxacin, respectively, were recovered from the urine.",Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625786/),[h·μg] / [ml],24.9,10778,DB00338,Omeprazole
,7625786,areas under the curves (AUC),"The mean peak concentrations in plasma (Cmax) and the areas under the curves (AUC), respectively, of lomefloxacin and ciprofloxacin, respectively, after prior treatment with placebo were 2.88 +/- 0.73 (mean +/- standard deviation) as against 2.60 +/- 0.76 micrograms/ml and 24.9 +/- 3.13 as against 11.9 +/- 1.89 micrograms.h/ml, and 72.4% +/- 5.10% as against 36.1% +/- 7.50% of the doses of lomefloxacin and ciprofloxacin, respectively, were recovered from the urine.",Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625786/),[h·μg] / [ml],11.9,10779,DB00338,Omeprazole
,7625786,half-life,"The Cmax of lomefloxacin was not significantly higher than that of ciprofloxacin, but lomefloxacin's AUC reached twice that of ciprofloxacin because of its significantly longer half-life in plasma (6.68 +/- 1.94 as against 4.15 +/- 0.92 h, respectively, P < or = 0.01).",Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625786/),h,6.68,10780,DB00338,Omeprazole
,7625786,half-life,"The Cmax of lomefloxacin was not significantly higher than that of ciprofloxacin, but lomefloxacin's AUC reached twice that of ciprofloxacin because of its significantly longer half-life in plasma (6.68 +/- 1.94 as against 4.15 +/- 0.92 h, respectively, P < or = 0.01).",Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625786/),h,4.15,10781,DB00338,Omeprazole
,31103048,gastric,"The observed pH values were significantly different among groups (p=0.0341), with the median (IQR) values of gastric pH of 3.5 (2.7-4.2), 6.7 (4.7-7.0), 5.6 (3.5-6.4) and 2.2 (1.6-3.1) in control, omeprazole 2 h, omeprazole 12 h and pentagastin group, respectively.",Gastric pH in Rats: Key Determinant for Preclinical Evaluation of pH-dependent Oral Drug Absorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31103048/),,3.5,11466,DB00338,Omeprazole
,31103048,gastric,"The observed pH values were significantly different among groups (p=0.0341), with the median (IQR) values of gastric pH of 3.5 (2.7-4.2), 6.7 (4.7-7.0), 5.6 (3.5-6.4) and 2.2 (1.6-3.1) in control, omeprazole 2 h, omeprazole 12 h and pentagastin group, respectively.",Gastric pH in Rats: Key Determinant for Preclinical Evaluation of pH-dependent Oral Drug Absorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31103048/),,6.7,11467,DB00338,Omeprazole
,31103048,gastric,"The observed pH values were significantly different among groups (p=0.0341), with the median (IQR) values of gastric pH of 3.5 (2.7-4.2), 6.7 (4.7-7.0), 5.6 (3.5-6.4) and 2.2 (1.6-3.1) in control, omeprazole 2 h, omeprazole 12 h and pentagastin group, respectively.",Gastric pH in Rats: Key Determinant for Preclinical Evaluation of pH-dependent Oral Drug Absorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31103048/),,5.6,11468,DB00338,Omeprazole
,31103048,gastric,"The observed pH values were significantly different among groups (p=0.0341), with the median (IQR) values of gastric pH of 3.5 (2.7-4.2), 6.7 (4.7-7.0), 5.6 (3.5-6.4) and 2.2 (1.6-3.1) in control, omeprazole 2 h, omeprazole 12 h and pentagastin group, respectively.",Gastric pH in Rats: Key Determinant for Preclinical Evaluation of pH-dependent Oral Drug Absorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31103048/),,2.2,11469,DB00338,Omeprazole
,30654691,T1/2,"3. The plasma concentration reached the Cmax within 1.0 h (inhalation) and descended with the T1/2 of 8.53 and 6.69 h for inhalation and i.v. administration, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),h,8.53,11633,DB00338,Omeprazole
,30654691,T1/2,"3. The plasma concentration reached the Cmax within 1.0 h (inhalation) and descended with the T1/2 of 8.53 and 6.69 h for inhalation and i.v. administration, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),h,6.69,11634,DB00338,Omeprazole
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,4.35,11635,DB00338,Omeprazole
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,8.67,11636,DB00338,Omeprazole
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,13.02,11637,DB00338,Omeprazole
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,14.78,11638,DB00338,Omeprazole
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,234.9,11639,DB00338,Omeprazole
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,525.4,11640,DB00338,Omeprazole
,16128503,C(max),"Including values of 0 for the patients with undetectable levels, the mean (+/- SD) C(max) was 0.153 +/- 0.241 ng/mL, and the T(max) in patients with detectable levels occurred at approximately 6 hours.",Omeprazole absorption from a compounded transdermal formulation in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16128503/),[ng] / [ml],0.153,12530,DB00338,Omeprazole
,16128503,T(max),"Including values of 0 for the patients with undetectable levels, the mean (+/- SD) C(max) was 0.153 +/- 0.241 ng/mL, and the T(max) in patients with detectable levels occurred at approximately 6 hours.",Omeprazole absorption from a compounded transdermal formulation in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16128503/),h,6,12531,DB00338,Omeprazole
,32110830,concentration,"Patients with no PPI had no significant difference in plasma voriconazole concentration when compared with those with PPI (2.63 ± 2.13 μg/mL [95% confidence interval {CI} 1.57-3.69] vs 2.11 ± 1.73 μg/mL [95%CI 1.67-2.55], P > .05).",A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110830/),[μg] / [ml],2.63,14376,DB00338,Omeprazole
,32110830,concentration,"Patients with no PPI had no significant difference in plasma voriconazole concentration when compared with those with PPI (2.63 ± 2.13 μg/mL [95% confidence interval {CI} 1.57-3.69] vs 2.11 ± 1.73 μg/mL [95%CI 1.67-2.55], P > .05).",A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110830/),[μg] / [ml],2.11,14377,DB00338,Omeprazole
,32110830,plasma concentration,"However, voriconazole plasma concentration was significantly lower in patients treated with pantoprazole vs those treated with omeprazole (1.44 ± 1.22 μg/mL [95%CI 0.94-1.94) vs 2.67 ± 1.88 μg/mL [95%CI 2.02-3.32], P = .013) suggesting a greater CYP2C19 enzyme inhibitory effect of omeprazole.",A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110830/),[μg] / [ml],1.44,14378,DB00338,Omeprazole
,32110830,plasma concentration,"However, voriconazole plasma concentration was significantly lower in patients treated with pantoprazole vs those treated with omeprazole (1.44 ± 1.22 μg/mL [95%CI 0.94-1.94) vs 2.67 ± 1.88 μg/mL [95%CI 2.02-3.32], P = .013) suggesting a greater CYP2C19 enzyme inhibitory effect of omeprazole.",A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110830/),[μg] / [ml],2.67,14379,DB00338,Omeprazole
,9754983,AUC ratio,"The AUC ratio, (NSAID +omeprazole):NSAID alone, was 1.11, 0.99, and 0.99 for diclofenac, naproxen, and piroxicam, respectively.",Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754983/),,1.11,15134,DB00338,Omeprazole
,9754983,AUC ratio,"The AUC ratio, (NSAID +omeprazole):NSAID alone, was 1.11, 0.99, and 0.99 for diclofenac, naproxen, and piroxicam, respectively.",Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754983/),,0.99,15135,DB00338,Omeprazole
,20498287,t(max),"Nilotinib t(max) was prolonged from 4.0 to 6.0 hours, but t(1/2) was not altered.",Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498287/),h,4.0 to 6.0,16195,DB00338,Omeprazole
,20498287,gastric pH,"Mean gastric pH was 1.0 +/- 0.5 at baseline and increased to 2.79 +/- 2.50, 3.98 +/- 2.27, 5.30 +/- 1.70, 5.38 +/- 1.26, and 5.31 +/- 1.42 at predose and 1, 2, 3, and 4 hours after the fifth esomeprazole dose, respectively.",Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498287/),,1.0,16196,DB00338,Omeprazole
,20498287,gastric pH,"Mean gastric pH was 1.0 +/- 0.5 at baseline and increased to 2.79 +/- 2.50, 3.98 +/- 2.27, 5.30 +/- 1.70, 5.38 +/- 1.26, and 5.31 +/- 1.42 at predose and 1, 2, 3, and 4 hours after the fifth esomeprazole dose, respectively.",Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498287/),,2.79,16197,DB00338,Omeprazole
,20498287,gastric pH,"Mean gastric pH was 1.0 +/- 0.5 at baseline and increased to 2.79 +/- 2.50, 3.98 +/- 2.27, 5.30 +/- 1.70, 5.38 +/- 1.26, and 5.31 +/- 1.42 at predose and 1, 2, 3, and 4 hours after the fifth esomeprazole dose, respectively.",Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498287/),,3.98,16198,DB00338,Omeprazole
,20498287,gastric pH,"Mean gastric pH was 1.0 +/- 0.5 at baseline and increased to 2.79 +/- 2.50, 3.98 +/- 2.27, 5.30 +/- 1.70, 5.38 +/- 1.26, and 5.31 +/- 1.42 at predose and 1, 2, 3, and 4 hours after the fifth esomeprazole dose, respectively.",Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498287/),,5.30,16199,DB00338,Omeprazole
,20498287,gastric pH,"Mean gastric pH was 1.0 +/- 0.5 at baseline and increased to 2.79 +/- 2.50, 3.98 +/- 2.27, 5.30 +/- 1.70, 5.38 +/- 1.26, and 5.31 +/- 1.42 at predose and 1, 2, 3, and 4 hours after the fifth esomeprazole dose, respectively.",Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498287/),,5.38,16200,DB00338,Omeprazole
,20498287,gastric pH,"Mean gastric pH was 1.0 +/- 0.5 at baseline and increased to 2.79 +/- 2.50, 3.98 +/- 2.27, 5.30 +/- 1.70, 5.38 +/- 1.26, and 5.31 +/- 1.42 at predose and 1, 2, 3, and 4 hours after the fifth esomeprazole dose, respectively.",Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498287/),,5.31,16201,DB00338,Omeprazole
,16338182,limit of quantification (LOQ),The limit of quantification (LOQ) achieved with this method was 5 ng/ml for 5-hydroxyomeprazole and 10 ng/ml for omeprazole and omeprazole-sulfone using 0.25 ml of plasma.,Sensitive quantification of omeprazole and its metabolites in human plasma by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16338182/),[ng] / [ml],5,16370,DB00338,Omeprazole
,16338182,limit of quantification (LOQ),The limit of quantification (LOQ) achieved with this method was 5 ng/ml for 5-hydroxyomeprazole and 10 ng/ml for omeprazole and omeprazole-sulfone using 0.25 ml of plasma.,Sensitive quantification of omeprazole and its metabolites in human plasma by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16338182/),[ng] / [ml],10,16371,DB00338,Omeprazole
,9842988,tmax,"Artemether was rapidly absorbed with a mean tmax of 0.8 h (95% confidence interval, CI=0.5-1.1) reaching a mean Cmax of 29 ng/ml (14-45 ng/ml).",The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842988/),h,0.8,17344,DB00338,Omeprazole
,9842988,Cmax,"Artemether was rapidly absorbed with a mean tmax of 0.8 h (95% confidence interval, CI=0.5-1.1) reaching a mean Cmax of 29 ng/ml (14-45 ng/ml).",The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842988/),[ng] / [ml],29,17345,DB00338,Omeprazole
,9842988,elimination half-life,The mean elimination half-life was 1.3 h (0.8-1.8 h).,The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842988/),h,1.3,17346,DB00338,Omeprazole
,9799054,AUC,"Geometric means of AUC (extent characteristic) and Cmax/AUC (rate characteristic) of carbamazepine were 292 and 287 mgxh/l, and 0.0150 and 0.0144 l/h (reference and test), respectively.",Pantoprazole does not interact with the pharmacokinetics of carbamazepine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799054/),[h·mg] / [l],292,20854,DB00338,Omeprazole
,9799054,Cmax/AUC,"Geometric means of AUC (extent characteristic) and Cmax/AUC (rate characteristic) of carbamazepine were 292 and 287 mgxh/l, and 0.0150 and 0.0144 l/h (reference and test), respectively.",Pantoprazole does not interact with the pharmacokinetics of carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799054/),[h·mg] / [l],287,20855,DB00338,Omeprazole
,9799054,Cmax/AUC,"Geometric means of AUC (extent characteristic) and Cmax/AUC (rate characteristic) of carbamazepine were 292 and 287 mgxh/l, and 0.0150 and 0.0144 l/h (reference and test), respectively.",Pantoprazole does not interact with the pharmacokinetics of carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799054/),[l] / [h],0.0150,20856,DB00338,Omeprazole
,9799054,Cmax/AUC,"Geometric means of AUC (extent characteristic) and Cmax/AUC (rate characteristic) of carbamazepine were 292 and 287 mgxh/l, and 0.0150 and 0.0144 l/h (reference and test), respectively.",Pantoprazole does not interact with the pharmacokinetics of carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799054/),[l] / [h],0.0144,20857,DB00338,Omeprazole
,9799054,rate characteristic,"Geometric means of AUC (extent characteristic) and Cmax/AUC (rate characteristic) of carbamazepine were 292 and 287 mgxh/l, and 0.0150 and 0.0144 l/h (reference and test), respectively.",Pantoprazole does not interact with the pharmacokinetics of carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799054/),[l] / [h],0.0144,20858,DB00338,Omeprazole
,32215046,flow rate,"The chromatographic separation was performed on a Waters XBridge™ C18 column (2.1 mm × 100 mm, 3.5 μm) using a gradient elution with the mobile phase consisting of acetonitrile and water (containing 0.1% formic acid) at a flow rate of 0.3 mL/min.",HPLC-MS/MS Analysis of Aconiti Lateralis Radix Praeparata and Its Combination with Red Ginseng Effect on Rat CYP450 Activities Using the Cocktail Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32215046/),[ml] / [min],0.3,20924,DB00338,Omeprazole
,28407418,bioavailability,"The bioavailability of esomeprazole administered as PO enteric-coated granules and as SC injections was 71.4 and 106%, respectively.","Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28407418/),%,71.4,21132,DB00338,Omeprazole
,28407418,bioavailability,"The bioavailability of esomeprazole administered as PO enteric-coated granules and as SC injections was 71.4 and 106%, respectively.","Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28407418/),%,106,21133,DB00338,Omeprazole
,28407418,half-life,The half-life was approximately 1 hour.,"Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28407418/),h,1,21134,DB00338,Omeprazole
,16087412,total time,"The peak was detected with an ultraviolet detector set at a wavelength of 288 nm, and the total time for chromatographic separation was approximately 25 min.","Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16087412/),min,25,21593,DB00338,Omeprazole
,16087412,absolute recoveries,"Mean absolute recoveries were 78.0 and 88.3% for rabeprazole and rabeprazole thioether, respectively.","Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16087412/),%,78.0,21594,DB00338,Omeprazole
,16087412,absolute recoveries,"Mean absolute recoveries were 78.0 and 88.3% for rabeprazole and rabeprazole thioether, respectively.","Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16087412/),%,88.3,21595,DB00338,Omeprazole
,16087412,limits of,The limits of quantification were 1 ng/ml for rabeprazole and 3 ng/ml for rabeprazole thioether.,"Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16087412/),[ng] / [ml],1,21596,DB00338,Omeprazole
,16087412,limits of,The limits of quantification were 1 ng/ml for rabeprazole and 3 ng/ml for rabeprazole thioether.,"Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16087412/),[ng] / [ml],3,21597,DB00338,Omeprazole
,24365987,plasma CL,"The typical values for plasma CL were 24.9 L·h·70 kg (10.08%), with a distributional clearance of 53.9 L·h·70 kg (11.00%) and central and peripheral compartment distribution volumes of 4.23 L/70 kg (19.62%) and 674 L/70 kg (0.89%), respectively.",Population pharmacokinetics of omeprazole in critically ill pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365987/),70·h·kg·l,24.9,21739,DB00338,Omeprazole
,24365987,distributional clearance,"The typical values for plasma CL were 24.9 L·h·70 kg (10.08%), with a distributional clearance of 53.9 L·h·70 kg (11.00%) and central and peripheral compartment distribution volumes of 4.23 L/70 kg (19.62%) and 674 L/70 kg (0.89%), respectively.",Population pharmacokinetics of omeprazole in critically ill pediatric patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365987/),70·h·kg·l,53.9,21740,DB00338,Omeprazole
,24365987,central,"The typical values for plasma CL were 24.9 L·h·70 kg (10.08%), with a distributional clearance of 53.9 L·h·70 kg (11.00%) and central and peripheral compartment distribution volumes of 4.23 L/70 kg (19.62%) and 674 L/70 kg (0.89%), respectively.",Population pharmacokinetics of omeprazole in critically ill pediatric patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365987/),[l] / [70·kg],4.23,21741,DB00338,Omeprazole
,24365987,peripheral compartment distribution volumes,"The typical values for plasma CL were 24.9 L·h·70 kg (10.08%), with a distributional clearance of 53.9 L·h·70 kg (11.00%) and central and peripheral compartment distribution volumes of 4.23 L/70 kg (19.62%) and 674 L/70 kg (0.89%), respectively.",Population pharmacokinetics of omeprazole in critically ill pediatric patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365987/),[l] / [70·kg],4.23,21742,DB00338,Omeprazole
,24365987,peripheral compartment distribution volumes,"The typical values for plasma CL were 24.9 L·h·70 kg (10.08%), with a distributional clearance of 53.9 L·h·70 kg (11.00%) and central and peripheral compartment distribution volumes of 4.23 L/70 kg (19.62%) and 674 L/70 kg (0.89%), respectively.",Population pharmacokinetics of omeprazole in critically ill pediatric patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365987/),[l] / [70·kg],674,21743,DB00338,Omeprazole
,25678106,clearances,"Based on the IIDMP experiments, hepatic in vivo clearances of phenacetin and omeprazole in the IIDMP were predicted to be 3.10 ± 0.36 and 1.46 ± 0.25 ml/min/kg body weight, respectively.",Investigation of omeprazole and phenacetin first-pass metabolism in humans using a microscale bioreactor and pharmacokinetic models. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25678106/),[ml] / [body·kg·min·weight],3.10,22604,DB00338,Omeprazole
,25678106,clearances,"Based on the IIDMP experiments, hepatic in vivo clearances of phenacetin and omeprazole in the IIDMP were predicted to be 3.10 ± 0.36 and 1.46 ± 0.25 ml/min/kg body weight, respectively.",Investigation of omeprazole and phenacetin first-pass metabolism in humans using a microscale bioreactor and pharmacokinetic models. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25678106/),[ml] / [body·kg·min·weight],1.46,22605,DB00338,Omeprazole
,25678106,oral bioavailability,Then the calculated hepatic and intestinal clearances led to predicting an oral bioavailability of 0.85 and 0.77 for phenacetin and omeprazole versus 0.92 and 0.78 using separate data from the simple monoculture of Caco-2 TC7 cells and hepatocytes in Petri dishes.,Investigation of omeprazole and phenacetin first-pass metabolism in humans using a microscale bioreactor and pharmacokinetic models. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25678106/),,0.85,22606,DB00338,Omeprazole
,25678106,oral bioavailability,Then the calculated hepatic and intestinal clearances led to predicting an oral bioavailability of 0.85 and 0.77 for phenacetin and omeprazole versus 0.92 and 0.78 using separate data from the simple monoculture of Caco-2 TC7 cells and hepatocytes in Petri dishes.,Investigation of omeprazole and phenacetin first-pass metabolism in humans using a microscale bioreactor and pharmacokinetic models. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25678106/),,0.77,22607,DB00338,Omeprazole
,25678106,oral bioavailability,Then the calculated hepatic and intestinal clearances led to predicting an oral bioavailability of 0.85 and 0.77 for phenacetin and omeprazole versus 0.92 and 0.78 using separate data from the simple monoculture of Caco-2 TC7 cells and hepatocytes in Petri dishes.,Investigation of omeprazole and phenacetin first-pass metabolism in humans using a microscale bioreactor and pharmacokinetic models. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25678106/),,0.92,22608,DB00338,Omeprazole
,25678106,oral bioavailability,Then the calculated hepatic and intestinal clearances led to predicting an oral bioavailability of 0.85 and 0.77 for phenacetin and omeprazole versus 0.92 and 0.78 using separate data from the simple monoculture of Caco-2 TC7 cells and hepatocytes in Petri dishes.,Investigation of omeprazole and phenacetin first-pass metabolism in humans using a microscale bioreactor and pharmacokinetic models. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25678106/),,0.78,22609,DB00338,Omeprazole
,25678106,oral bioavailability,"When compared with the in vivo data, the results of oral bioavailability were overestimated (0.37 and 0.71, respectively).",Investigation of omeprazole and phenacetin first-pass metabolism in humans using a microscale bioreactor and pharmacokinetic models. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25678106/),,0.37,22610,DB00338,Omeprazole
,25678106,oral bioavailability,"When compared with the in vivo data, the results of oral bioavailability were overestimated (0.37 and 0.71, respectively).",Investigation of omeprazole and phenacetin first-pass metabolism in humans using a microscale bioreactor and pharmacokinetic models. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25678106/),,0.71,22611,DB00338,Omeprazole
,30317077,run time,"The separation was carried out on a ZORBAX Eclipse Plus C18 Rapid Resolution High Definition column with a gradient elution, using water containing 0.1% formic acid (A) and acetonitrile (B) in a run time of only 3.0 min.","A UHPLC-MS/MS method coupled with liquid-liquid extraction for the quantitation of phenacetin, omeprazole, metoprolol, midazolam and their metabolites in rat plasma and its application to the study of four CYP450 activities. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30317077/),min,3.0,22823,DB00338,Omeprazole
,31662775,AUC(0-24),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],283.7,23877,DB00338,Omeprazole
,31662775,AUC(0-24),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],295.7,23878,DB00338,Omeprazole
,31662775,AUC(0-24),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],416.8,23879,DB00338,Omeprazole
,31662775,AUC(0-24),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],540.7,23880,DB00338,Omeprazole
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],292.0,23881,DB00338,Omeprazole
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],416.8,23882,DB00338,Omeprazole
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],424.9,23883,DB00338,Omeprazole
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],540.7,23884,DB00338,Omeprazole
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],595.3,23885,DB00338,Omeprazole
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],760.6,23886,DB00338,Omeprazole
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],788.7,23887,DB00338,Omeprazole
>,10384859,bioavailability,"Metronidazole given orally is absorbed almost completely, with bioavailability > 90% for tablets; absorption is unaffected by infection.",Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10384859/),%,90,25265,DB00338,Omeprazole
,10384859,volume of distribution at steady state,The volume of distribution at steady state in adults is 0.51 to 1.1 L/kg.,Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10384859/),[l] / [kg],0.51 to 1.1,25266,DB00338,Omeprazole
,22832034,AUC(τ),"The mean AUC(τ) ranged from 6.9 μmol · h/L (10 mg, 6-11 years) to 17.6 μmol · h/L (40 mg, 12-17 years).","Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22832034/),[h·μM] / [l],6.9,26242,DB00338,Omeprazole
,22832034,AUC(τ),"The mean AUC(τ) ranged from 6.9 μmol · h/L (10 mg, 6-11 years) to 17.6 μmol · h/L (40 mg, 12-17 years).","Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22832034/),[h·μM] / [l],17.6,26243,DB00338,Omeprazole
,22832034,"C(ss,max)","The mean C(ss,max) ranged from 3.7 μmol/L (0.5 mg/kg, 0-1 month) to 10.5 μmol/L (40 mg, 12-17 years).","Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22832034/),[μM] / [l],3.7,26244,DB00338,Omeprazole
,22832034,"C(ss,max)","The mean C(ss,max) ranged from 3.7 μmol/L (0.5 mg/kg, 0-1 month) to 10.5 μmol/L (40 mg, 12-17 years).","Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22832034/),[μM] / [l],10.5,26245,DB00338,Omeprazole
,15145965,MR,"Among the subjects, there was a gene-dose effect, and the mean MR was 1.76, 3.45, and 33.08, respectively, in the homozygous extensive metabolizers (wt/wt, n = 9), heterozygous extensive metabolizers (wt/m1 or wt/m2, n = 10), and poor metabolizers (m1/m1 or m1/m2, n = 7).",Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15145965/),,1.76,26653,DB00338,Omeprazole
,15145965,MR,"Among the subjects, there was a gene-dose effect, and the mean MR was 1.76, 3.45, and 33.08, respectively, in the homozygous extensive metabolizers (wt/wt, n = 9), heterozygous extensive metabolizers (wt/m1 or wt/m2, n = 10), and poor metabolizers (m1/m1 or m1/m2, n = 7).",Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15145965/),,3.45,26654,DB00338,Omeprazole
,15145965,MR,"Among the subjects, there was a gene-dose effect, and the mean MR was 1.76, 3.45, and 33.08, respectively, in the homozygous extensive metabolizers (wt/wt, n = 9), heterozygous extensive metabolizers (wt/m1 or wt/m2, n = 10), and poor metabolizers (m1/m1 or m1/m2, n = 7).",Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15145965/),,33.08,26655,DB00338,Omeprazole
,25525762,bioavailability,Omeprazole (OME) is a proton pump inhibitor with a 58% bioavailability after a single oral dose.,Improvement and validation of a high-performance liquid chromatography in tandem mass spectrometry method for monitoring of omeprazole in plasma. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25525762/),%,58,26728,DB00338,Omeprazole
,25525762,flow rate,"The flow rate was 0.8 mL/min, and the chromatogram run time was 1.2 minutes.",Improvement and validation of a high-performance liquid chromatography in tandem mass spectrometry method for monitoring of omeprazole in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25525762/),[ml] / [min],0.8,26729,DB00338,Omeprazole
,30030850,Rs,"Satisfactory resolution (Rs = 2.0) was achieved within 7.3 min on a Chiralpak ID column (250 × 4.6 mm, 5 μm) employing acetonitrile-water (60:40, v/v) as the mobile phase at a flow rate of 0.6 mL/min.",Enantioselective analysis of lansoprazole in rat plasma by LC-MS/MS: Application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30030850/),,2.0,27316,DB00338,Omeprazole
,30030850,flow rate,"Satisfactory resolution (Rs = 2.0) was achieved within 7.3 min on a Chiralpak ID column (250 × 4.6 mm, 5 μm) employing acetonitrile-water (60:40, v/v) as the mobile phase at a flow rate of 0.6 mL/min.",Enantioselective analysis of lansoprazole in rat plasma by LC-MS/MS: Application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30030850/),[ml] / [min],0.6,27317,DB00338,Omeprazole
,26114209,Bioavailabilities,"3. Bioavailabilities were ∼100% for caffeine and warfarin, but <25% for omeprazole and metoprolol.","Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114209/),%,∼100,27489,DB00338,Omeprazole
<,26114209,Bioavailabilities,"3. Bioavailabilities were ∼100% for caffeine and warfarin, but <25% for omeprazole and metoprolol.","Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114209/),%,25,27490,DB00338,Omeprazole
,26114209,Bioavailability,"Bioavailability of midazolam was 4% in marmosets, presumably because of contribution of marmoset P450 3A4 expressed in small intestine and liver, with a high catalytic efficiency for midazolam 1'-hydroxylation as evident in the recombinant system.","Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114209/),%,4,27491,DB00338,Omeprazole
,8220911,Kis,6. Sulphaphenazole competitively inhibits the 7- and in some samples partly (up to 50%) the 6-hydroxylation of S-warfarin as well as the 7-hydroxylation of R- and S-acenocoumarol and the 6-hydroxylation of S-acenocoumarol (Kis ranging from 0.5-1.3 microM).,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,0.5-1.3,27727,DB00338,Omeprazole
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,99,27728,DB00338,Omeprazole
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,117,27729,DB00338,Omeprazole
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,219,27730,DB00338,Omeprazole
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,7.2,27731,DB00338,Omeprazole
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,6.1,27732,DB00338,Omeprazole
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,7.7,27733,DB00338,Omeprazole
,11984146,maximum plasma concentration (Cmax),"Esomeprazole was absorbed rapidly (mean maximum plasma concentration (Cmax) 6.1 micromol/l, mean time to Cmax (tmax) 1.9 h) and eliminated rapidly (mean plasma elimination half-life (t1/2) 2.1 h).",Pharmacokinetic study of esomeprazole in patients with hepatic impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11984146/),[μM] / [l],6.1,28385,DB00338,Omeprazole
,11984146,time to Cmax (tmax),"Esomeprazole was absorbed rapidly (mean maximum plasma concentration (Cmax) 6.1 micromol/l, mean time to Cmax (tmax) 1.9 h) and eliminated rapidly (mean plasma elimination half-life (t1/2) 2.1 h).",Pharmacokinetic study of esomeprazole in patients with hepatic impairment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11984146/),h,1.9,28386,DB00338,Omeprazole
,11984146,plasma elimination half-life (t1/2),"Esomeprazole was absorbed rapidly (mean maximum plasma concentration (Cmax) 6.1 micromol/l, mean time to Cmax (tmax) 1.9 h) and eliminated rapidly (mean plasma elimination half-life (t1/2) 2.1 h).",Pharmacokinetic study of esomeprazole in patients with hepatic impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11984146/),h,2.1,28387,DB00338,Omeprazole
,15080766,C(max),"Arithmetic mean plasma lumiracoxib concentration-time profiles were similar for all treatments, with a rapid rise in concentration after administration, reaching C(max) values (mean +/- SD) of 9.24 +/- 1.96, 8.81 +/- 2.30, and 10.43 +/- 3.24 mg/L within 2-3 hours for treatments A, B and C, respectively.",Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080766/),[mg] / [l],9.24,28553,DB00338,Omeprazole
,15080766,C(max),"Arithmetic mean plasma lumiracoxib concentration-time profiles were similar for all treatments, with a rapid rise in concentration after administration, reaching C(max) values (mean +/- SD) of 9.24 +/- 1.96, 8.81 +/- 2.30, and 10.43 +/- 3.24 mg/L within 2-3 hours for treatments A, B and C, respectively.",Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080766/),[mg] / [l],8.81,28554,DB00338,Omeprazole
,15080766,C(max),"Arithmetic mean plasma lumiracoxib concentration-time profiles were similar for all treatments, with a rapid rise in concentration after administration, reaching C(max) values (mean +/- SD) of 9.24 +/- 1.96, 8.81 +/- 2.30, and 10.43 +/- 3.24 mg/L within 2-3 hours for treatments A, B and C, respectively.",Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080766/),[mg] / [l],10.43,28555,DB00338,Omeprazole
,15080766,AUC( infinity ),"AUC( infinity ) was similar for the three treatments (36.75 +/- 7.73, 34.88 +/- 8.40 and 35.50 +/- 5.72 mg.",Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080766/),mg,36.75,28556,DB00338,Omeprazole
,15080766,AUC( infinity ),"AUC( infinity ) was similar for the three treatments (36.75 +/- 7.73, 34.88 +/- 8.40 and 35.50 +/- 5.72 mg.",Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080766/),mg,34.88,28557,DB00338,Omeprazole
,15080766,AUC( infinity ),"AUC( infinity ) was similar for the three treatments (36.75 +/- 7.73, 34.88 +/- 8.40 and 35.50 +/- 5.72 mg.",Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080766/),mg,35.50,28558,DB00338,Omeprazole
,16487225,relative AUC ratios,"The area under the plasma concentration-time curves (AUC) of (R)-rabeprazole in homEMs, hetEMs and PMs were 1.8-, 2.2- and 2.4-fold, respectively, greater than those of (S)-rabeprazole; the relative AUC ratios of (R)- and (S)-rabeprazole in homEMs, hetEMs and PMs were 1:1.1:2.1 and 1:0.9:1.5, respectively.",Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487225/),,1,30554,DB00338,Omeprazole
,16487225,elimination half-life,"There was no difference between homEMs and PMs in the elimination half-life of (S)-rabeprazole, whereas the elimination half-life of (R)-rabeprazole was significantly longer in PMs than in homEMs [1.7 h (1.4, 2.0) (mean (95% confidence interval)]vs. 0.8 h (0.6, 1.0), respectively, P<0.0001).",Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487225/),h,1.7,30555,DB00338,Omeprazole
,16487225,elimination half-life,"There was no difference between homEMs and PMs in the elimination half-life of (S)-rabeprazole, whereas the elimination half-life of (R)-rabeprazole was significantly longer in PMs than in homEMs [1.7 h (1.4, 2.0) (mean (95% confidence interval)]vs. 0.8 h (0.6, 1.0), respectively, P<0.0001).",Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487225/),h,0.8,30556,DB00338,Omeprazole
,15447734,AUCs (4 h,"The mean 24 hr pH increased significantly in all three genotypes (paired t-test; P<0.0001), and the AUCs (4 hr) of gastrin in all patients increased markedly from 129+/-73 to 298+/-142 pMhr (P<0.0001).",Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15447734/),pMhr,129,32960,DB00338,Omeprazole
,15447734,AUCs (4 h,"The mean 24 hr pH increased significantly in all three genotypes (paired t-test; P<0.0001), and the AUCs (4 hr) of gastrin in all patients increased markedly from 129+/-73 to 298+/-142 pMhr (P<0.0001).",Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15447734/),pMhr,298,32961,DB00338,Omeprazole
,19701234,flow rate,"Separation of analytes and the internal standard (IS), omeprazole, was performed on a Thermo HyPURITY C18 column (150x2.1 mm, 5 microm) with a mobile phase consisting of 10 mmol/L ammonium formate water-acetonitrile solution (50:50, v/v) at a flow rate of 0.25 mL/min.",An improved LC-MS/MS method for quantitative determination of ilaprazole and its metabolites in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19701234/),[ml] / [min],0.25,33401,DB00338,Omeprazole
,19701234,m/,"The API4000 triple quadruple mass spectrometer was operated in multiple reactions monitoring mode via positive electrospray ionization interface using the transition m/z 367.2 --> m/z184.0 for ilaprazole, m/z 383.3 --> m/z 184.1 for ilaprazole sulfone, m/z 351.2 --> m/z 168.1 for ilaprazole thiol ether and m/z 346.2 --> m/z 198.0 for omeprazole.",An improved LC-MS/MS method for quantitative determination of ilaprazole and its metabolites in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19701234/),,351.2,33402,DB00338,Omeprazole
,8017592,areas under the curve at infinity,"The mean (95% CI) areas under the curve at infinity for lignocaine after pretreatment with omeprazole or placebo were 6.67 (4.90-8.45) mumol.h.l-1 and 6.14 (5.05-7.23) mumol.h.l-1, respectively (p = 0.44).",The effect of oral omeprazole on the disposition of lignocaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8017592/),[h·μM] / [l],6.67,33472,DB00338,Omeprazole
,8017592,areas under the curve at infinity,"The mean (95% CI) areas under the curve at infinity for lignocaine after pretreatment with omeprazole or placebo were 6.67 (4.90-8.45) mumol.h.l-1 and 6.14 (5.05-7.23) mumol.h.l-1, respectively (p = 0.44).",The effect of oral omeprazole on the disposition of lignocaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8017592/),[h·μM] / [l],6.14,33473,DB00338,Omeprazole
,8017592,areas,The respective areas for monoethylglycinexylidine were 1.85 (1.25-2.45) mumol.h.l-1 and 1.79 (1.44-2.14) mumol.h.l-1 (p = 0.78).,The effect of oral omeprazole on the disposition of lignocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8017592/),[h·μM] / [l],1.85,33474,DB00338,Omeprazole
,8017592,areas,The respective areas for monoethylglycinexylidine were 1.85 (1.25-2.45) mumol.h.l-1 and 1.79 (1.44-2.14) mumol.h.l-1 (p = 0.78).,The effect of oral omeprazole on the disposition of lignocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8017592/),[h·μM] / [l],1.79,33475,DB00338,Omeprazole
,12607792,C(max),"Mean lansoprazole C(max) values of 790.9 ng/mL and 898.5 ng/mL and T(max) values of 1.5 hours and 1.7 hours were observed in the < or = 30 kg and the > 30 kg body weight treatment groups, respectively.",Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12607792/),[ng] / [ml],790.9,34854,DB00338,Omeprazole
,12607792,C(max),"Mean lansoprazole C(max) values of 790.9 ng/mL and 898.5 ng/mL and T(max) values of 1.5 hours and 1.7 hours were observed in the < or = 30 kg and the > 30 kg body weight treatment groups, respectively.",Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12607792/),[ng] / [ml],898.5,34855,DB00338,Omeprazole
,12607792,T(max),"Mean lansoprazole C(max) values of 790.9 ng/mL and 898.5 ng/mL and T(max) values of 1.5 hours and 1.7 hours were observed in the < or = 30 kg and the > 30 kg body weight treatment groups, respectively.",Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12607792/),h,1.5,34856,DB00338,Omeprazole
,12607792,T(max),"Mean lansoprazole C(max) values of 790.9 ng/mL and 898.5 ng/mL and T(max) values of 1.5 hours and 1.7 hours were observed in the < or = 30 kg and the > 30 kg body weight treatment groups, respectively.",Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12607792/),h,1.7,34857,DB00338,Omeprazole
,12607792,AUC0-24,"AUC0-24 values of 1707 ng x h/mL and 1883 ng x h/mL and T1/2 values of 0.68 hours and 0.71 hours were observed in the < or = 30 kg and > 30 kg lansoprazole body weight treatment groups, respectively.",Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12607792/),[h·ng] / [ml],1707,34858,DB00338,Omeprazole
,12607792,AUC0-24,"AUC0-24 values of 1707 ng x h/mL and 1883 ng x h/mL and T1/2 values of 0.68 hours and 0.71 hours were observed in the < or = 30 kg and > 30 kg lansoprazole body weight treatment groups, respectively.",Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12607792/),[h·ng] / [ml],1883,34859,DB00338,Omeprazole
,12607792,T1/2,"AUC0-24 values of 1707 ng x h/mL and 1883 ng x h/mL and T1/2 values of 0.68 hours and 0.71 hours were observed in the < or = 30 kg and > 30 kg lansoprazole body weight treatment groups, respectively.",Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12607792/),h,0.68,34860,DB00338,Omeprazole
,12607792,T1/2,"AUC0-24 values of 1707 ng x h/mL and 1883 ng x h/mL and T1/2 values of 0.68 hours and 0.71 hours were observed in the < or = 30 kg and > 30 kg lansoprazole body weight treatment groups, respectively.",Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12607792/),h,0.71,34861,DB00338,Omeprazole
,12820812,area under the concentration-time curve,"The mean +/- SD values of area under the concentration-time curve of rabeprazole and rabeprazole thioether were significantly higher in poor metabolizers than in extensive metabolizers on day 1 (5357 +/- 883 vs 1131 +/- 512 ng x hr/ml and 1703 +/- 432 vs 561 +/- 358 ng x hr/ml, respectively; p<0.001) and on day 4 (5601 +/- 669 vs 1619 +/- 778 ng x hr/ml and 1914 +/- 378 vs 511 +/- 360 ng x hr/ml, respectively; p<0.001).",Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12820812/),[h·ng] / [ml],5357,37004,DB00338,Omeprazole
,12820812,area under the concentration-time curve,"The mean +/- SD values of area under the concentration-time curve of rabeprazole and rabeprazole thioether were significantly higher in poor metabolizers than in extensive metabolizers on day 1 (5357 +/- 883 vs 1131 +/- 512 ng x hr/ml and 1703 +/- 432 vs 561 +/- 358 ng x hr/ml, respectively; p<0.001) and on day 4 (5601 +/- 669 vs 1619 +/- 778 ng x hr/ml and 1914 +/- 378 vs 511 +/- 360 ng x hr/ml, respectively; p<0.001).",Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12820812/),[h·ng] / [ml],1131,37005,DB00338,Omeprazole
,12820812,area under the concentration-time curve,"The mean +/- SD values of area under the concentration-time curve of rabeprazole and rabeprazole thioether were significantly higher in poor metabolizers than in extensive metabolizers on day 1 (5357 +/- 883 vs 1131 +/- 512 ng x hr/ml and 1703 +/- 432 vs 561 +/- 358 ng x hr/ml, respectively; p<0.001) and on day 4 (5601 +/- 669 vs 1619 +/- 778 ng x hr/ml and 1914 +/- 378 vs 511 +/- 360 ng x hr/ml, respectively; p<0.001).",Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12820812/),[h·ng] / [ml],1703,37006,DB00338,Omeprazole
,12820812,area under the concentration-time curve,"The mean +/- SD values of area under the concentration-time curve of rabeprazole and rabeprazole thioether were significantly higher in poor metabolizers than in extensive metabolizers on day 1 (5357 +/- 883 vs 1131 +/- 512 ng x hr/ml and 1703 +/- 432 vs 561 +/- 358 ng x hr/ml, respectively; p<0.001) and on day 4 (5601 +/- 669 vs 1619 +/- 778 ng x hr/ml and 1914 +/- 378 vs 511 +/- 360 ng x hr/ml, respectively; p<0.001).",Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12820812/),[h·ng] / [ml],561,37007,DB00338,Omeprazole
,12820812,area under the concentration-time curve,"The mean +/- SD values of area under the concentration-time curve of rabeprazole and rabeprazole thioether were significantly higher in poor metabolizers than in extensive metabolizers on day 1 (5357 +/- 883 vs 1131 +/- 512 ng x hr/ml and 1703 +/- 432 vs 561 +/- 358 ng x hr/ml, respectively; p<0.001) and on day 4 (5601 +/- 669 vs 1619 +/- 778 ng x hr/ml and 1914 +/- 378 vs 511 +/- 360 ng x hr/ml, respectively; p<0.001).",Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12820812/),[h·ng] / [ml],5601,37008,DB00338,Omeprazole
,12820812,area under the concentration-time curve,"The mean +/- SD values of area under the concentration-time curve of rabeprazole and rabeprazole thioether were significantly higher in poor metabolizers than in extensive metabolizers on day 1 (5357 +/- 883 vs 1131 +/- 512 ng x hr/ml and 1703 +/- 432 vs 561 +/- 358 ng x hr/ml, respectively; p<0.001) and on day 4 (5601 +/- 669 vs 1619 +/- 778 ng x hr/ml and 1914 +/- 378 vs 511 +/- 360 ng x hr/ml, respectively; p<0.001).",Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12820812/),[h·ng] / [ml],1619,37009,DB00338,Omeprazole
,12820812,area under the concentration-time curve,"The mean +/- SD values of area under the concentration-time curve of rabeprazole and rabeprazole thioether were significantly higher in poor metabolizers than in extensive metabolizers on day 1 (5357 +/- 883 vs 1131 +/- 512 ng x hr/ml and 1703 +/- 432 vs 561 +/- 358 ng x hr/ml, respectively; p<0.001) and on day 4 (5601 +/- 669 vs 1619 +/- 778 ng x hr/ml and 1914 +/- 378 vs 511 +/- 360 ng x hr/ml, respectively; p<0.001).",Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12820812/),[h·ng] / [ml],1914,37010,DB00338,Omeprazole
,12820812,area under the concentration-time curve,"The mean +/- SD values of area under the concentration-time curve of rabeprazole and rabeprazole thioether were significantly higher in poor metabolizers than in extensive metabolizers on day 1 (5357 +/- 883 vs 1131 +/- 512 ng x hr/ml and 1703 +/- 432 vs 561 +/- 358 ng x hr/ml, respectively; p<0.001) and on day 4 (5601 +/- 669 vs 1619 +/- 778 ng x hr/ml and 1914 +/- 378 vs 511 +/- 360 ng x hr/ml, respectively; p<0.001).",Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12820812/),[h·ng] / [ml],511,37011,DB00338,Omeprazole
,9692688,first pass metabolism,"Following food, and with ethanol taken in the form of beer, mean first pass metabolism of ethanol was 58% (range 34-78%).","Omeprazole, ranitidine, and cimetidine have no effect on peak blood ethanol concentrations, first pass metabolism or area under the time-ethanol curve under 'real-life' drinking conditions. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9692688/),%,58,37226,DB00338,Omeprazole
,28801980,M,"In a retrospective study, patients who received a PPI had significantly higher MTX levels at 48 h (0.38 vs. 0.15 μmol l-1 , respectively, p = 0.000018) and 72 h (0.13 vs. 0.05 μmol l-1 , respectively, p = 0.0002) compared with patients who did not receive a PPI (but received famotidine).",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),[μM] / [l],0.38,37476,DB00338,Omeprazole
,28801980,M,"In a retrospective study, patients who received a PPI had significantly higher MTX levels at 48 h (0.38 vs. 0.15 μmol l-1 , respectively, p = 0.000018) and 72 h (0.13 vs. 0.05 μmol l-1 , respectively, p = 0.0002) compared with patients who did not receive a PPI (but received famotidine).",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),[μM] / [l],0.15,37477,DB00338,Omeprazole
,28801980,M,"In a retrospective study, patients who received a PPI had significantly higher MTX levels at 48 h (0.38 vs. 0.15 μmol l-1 , respectively, p = 0.000018) and 72 h (0.13 vs. 0.05 μmol l-1 , respectively, p = 0.0002) compared with patients who did not receive a PPI (but received famotidine).",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),[μM] / [l],0.13,37478,DB00338,Omeprazole
,28801980,M,"In a retrospective study, patients who received a PPI had significantly higher MTX levels at 48 h (0.38 vs. 0.15 μmol l-1 , respectively, p = 0.000018) and 72 h (0.13 vs. 0.05 μmol l-1 , respectively, p = 0.0002) compared with patients who did not receive a PPI (but received famotidine).",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),[μM] / [l],0.05,37479,DB00338,Omeprazole
,28801980,IC50,"Moreover, in vitro experiments demonstrated that PPIs (esomeprazole, lansoprazole, omeprazole and rabeprazole) inhibited hOAT3-mediated uptake of MTX in a concentration-dependent manner (IC50 values of 0.40-5.5 μ m), with a rank order of lansoprazole > esomeprazole > rabeprazole > omeprazole.",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),m·μ,0.40-5.5,37480,DB00338,Omeprazole
,19820270,exposure,"For LDX monotherapy, d-amphetamine mean (SD) exposure was 45.0 (13.97) ng/mL and 713.0 (134.75) ng . h/mL; when coadministered with omeprazole it was 46.3 (9.71) ng/mL and 761.6 (191.13) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[ng] / [ml],45.0,38540,DB00338,Omeprazole
,19820270,exposure,"For LDX monotherapy, d-amphetamine mean (SD) exposure was 45.0 (13.97) ng/mL and 713.0 (134.75) ng . h/mL; when coadministered with omeprazole it was 46.3 (9.71) ng/mL and 761.6 (191.13) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[h·ng] / [ml],713.0,38541,DB00338,Omeprazole
,19820270,exposure,"For LDX monotherapy, d-amphetamine mean (SD) exposure was 45.0 (13.97) ng/mL and 713.0 (134.75) ng . h/mL; when coadministered with omeprazole it was 46.3 (9.71) ng/mL and 761.6 (191.13) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[h·ng] / [ml],761.6,38542,DB00338,Omeprazole
,19820270,Cmax,"For LDX monotherapy, d-amphetamine mean (SD) exposure was 45.0 (13.97) ng/mL and 713.0 (134.75) ng . h/mL; when coadministered with omeprazole it was 46.3 (9.71) ng/mL and 761.6 (191.13) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[ng] / [ml],46.3,38543,DB00338,Omeprazole
,19820270,Cmax,"For LDX monotherapy, d-amphetamine mean (SD) exposure was 45.0 (13.97) ng/mL and 713.0 (134.75) ng . h/mL; when coadministered with omeprazole it was 46.3 (9.71) ng/mL and 761.6 (191.13) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[h·ng] / [ml],761.6,38544,DB00338,Omeprazole
,19820270,AUCinf,"For LDX monotherapy, d-amphetamine mean (SD) exposure was 45.0 (13.97) ng/mL and 713.0 (134.75) ng . h/mL; when coadministered with omeprazole it was 46.3 (9.71) ng/mL and 761.6 (191.13) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[h·ng] / [ml],761.6,38545,DB00338,Omeprazole
,19820270,Tmax,The median Tmax was 3 hours with and without omeprazole.,Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),h,3,38546,DB00338,Omeprazole
,19820270,exposure,"For MAS XR monotherapy, total amphetamine mean (SD) exposure was 36.6 (9.19) ng/mL and 640.8 (95.66) ng . h/mL; when coadministered with omeprazole it was 38.1 (7.35) ng/mL and 643.9 (143.16) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[ng] / [ml],36.6,38547,DB00338,Omeprazole
,19820270,exposure,"For MAS XR monotherapy, total amphetamine mean (SD) exposure was 36.6 (9.19) ng/mL and 640.8 (95.66) ng . h/mL; when coadministered with omeprazole it was 38.1 (7.35) ng/mL and 643.9 (143.16) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[h·ng] / [ml],640.8,38548,DB00338,Omeprazole
,19820270,exposure,"For MAS XR monotherapy, total amphetamine mean (SD) exposure was 36.6 (9.19) ng/mL and 640.8 (95.66) ng . h/mL; when coadministered with omeprazole it was 38.1 (7.35) ng/mL and 643.9 (143.16) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[h·ng] / [ml],643.9,38549,DB00338,Omeprazole
,19820270,Cmax,"For MAS XR monotherapy, total amphetamine mean (SD) exposure was 36.6 (9.19) ng/mL and 640.8 (95.66) ng . h/mL; when coadministered with omeprazole it was 38.1 (7.35) ng/mL and 643.9 (143.16) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[ng] / [ml],38.1,38550,DB00338,Omeprazole
,19820270,Cmax,"For MAS XR monotherapy, total amphetamine mean (SD) exposure was 36.6 (9.19) ng/mL and 640.8 (95.66) ng . h/mL; when coadministered with omeprazole it was 38.1 (7.35) ng/mL and 643.9 (143.16) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[h·ng] / [ml],643.9,38551,DB00338,Omeprazole
,19820270,AUCinf,"For MAS XR monotherapy, total amphetamine mean (SD) exposure was 36.6 (9.19) ng/mL and 640.8 (95.66) ng . h/mL; when coadministered with omeprazole it was 38.1 (7.35) ng/mL and 643.9 (143.16) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[h·ng] / [ml],643.9,38552,DB00338,Omeprazole
,19820270,Tmax,"The median Tmax was 5 hours and 2.75 hours without and with omeprazole, respectively; 57.1% to 61.9% of subjects receiving MAS XR and 25% receiving LDX showed an earlier (>or= 1 hour) Tmax with omeprazole.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),h,5,38553,DB00338,Omeprazole
,19820270,Tmax,"The median Tmax was 5 hours and 2.75 hours without and with omeprazole, respectively; 57.1% to 61.9% of subjects receiving MAS XR and 25% receiving LDX showed an earlier (>or= 1 hour) Tmax with omeprazole.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),h,2.75,38554,DB00338,Omeprazole
,10932486,Cmax,"The mean Cmax values were 14.62 +/- 5.39 and 12.65 +/- 4.76 micrograms/ml, the Tmax were 2.3 +/- 1.0 and 2.0 +/- 0.9 hour and the AUC0-6 were 40.79 +/- 13.26 and 38.75 +/- 15.04 micrograms/ml.h in the group I and group II, respectively.",Effect of omeprazole on gastric mucosa and serum levels of amoxicillin in patients with non-ulcer dyspepsia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10932486/),[μg] / [ml],14.62,39340,DB00338,Omeprazole
,10932486,Cmax,"The mean Cmax values were 14.62 +/- 5.39 and 12.65 +/- 4.76 micrograms/ml, the Tmax were 2.3 +/- 1.0 and 2.0 +/- 0.9 hour and the AUC0-6 were 40.79 +/- 13.26 and 38.75 +/- 15.04 micrograms/ml.h in the group I and group II, respectively.",Effect of omeprazole on gastric mucosa and serum levels of amoxicillin in patients with non-ulcer dyspepsia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10932486/),[μg] / [ml],12.65,39341,DB00338,Omeprazole
,10932486,Tmax,"The mean Cmax values were 14.62 +/- 5.39 and 12.65 +/- 4.76 micrograms/ml, the Tmax were 2.3 +/- 1.0 and 2.0 +/- 0.9 hour and the AUC0-6 were 40.79 +/- 13.26 and 38.75 +/- 15.04 micrograms/ml.h in the group I and group II, respectively.",Effect of omeprazole on gastric mucosa and serum levels of amoxicillin in patients with non-ulcer dyspepsia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10932486/),h,2.3,39342,DB00338,Omeprazole
,10932486,Tmax,"The mean Cmax values were 14.62 +/- 5.39 and 12.65 +/- 4.76 micrograms/ml, the Tmax were 2.3 +/- 1.0 and 2.0 +/- 0.9 hour and the AUC0-6 were 40.79 +/- 13.26 and 38.75 +/- 15.04 micrograms/ml.h in the group I and group II, respectively.",Effect of omeprazole on gastric mucosa and serum levels of amoxicillin in patients with non-ulcer dyspepsia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10932486/),h,2.0,39343,DB00338,Omeprazole
,10932486,AUC0-6,"The mean Cmax values were 14.62 +/- 5.39 and 12.65 +/- 4.76 micrograms/ml, the Tmax were 2.3 +/- 1.0 and 2.0 +/- 0.9 hour and the AUC0-6 were 40.79 +/- 13.26 and 38.75 +/- 15.04 micrograms/ml.h in the group I and group II, respectively.",Effect of omeprazole on gastric mucosa and serum levels of amoxicillin in patients with non-ulcer dyspepsia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10932486/),[μg] / [h·ml],40.79,39344,DB00338,Omeprazole
,10932486,AUC0-6,"The mean Cmax values were 14.62 +/- 5.39 and 12.65 +/- 4.76 micrograms/ml, the Tmax were 2.3 +/- 1.0 and 2.0 +/- 0.9 hour and the AUC0-6 were 40.79 +/- 13.26 and 38.75 +/- 15.04 micrograms/ml.h in the group I and group II, respectively.",Effect of omeprazole on gastric mucosa and serum levels of amoxicillin in patients with non-ulcer dyspepsia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10932486/),[μg] / [h·ml],38.75,39345,DB00338,Omeprazole
,11452243,area under the plasma concentration versus time curve (AUC(0-infinity)),Six poor metabolizers with m1 mutation had area under the plasma concentration versus time curve (AUC(0-infinity)) values (983.6 +/- 199.3 microg x h/L versus 697.6 +/- 133.0 microg x h/L; P <.05) and terminal elimination half-life values of sertraline (35.5 +/- 5.6 hours versus 23.5 +/- 4.4 hours; P <.01) that were significantly higher than the values in 6 extensive metabolizers who were either homozygous or heterozygous for CYP2C19*1.,Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452243/),[h·μg] / [l],983.6,39546,DB00338,Omeprazole
,11452243,area under the plasma concentration versus time curve (AUC(0-infinity)),Six poor metabolizers with m1 mutation had area under the plasma concentration versus time curve (AUC(0-infinity)) values (983.6 +/- 199.3 microg x h/L versus 697.6 +/- 133.0 microg x h/L; P <.05) and terminal elimination half-life values of sertraline (35.5 +/- 5.6 hours versus 23.5 +/- 4.4 hours; P <.01) that were significantly higher than the values in 6 extensive metabolizers who were either homozygous or heterozygous for CYP2C19*1.,Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452243/),[h·μg] / [l],697.6,39547,DB00338,Omeprazole
,11452243,terminal elimination half-life,Six poor metabolizers with m1 mutation had area under the plasma concentration versus time curve (AUC(0-infinity)) values (983.6 +/- 199.3 microg x h/L versus 697.6 +/- 133.0 microg x h/L; P <.05) and terminal elimination half-life values of sertraline (35.5 +/- 5.6 hours versus 23.5 +/- 4.4 hours; P <.01) that were significantly higher than the values in 6 extensive metabolizers who were either homozygous or heterozygous for CYP2C19*1.,Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452243/),h,35.5,39548,DB00338,Omeprazole
,11452243,terminal elimination half-life,Six poor metabolizers with m1 mutation had area under the plasma concentration versus time curve (AUC(0-infinity)) values (983.6 +/- 199.3 microg x h/L versus 697.6 +/- 133.0 microg x h/L; P <.05) and terminal elimination half-life values of sertraline (35.5 +/- 5.6 hours versus 23.5 +/- 4.4 hours; P <.01) that were significantly higher than the values in 6 extensive metabolizers who were either homozygous or heterozygous for CYP2C19*1.,Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452243/),h,23.5,39549,DB00338,Omeprazole
,11452243,oral clearance,The oral clearance of sertraline in poor metabolizers (105.3 +/- 19.4 L/h) was significantly lower than that of extensive metabolizers (148.4 +/- 28.6 L/h).,Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452243/),[l] / [h],105.3,39550,DB00338,Omeprazole
,11452243,oral clearance,The oral clearance of sertraline in poor metabolizers (105.3 +/- 19.4 L/h) was significantly lower than that of extensive metabolizers (148.4 +/- 28.6 L/h).,Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452243/),[l] / [h],148.4,39551,DB00338,Omeprazole
,11452243,area under the concentration-time curve from 0 to 144 hours,The area under the concentration-time curve from 0 to 144 hours and the maximum plasma concentration of desmethylsertraline in poor metabolizers were significantly lower than the values of extensive metabolizers (627.6 +/- 203.8 microg x h/L versus 972.1 +/- 270.3 microg x h/L; P <.05; and 23.6 +/- 6.5 nmol/L versus 32.4 +/- 8.2 nmol/L; P <.01; respectively).,Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452243/),[h·μg] / [l],627.6,39552,DB00338,Omeprazole
,11452243,area under the concentration-time curve from 0 to 144 hours,The area under the concentration-time curve from 0 to 144 hours and the maximum plasma concentration of desmethylsertraline in poor metabolizers were significantly lower than the values of extensive metabolizers (627.6 +/- 203.8 microg x h/L versus 972.1 +/- 270.3 microg x h/L; P <.05; and 23.6 +/- 6.5 nmol/L versus 32.4 +/- 8.2 nmol/L; P <.01; respectively).,Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452243/),[h·μg] / [l],972.1,39553,DB00338,Omeprazole
,11452243,maximum plasma concentration,The area under the concentration-time curve from 0 to 144 hours and the maximum plasma concentration of desmethylsertraline in poor metabolizers were significantly lower than the values of extensive metabolizers (627.6 +/- 203.8 microg x h/L versus 972.1 +/- 270.3 microg x h/L; P <.05; and 23.6 +/- 6.5 nmol/L versus 32.4 +/- 8.2 nmol/L; P <.01; respectively).,Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452243/),[nM] / [l],23.6,39554,DB00338,Omeprazole
,11452243,maximum plasma concentration,The area under the concentration-time curve from 0 to 144 hours and the maximum plasma concentration of desmethylsertraline in poor metabolizers were significantly lower than the values of extensive metabolizers (627.6 +/- 203.8 microg x h/L versus 972.1 +/- 270.3 microg x h/L; P <.05; and 23.6 +/- 6.5 nmol/L versus 32.4 +/- 8.2 nmol/L; P <.01; respectively).,Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452243/),[nM] / [l],32.4,39555,DB00338,Omeprazole
,16272957,accumulation ratio,"No significant intergenotypic differences in the pharmacokinetic parameters of ticlopidine were observed, although the accumulation ratio tended to be greater in hmEMs than in PMs (2.4 +/- 0.2 versus 1.7 +/- 0.2).","Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16272957/),,2.4,40201,DB00338,Omeprazole
,16272957,accumulation ratio,"No significant intergenotypic differences in the pharmacokinetic parameters of ticlopidine were observed, although the accumulation ratio tended to be greater in hmEMs than in PMs (2.4 +/- 0.2 versus 1.7 +/- 0.2).","Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16272957/),,1.7,40202,DB00338,Omeprazole
,12011821,maximal concentration (C(max)),"In group A, maximal concentration (C(max)) was 1023 +/- 775 (mg. L(-1))/(17 mg.",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),[-1·mg] / [l],1023,40444,DB00338,Omeprazole
,12011821,time to reach C(max),"m(-2)), time to reach C(max) was 1.8 +/- 0.8 hours, elimination half-life was 1.5 +/- 2.0 hours, area under the concentration-time curve from time zero to infinity [AUC(0-infinity)] was 3503 +/- 6025 (mg. L(-1).",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),h,1.8,40445,DB00338,Omeprazole
,12011821,elimination half-life,"m(-2)), time to reach C(max) was 1.8 +/- 0.8 hours, elimination half-life was 1.5 +/- 2.0 hours, area under the concentration-time curve from time zero to infinity [AUC(0-infinity)] was 3503 +/- 6025 (mg. L(-1).",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),h,1.5,40446,DB00338,Omeprazole
,12011821,area under the concentration-time curve from time zero to infinity [AUC(0-infinity)],"m(-2)), time to reach C(max) was 1.8 +/- 0.8 hours, elimination half-life was 1.5 +/- 2.0 hours, area under the concentration-time curve from time zero to infinity [AUC(0-infinity)] was 3503 +/- 6025 (mg. L(-1).",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),[mg] / [l],3503,40447,DB00338,Omeprazole
,12011821,apparent plasma clearance,"m(-2)), apparent plasma clearance was 0.57 +/- 0.47 L. h(-1).",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),[l] / [h],0.57,40448,DB00338,Omeprazole
,12011821,apparent volume of distribution,"kg(-1), and apparent volume of distribution was 0.61 +/- 0.36 L. kg(-1).",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),[l] / [kg],0.61,40449,DB00338,Omeprazole
,12011821,C(max),"In group B, C(max) was 750 +/- 511 (mg. L(-1))/(17 mg.",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),[-1·mg] / [l],750,40450,DB00338,Omeprazole
,12011821,time to reach C(max),"m(-2)), time to reach C(max) was 1.8 +/- 1.1 hours, elimination half-life was 1.2 +/- 1.1 hours, AUC(0-infinity) was 2351 +/- 3691 (mg. L(-1).",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),h,1.8,40451,DB00338,Omeprazole
,12011821,elimination half-life,"m(-2)), time to reach C(max) was 1.8 +/- 1.1 hours, elimination half-life was 1.2 +/- 1.1 hours, AUC(0-infinity) was 2351 +/- 3691 (mg. L(-1).",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),h,1.2,40452,DB00338,Omeprazole
,12011821,AUC(0-infinity),"m(-2)), time to reach C(max) was 1.8 +/- 1.1 hours, elimination half-life was 1.2 +/- 1.1 hours, AUC(0-infinity) was 2351 +/- 3691 (mg. L(-1).",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),[mg] / [l],2351,40453,DB00338,Omeprazole
,12011821,apparent plasma clearance,"m(-2)), apparent plasma clearance was 0.71 +/- 0.50 L. h(-1).",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),[l] / [h],0.71,40454,DB00338,Omeprazole
,12011821,apparent volume of distribution,"kg(-1), and apparent volume of distribution was 0.9 +/- 0.7 L. kg(-1).",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),[l] / [kg],0.9,40455,DB00338,Omeprazole
,12011821,percentage of time,"The values for 24-hour percentage of time at gastric pH <4 and pH <3 were 61% +/- 21% and 51% +/- 21% (group A) and 47% +/- 24% and 37% +/- 21% (group B), respectively.",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),%,61,40456,DB00338,Omeprazole
,12011821,percentage of time,"The values for 24-hour percentage of time at gastric pH <4 and pH <3 were 61% +/- 21% and 51% +/- 21% (group A) and 47% +/- 24% and 37% +/- 21% (group B), respectively.",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),%,51,40457,DB00338,Omeprazole
,12011821,percentage of time,"The values for 24-hour percentage of time at gastric pH <4 and pH <3 were 61% +/- 21% and 51% +/- 21% (group A) and 47% +/- 24% and 37% +/- 21% (group B), respectively.",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),%,47,40458,DB00338,Omeprazole
,12011821,percentage of time,"The values for 24-hour percentage of time at gastric pH <4 and pH <3 were 61% +/- 21% and 51% +/- 21% (group A) and 47% +/- 24% and 37% +/- 21% (group B), respectively.",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),%,37,40459,DB00338,Omeprazole
,17617287,Reconstitution time,Reconstitution time was 2 minutes with water and 9 to 10 minutes with apple or orange juice.,A new esomeprazole packet (sachet) formulation for suspension: in vitro characteristics and comparative pharmacokinetics versus intact capsules/tablets in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17617287/),min,2,40481,DB00338,Omeprazole
,17617287,Reconstitution time,Reconstitution time was 2 minutes with water and 9 to 10 minutes with apple or orange juice.,A new esomeprazole packet (sachet) formulation for suspension: in vitro characteristics and comparative pharmacokinetics versus intact capsules/tablets in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17617287/),min,9 to 10,40482,DB00338,Omeprazole
,17701405,HI,"Additionally, there was no significant difference between HI(3h) of IV and that of PO (12.9 +/- 15.9 and 12.9 +/- 15.1, p = 0.997).",Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17701405/),,12,40644,DB00338,Omeprazole
,8405016,total plasma clearance,The plasma pharmacokinetics of pantoprazole following intravenous infusion in this group of subjects were characterised by a total plasma clearance of 0.13 l.h-1 x kg-1 and apparent terminal elimination half-life 1.9 h.,Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8405016/),[l] / [h·kg],0.13,41440,DB00338,Omeprazole
,8405016,apparent terminal elimination half-life,The plasma pharmacokinetics of pantoprazole following intravenous infusion in this group of subjects were characterised by a total plasma clearance of 0.13 l.h-1 x kg-1 and apparent terminal elimination half-life 1.9 h.,Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8405016/),h,1.9,41441,DB00338,Omeprazole
,8405016,apparent volume of distribution,The apparent volume of distribution estimated at steady state (0.17 l.kg-1) was compatible with the localization of a major fraction of the compound in extracellular water.,Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8405016/),[l] / [kg],0.17,41442,DB00338,Omeprazole
,8405016,absolute systemic bioavailability,"Pantoprazole was well absorbed following oral administration; the absolute systemic bioavailability of the compound was estimated as 77% (95% CI, 67 to 89%).",Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8405016/),%,77,41443,DB00338,Omeprazole
,12369444,absolute bioavailability,The substance has an absolute bioavailability upon oral administration of approximately 52% which is robust against food intake or administration of antacids.,Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12369444/),%,52,41783,DB00338,Omeprazole
,12369444,Elimination half-life,Elimination half-life is about 1 h.,Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12369444/),h,1,41784,DB00338,Omeprazole
,18076214,elimination half-lives,The currently available PPIs have short elimination half-lives ranging from 1 to 1.5 hours.,Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18076214/),h,1 to 1.5,42062,DB00338,Omeprazole
,10584979,K(i),"In vitro, omeprazole was mainly a competitive CYP1A2 inhibitor with K(i) values of around 150 microM.",Omeprazole weakly inhibits CYP1A2 activity in man. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584979/),μM,150,42427,DB00338,Omeprazole
,8864328,clearance,"There was no effect on diazepam clearance (0.021 1 h-1 kg-1 for test and reference) and elimination half-life (36.8 for test, 40.4 h for reference).",Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864328/),[1] / [h·kg],0.021,44920,DB00338,Omeprazole
,8864328,elimination half-life,"There was no effect on diazepam clearance (0.021 1 h-1 kg-1 for test and reference) and elimination half-life (36.8 for test, 40.4 h for reference).",Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864328/),h,36.8,44921,DB00338,Omeprazole
,8864328,elimination half-life,"There was no effect on diazepam clearance (0.021 1 h-1 kg-1 for test and reference) and elimination half-life (36.8 for test, 40.4 h for reference).",Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864328/),h,40.4,44922,DB00338,Omeprazole
,27121938,bioavailability,"Esomeprazole treatment resulted in decreased lapatinib bioavailability (mean 26%, range 6-49%) that was inversely associated with patient age as a significant covariate.",Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121938/),%,26,44928,DB00338,Omeprazole
,31332820,percentages time,The mean percentages time of intragastric pH >6 was 63.6 and 51.7% for healthy subjects after receiving ilaprazole 30 mg and esomeprazole 80 mg.,"Efficacy, safety and pharmacokinetics of ilaprazole infusion in healthy subjects and patients with esomeprazole as positive control. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31332820/),%,63.6,45365,DB00338,Omeprazole
,31332820,percentages time,The mean percentages time of intragastric pH >6 was 63.6 and 51.7% for healthy subjects after receiving ilaprazole 30 mg and esomeprazole 80 mg.,"Efficacy, safety and pharmacokinetics of ilaprazole infusion in healthy subjects and patients with esomeprazole as positive control. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31332820/),%,51.7,45366,DB00338,Omeprazole
,27166533,Cmax,"There was a significant increase in Cmax (from 2 to 2.9μg/ml, p=0.004**), (from 6.67 to 8.74μg-hr/ml, p=0.05*) and elimination half-life (from 1.05 to 2.1 hr, p=0.0001*) of omeprazole in females compared with males.",Variation in pharmacokinetics of omeprazole and its metabolites by gender and CYP2C19 genotype in Pakistani male and female subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27166533/),[μg] / [ml],2,46433,DB00338,Omeprazole
,27166533,Cmax,"There was a significant increase in Cmax (from 2 to 2.9μg/ml, p=0.004**), (from 6.67 to 8.74μg-hr/ml, p=0.05*) and elimination half-life (from 1.05 to 2.1 hr, p=0.0001*) of omeprazole in females compared with males.",Variation in pharmacokinetics of omeprazole and its metabolites by gender and CYP2C19 genotype in Pakistani male and female subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27166533/),[μg] / [ml],2.9,46434,DB00338,Omeprazole
,27166533,Cmax,"There was a significant increase in Cmax (from 2 to 2.9μg/ml, p=0.004**), (from 6.67 to 8.74μg-hr/ml, p=0.05*) and elimination half-life (from 1.05 to 2.1 hr, p=0.0001*) of omeprazole in females compared with males.",Variation in pharmacokinetics of omeprazole and its metabolites by gender and CYP2C19 genotype in Pakistani male and female subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27166533/),[μg-hr] / [ml],6.67,46435,DB00338,Omeprazole
,27166533,Cmax,"There was a significant increase in Cmax (from 2 to 2.9μg/ml, p=0.004**), (from 6.67 to 8.74μg-hr/ml, p=0.05*) and elimination half-life (from 1.05 to 2.1 hr, p=0.0001*) of omeprazole in females compared with males.",Variation in pharmacokinetics of omeprazole and its metabolites by gender and CYP2C19 genotype in Pakistani male and female subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27166533/),[μg-hr] / [ml],8,46436,DB00338,Omeprazole
,27166533,elimination half-life,"There was a significant increase in Cmax (from 2 to 2.9μg/ml, p=0.004**), (from 6.67 to 8.74μg-hr/ml, p=0.05*) and elimination half-life (from 1.05 to 2.1 hr, p=0.0001*) of omeprazole in females compared with males.",Variation in pharmacokinetics of omeprazole and its metabolites by gender and CYP2C19 genotype in Pakistani male and female subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27166533/),h,1.05,46437,DB00338,Omeprazole
,17395892,maximum observed concentration,"Geometric means for the maximum observed concentration and area under the concentration-time curve from time 0 extrapolated to infinity were 9.6 microg/mL (18.2%) and 132.0 microg.h/mL (18.9%), respectively, for garenoxacin alone and 9.3 microg/mL (21.6%) and 140.4 microg.h/mL (22.1%), respectively, for coadministered garenoxacin and omeprazole.",The effect of omeprazole on the bioavailability and safety of garenoxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17395892/),[μg] / [ml],9.6,47109,DB00338,Omeprazole
,17395892,maximum observed concentration,"Geometric means for the maximum observed concentration and area under the concentration-time curve from time 0 extrapolated to infinity were 9.6 microg/mL (18.2%) and 132.0 microg.h/mL (18.9%), respectively, for garenoxacin alone and 9.3 microg/mL (21.6%) and 140.4 microg.h/mL (22.1%), respectively, for coadministered garenoxacin and omeprazole.",The effect of omeprazole on the bioavailability and safety of garenoxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17395892/),[μg] / [ml],9.3,47110,DB00338,Omeprazole
,17395892,area under the concentration-time curve from time 0,"Geometric means for the maximum observed concentration and area under the concentration-time curve from time 0 extrapolated to infinity were 9.6 microg/mL (18.2%) and 132.0 microg.h/mL (18.9%), respectively, for garenoxacin alone and 9.3 microg/mL (21.6%) and 140.4 microg.h/mL (22.1%), respectively, for coadministered garenoxacin and omeprazole.",The effect of omeprazole on the bioavailability and safety of garenoxacin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17395892/),[h·μg] / [ml],132.0,47111,DB00338,Omeprazole
,17395892,area under the concentration-time curve from time 0,"Geometric means for the maximum observed concentration and area under the concentration-time curve from time 0 extrapolated to infinity were 9.6 microg/mL (18.2%) and 132.0 microg.h/mL (18.9%), respectively, for garenoxacin alone and 9.3 microg/mL (21.6%) and 140.4 microg.h/mL (22.1%), respectively, for coadministered garenoxacin and omeprazole.",The effect of omeprazole on the bioavailability and safety of garenoxacin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17395892/),[μg] / [ml],9.3,47112,DB00338,Omeprazole
,17395892,area under the concentration-time curve from time 0,"Geometric means for the maximum observed concentration and area under the concentration-time curve from time 0 extrapolated to infinity were 9.6 microg/mL (18.2%) and 132.0 microg.h/mL (18.9%), respectively, for garenoxacin alone and 9.3 microg/mL (21.6%) and 140.4 microg.h/mL (22.1%), respectively, for coadministered garenoxacin and omeprazole.",The effect of omeprazole on the bioavailability and safety of garenoxacin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17395892/),[h·μg] / [ml],140.4,47113,DB00338,Omeprazole
,7656504,plasma elimination half-life (t1/2),Mean plasma elimination half-life (t1/2) is between 1.3 and 2.1 hours in healthy volunteers.,Clinical pharmacokinetics of lansoprazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7656504/),h,1.3 and 2.1,47682,DB00338,Omeprazole
,24892629,relative bioavailability,The optimal formulation achieved good SR feature both in vitro and in vivo with a relative bioavailability of 103.50%.,Preparation and in vitro/in vivo evaluation of esomeprazole magnesium-modified release pellets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24892629/),%,103.50,48106,DB00338,Omeprazole
,8592663,steady state plasma concentrations,Zero order infusions together with matched bolus doses of omeprazole were used to achieve a range of steady state plasma concentrations (10-50mg/L) and to study the diazepam-omeprazole interaction in vivo.,Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592663/),[mg] / [l],10-50,49348,DB00338,Omeprazole
,8592663,KIs,"The 3-hydroxlation pathway was more prone to inhibition (KIs 108 +/- 30 and 28 +/- 11 microM in microsomes and hepatocytes, respectively) than the demethylation pathway (KIs of 226 +/- 76 and 59 +/- 27 microM in microsomes and hepatocytes, respectively).",Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592663/),μM,108,49349,DB00338,Omeprazole
,8592663,KIs,"The 3-hydroxlation pathway was more prone to inhibition (KIs 108 +/- 30 and 28 +/- 11 microM in microsomes and hepatocytes, respectively) than the demethylation pathway (KIs of 226 +/- 76 and 59 +/- 27 microM in microsomes and hepatocytes, respectively).",Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592663/),μM,28,49350,DB00338,Omeprazole
,8592663,KIs,"The 3-hydroxlation pathway was more prone to inhibition (KIs 108 +/- 30 and 28 +/- 11 microM in microsomes and hepatocytes, respectively) than the demethylation pathway (KIs of 226 +/- 76 and 59 +/- 27 microM in microsomes and hepatocytes, respectively).",Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592663/),μM,226,49351,DB00338,Omeprazole
,8592663,KIs,"The 3-hydroxlation pathway was more prone to inhibition (KIs 108 +/- 30 and 28 +/- 11 microM in microsomes and hepatocytes, respectively) than the demethylation pathway (KIs of 226 +/- 76 and 59 +/- 27 microM in microsomes and hepatocytes, respectively).",Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592663/),μM,59,49352,DB00338,Omeprazole
larger,8592663,Km/KI ratios,"In both in vitro systems, the mechanism of inhibition was competitive with Km/KI ratios larger than 1 for the 3HDZ pathway and smaller than 1 for the NDZ pathway.",Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592663/),,1,49353,DB00338,Omeprazole
smaller,8592663,Km/KI ratios,"In both in vitro systems, the mechanism of inhibition was competitive with Km/KI ratios larger than 1 for the 3HDZ pathway and smaller than 1 for the NDZ pathway.",Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592663/),,1,49354,DB00338,Omeprazole
,8592663,KI,There was an omeprazole concentration dependent decrease in diazepam clearance in vivo which could be modelled using a simple inhibition equation with a KI of 57 microM (19.8mg/L).,Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592663/),μM,57,49355,DB00338,Omeprazole
,8592663,KI,There was an omeprazole concentration dependent decrease in diazepam clearance in vivo which could be modelled using a simple inhibition equation with a KI of 57 microM (19.8mg/L).,Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592663/),[mg] / [l],19.8,49356,DB00338,Omeprazole
,17202439,area under the plasma concentration-time curve (AUC,"The following pharmacokinetic parameters were changed in PCM rats and partially returned to control levels in PCMC rats: the area under the plasma concentration-time curve (AUC; 387, 762, and 539 microg min/mL for control, PCM, and PCMC rats, respectively, after intravenous [IV] administration, and the corresponding values after oral administration: 115, 304, and 201 microg min/mL), total body clearance (51.7, 25.5, and 37.1 mL/min/kg, respectively), nonrenal clearance (51.5, 25.4, and 36.1 mL/min/kg, respectively), and in vitro intrinsic clearance (0.158, 0.118, and 0.138 mL/min/mg protein).",Effects of cysteine on the pharmacokinetic parameters of omeprazole in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels by oral cysteine supplementation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202439/),[min·μg] / [ml],387,51213,DB00338,Omeprazole
,17202439,area under the plasma concentration-time curve (AUC,"The following pharmacokinetic parameters were changed in PCM rats and partially returned to control levels in PCMC rats: the area under the plasma concentration-time curve (AUC; 387, 762, and 539 microg min/mL for control, PCM, and PCMC rats, respectively, after intravenous [IV] administration, and the corresponding values after oral administration: 115, 304, and 201 microg min/mL), total body clearance (51.7, 25.5, and 37.1 mL/min/kg, respectively), nonrenal clearance (51.5, 25.4, and 36.1 mL/min/kg, respectively), and in vitro intrinsic clearance (0.158, 0.118, and 0.138 mL/min/mg protein).",Effects of cysteine on the pharmacokinetic parameters of omeprazole in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels by oral cysteine supplementation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202439/),[min·μg] / [ml],762,51214,DB00338,Omeprazole
,17202439,area under the plasma concentration-time curve (AUC,"The following pharmacokinetic parameters were changed in PCM rats and partially returned to control levels in PCMC rats: the area under the plasma concentration-time curve (AUC; 387, 762, and 539 microg min/mL for control, PCM, and PCMC rats, respectively, after intravenous [IV] administration, and the corresponding values after oral administration: 115, 304, and 201 microg min/mL), total body clearance (51.7, 25.5, and 37.1 mL/min/kg, respectively), nonrenal clearance (51.5, 25.4, and 36.1 mL/min/kg, respectively), and in vitro intrinsic clearance (0.158, 0.118, and 0.138 mL/min/mg protein).",Effects of cysteine on the pharmacokinetic parameters of omeprazole in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels by oral cysteine supplementation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202439/),[min·μg] / [ml],539,51215,DB00338,Omeprazole
,17202439,area under the plasma concentration-time curve (AUC,"The following pharmacokinetic parameters were changed in PCM rats and partially returned to control levels in PCMC rats: the area under the plasma concentration-time curve (AUC; 387, 762, and 539 microg min/mL for control, PCM, and PCMC rats, respectively, after intravenous [IV] administration, and the corresponding values after oral administration: 115, 304, and 201 microg min/mL), total body clearance (51.7, 25.5, and 37.1 mL/min/kg, respectively), nonrenal clearance (51.5, 25.4, and 36.1 mL/min/kg, respectively), and in vitro intrinsic clearance (0.158, 0.118, and 0.138 mL/min/mg protein).",Effects of cysteine on the pharmacokinetic parameters of omeprazole in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels by oral cysteine supplementation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202439/),[min·μg] / [ml],115,51216,DB00338,Omeprazole
,17202439,area under the plasma concentration-time curve (AUC,"The following pharmacokinetic parameters were changed in PCM rats and partially returned to control levels in PCMC rats: the area under the plasma concentration-time curve (AUC; 387, 762, and 539 microg min/mL for control, PCM, and PCMC rats, respectively, after intravenous [IV] administration, and the corresponding values after oral administration: 115, 304, and 201 microg min/mL), total body clearance (51.7, 25.5, and 37.1 mL/min/kg, respectively), nonrenal clearance (51.5, 25.4, and 36.1 mL/min/kg, respectively), and in vitro intrinsic clearance (0.158, 0.118, and 0.138 mL/min/mg protein).",Effects of cysteine on the pharmacokinetic parameters of omeprazole in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels by oral cysteine supplementation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202439/),[min·μg] / [ml],304,51217,DB00338,Omeprazole
,17202439,area under the plasma concentration-time curve (AUC,"The following pharmacokinetic parameters were changed in PCM rats and partially returned to control levels in PCMC rats: the area under the plasma concentration-time curve (AUC; 387, 762, and 539 microg min/mL for control, PCM, and PCMC rats, respectively, after intravenous [IV] administration, and the corresponding values after oral administration: 115, 304, and 201 microg min/mL), total body clearance (51.7, 25.5, and 37.1 mL/min/kg, respectively), nonrenal clearance (51.5, 25.4, and 36.1 mL/min/kg, respectively), and in vitro intrinsic clearance (0.158, 0.118, and 0.138 mL/min/mg protein).",Effects of cysteine on the pharmacokinetic parameters of omeprazole in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels by oral cysteine supplementation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202439/),[min·μg] / [ml],201,51218,DB00338,Omeprazole
,17202439,total body clearance,"The following pharmacokinetic parameters were changed in PCM rats and partially returned to control levels in PCMC rats: the area under the plasma concentration-time curve (AUC; 387, 762, and 539 microg min/mL for control, PCM, and PCMC rats, respectively, after intravenous [IV] administration, and the corresponding values after oral administration: 115, 304, and 201 microg min/mL), total body clearance (51.7, 25.5, and 37.1 mL/min/kg, respectively), nonrenal clearance (51.5, 25.4, and 36.1 mL/min/kg, respectively), and in vitro intrinsic clearance (0.158, 0.118, and 0.138 mL/min/mg protein).",Effects of cysteine on the pharmacokinetic parameters of omeprazole in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels by oral cysteine supplementation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202439/),[ml] / [kg·min],51.7,51219,DB00338,Omeprazole
,17202439,total body clearance,"The following pharmacokinetic parameters were changed in PCM rats and partially returned to control levels in PCMC rats: the area under the plasma concentration-time curve (AUC; 387, 762, and 539 microg min/mL for control, PCM, and PCMC rats, respectively, after intravenous [IV] administration, and the corresponding values after oral administration: 115, 304, and 201 microg min/mL), total body clearance (51.7, 25.5, and 37.1 mL/min/kg, respectively), nonrenal clearance (51.5, 25.4, and 36.1 mL/min/kg, respectively), and in vitro intrinsic clearance (0.158, 0.118, and 0.138 mL/min/mg protein).",Effects of cysteine on the pharmacokinetic parameters of omeprazole in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels by oral cysteine supplementation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202439/),[ml] / [kg·min],25.5,51220,DB00338,Omeprazole
,17202439,total body clearance,"The following pharmacokinetic parameters were changed in PCM rats and partially returned to control levels in PCMC rats: the area under the plasma concentration-time curve (AUC; 387, 762, and 539 microg min/mL for control, PCM, and PCMC rats, respectively, after intravenous [IV] administration, and the corresponding values after oral administration: 115, 304, and 201 microg min/mL), total body clearance (51.7, 25.5, and 37.1 mL/min/kg, respectively), nonrenal clearance (51.5, 25.4, and 36.1 mL/min/kg, respectively), and in vitro intrinsic clearance (0.158, 0.118, and 0.138 mL/min/mg protein).",Effects of cysteine on the pharmacokinetic parameters of omeprazole in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels by oral cysteine supplementation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202439/),[ml] / [kg·min],37.1,51221,DB00338,Omeprazole
,17202439,nonrenal clearance,"The following pharmacokinetic parameters were changed in PCM rats and partially returned to control levels in PCMC rats: the area under the plasma concentration-time curve (AUC; 387, 762, and 539 microg min/mL for control, PCM, and PCMC rats, respectively, after intravenous [IV] administration, and the corresponding values after oral administration: 115, 304, and 201 microg min/mL), total body clearance (51.7, 25.5, and 37.1 mL/min/kg, respectively), nonrenal clearance (51.5, 25.4, and 36.1 mL/min/kg, respectively), and in vitro intrinsic clearance (0.158, 0.118, and 0.138 mL/min/mg protein).",Effects of cysteine on the pharmacokinetic parameters of omeprazole in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels by oral cysteine supplementation. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202439/),[ml] / [kg·min],51.5,51222,DB00338,Omeprazole
,17202439,nonrenal clearance,"The following pharmacokinetic parameters were changed in PCM rats and partially returned to control levels in PCMC rats: the area under the plasma concentration-time curve (AUC; 387, 762, and 539 microg min/mL for control, PCM, and PCMC rats, respectively, after intravenous [IV] administration, and the corresponding values after oral administration: 115, 304, and 201 microg min/mL), total body clearance (51.7, 25.5, and 37.1 mL/min/kg, respectively), nonrenal clearance (51.5, 25.4, and 36.1 mL/min/kg, respectively), and in vitro intrinsic clearance (0.158, 0.118, and 0.138 mL/min/mg protein).",Effects of cysteine on the pharmacokinetic parameters of omeprazole in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels by oral cysteine supplementation. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202439/),[ml] / [kg·min],25.4,51223,DB00338,Omeprazole
,17202439,nonrenal clearance,"The following pharmacokinetic parameters were changed in PCM rats and partially returned to control levels in PCMC rats: the area under the plasma concentration-time curve (AUC; 387, 762, and 539 microg min/mL for control, PCM, and PCMC rats, respectively, after intravenous [IV] administration, and the corresponding values after oral administration: 115, 304, and 201 microg min/mL), total body clearance (51.7, 25.5, and 37.1 mL/min/kg, respectively), nonrenal clearance (51.5, 25.4, and 36.1 mL/min/kg, respectively), and in vitro intrinsic clearance (0.158, 0.118, and 0.138 mL/min/mg protein).",Effects of cysteine on the pharmacokinetic parameters of omeprazole in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels by oral cysteine supplementation. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202439/),[ml] / [kg·min],36.1,51224,DB00338,Omeprazole
,17202439,intrinsic clearance,"The following pharmacokinetic parameters were changed in PCM rats and partially returned to control levels in PCMC rats: the area under the plasma concentration-time curve (AUC; 387, 762, and 539 microg min/mL for control, PCM, and PCMC rats, respectively, after intravenous [IV] administration, and the corresponding values after oral administration: 115, 304, and 201 microg min/mL), total body clearance (51.7, 25.5, and 37.1 mL/min/kg, respectively), nonrenal clearance (51.5, 25.4, and 36.1 mL/min/kg, respectively), and in vitro intrinsic clearance (0.158, 0.118, and 0.138 mL/min/mg protein).",Effects of cysteine on the pharmacokinetic parameters of omeprazole in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels by oral cysteine supplementation. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202439/),[ml] / [mg·min],0.158,51225,DB00338,Omeprazole
,17202439,intrinsic clearance,"The following pharmacokinetic parameters were changed in PCM rats and partially returned to control levels in PCMC rats: the area under the plasma concentration-time curve (AUC; 387, 762, and 539 microg min/mL for control, PCM, and PCMC rats, respectively, after intravenous [IV] administration, and the corresponding values after oral administration: 115, 304, and 201 microg min/mL), total body clearance (51.7, 25.5, and 37.1 mL/min/kg, respectively), nonrenal clearance (51.5, 25.4, and 36.1 mL/min/kg, respectively), and in vitro intrinsic clearance (0.158, 0.118, and 0.138 mL/min/mg protein).",Effects of cysteine on the pharmacokinetic parameters of omeprazole in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels by oral cysteine supplementation. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202439/),[ml] / [mg·min],0.118,51226,DB00338,Omeprazole
,17202439,intrinsic clearance,"The following pharmacokinetic parameters were changed in PCM rats and partially returned to control levels in PCMC rats: the area under the plasma concentration-time curve (AUC; 387, 762, and 539 microg min/mL for control, PCM, and PCMC rats, respectively, after intravenous [IV] administration, and the corresponding values after oral administration: 115, 304, and 201 microg min/mL), total body clearance (51.7, 25.5, and 37.1 mL/min/kg, respectively), nonrenal clearance (51.5, 25.4, and 36.1 mL/min/kg, respectively), and in vitro intrinsic clearance (0.158, 0.118, and 0.138 mL/min/mg protein).",Effects of cysteine on the pharmacokinetic parameters of omeprazole in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels by oral cysteine supplementation. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202439/),[ml] / [mg·min],0.138,51227,DB00338,Omeprazole
,10349786,tmax,"In relation to the time for achieving (Cmax (tmax), the difference between the two formulations and the confidence interval of 95% for the tmax was 0.75 (-0.5-1.75) h indicating that no significant differences were observed between the two treatments.",[A relative bioavailability study of 2 oral formulations of omeprazole after their administration in repeated doses to healthy volunteers]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10349786/),h,0.75,52508,DB00338,Omeprazole
,11907488,clearance,"At the higher but not the lower steady-state dose of fluvoxamine, a significantly lower clearance in PMs compared with EMs was observed (geometric mean, 0.86 versus 1.4 L/h per kilogram; P <.05).",Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907488/),[l] / [h·kg],0.86,53686,DB00338,Omeprazole
,11907488,clearance,"At the higher but not the lower steady-state dose of fluvoxamine, a significantly lower clearance in PMs compared with EMs was observed (geometric mean, 0.86 versus 1.4 L/h per kilogram; P <.05).",Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907488/),[l] / [h·kg],1.4,53687,DB00338,Omeprazole
,11232677,maximum mean,"Nasogastric administration of SOS resulted in lower maximum mean +/- SD serum concentrations compared to jejunal/duodenal dosing (0.970 +/- 0.436 vs 1.833 +/- 0.416 microg/ml, p = 0.006).","A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11232677/),[μg] / [ml],0.970,54977,DB00338,Omeprazole
,11232677,maximum mean,"Nasogastric administration of SOS resulted in lower maximum mean +/- SD serum concentrations compared to jejunal/duodenal dosing (0.970 +/- 0.436 vs 1.833 +/- 0.416 microg/ml, p = 0.006).","A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11232677/),[μg] / [ml],1.833,54978,DB00338,Omeprazole
,11232677,serum concentrations,"Nasogastric administration of SOS resulted in lower maximum mean +/- SD serum concentrations compared to jejunal/duodenal dosing (0.970 +/- 0.436 vs 1.833 +/- 0.416 microg/ml, p = 0.006).","A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11232677/),[μg] / [ml],0.970,54979,DB00338,Omeprazole
,11232677,serum concentrations,"Nasogastric administration of SOS resulted in lower maximum mean +/- SD serum concentrations compared to jejunal/duodenal dosing (0.970 +/- 0.436 vs 1.833 +/- 0.416 microg/ml, p = 0.006).","A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11232677/),[μg] / [ml],1.833,54980,DB00338,Omeprazole
,11232677,absorption,"SOS absorption was significantly slower when administered via nasogastric tube (108.3 +/- 42.0 vs 12.1 +/- 7.9 min, p < 0.001).","A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11232677/),min,108.3,54981,DB00338,Omeprazole
,11232677,absorption,"SOS absorption was significantly slower when administered via nasogastric tube (108.3 +/- 42.0 vs 12.1 +/- 7.9 min, p < 0.001).","A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11232677/),min,12.1,54982,DB00338,Omeprazole
,11232677,area under the serum concentration-time curves (AUC(0-infinity)),"However, all routes of administration resulted in similar SOS area under the serum concentration-time curves (AUC(0-infinity)) (415.1 +/- 291.8 vs 396.7 +/- 388.1 microg x min/ml, p = 0.91) [corrected].","A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11232677/),[min·μg] / [ml],415.1,54983,DB00338,Omeprazole
,11232677,area under the serum concentration-time curves (AUC(0-infinity)),"However, all routes of administration resulted in similar SOS area under the serum concentration-time curves (AUC(0-infinity)) (415.1 +/- 291.8 vs 396.7 +/- 388.1 microg x min/ml, p = 0.91) [corrected].","A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11232677/),[min·μg] / [ml],396.7,54984,DB00338,Omeprazole
more,15556540,Recovery,Recovery of rabeprazole as well as the internal standard from human plasma was more than 90.0%.,"Direct injection, column switching-liquid chromatographic technique for the estimation of rabeprazole in bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556540/),%,90.0,55361,DB00338,Omeprazole
,30216801,VRC,"Interestingly, patients in the PPIs groups were more likely to reach the therapeutic VRC range of 1-5.5 μg/mL in steady state when compared with control patients (75-81% VS 69%).",The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30216801/),[μg] / [ml],1-5.5,56720,DB00338,Omeprazole
,11488780,Cmax,Administration of omeprazole caused a significant reduction of Cmax [0.34 microg x ml(-1) (range 0.25-0.43) vs 0.24 microg x ml(-1) (range 0.15-0.34)] with no significant delay in absorption tmax [2.5 h (range 1.85-3.0) vs 2.4 h (range 2.06-2.71)].,Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488780/),[μg] / [ml],0.34,58138,DB00338,Omeprazole
,11488780,Cmax,Administration of omeprazole caused a significant reduction of Cmax [0.34 microg x ml(-1) (range 0.25-0.43) vs 0.24 microg x ml(-1) (range 0.15-0.34)] with no significant delay in absorption tmax [2.5 h (range 1.85-3.0) vs 2.4 h (range 2.06-2.71)].,Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488780/),[μg] / [ml],0.24,58139,DB00338,Omeprazole
,11488780,absorption tmax,Administration of omeprazole caused a significant reduction of Cmax [0.34 microg x ml(-1) (range 0.25-0.43) vs 0.24 microg x ml(-1) (range 0.15-0.34)] with no significant delay in absorption tmax [2.5 h (range 1.85-3.0) vs 2.4 h (range 2.06-2.71)].,Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488780/),h,2.5,58140,DB00338,Omeprazole
,11488780,absorption tmax,Administration of omeprazole caused a significant reduction of Cmax [0.34 microg x ml(-1) (range 0.25-0.43) vs 0.24 microg x ml(-1) (range 0.15-0.34)] with no significant delay in absorption tmax [2.5 h (range 1.85-3.0) vs 2.4 h (range 2.06-2.71)].,Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488780/),h,2.4,58141,DB00338,Omeprazole
,17590865,linear dynamic range,A linear dynamic range of 20-6000 ng/mL was established.,Quantification of tenatoprazole in rat plasma by HPLC: validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17590865/),[ng] / [ml],20-6000,58299,DB00338,Omeprazole
,31290355,AUC0-t,"The results indicated that co-administration of AS-IV could decrease the systemic exposure of omeprazole significantly (p < 0.05), including AUC0-t (717.20 ± 177.63 vs. 1166.25 ± 186.65 ng h/mL) and Cmax (272.35 ± 25.81 vs. 366.34 ± 32.57 ng/mL).",Effects of astragaloside IV on the pharmacokinetics of omeprazole in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31290355/),[h·ng] / [ml],717.20,58840,DB00338,Omeprazole
,31290355,AUC0-t,"The results indicated that co-administration of AS-IV could decrease the systemic exposure of omeprazole significantly (p < 0.05), including AUC0-t (717.20 ± 177.63 vs. 1166.25 ± 186.65 ng h/mL) and Cmax (272.35 ± 25.81 vs. 366.34 ± 32.57 ng/mL).",Effects of astragaloside IV on the pharmacokinetics of omeprazole in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31290355/),[h·ng] / [ml],1166.25,58841,DB00338,Omeprazole
,31290355,Cmax,"The results indicated that co-administration of AS-IV could decrease the systemic exposure of omeprazole significantly (p < 0.05), including AUC0-t (717.20 ± 177.63 vs. 1166.25 ± 186.65 ng h/mL) and Cmax (272.35 ± 25.81 vs. 366.34 ± 32.57 ng/mL).",Effects of astragaloside IV on the pharmacokinetics of omeprazole in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31290355/),[ng] / [ml],272.35,58842,DB00338,Omeprazole
,31290355,Cmax,"The results indicated that co-administration of AS-IV could decrease the systemic exposure of omeprazole significantly (p < 0.05), including AUC0-t (717.20 ± 177.63 vs. 1166.25 ± 186.65 ng h/mL) and Cmax (272.35 ± 25.81 vs. 366.34 ± 32.57 ng/mL).",Effects of astragaloside IV on the pharmacokinetics of omeprazole in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31290355/),[ng] / [ml],366.34,58843,DB00338,Omeprazole
,31290355,t1/2,"The t1/2 of omeprazole also decreased significantly (1.78 ± 0.15 vs. 2.23 ± 0.27 h, p < 0.05).",Effects of astragaloside IV on the pharmacokinetics of omeprazole in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31290355/),h,1.78,58844,DB00338,Omeprazole
,31290355,t1/2,"The t1/2 of omeprazole also decreased significantly (1.78 ± 0.15 vs. 2.23 ± 0.27 h, p < 0.05).",Effects of astragaloside IV on the pharmacokinetics of omeprazole in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31290355/),h,2.23,58845,DB00338,Omeprazole
,31290355,efflux ratio,"The efflux ratio of omeprazole across the Caco-2 cell transwell model increased significantly from 1.73 to 2.67 (p < 0.05), and the metabolic stability of omeprazole was decreased from 42.6 ± 7.8 to 26.2 ± 5.1 min with the pretreatment of AS-IV (p < 0.05).",Effects of astragaloside IV on the pharmacokinetics of omeprazole in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31290355/),,1.73,58846,DB00338,Omeprazole
,31290355,efflux ratio,"The efflux ratio of omeprazole across the Caco-2 cell transwell model increased significantly from 1.73 to 2.67 (p < 0.05), and the metabolic stability of omeprazole was decreased from 42.6 ± 7.8 to 26.2 ± 5.1 min with the pretreatment of AS-IV (p < 0.05).",Effects of astragaloside IV on the pharmacokinetics of omeprazole in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31290355/),,2.67,58847,DB00338,Omeprazole
,31290355,metabolic stability,"The efflux ratio of omeprazole across the Caco-2 cell transwell model increased significantly from 1.73 to 2.67 (p < 0.05), and the metabolic stability of omeprazole was decreased from 42.6 ± 7.8 to 26.2 ± 5.1 min with the pretreatment of AS-IV (p < 0.05).",Effects of astragaloside IV on the pharmacokinetics of omeprazole in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31290355/),min,42.6,58848,DB00338,Omeprazole
,31290355,metabolic stability,"The efflux ratio of omeprazole across the Caco-2 cell transwell model increased significantly from 1.73 to 2.67 (p < 0.05), and the metabolic stability of omeprazole was decreased from 42.6 ± 7.8 to 26.2 ± 5.1 min with the pretreatment of AS-IV (p < 0.05).",Effects of astragaloside IV on the pharmacokinetics of omeprazole in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31290355/),min,26.2,58849,DB00338,Omeprazole
,7820333,gastric emptying time,"Omeprazole pretreatment significantly raised the median gastric pH (from pH 1.1 to pH 4.7, p < 0.0001), but had no significant influence on gastric emptying time of the pH capsule (median = 4.3 vs 4.9 hours).",The influence of gastric pH on the pharmacokinetics of fluconazole: the effect of omeprazole. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7820333/),h,4.3,59131,DB00338,Omeprazole
,7820333,gastric emptying time,"Omeprazole pretreatment significantly raised the median gastric pH (from pH 1.1 to pH 4.7, p < 0.0001), but had no significant influence on gastric emptying time of the pH capsule (median = 4.3 vs 4.9 hours).",The influence of gastric pH on the pharmacokinetics of fluconazole: the effect of omeprazole. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7820333/),h,4.9,59132,DB00338,Omeprazole
,7820333,Cmax,"The pharmacokinetics of fluconazole were unchanged; plasma parameters were Cmax = 2.04 micrograms/ml, tmax = 4.08 h and AUC = 98.91 h micrograms/ml after the omeprazole treatment, compared to 2.06 microliters/ml, 3.92 hours and 97.29 h micrograms/ml, respectively.",The influence of gastric pH on the pharmacokinetics of fluconazole: the effect of omeprazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7820333/),[μg] / [ml],2.04,59133,DB00338,Omeprazole
,7820333,tmax,"The pharmacokinetics of fluconazole were unchanged; plasma parameters were Cmax = 2.04 micrograms/ml, tmax = 4.08 h and AUC = 98.91 h micrograms/ml after the omeprazole treatment, compared to 2.06 microliters/ml, 3.92 hours and 97.29 h micrograms/ml, respectively.",The influence of gastric pH on the pharmacokinetics of fluconazole: the effect of omeprazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7820333/),h,4.08,59134,DB00338,Omeprazole
,7820333,AUC,"The pharmacokinetics of fluconazole were unchanged; plasma parameters were Cmax = 2.04 micrograms/ml, tmax = 4.08 h and AUC = 98.91 h micrograms/ml after the omeprazole treatment, compared to 2.06 microliters/ml, 3.92 hours and 97.29 h micrograms/ml, respectively.",The influence of gastric pH on the pharmacokinetics of fluconazole: the effect of omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7820333/),[h·μg] / [ml],98.91,59135,DB00338,Omeprazole
,7820333,AUC,"The pharmacokinetics of fluconazole were unchanged; plasma parameters were Cmax = 2.04 micrograms/ml, tmax = 4.08 h and AUC = 98.91 h micrograms/ml after the omeprazole treatment, compared to 2.06 microliters/ml, 3.92 hours and 97.29 h micrograms/ml, respectively.",The influence of gastric pH on the pharmacokinetics of fluconazole: the effect of omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7820333/),h,3.92,59136,DB00338,Omeprazole
,7820333,AUC,"The pharmacokinetics of fluconazole were unchanged; plasma parameters were Cmax = 2.04 micrograms/ml, tmax = 4.08 h and AUC = 98.91 h micrograms/ml after the omeprazole treatment, compared to 2.06 microliters/ml, 3.92 hours and 97.29 h micrograms/ml, respectively.",The influence of gastric pH on the pharmacokinetics of fluconazole: the effect of omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7820333/),[h·μg] / [ml],97.29,59137,DB00338,Omeprazole
,7820333,bioavailability ratio,The median bioavailability ratio of fluconazole before and after omeprazole treatment was 1.00.,The influence of gastric pH on the pharmacokinetics of fluconazole: the effect of omeprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7820333/),,1.00,59138,DB00338,Omeprazole
,30045358,CL/F,Median CL/F was 23.7 L/h by NCA and 19.3 L/h by population PK modeling.,Evaluation of Omeprazole Limited Sampling Strategies to Estimate Constitutive Cytochrome P450 2C19 Activity in Healthy Adults. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30045358/),[l] / [h],23.7,60590,DB00338,Omeprazole
,30045358,CL/F,Median CL/F was 23.7 L/h by NCA and 19.3 L/h by population PK modeling.,Evaluation of Omeprazole Limited Sampling Strategies to Estimate Constitutive Cytochrome P450 2C19 Activity in Healthy Adults. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30045358/),[l] / [h],19.3,60591,DB00338,Omeprazole
,2315973,Maximum concentration,Maximum concentration (0.7-4.6 mumol/L) was reached between 10 and 25 min after oral dosing.,The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315973/),[μM] / [l],0.7-4.6,61975,DB00338,Omeprazole
,2315973,bioavailability,The median bioavailability was 39% (25-117%) and the median systemic plasma clearance was 624 ml/min (range of 59-828 ml/min).,The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315973/),%,39,61976,DB00338,Omeprazole
,2315973,systemic plasma clearance,The median bioavailability was 39% (25-117%) and the median systemic plasma clearance was 624 ml/min (range of 59-828 ml/min).,The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315973/),[ml] / [min],624,61977,DB00338,Omeprazole
,2315973,t1/2,The corresponding t1/2 for the i.v. dose was 35 min (16-150 min) and 39 min (14-186 min) after oral administration.,The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315973/),min,35,61978,DB00338,Omeprazole
,2315973,t1/2,The corresponding t1/2 for the i.v. dose was 35 min (16-150 min) and 39 min (14-186 min) after oral administration.,The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315973/),min,39,61979,DB00338,Omeprazole
,2315973,t1/2 lambda 1,The drug was rapidly distributed to extravascular sites (mean t1/2 lambda 1 = 3.0 +/- 0.8 min).,The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315973/),min,3.0,61980,DB00338,Omeprazole
,2315973,Vss,Mean Vss was 0.23 +/- 0.04 L/kg.,The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315973/),[l] / [kg],0.23,61981,DB00338,Omeprazole
,2315973,urinary recovery,"The mean urinary recovery of the radioactive dose during 96 h was 78.3 +/- 2.3 and 75.7 +/- 2.6% for the i.v. and oral dose, respectively.",The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315973/),%,78.3,61982,DB00338,Omeprazole
,2315973,urinary recovery,"The mean urinary recovery of the radioactive dose during 96 h was 78.3 +/- 2.3 and 75.7 +/- 2.6% for the i.v. and oral dose, respectively.",The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315973/),%,75.7,61983,DB00338,Omeprazole
,2315973,excretion,The excretion of hydroxyomeprazole during the first 12 h varied between 4.6 to 15.5% of a given dose.,The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315973/),%,4.6 to 15.5,61984,DB00338,Omeprazole
,2315973,recovery of radioactivity,The mean recovery of radioactivity in the feces was 19.3 +/- 3.1% of a given i.v. dose and 18.2 +/- 2.3% when given orally.,The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315973/),%,19.3,61985,DB00338,Omeprazole
,2315973,recovery of radioactivity,The mean recovery of radioactivity in the feces was 19.3 +/- 3.1% of a given i.v. dose and 18.2 +/- 2.3% when given orally.,The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315973/),%,18.2,61986,DB00338,Omeprazole
,2315973,half-life,"The half-life, with a maximum of approximately 3 h, is too short to cause accumulation when the drug is administered in a once-daily regimen.",The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315973/),h,3,61987,DB00338,Omeprazole
,15448955,R/S ratios,"The R/S ratios for the AUC of lansoprazole for the homEMs, hetEMs and PMs were 12.7, 8.5 and 5.8, respectively, suggesting a significant effect of CYP2C19 polymorphisms on the stereoselective disposition of lansoprazole.","Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15448955/),,12.7,62545,DB00338,Omeprazole
,15448955,R/S ratios,"The R/S ratios for the AUC of lansoprazole for the homEMs, hetEMs and PMs were 12.7, 8.5 and 5.8, respectively, suggesting a significant effect of CYP2C19 polymorphisms on the stereoselective disposition of lansoprazole.","Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15448955/),,8.5,62546,DB00338,Omeprazole
,15448955,R/S ratios,"The R/S ratios for the AUC of lansoprazole for the homEMs, hetEMs and PMs were 12.7, 8.5 and 5.8, respectively, suggesting a significant effect of CYP2C19 polymorphisms on the stereoselective disposition of lansoprazole.","Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15448955/),,5.8,62547,DB00338,Omeprazole
,17396620,Cmax,"Mean +/- SD of Cmax, Tmax, AUC(0 --> t), AUC(0 --> infinity), and t1/2 were 0.41 +/- 0.21 and 0.48 +/- 0.27 microg/ml, 1.98 +/- 1.02 and 1.63 +/- 0.78 h, 0.95 +/- 0.78 and 1.00 +/- 0.90 microg x h/ml, 0.99 +/- 0.81 and 1.04 +/- 0.95 microg x h/ml, and 1.30 +/- 0.64 and 1.14 +/- 0.61 h for the test and reference formulations, respectively.",Bioequivalence assessment of two capsule formulations of omeprazole in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17396620/),[μg] / [ml],0.41,63330,DB00338,Omeprazole
,17396620,Tmax,"Mean +/- SD of Cmax, Tmax, AUC(0 --> t), AUC(0 --> infinity), and t1/2 were 0.41 +/- 0.21 and 0.48 +/- 0.27 microg/ml, 1.98 +/- 1.02 and 1.63 +/- 0.78 h, 0.95 +/- 0.78 and 1.00 +/- 0.90 microg x h/ml, 0.99 +/- 0.81 and 1.04 +/- 0.95 microg x h/ml, and 1.30 +/- 0.64 and 1.14 +/- 0.61 h for the test and reference formulations, respectively.",Bioequivalence assessment of two capsule formulations of omeprazole in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17396620/),[h·μg] / [ml],0.99,63331,DB00338,Omeprazole
,17396620,AUC(0 --> t),"Mean +/- SD of Cmax, Tmax, AUC(0 --> t), AUC(0 --> infinity), and t1/2 were 0.41 +/- 0.21 and 0.48 +/- 0.27 microg/ml, 1.98 +/- 1.02 and 1.63 +/- 0.78 h, 0.95 +/- 0.78 and 1.00 +/- 0.90 microg x h/ml, 0.99 +/- 0.81 and 1.04 +/- 0.95 microg x h/ml, and 1.30 +/- 0.64 and 1.14 +/- 0.61 h for the test and reference formulations, respectively.",Bioequivalence assessment of two capsule formulations of omeprazole in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17396620/),[h·μg] / [ml],0.99,63332,DB00338,Omeprazole
,17396620,AUC(0 --> infinity),"Mean +/- SD of Cmax, Tmax, AUC(0 --> t), AUC(0 --> infinity), and t1/2 were 0.41 +/- 0.21 and 0.48 +/- 0.27 microg/ml, 1.98 +/- 1.02 and 1.63 +/- 0.78 h, 0.95 +/- 0.78 and 1.00 +/- 0.90 microg x h/ml, 0.99 +/- 0.81 and 1.04 +/- 0.95 microg x h/ml, and 1.30 +/- 0.64 and 1.14 +/- 0.61 h for the test and reference formulations, respectively.",Bioequivalence assessment of two capsule formulations of omeprazole in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17396620/),[h·μg] / [ml],0.99,63333,DB00338,Omeprazole
,17396620,t1/2,"Mean +/- SD of Cmax, Tmax, AUC(0 --> t), AUC(0 --> infinity), and t1/2 were 0.41 +/- 0.21 and 0.48 +/- 0.27 microg/ml, 1.98 +/- 1.02 and 1.63 +/- 0.78 h, 0.95 +/- 0.78 and 1.00 +/- 0.90 microg x h/ml, 0.99 +/- 0.81 and 1.04 +/- 0.95 microg x h/ml, and 1.30 +/- 0.64 and 1.14 +/- 0.61 h for the test and reference formulations, respectively.",Bioequivalence assessment of two capsule formulations of omeprazole in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17396620/),[h·μg] / [ml],1.04,63334,DB00338,Omeprazole
,17396620,t1/2,"Mean +/- SD of Cmax, Tmax, AUC(0 --> t), AUC(0 --> infinity), and t1/2 were 0.41 +/- 0.21 and 0.48 +/- 0.27 microg/ml, 1.98 +/- 1.02 and 1.63 +/- 0.78 h, 0.95 +/- 0.78 and 1.00 +/- 0.90 microg x h/ml, 0.99 +/- 0.81 and 1.04 +/- 0.95 microg x h/ml, and 1.30 +/- 0.64 and 1.14 +/- 0.61 h for the test and reference formulations, respectively.",Bioequivalence assessment of two capsule formulations of omeprazole in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17396620/),h,1.30,63335,DB00338,Omeprazole
,17396620,t1/2,"Mean +/- SD of Cmax, Tmax, AUC(0 --> t), AUC(0 --> infinity), and t1/2 were 0.41 +/- 0.21 and 0.48 +/- 0.27 microg/ml, 1.98 +/- 1.02 and 1.63 +/- 0.78 h, 0.95 +/- 0.78 and 1.00 +/- 0.90 microg x h/ml, 0.99 +/- 0.81 and 1.04 +/- 0.95 microg x h/ml, and 1.30 +/- 0.64 and 1.14 +/- 0.61 h for the test and reference formulations, respectively.",Bioequivalence assessment of two capsule formulations of omeprazole in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17396620/),h,1.14,63336,DB00338,Omeprazole
,25922056,limit of detection (LOD),"The DESI-MS/MS method exhibited for the esomepazole excellent sensitivity (limit of detection (LOD)=60 ng/mL), linearity (0.2-20 µg/mL concentration range; y=23848(±361)X, n=15; r(2) =0.987) and precision (RSD<9%) by using an internal standard method.",Development and validation of a DESI-HRMS/MS method for the fast profiling of esomeprazole and its metabolites in rat plasma: a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25922056/),[ng] / [ml],60,63839,DB00338,Omeprazole
,18030229,AUC0-t,"The geometric mean AUC0-t of esomeprazole were 0.24 and 1.79 micromol x h/L for the 0.25 mg/kg and 1 mg/kg dosages of esomeprazole, respectively.",Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18030229/),[h·μM] / [l],0.24,64004,DB00338,Omeprazole
,18030229,AUC0-t,"The geometric mean AUC0-t of esomeprazole were 0.24 and 1.79 micromol x h/L for the 0.25 mg/kg and 1 mg/kg dosages of esomeprazole, respectively.",Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18030229/),[h·μM] / [l],1.79,64005,DB00338,Omeprazole
,11999727,flow-rate,The analytical column was YMC-Pack Pro C18(50x2.0 mm I.D.) using acetonitrile-50 mM ammonium acetate (pH 7.25) (1:4) at a flow-rate of 0.2 ml/min.,Determination of omeprazole and its metabolites in human plasma by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999727/),[ml] / [min],0.2,64188,DB00338,Omeprazole
,26902772,mean residence time,"In vivo pharmacokinetics, EMZ-MRPs had significantly larger AUC0-t (p < 0.01), 1.67 times more than that of EMZ-IRPs, and prolonged mean residence time (7.55 ± 0.12 h) than that of IRPs (1.46 ± 0.39 h).",Novel naproxen/esomeprazole magnesium compound pellets based on acid-independent mechanism: in vitro and in vivo evaluation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902772/),h,7.55,65732,DB00338,Omeprazole
,26902772,mean residence time,"In vivo pharmacokinetics, EMZ-MRPs had significantly larger AUC0-t (p < 0.01), 1.67 times more than that of EMZ-IRPs, and prolonged mean residence time (7.55 ± 0.12 h) than that of IRPs (1.46 ± 0.39 h).",Novel naproxen/esomeprazole magnesium compound pellets based on acid-independent mechanism: in vitro and in vivo evaluation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902772/),h,1.46,65733,DB00338,Omeprazole
,22108788,Plasma concentrations,"Plasma concentrations of voriconazole and methadone were high, 12.4 mg/l (therapeutic range: 1-4 mg/l) and 1.6 mg/l (therapeutic range: 0.2-0.4 mg/l), respectively.","Ventricular bigeminy associated with voriconazole, methadone and esomeprazole. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22108788/),[mg] / [l],12.4,66152,DB00338,Omeprazole
,22108788,Plasma concentrations,"Plasma concentrations of voriconazole and methadone were high, 12.4 mg/l (therapeutic range: 1-4 mg/l) and 1.6 mg/l (therapeutic range: 0.2-0.4 mg/l), respectively.","Ventricular bigeminy associated with voriconazole, methadone and esomeprazole. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22108788/),[mg] / [l],1.6,66153,DB00338,Omeprazole
,16012079,Cmax,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],954,66805,DB00338,Omeprazole
,16012079,Cmax,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],167,66806,DB00338,Omeprazole
,16012079,AUC0-24,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],167,66807,DB00338,Omeprazole
,16012079,AUC0-24,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[nghml],4787,66808,DB00338,Omeprazole
,16012079,AUC0-24,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[nghml],451,66809,DB00338,Omeprazole
,16012079,elimination half-life,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),h,2.3,66810,DB00338,Omeprazole
,16012079,elimination half-life,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),h,1.2,66811,DB00338,Omeprazole
,16012079,elimination half-life,"In contrast, although the elimination half-life of (R)-rabeprazole was significantly longer than that of the (S)-enantiomer (2.1+/-0.5 vs. 1.3+/-0.9h, respectively; P<0.05), there was no difference in Cmax between the (R)- and (S)-enantiomer (186+/-40 vs. 200+/-92 ngml(-1), respectively).",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),h,2.1,66812,DB00338,Omeprazole
,16012079,elimination half-life,"In contrast, although the elimination half-life of (R)-rabeprazole was significantly longer than that of the (S)-enantiomer (2.1+/-0.5 vs. 1.3+/-0.9h, respectively; P<0.05), there was no difference in Cmax between the (R)- and (S)-enantiomer (186+/-40 vs. 200+/-92 ngml(-1), respectively).",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),h,1.3,66813,DB00338,Omeprazole
,16012079,Cmax,"In contrast, although the elimination half-life of (R)-rabeprazole was significantly longer than that of the (S)-enantiomer (2.1+/-0.5 vs. 1.3+/-0.9h, respectively; P<0.05), there was no difference in Cmax between the (R)- and (S)-enantiomer (186+/-40 vs. 200+/-92 ngml(-1), respectively).",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],186,66814,DB00338,Omeprazole
,16012079,Cmax,"In contrast, although the elimination half-life of (R)-rabeprazole was significantly longer than that of the (S)-enantiomer (2.1+/-0.5 vs. 1.3+/-0.9h, respectively; P<0.05), there was no difference in Cmax between the (R)- and (S)-enantiomer (186+/-40 vs. 200+/-92 ngml(-1), respectively).",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],200,66815,DB00338,Omeprazole
,16573800,pH,"Mean intragastric pH values for lansoprazole regimens ranged from 4.8 to 5.2 (0-24 h), 5.5 to 6.0 (>24 to 48 h) and 5.2 to 5.6 (0-48 h).",Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16573800/),,4.8 to 5.2,67393,DB00338,Omeprazole
,16573800,pH,"Mean intragastric pH values for lansoprazole regimens ranged from 4.8 to 5.2 (0-24 h), 5.5 to 6.0 (>24 to 48 h) and 5.2 to 5.6 (0-48 h).",Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16573800/),,5.5 to 6.0,67394,DB00338,Omeprazole
,16573800,pH,"Mean intragastric pH values for lansoprazole regimens ranged from 4.8 to 5.2 (0-24 h), 5.5 to 6.0 (>24 to 48 h) and 5.2 to 5.6 (0-48 h).",Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16573800/),,5.2 to 5.6,67395,DB00338,Omeprazole
,16573800,systemic clearance,"The mean systemic clearance of lansoprazole was lower in CYP2C19 heterozygous metabolizers than in homozygous extensive metabolizers (9.2 vs. 16.5 L/h), with substantial variability resulting in overlapping ranges of clearance values for both subpopulations.",Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16573800/),[l] / [h],9.2,67396,DB00338,Omeprazole
,16573800,systemic clearance,"The mean systemic clearance of lansoprazole was lower in CYP2C19 heterozygous metabolizers than in homozygous extensive metabolizers (9.2 vs. 16.5 L/h), with substantial variability resulting in overlapping ranges of clearance values for both subpopulations.",Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16573800/),[l] / [h],16.5,67397,DB00338,Omeprazole
,12953341,tmax,"Pharmacokinetic parameters (mean +/- SD, range) were as follows: tmax (2.1 +/- 1.2, 1-6 h), Cmax (331.1 +/- 333.6, 20.8-885.8 ng/mL), AUC0-->infinity (809.5 +/- 893.8, 236.9-1330.9 ng/mL.h), t1/2 (0.98 +/- 0.22, 0.7-1.4 h), and CL/F (1.8 +/- 1.4, 0.3-5.8 L/h/kg).",Omeprazole disposition in children following single-dose administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12953341/),h,2.1,70003,DB00338,Omeprazole
,12953341,Cmax,"Pharmacokinetic parameters (mean +/- SD, range) were as follows: tmax (2.1 +/- 1.2, 1-6 h), Cmax (331.1 +/- 333.6, 20.8-885.8 ng/mL), AUC0-->infinity (809.5 +/- 893.8, 236.9-1330.9 ng/mL.h), t1/2 (0.98 +/- 0.22, 0.7-1.4 h), and CL/F (1.8 +/- 1.4, 0.3-5.8 L/h/kg).",Omeprazole disposition in children following single-dose administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12953341/),[ng] / [ml],331.1,70004,DB00338,Omeprazole
,12953341,AUC0-->infinity,"Pharmacokinetic parameters (mean +/- SD, range) were as follows: tmax (2.1 +/- 1.2, 1-6 h), Cmax (331.1 +/- 333.6, 20.8-885.8 ng/mL), AUC0-->infinity (809.5 +/- 893.8, 236.9-1330.9 ng/mL.h), t1/2 (0.98 +/- 0.22, 0.7-1.4 h), and CL/F (1.8 +/- 1.4, 0.3-5.8 L/h/kg).",Omeprazole disposition in children following single-dose administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12953341/),[ng] / [h·ml],809.5,70005,DB00338,Omeprazole
,12953341,t1/2,"Pharmacokinetic parameters (mean +/- SD, range) were as follows: tmax (2.1 +/- 1.2, 1-6 h), Cmax (331.1 +/- 333.6, 20.8-885.8 ng/mL), AUC0-->infinity (809.5 +/- 893.8, 236.9-1330.9 ng/mL.h), t1/2 (0.98 +/- 0.22, 0.7-1.4 h), and CL/F (1.8 +/- 1.4, 0.3-5.8 L/h/kg).",Omeprazole disposition in children following single-dose administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12953341/),h,0.98,70006,DB00338,Omeprazole
,12953341,CL/F,"Pharmacokinetic parameters (mean +/- SD, range) were as follows: tmax (2.1 +/- 1.2, 1-6 h), Cmax (331.1 +/- 333.6, 20.8-885.8 ng/mL), AUC0-->infinity (809.5 +/- 893.8, 236.9-1330.9 ng/mL.h), t1/2 (0.98 +/- 0.22, 0.7-1.4 h), and CL/F (1.8 +/- 1.4, 0.3-5.8 L/h/kg).",Omeprazole disposition in children following single-dose administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12953341/),[l] / [h·kg],1.8,70007,DB00338,Omeprazole
,12953341,t1/2,The range of t1/2 values for omeprazole was similar to those reported in adults (1-1.5 h).,Omeprazole disposition in children following single-dose administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12953341/),h,1-1.5,70008,DB00338,Omeprazole
,16611279,percentage of time,"The mean 24-h percentage of time over pH 4 was 62, 72 and 64 after breakfast, dinner and bedtime dosing, respectively (N.S.), and 54, 68 and 56 during night-time (P = 0.06).","Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16611279/),,62,71678,DB00338,Omeprazole
,16611279,percentage of time,"The mean 24-h percentage of time over pH 4 was 62, 72 and 64 after breakfast, dinner and bedtime dosing, respectively (N.S.), and 54, 68 and 56 during night-time (P = 0.06).","Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16611279/),,72,71679,DB00338,Omeprazole
,16611279,percentage of time,"The mean 24-h percentage of time over pH 4 was 62, 72 and 64 after breakfast, dinner and bedtime dosing, respectively (N.S.), and 54, 68 and 56 during night-time (P = 0.06).","Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16611279/),,64,71680,DB00338,Omeprazole
,16611279,percentage of time,"The mean 24-h percentage of time over pH 4 was 62, 72 and 64 after breakfast, dinner and bedtime dosing, respectively (N.S.), and 54, 68 and 56 during night-time (P = 0.06).","Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16611279/),,54,71681,DB00338,Omeprazole
,16611279,percentage of time,"The mean 24-h percentage of time over pH 4 was 62, 72 and 64 after breakfast, dinner and bedtime dosing, respectively (N.S.), and 54, 68 and 56 during night-time (P = 0.06).","Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16611279/),,68,71682,DB00338,Omeprazole
,16611279,percentage of time,"The mean 24-h percentage of time over pH 4 was 62, 72 and 64 after breakfast, dinner and bedtime dosing, respectively (N.S.), and 54, 68 and 56 during night-time (P = 0.06).","Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16611279/),,56,71683,DB00338,Omeprazole
,16611279,duration,"Nocturnal acid breakthrough incidence decreased from 100% at baseline to 83%, 55% and 75% after 7.00 AM, 7.00 PM and 9.30 PM dosing, respectively (P = 0.18), and its mean duration dropped from 6.2 to 2.8, 1.0 and 2.2 h, respectively (P < 0.05).","Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16611279/),,6.2,71684,DB00338,Omeprazole
,16611279,duration,"Nocturnal acid breakthrough incidence decreased from 100% at baseline to 83%, 55% and 75% after 7.00 AM, 7.00 PM and 9.30 PM dosing, respectively (P = 0.18), and its mean duration dropped from 6.2 to 2.8, 1.0 and 2.2 h, respectively (P < 0.05).","Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16611279/),,2.8,71685,DB00338,Omeprazole
,16611279,duration,"Nocturnal acid breakthrough incidence decreased from 100% at baseline to 83%, 55% and 75% after 7.00 AM, 7.00 PM and 9.30 PM dosing, respectively (P = 0.18), and its mean duration dropped from 6.2 to 2.8, 1.0 and 2.2 h, respectively (P < 0.05).","Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16611279/),,1.0,71686,DB00338,Omeprazole
,16611279,duration,"Nocturnal acid breakthrough incidence decreased from 100% at baseline to 83%, 55% and 75% after 7.00 AM, 7.00 PM and 9.30 PM dosing, respectively (P = 0.18), and its mean duration dropped from 6.2 to 2.8, 1.0 and 2.2 h, respectively (P < 0.05).","Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16611279/),,2.2,71687,DB00338,Omeprazole
,3858978,binding,"The binding is lower in the dog and rat (90 and 87%, respectively).",Pharmacokinetics and metabolism of omeprazole in animals and man--an overview. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3858978/),%,90,71897,DB00338,Omeprazole
,3858978,binding,"The binding is lower in the dog and rat (90 and 87%, respectively).",Pharmacokinetics and metabolism of omeprazole in animals and man--an overview. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3858978/),%,87,71898,DB00338,Omeprazole
,3858978,elimination half-life,"The mean elimination half-life in man and in the dog is about 1 hour, whereas half-lives in the range of 5 to 15 minutes have been recorded in the mouse.",Pharmacokinetics and metabolism of omeprazole in animals and man--an overview. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3858978/),h,1,71899,DB00338,Omeprazole
,3858978,half-lives,"The mean elimination half-life in man and in the dog is about 1 hour, whereas half-lives in the range of 5 to 15 minutes have been recorded in the mouse.",Pharmacokinetics and metabolism of omeprazole in animals and man--an overview. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3858978/),min,5 to 15,71900,DB00338,Omeprazole
,3858978,total body clearance,"In two studies in man, the mean total body clearance was 880 and 1097 ml X min-1, indicating that omeprazole belongs to the group of high clearance drugs.",Pharmacokinetics and metabolism of omeprazole in animals and man--an overview. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3858978/),[ml] / [min],880,71901,DB00338,Omeprazole
,3858978,total body clearance,"In two studies in man, the mean total body clearance was 880 and 1097 ml X min-1, indicating that omeprazole belongs to the group of high clearance drugs.",Pharmacokinetics and metabolism of omeprazole in animals and man--an overview. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3858978/),[ml] / [min],1097,71902,DB00338,Omeprazole
,3858978,total body clearance,"In the dog, too, the drug appears to be rapidly cleared from the blood, the mean total body clearance being about 10.5 ml X min-1 X kg-1.",Pharmacokinetics and metabolism of omeprazole in animals and man--an overview. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3858978/),[ml] / [kg·min],10.5,71903,DB00338,Omeprazole
,8894114,Cmax,Omeprazole caused a significant increase in methadone levels (Cmax = 156 +/- 6.5 ng mL-1 against 51 +/- 5.8 ng mL-1 in control; p < 0.05).,The effect of changes in gastric pH induced by omeprazole on the absorption and respiratory depression of methadone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894114/),[ng] / [ml],156,71943,DB00338,Omeprazole
,8894114,Cmax,Omeprazole caused a significant increase in methadone levels (Cmax = 156 +/- 6.5 ng mL-1 against 51 +/- 5.8 ng mL-1 in control; p < 0.05).,The effect of changes in gastric pH induced by omeprazole on the absorption and respiratory depression of methadone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894114/),[ng] / [ml],51,71944,DB00338,Omeprazole
,8894114,AUC0-180,AUC0-180 was higher (p < 0.05) after omeprazole treatment (18.6 +/- 1.4 micrograms mL-1 min) than in control (6.8 +/- 0.6 microgram mL-1 min).,The effect of changes in gastric pH induced by omeprazole on the absorption and respiratory depression of methadone. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894114/),[min·μg] / [ml],18.6,71945,DB00338,Omeprazole
,8894114,AUC0-180,AUC0-180 was higher (p < 0.05) after omeprazole treatment (18.6 +/- 1.4 micrograms mL-1 min) than in control (6.8 +/- 0.6 microgram mL-1 min).,The effect of changes in gastric pH induced by omeprazole on the absorption and respiratory depression of methadone. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894114/),[min·μg] / [ml],6.8,71946,DB00338,Omeprazole
,15652200,C(max),"After small intestinal administration of LPZ, 5.0 mg/kg, solution with HCO-60 showed the highest plasma LPZ concentration versus time curve of which C(max) and AUC was 0.46+/-0.01 microg/mL and 0.73+/-0.03 microgh/mL.",Effect of adsorbents on the absorption of lansoprazole with surfactant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652200/),[μg] / [ml],0.46,72253,DB00338,Omeprazole
,15652200,AUC,"After small intestinal administration of LPZ, 5.0 mg/kg, solution with HCO-60 showed the highest plasma LPZ concentration versus time curve of which C(max) and AUC was 0.46+/-0.01 microg/mL and 0.73+/-0.03 microgh/mL.",Effect of adsorbents on the absorption of lansoprazole with surfactant. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652200/),[μgh] / [ml],0.73,72254,DB00338,Omeprazole
,15652200,BA,"By comparing to that after i.v. injection of LPZ solution, 2.0 mg/kg, the BA of LPZ from HCO-60 solution was 39.0%, which was about seven times higher than that of LPZ powder.",Effect of adsorbents on the absorption of lansoprazole with surfactant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652200/),%,39.0,72255,DB00338,Omeprazole
,15652200,T50%,"Sylysia 320, Neusilin S2 and Neusilin NS2 showed the T50% of about 1h.",Effect of adsorbents on the absorption of lansoprazole with surfactant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652200/),h,1,72256,DB00338,Omeprazole
,15652200,AUC,The AUC of Sylysia 550 system was 2.16+/-0.26 microgh/mL and was greater than enteric tablet and the BA of 71.7% was obtained.,Effect of adsorbents on the absorption of lansoprazole with surfactant. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652200/),[μgh] / [ml],2.16,72257,DB00338,Omeprazole
,7751591,plasma half-life,There were significant changes in caffeine plasma half-life (6.2 vs. 3.5 h; p < 0.004) and caffeine plasma clearance (1.3 vs. 2.2 ml/kg per min; p < 0.004) with rifampin.,The influence of rifampin treatment on caffeine clearance in healthy man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751591/),h,6.2,73374,DB00338,Omeprazole
,7751591,plasma half-life,There were significant changes in caffeine plasma half-life (6.2 vs. 3.5 h; p < 0.004) and caffeine plasma clearance (1.3 vs. 2.2 ml/kg per min; p < 0.004) with rifampin.,The influence of rifampin treatment on caffeine clearance in healthy man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751591/),h,3.5,73375,DB00338,Omeprazole
,7751591,plasma clearance,There were significant changes in caffeine plasma half-life (6.2 vs. 3.5 h; p < 0.004) and caffeine plasma clearance (1.3 vs. 2.2 ml/kg per min; p < 0.004) with rifampin.,The influence of rifampin treatment on caffeine clearance in healthy man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751591/),[ml] / [kg·min],1.3,73376,DB00338,Omeprazole
,7751591,plasma clearance,There were significant changes in caffeine plasma half-life (6.2 vs. 3.5 h; p < 0.004) and caffeine plasma clearance (1.3 vs. 2.2 ml/kg per min; p < 0.004) with rifampin.,The influence of rifampin treatment on caffeine clearance in healthy man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751591/),[ml] / [kg·min],2.2,73377,DB00338,Omeprazole
,20678688,C(max),"From serum data, the mean (SD) values for the test and reference products were as follows: 5.26 (1.57) and 5.54 (2.94) micromol/L for C(max); 2.53 (0.67) and 2.07 (0.65) hours for T(max); 15.74 (6.50) and 16.68 (6.77) micromol/L/h for AUC(0-12); and 17.15 (7.58) and 18.26 (7.31) micromol/L/h for AUC(0-infinity), respectively.","Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678688/),[μM] / [l],5.26,73389,DB00338,Omeprazole
,20678688,C(max),"From serum data, the mean (SD) values for the test and reference products were as follows: 5.26 (1.57) and 5.54 (2.94) micromol/L for C(max); 2.53 (0.67) and 2.07 (0.65) hours for T(max); 15.74 (6.50) and 16.68 (6.77) micromol/L/h for AUC(0-12); and 17.15 (7.58) and 18.26 (7.31) micromol/L/h for AUC(0-infinity), respectively.","Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678688/),[μM] / [l],5.54,73390,DB00338,Omeprazole
,20678688,T(max),"From serum data, the mean (SD) values for the test and reference products were as follows: 5.26 (1.57) and 5.54 (2.94) micromol/L for C(max); 2.53 (0.67) and 2.07 (0.65) hours for T(max); 15.74 (6.50) and 16.68 (6.77) micromol/L/h for AUC(0-12); and 17.15 (7.58) and 18.26 (7.31) micromol/L/h for AUC(0-infinity), respectively.","Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678688/),h,2.53,73391,DB00338,Omeprazole
,20678688,T(max),"From serum data, the mean (SD) values for the test and reference products were as follows: 5.26 (1.57) and 5.54 (2.94) micromol/L for C(max); 2.53 (0.67) and 2.07 (0.65) hours for T(max); 15.74 (6.50) and 16.68 (6.77) micromol/L/h for AUC(0-12); and 17.15 (7.58) and 18.26 (7.31) micromol/L/h for AUC(0-infinity), respectively.","Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678688/),h,2.07,73392,DB00338,Omeprazole
,20678688,AUC(0-12),"From serum data, the mean (SD) values for the test and reference products were as follows: 5.26 (1.57) and 5.54 (2.94) micromol/L for C(max); 2.53 (0.67) and 2.07 (0.65) hours for T(max); 15.74 (6.50) and 16.68 (6.77) micromol/L/h for AUC(0-12); and 17.15 (7.58) and 18.26 (7.31) micromol/L/h for AUC(0-infinity), respectively.","Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678688/),[μM] / [h·l],15.74,73393,DB00338,Omeprazole
,20678688,AUC(0-12),"From serum data, the mean (SD) values for the test and reference products were as follows: 5.26 (1.57) and 5.54 (2.94) micromol/L for C(max); 2.53 (0.67) and 2.07 (0.65) hours for T(max); 15.74 (6.50) and 16.68 (6.77) micromol/L/h for AUC(0-12); and 17.15 (7.58) and 18.26 (7.31) micromol/L/h for AUC(0-infinity), respectively.","Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678688/),[μM] / [h·l],16.68,73394,DB00338,Omeprazole
,20678688,AUC(0-infinity),"From serum data, the mean (SD) values for the test and reference products were as follows: 5.26 (1.57) and 5.54 (2.94) micromol/L for C(max); 2.53 (0.67) and 2.07 (0.65) hours for T(max); 15.74 (6.50) and 16.68 (6.77) micromol/L/h for AUC(0-12); and 17.15 (7.58) and 18.26 (7.31) micromol/L/h for AUC(0-infinity), respectively.","Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678688/),[μM] / [h·l],17.15,73395,DB00338,Omeprazole
,20678688,AUC(0-infinity),"From serum data, the mean (SD) values for the test and reference products were as follows: 5.26 (1.57) and 5.54 (2.94) micromol/L for C(max); 2.53 (0.67) and 2.07 (0.65) hours for T(max); 15.74 (6.50) and 16.68 (6.77) micromol/L/h for AUC(0-12); and 17.15 (7.58) and 18.26 (7.31) micromol/L/h for AUC(0-infinity), respectively.","Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678688/),[μM] / [h·l],18.26,73396,DB00338,Omeprazole
,20678688,T(max),"The mean T(max) was found to be significantly different between the test and reference formulations (2.53 [0.67] vs 2.07 [0.65] hours, respectively; P < 0.05).","Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678688/),h,2.53,73397,DB00338,Omeprazole
,20678688,T(max),"The mean T(max) was found to be significantly different between the test and reference formulations (2.53 [0.67] vs 2.07 [0.65] hours, respectively; P < 0.05).","Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678688/),h,2.07,73398,DB00338,Omeprazole
,18937302,flow rate,"Chromatographic separation was achieved with 0.01 M ammonium acetate:acetonitrile (40:60, v/v) at a flow rate of 0.25 mL/min on an Inertsil ODS 3 column with a total run time 2.5 min.",Highly sensitive method for the determination of omeprazole in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18937302/),[ml] / [min],0.25,74387,DB00338,Omeprazole
,18937302,total run time,"Chromatographic separation was achieved with 0.01 M ammonium acetate:acetonitrile (40:60, v/v) at a flow rate of 0.25 mL/min on an Inertsil ODS 3 column with a total run time 2.5 min.",Highly sensitive method for the determination of omeprazole in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18937302/),min,2.5,74388,DB00338,Omeprazole
,18937302,ion transitions,The MS/MS ion transitions monitored were 346.1 --> 198.1 for OPZ and 370.1 --> 252.1 for IS.,Highly sensitive method for the determination of omeprazole in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18937302/),,346.1,74389,DB00338,Omeprazole
,18937302,ion transitions,The MS/MS ion transitions monitored were 346.1 --> 198.1 for OPZ and 370.1 --> 252.1 for IS.,Highly sensitive method for the determination of omeprazole in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18937302/),,198.1,74390,DB00338,Omeprazole
,18937302,ion transitions,The MS/MS ion transitions monitored were 346.1 --> 198.1 for OPZ and 370.1 --> 252.1 for IS.,Highly sensitive method for the determination of omeprazole in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18937302/),,370.1,74391,DB00338,Omeprazole
,18937302,ion transitions,The MS/MS ion transitions monitored were 346.1 --> 198.1 for OPZ and 370.1 --> 252.1 for IS.,Highly sensitive method for the determination of omeprazole in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18937302/),,252.1,74392,DB00338,Omeprazole
,3443142,Areas under the propranolol concentration/time curves,"Areas under the propranolol concentration/time curves were not significantly increased by omeprazole treatment: off treatment mean 787.6, on treatment 802.5 ng-1.ml.h.",Propranolol steady-state pharmacokinetics are unaltered by omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443142/),[h·ml] / [ng],787.6,76702,DB00338,Omeprazole
,3443142,Areas under the propranolol concentration/time curves,"Areas under the propranolol concentration/time curves were not significantly increased by omeprazole treatment: off treatment mean 787.6, on treatment 802.5 ng-1.ml.h.",Propranolol steady-state pharmacokinetics are unaltered by omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443142/),[h·ml] / [ng],802.5,76703,DB00338,Omeprazole
,8675169,plasma clearance,"Comparing the omeprazole doses of 40 mg and 60 mg in eight EMs on day 7 of treatment showed that CYP2C19-dependent plasma clearance of omeprazole and omeprazole sulfone was reduced from 19.0 to 8.4 L/h (P < .001) and from 19.8 to 9.2 L/h (P = .012), respectively.",Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8675169/),[l] / [h],19.0 to 8.4,77136,DB00338,Omeprazole
,8675169,plasma clearance,"Comparing the omeprazole doses of 40 mg and 60 mg in eight EMs on day 7 of treatment showed that CYP2C19-dependent plasma clearance of omeprazole and omeprazole sulfone was reduced from 19.0 to 8.4 L/h (P < .001) and from 19.8 to 9.2 L/h (P = .012), respectively.",Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8675169/),[l] / [h],19.8 to 9.2,77137,DB00338,Omeprazole
,8675169,formation half-life,"Similarly, formation half-life of 5'-hydroxyomeprazole increased from 0.58 to 1.45 hours (P = .025) with the higher dose.",Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8675169/),h,0.58,77138,DB00338,Omeprazole
,8675169,formation half-life,"Similarly, formation half-life of 5'-hydroxyomeprazole increased from 0.58 to 1.45 hours (P = .025) with the higher dose.",Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8675169/),h,1.45,77139,DB00338,Omeprazole
greater,8925064,recoveries,The recoveries of E3810 enantiomers and internal standard were greater than 91%.,"Enantioselective high-performance liquid chromatographic assay for determination of the enantiomers of a new anti-ulcer agent, E3810, in beagle dog plasma and rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8925064/),%,91,77989,DB00338,Omeprazole
,20829132,flow rate,"Separation of the drug, its metabolite and the I.S. were achieved using acetonitrile-water (70:30, v/v) as mobile phase at flow rate of 0.5mL/min on a MZ PerfectSil target C18 column.",Application of one-step liquid chromatography-electrospray tandem MS/MS and collision-induced dissociation to quantification of ezetimibe and identification of its glucuronated metabolite in human serum: A pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20829132/),[ml] / [min],0.5,78563,DB00338,Omeprazole
,15145972,C(min),"After the last dose, mean (CV) C(min) for plasma bismuth was 2882 pg/mL (36%) and 1195 pg/mL (23%) (p< 0.001), with and without OM, respectively.","Influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15145972/),[pg] / [ml],2882,80074,DB00338,Omeprazole
,15145972,C(min),"After the last dose, mean (CV) C(min) for plasma bismuth was 2882 pg/mL (36%) and 1195 pg/mL (23%) (p< 0.001), with and without OM, respectively.","Influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15145972/),[pg] / [ml],1195,80075,DB00338,Omeprazole
,15145972,C(max),"Mean (CV) C(max) was 25493 pg/mL (69%) and 8061 pg/mL (28%) (p < 0.001) with and without OM, respectively.","Influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15145972/),[pg] / [ml],25493,80076,DB00338,Omeprazole
,15145972,C(max),"Mean (CV) C(max) was 25493 pg/mL (69%) and 8061 pg/mL (28%) (p < 0.001) with and without OM, respectively.","Influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15145972/),[pg] / [ml],8061,80077,DB00338,Omeprazole
,15975247,flow rate,"Following a protein precipitation procedure, the samples are separated using reversed-phase HPLC (C18) by a gradient of acetonitrile and ammonium acetate (pH 6.0) at a flow rate of 1.0 mL/min and quantitated using UV detection at 290 nm.",Simultaneous determination of pantoprazole and its two metabolites in dog plasma by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15975247/),[ml] / [min],1.0,81301,DB00338,Omeprazole
,16120067,t(1/2),"Co-administration with cimetidine caused a moderate increase in the systemic exposure [AUC0, infinity] to escitalopram (geometric mean ratio = 1.72, [95% CI 1.34, 2.21]) and a small increase in t(1/2) from 23.7 to 29.0 h (5.24 h [3.75, 6.70]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),h,23.7,81356,DB00338,Omeprazole
,16120067,t(1/2),"Co-administration with cimetidine caused a moderate increase in the systemic exposure [AUC0, infinity] to escitalopram (geometric mean ratio = 1.72, [95% CI 1.34, 2.21]) and a small increase in t(1/2) from 23.7 to 29.0 h (5.24 h [3.75, 6.70]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),h,29.0,81357,DB00338,Omeprazole
,16120067,t(1/2),"Co-administration with cimetidine caused a moderate increase in the systemic exposure [AUC0, infinity] to escitalopram (geometric mean ratio = 1.72, [95% CI 1.34, 2.21]) and a small increase in t(1/2) from 23.7 to 29.0 h (5.24 h [3.75, 6.70]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),h,5.24,81358,DB00338,Omeprazole
,16120067,"AUC(0, infinity)","Co-administration with omeprazole also resulted in a moderate increase in the escitalopram AUC(0, infinity) (1.51 [1.39, 1.64]) and a small increase in t(1/2) from 26.5 to 34.8 h (8.3 h [6.44, 10.2]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),,1.51,81359,DB00338,Omeprazole
,16120067,t(1/2),"Co-administration with omeprazole also resulted in a moderate increase in the escitalopram AUC(0, infinity) (1.51 [1.39, 1.64]) and a small increase in t(1/2) from 26.5 to 34.8 h (8.3 h [6.44, 10.2]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),h,26.5,81360,DB00338,Omeprazole
,16120067,t(1/2),"Co-administration with omeprazole also resulted in a moderate increase in the escitalopram AUC(0, infinity) (1.51 [1.39, 1.64]) and a small increase in t(1/2) from 26.5 to 34.8 h (8.3 h [6.44, 10.2]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),h,34.8,81361,DB00338,Omeprazole
,16120067,t(1/2),"Co-administration with omeprazole also resulted in a moderate increase in the escitalopram AUC(0, infinity) (1.51 [1.39, 1.64]) and a small increase in t(1/2) from 26.5 to 34.8 h (8.3 h [6.44, 10.2]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),h,8.3,81362,DB00338,Omeprazole
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.95,81454,DB00338,Omeprazole
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,1.01,81455,DB00338,Omeprazole
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.97,81456,DB00338,Omeprazole
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.98,81457,DB00338,Omeprazole
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,1.36,81458,DB00338,Omeprazole
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.90,81459,DB00338,Omeprazole
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.79,81460,DB00338,Omeprazole
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.98,81461,DB00338,Omeprazole
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.66,81462,DB00338,Omeprazole
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,1.90,81463,DB00338,Omeprazole
,22180371,T(max),The mean T(max) in both regimens was estimated for 1.5 h.,Omeprazole does not change the oral bioavailability or pharmacokinetics of vinpocetine in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22180371/),h,1.5,82468,DB00338,Omeprazole
,19189088,AUC(OR),"A statistically significant difference was seen in the AUC(0-infinity) of bromazepam, with nasogastric administration decreasing availability by about 25%: AUC(OR) = 2501 ng mL(-1) h; AUC(NT) = 1855 ng mL(-1) h (p < 0.05); ratio (geometric mean) = 0.74 [90% confidence interval (CI) 0.64-0.87].","The bioavailability of bromazepam, omeprazole and paracetamol given by nasogastric feeding tube. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19189088/),[h·ng] / [ml],2501,83958,DB00338,Omeprazole
,19189088,AUC(NT),"A statistically significant difference was seen in the AUC(0-infinity) of bromazepam, with nasogastric administration decreasing availability by about 25%: AUC(OR) = 2501 ng mL(-1) h; AUC(NT) = 1855 ng mL(-1) h (p < 0.05); ratio (geometric mean) = 0.74 [90% confidence interval (CI) 0.64-0.87].","The bioavailability of bromazepam, omeprazole and paracetamol given by nasogastric feeding tube. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19189088/),[h·ng] / [ml],1855,83959,DB00338,Omeprazole
,19189088,half-life,"However, this does not appear to be clinically relevant given the usual dosage range and the drug's half-life (approx. 30 h).","The bioavailability of bromazepam, omeprazole and paracetamol given by nasogastric feeding tube. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19189088/),h,30,83960,DB00338,Omeprazole
,19189088,AUC(OR),A large interindividual variability in omeprazole parameters prevented any statistical conclusion from being drawn in terms of both modes of administration despite their similar average profile: AUC(OR) = 579 ng mL(-1) h; AUC(NT) = 587 ng mL(-1) h (p > 0.05); ratio (geometric mean) = 1.01 (90% CI 0.64-1.61).,"The bioavailability of bromazepam, omeprazole and paracetamol given by nasogastric feeding tube. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19189088/),[h·ng] / [ml],579,83961,DB00338,Omeprazole
,19189088,AUC(NT),A large interindividual variability in omeprazole parameters prevented any statistical conclusion from being drawn in terms of both modes of administration despite their similar average profile: AUC(OR) = 579 ng mL(-1) h; AUC(NT) = 587 ng mL(-1) h (p > 0.05); ratio (geometric mean) = 1.01 (90% CI 0.64-1.61).,"The bioavailability of bromazepam, omeprazole and paracetamol given by nasogastric feeding tube. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19189088/),[h·ng] / [ml],587,83962,DB00338,Omeprazole
,19189088,AUC(OR),The narrow 90% confidence limits of paracetamol indicate bioequivalence: AUC(OR) = 37 microg mL(-1) h; AUC(NT) = 41 microg mL(-1) h(p > 0.05); ratio (geometric mean) = 1.12 (90% CI 0.98-1.28).,"The bioavailability of bromazepam, omeprazole and paracetamol given by nasogastric feeding tube. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19189088/),[h·μg] / [ml],37,83963,DB00338,Omeprazole
,19189088,AUC(NT),The narrow 90% confidence limits of paracetamol indicate bioequivalence: AUC(OR) = 37 microg mL(-1) h; AUC(NT) = 41 microg mL(-1) h(p > 0.05); ratio (geometric mean) = 1.12 (90% CI 0.98-1.28).,"The bioavailability of bromazepam, omeprazole and paracetamol given by nasogastric feeding tube. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19189088/),[h·μg] / [ml],41,83964,DB00338,Omeprazole
,11932962,area under the plasma concentration-time curve of o,"In treated group, the area under the plasma concentration-time curve of omeprazole from time zero to time infinity (AUC) was significantly greater (3090 vs 491 ng h/ml), terminal half-life of omeprazole was significantly longer (2.59 vs 0.85 h), and peak plasma concentration of omeprazole (C(max)) was significantly higher (746 vs 311 ng/ml) than that in control group.",Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11932962/),[h·ng] / [ml],3090,84347,DB00338,Omeprazole
,11932962,area under the plasma concentration-time curve of o,"In treated group, the area under the plasma concentration-time curve of omeprazole from time zero to time infinity (AUC) was significantly greater (3090 vs 491 ng h/ml), terminal half-life of omeprazole was significantly longer (2.59 vs 0.85 h), and peak plasma concentration of omeprazole (C(max)) was significantly higher (746 vs 311 ng/ml) than that in control group.",Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11932962/),[h·ng] / [ml],491,84348,DB00338,Omeprazole
,11932962,terminal half-life,"In treated group, the area under the plasma concentration-time curve of omeprazole from time zero to time infinity (AUC) was significantly greater (3090 vs 491 ng h/ml), terminal half-life of omeprazole was significantly longer (2.59 vs 0.85 h), and peak plasma concentration of omeprazole (C(max)) was significantly higher (746 vs 311 ng/ml) than that in control group.",Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11932962/),h,2.59,84349,DB00338,Omeprazole
,11932962,terminal half-life,"In treated group, the area under the plasma concentration-time curve of omeprazole from time zero to time infinity (AUC) was significantly greater (3090 vs 491 ng h/ml), terminal half-life of omeprazole was significantly longer (2.59 vs 0.85 h), and peak plasma concentration of omeprazole (C(max)) was significantly higher (746 vs 311 ng/ml) than that in control group.",Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11932962/),h,0.85,84350,DB00338,Omeprazole
,11932962,peak plasma concentration of omeprazole (C(max)),"In treated group, the area under the plasma concentration-time curve of omeprazole from time zero to time infinity (AUC) was significantly greater (3090 vs 491 ng h/ml), terminal half-life of omeprazole was significantly longer (2.59 vs 0.85 h), and peak plasma concentration of omeprazole (C(max)) was significantly higher (746 vs 311 ng/ml) than that in control group.",Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11932962/),[ng] / [ml],746,84351,DB00338,Omeprazole
,11932962,peak plasma concentration of omeprazole (C(max)),"In treated group, the area under the plasma concentration-time curve of omeprazole from time zero to time infinity (AUC) was significantly greater (3090 vs 491 ng h/ml), terminal half-life of omeprazole was significantly longer (2.59 vs 0.85 h), and peak plasma concentration of omeprazole (C(max)) was significantly higher (746 vs 311 ng/ml) than that in control group.",Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11932962/),[ng] / [ml],311,84352,DB00338,Omeprazole
,11348484,elimination half-life,Pharmacokinetics parameters after ranitidine administration to six llamas showed a mean elimination half-life of 1.53 +/- 0.26 h.,Pharmacokinetics and pharmacodynamics of antiulcer agents in llama. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348484/),h,1.53,84527,DB00338,Omeprazole
,11348484,volume of distribution (Vdss),"The mean volume of distribution (Vdss) in llamas was 1.77 +/- 0.31 L/kg, and mean body clearance in llamas was 0.778 +/- 0.109 L/kg/h.",Pharmacokinetics and pharmacodynamics of antiulcer agents in llama. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348484/),[l] / [kg],1.77,84528,DB00338,Omeprazole
,11348484,body clearance,"The mean volume of distribution (Vdss) in llamas was 1.77 +/- 0.31 L/kg, and mean body clearance in llamas was 0.778 +/- 0.109 L/kg/h.",Pharmacokinetics and pharmacodynamics of antiulcer agents in llama. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348484/),[l] / [h·kg],0.778,84529,DB00338,Omeprazole
,11348484,half-life,"The mean half-life of 0.2 mg/kg i.v. omeprazole was shorter than that of 0.4 and 0.8 mg/kg i.v. omeprazole, i.e. 0.61, 0.72 and 1.07 h, respectively.",Pharmacokinetics and pharmacodynamics of antiulcer agents in llama. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348484/),h,0.61,84530,DB00338,Omeprazole
,11348484,half-life,"The mean half-life of 0.2 mg/kg i.v. omeprazole was shorter than that of 0.4 and 0.8 mg/kg i.v. omeprazole, i.e. 0.61, 0.72 and 1.07 h, respectively.",Pharmacokinetics and pharmacodynamics of antiulcer agents in llama. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348484/),h,0.72,84531,DB00338,Omeprazole
,11348484,half-life,"The mean half-life of 0.2 mg/kg i.v. omeprazole was shorter than that of 0.4 and 0.8 mg/kg i.v. omeprazole, i.e. 0.61, 0.72 and 1.07 h, respectively.",Pharmacokinetics and pharmacodynamics of antiulcer agents in llama. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348484/),h,1.07,84532,DB00338,Omeprazole
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,27,85677,DB00338,Omeprazole
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,54,85678,DB00338,Omeprazole
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,44,85679,DB00338,Omeprazole
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,160,85680,DB00338,Omeprazole
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,74,85681,DB00338,Omeprazole
,8540719,area under the concentration-time curve from 0 to 24 h,Clarithromycin increased mean omeprazole area under the concentration-time curve from 0 to 24 h from 3.3 +/- 2.0 to 6.3 +/- 4.5 micrograms.h/ml (P < 0.05) and harmonic mean half-life from 1.2 to 1.6 h (P < 0.05) but did not significantly alter the effect of omeprazole on gastric pH.,Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540719/),[h·μg] / [ml],3.3,86225,DB00338,Omeprazole
,8540719,area under the concentration-time curve from 0 to 24 h,Clarithromycin increased mean omeprazole area under the concentration-time curve from 0 to 24 h from 3.3 +/- 2.0 to 6.3 +/- 4.5 micrograms.h/ml (P < 0.05) and harmonic mean half-life from 1.2 to 1.6 h (P < 0.05) but did not significantly alter the effect of omeprazole on gastric pH.,Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540719/),[h·μg] / [ml],6.3,86226,DB00338,Omeprazole
,8540719,half-life,Clarithromycin increased mean omeprazole area under the concentration-time curve from 0 to 24 h from 3.3 +/- 2.0 to 6.3 +/- 4.5 micrograms.h/ml (P < 0.05) and harmonic mean half-life from 1.2 to 1.6 h (P < 0.05) but did not significantly alter the effect of omeprazole on gastric pH.,Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540719/),h,1.2 to 1.6,86227,DB00338,Omeprazole
,8540719,area under the concentration-time curve from 0 to 8 h,Mean clarithromycin area under the concentration-time curve from 0 to 8 h increased from 22.9 +/- 5.5 (placebo) to 26.4 +/- 5.7 micrograms.h/ml (omeprazole) (P < 0.05) when clarithromycin was administered with omeprazole.,Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540719/),[h·μg] / [ml],22.9,86228,DB00338,Omeprazole
,8540719,area under the concentration-time curve from 0 to 8 h,Mean clarithromycin area under the concentration-time curve from 0 to 8 h increased from 22.9 +/- 5.5 (placebo) to 26.4 +/- 5.7 micrograms.h/ml (omeprazole) (P < 0.05) when clarithromycin was administered with omeprazole.,Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540719/),[h·μg] / [ml],26.4,86229,DB00338,Omeprazole
,8540719,maximum observed concentrations,"Mean maximum observed concentrations of clarithromycin in the gastric fundus increased from 20.8 +/- 7.6 (placebo) to 24.3 +/- 6.4 micrograms/g (omeprazole), and those in the gastric mucous from 4.2 +/- 7.7 placebo to 39.3 +/- 32.8 micrograms/g (omeprazole).",Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540719/),[μg] / [g],20.8,86230,DB00338,Omeprazole
,8540719,maximum observed concentrations,"Mean maximum observed concentrations of clarithromycin in the gastric fundus increased from 20.8 +/- 7.6 (placebo) to 24.3 +/- 6.4 micrograms/g (omeprazole), and those in the gastric mucous from 4.2 +/- 7.7 placebo to 39.3 +/- 32.8 micrograms/g (omeprazole).",Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540719/),[μg] / [g],24.3,86231,DB00338,Omeprazole
,8540719,maximum observed concentrations,"Mean maximum observed concentrations of clarithromycin in the gastric fundus increased from 20.8 +/- 7.6 (placebo) to 24.3 +/- 6.4 micrograms/g (omeprazole), and those in the gastric mucous from 4.2 +/- 7.7 placebo to 39.3 +/- 32.8 micrograms/g (omeprazole).",Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540719/),[μg] / [g],4.2,86232,DB00338,Omeprazole
,8540719,maximum observed concentrations,"Mean maximum observed concentrations of clarithromycin in the gastric fundus increased from 20.8 +/- 7.6 (placebo) to 24.3 +/- 6.4 micrograms/g (omeprazole), and those in the gastric mucous from 4.2 +/- 7.7 placebo to 39.3 +/- 32.8 micrograms/g (omeprazole).",Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540719/),[μg] / [g],39.3,86233,DB00338,Omeprazole
,9877309,metabolic ratio,The in-vitro metabolic study showed that the mean metabolic ratio (45.9%) for (-)-lansoprazole was significantly greater than that (19.8%) for the (+) enantiomer in rat liver microsomes at 5.6 microM lansoprazole.,Pharmacokinetic differences between lansoprazole enantiomers in rats. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9877309/),,45,87735,DB00338,Omeprazole
,9877309,metabolic ratio,The in-vitro metabolic study showed that the mean metabolic ratio (45.9%) for (-)-lansoprazole was significantly greater than that (19.8%) for the (+) enantiomer in rat liver microsomes at 5.6 microM lansoprazole.,Pharmacokinetic differences between lansoprazole enantiomers in rats. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9877309/),,19,87736,DB00338,Omeprazole
,17898705,trough concentration (C(trough)),"GM (90% CI) for saquinavir area under the curve (AUC)(0-12) (ng h/ml), trough concentration (C(trough)) (ng/ml), and maximum concentration (C(max)) (ng/ml) were 14,698 (13,242-20,636), 433 (368-758), 2,513 (2,243-3,329) without omeprazole; 22,646 (18,536-131,861), 750 (619-1,280), 3,890 (3,223-5,133) with omeprazole simultaneously; and 24,549 (20,884-38,894), 851 (720-1,782), 4,141 (3,554-5,992) with omeprazole 2 h earlier.",Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898705/),[ng] / [ml],"14,698",88006,DB00338,Omeprazole
,17898705,trough concentration (C(trough)),"GM (90% CI) for saquinavir area under the curve (AUC)(0-12) (ng h/ml), trough concentration (C(trough)) (ng/ml), and maximum concentration (C(max)) (ng/ml) were 14,698 (13,242-20,636), 433 (368-758), 2,513 (2,243-3,329) without omeprazole; 22,646 (18,536-131,861), 750 (619-1,280), 3,890 (3,223-5,133) with omeprazole simultaneously; and 24,549 (20,884-38,894), 851 (720-1,782), 4,141 (3,554-5,992) with omeprazole 2 h earlier.",Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898705/),[ng] / [ml],433,88007,DB00338,Omeprazole
,17898705,trough concentration (C(trough)),"GM (90% CI) for saquinavir area under the curve (AUC)(0-12) (ng h/ml), trough concentration (C(trough)) (ng/ml), and maximum concentration (C(max)) (ng/ml) were 14,698 (13,242-20,636), 433 (368-758), 2,513 (2,243-3,329) without omeprazole; 22,646 (18,536-131,861), 750 (619-1,280), 3,890 (3,223-5,133) with omeprazole simultaneously; and 24,549 (20,884-38,894), 851 (720-1,782), 4,141 (3,554-5,992) with omeprazole 2 h earlier.",Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898705/),[ng] / [ml],"22,646",88008,DB00338,Omeprazole
,17898705,trough concentration (C(trough)),"GM (90% CI) for saquinavir area under the curve (AUC)(0-12) (ng h/ml), trough concentration (C(trough)) (ng/ml), and maximum concentration (C(max)) (ng/ml) were 14,698 (13,242-20,636), 433 (368-758), 2,513 (2,243-3,329) without omeprazole; 22,646 (18,536-131,861), 750 (619-1,280), 3,890 (3,223-5,133) with omeprazole simultaneously; and 24,549 (20,884-38,894), 851 (720-1,782), 4,141 (3,554-5,992) with omeprazole 2 h earlier.",Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898705/),[ng] / [ml],"24,549",88009,DB00338,Omeprazole
,17898705,trough concentration (C(trough)),"GM (90% CI) for saquinavir area under the curve (AUC)(0-12) (ng h/ml), trough concentration (C(trough)) (ng/ml), and maximum concentration (C(max)) (ng/ml) were 14,698 (13,242-20,636), 433 (368-758), 2,513 (2,243-3,329) without omeprazole; 22,646 (18,536-131,861), 750 (619-1,280), 3,890 (3,223-5,133) with omeprazole simultaneously; and 24,549 (20,884-38,894), 851 (720-1,782), 4,141 (3,554-5,992) with omeprazole 2 h earlier.",Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898705/),[ng] / [ml],851,88010,DB00338,Omeprazole
,17898705,maximum concentration (C(max)),"GM (90% CI) for saquinavir area under the curve (AUC)(0-12) (ng h/ml), trough concentration (C(trough)) (ng/ml), and maximum concentration (C(max)) (ng/ml) were 14,698 (13,242-20,636), 433 (368-758), 2,513 (2,243-3,329) without omeprazole; 22,646 (18,536-131,861), 750 (619-1,280), 3,890 (3,223-5,133) with omeprazole simultaneously; and 24,549 (20,884-38,894), 851 (720-1,782), 4,141 (3,554-5,992) with omeprazole 2 h earlier.",Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898705/),[ng] / [ml],"3,890",88011,DB00338,Omeprazole
,17898705,maximum concentration (C(max)),"GM (90% CI) for saquinavir area under the curve (AUC)(0-12) (ng h/ml), trough concentration (C(trough)) (ng/ml), and maximum concentration (C(max)) (ng/ml) were 14,698 (13,242-20,636), 433 (368-758), 2,513 (2,243-3,329) without omeprazole; 22,646 (18,536-131,861), 750 (619-1,280), 3,890 (3,223-5,133) with omeprazole simultaneously; and 24,549 (20,884-38,894), 851 (720-1,782), 4,141 (3,554-5,992) with omeprazole 2 h earlier.",Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898705/),[ng] / [ml],"24,549",88012,DB00338,Omeprazole
,17898705,maximum concentration (C(max)),"GM (90% CI) for saquinavir area under the curve (AUC)(0-12) (ng h/ml), trough concentration (C(trough)) (ng/ml), and maximum concentration (C(max)) (ng/ml) were 14,698 (13,242-20,636), 433 (368-758), 2,513 (2,243-3,329) without omeprazole; 22,646 (18,536-131,861), 750 (619-1,280), 3,890 (3,223-5,133) with omeprazole simultaneously; and 24,549 (20,884-38,894), 851 (720-1,782), 4,141 (3,554-5,992) with omeprazole 2 h earlier.",Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898705/),[ng] / [ml],851,88013,DB00338,Omeprazole
,17898705,maximum concentration (C(max)),"GM (90% CI) for saquinavir area under the curve (AUC)(0-12) (ng h/ml), trough concentration (C(trough)) (ng/ml), and maximum concentration (C(max)) (ng/ml) were 14,698 (13,242-20,636), 433 (368-758), 2,513 (2,243-3,329) without omeprazole; 22,646 (18,536-131,861), 750 (619-1,280), 3,890 (3,223-5,133) with omeprazole simultaneously; and 24,549 (20,884-38,894), 851 (720-1,782), 4,141 (3,554-5,992) with omeprazole 2 h earlier.",Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898705/),[ng] / [ml],"4,141",88014,DB00338,Omeprazole
,16372823,acid dissociation constant [pKa],"Lumiracoxib possesses a carboxylic acid group that makes it weakly acidic (acid dissociation constant [pKa] 4.7), distinguishing it from other selective COX-2 inhibitors.",Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372823/),,4.7,89509,DB00338,Omeprazole
,16372823,oral bioavailability,Lumiracoxib has good oral bioavailability (74%).,Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372823/),%,74,89510,DB00338,Omeprazole
,16372823,elimination half-life,Lumiracoxib has a short elimination half-life from plasma (mean 4 hours) and demonstrates dose-proportional plasma pharmacokinetics with no accumulation during multiple dosing.,Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372823/),h,4,89511,DB00338,Omeprazole
,27345284,tmax,Median tmax was 5 hours with food and 3 hours under fasted conditions.,"Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27345284/),h,5,89865,DB00338,Omeprazole
,27345284,tmax,Median tmax was 5 hours with food and 3 hours under fasted conditions.,"Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27345284/),h,3,89866,DB00338,Omeprazole
,11286324,plasma AUCinfinity,"On day 5, the mean plasma AUCinfinity of esomeprazole was 16.0 micromol x h/L, Cmax was 5.6 micromol/L, tmax was 1.5 hours and t(1/2z) was 1.7 hours.",Pharmacokinetic study of esomeprazole in the elderly. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286324/),[h·μM] / [l],16.0,90241,DB00338,Omeprazole
,11286324,Cmax,"On day 5, the mean plasma AUCinfinity of esomeprazole was 16.0 micromol x h/L, Cmax was 5.6 micromol/L, tmax was 1.5 hours and t(1/2z) was 1.7 hours.",Pharmacokinetic study of esomeprazole in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286324/),[μM] / [l],5.6,90242,DB00338,Omeprazole
,11286324,tmax,"On day 5, the mean plasma AUCinfinity of esomeprazole was 16.0 micromol x h/L, Cmax was 5.6 micromol/L, tmax was 1.5 hours and t(1/2z) was 1.7 hours.",Pharmacokinetic study of esomeprazole in the elderly. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286324/),h,1.5,90243,DB00338,Omeprazole
,11286324,t(1/2z),"On day 5, the mean plasma AUCinfinity of esomeprazole was 16.0 micromol x h/L, Cmax was 5.6 micromol/L, tmax was 1.5 hours and t(1/2z) was 1.7 hours.",Pharmacokinetic study of esomeprazole in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286324/),h,1.7,90244,DB00338,Omeprazole
,17080510,retention times,"The retention times for tenatoprazole and internal standard were 7.1 and 12.3 min, respectively.",HPLC determination and pharmacokinetic study of tenatoprazole in dog plasma after oral administration of enteric-coated capsule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080510/),min,7.1,90415,DB00338,Omeprazole
,17080510,retention times,"The retention times for tenatoprazole and internal standard were 7.1 and 12.3 min, respectively.",HPLC determination and pharmacokinetic study of tenatoprazole in dog plasma after oral administration of enteric-coated capsule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080510/),min,12.3,90416,DB00338,Omeprazole
,17080510,C(max),The plasma concentration of tenatoprazole from six dogs showed a mean C(max) of 2.63 microg/mL at T(max) of 1.89 h.,HPLC determination and pharmacokinetic study of tenatoprazole in dog plasma after oral administration of enteric-coated capsule. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080510/),[μg] / [ml],2.63,90417,DB00338,Omeprazole
,17080510,T(max),The plasma concentration of tenatoprazole from six dogs showed a mean C(max) of 2.63 microg/mL at T(max) of 1.89 h.,HPLC determination and pharmacokinetic study of tenatoprazole in dog plasma after oral administration of enteric-coated capsule. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080510/),h,1.89,90418,DB00338,Omeprazole
,22128412,Cmax,"Pharmacokinetic parameters were obtained by non-compartmental analysis and values (+/- s.e.m.) obtained were as follows: Cmax 354.28 +/- 51.57 and 308.95 +/- 44.42 ng/ml, t(max) 2.26 +/- 0.22 and 2.63 +/- 0.24 h and AUC(8h) 701.01 +/- 109.34 and 774.13 +/- 132.84 ngh/ml for formulations A and B respectively.",Comparative bioavailability of two oral formulations of omeprazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22128412/),[ng] / [ml],354.28,91448,DB00338,Omeprazole
,22128412,Cmax,"Pharmacokinetic parameters were obtained by non-compartmental analysis and values (+/- s.e.m.) obtained were as follows: Cmax 354.28 +/- 51.57 and 308.95 +/- 44.42 ng/ml, t(max) 2.26 +/- 0.22 and 2.63 +/- 0.24 h and AUC(8h) 701.01 +/- 109.34 and 774.13 +/- 132.84 ngh/ml for formulations A and B respectively.",Comparative bioavailability of two oral formulations of omeprazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22128412/),[ng] / [ml],308.95,91449,DB00338,Omeprazole
,22128412,t(max),"Pharmacokinetic parameters were obtained by non-compartmental analysis and values (+/- s.e.m.) obtained were as follows: Cmax 354.28 +/- 51.57 and 308.95 +/- 44.42 ng/ml, t(max) 2.26 +/- 0.22 and 2.63 +/- 0.24 h and AUC(8h) 701.01 +/- 109.34 and 774.13 +/- 132.84 ngh/ml for formulations A and B respectively.",Comparative bioavailability of two oral formulations of omeprazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22128412/),h,2.26,91450,DB00338,Omeprazole
,22128412,t(max),"Pharmacokinetic parameters were obtained by non-compartmental analysis and values (+/- s.e.m.) obtained were as follows: Cmax 354.28 +/- 51.57 and 308.95 +/- 44.42 ng/ml, t(max) 2.26 +/- 0.22 and 2.63 +/- 0.24 h and AUC(8h) 701.01 +/- 109.34 and 774.13 +/- 132.84 ngh/ml for formulations A and B respectively.",Comparative bioavailability of two oral formulations of omeprazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22128412/),h,2.63,91451,DB00338,Omeprazole
,22128412,AUC(8h),"Pharmacokinetic parameters were obtained by non-compartmental analysis and values (+/- s.e.m.) obtained were as follows: Cmax 354.28 +/- 51.57 and 308.95 +/- 44.42 ng/ml, t(max) 2.26 +/- 0.22 and 2.63 +/- 0.24 h and AUC(8h) 701.01 +/- 109.34 and 774.13 +/- 132.84 ngh/ml for formulations A and B respectively.",Comparative bioavailability of two oral formulations of omeprazole. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22128412/),[ngh] / [ml],701.01,91452,DB00338,Omeprazole
,22128412,AUC(8h),"Pharmacokinetic parameters were obtained by non-compartmental analysis and values (+/- s.e.m.) obtained were as follows: Cmax 354.28 +/- 51.57 and 308.95 +/- 44.42 ng/ml, t(max) 2.26 +/- 0.22 and 2.63 +/- 0.24 h and AUC(8h) 701.01 +/- 109.34 and 774.13 +/- 132.84 ngh/ml for formulations A and B respectively.",Comparative bioavailability of two oral formulations of omeprazole. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22128412/),[ngh] / [ml],774.13,91453,DB00338,Omeprazole
,21618562,total run time,The total run time was 2.00 min and the elution of DEX and IS occurred at 1.20 min.,Development and validation of a highly sensitive LC-MS/MS method for quantitation of dexlansoprazole in human plasma: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21618562/),min,2.00,93251,DB00338,Omeprazole
,21618562,flow rate,"This was achieved with a mobile phase consisting of 0.2% ammonia-acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on an X-terra RP 18 (50 × 4.6 mm, 5 µm) column.",Development and validation of a highly sensitive LC-MS/MS method for quantitation of dexlansoprazole in human plasma: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21618562/),[ml] / [min],0.50,93252,DB00338,Omeprazole
,8897077,maximum concentration in serum (Cmax),The mean maximum concentration in serum (Cmax) ranged from 1.77-9.25 micrograms/ml for the 20-120 mg dose and the mean time to reach Cmax (tmax) ranged from 1.92-2.42 h.,"Pharmacokinetics and tolerance of pantoprazole, a proton pump inhibitor after single and multiple oral doses in healthy Japanese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897077/),[μg] / [ml],1.77-9.25,94601,DB00338,Omeprazole
,8897077,time to reach Cmax (tmax),The mean maximum concentration in serum (Cmax) ranged from 1.77-9.25 micrograms/ml for the 20-120 mg dose and the mean time to reach Cmax (tmax) ranged from 1.92-2.42 h.,"Pharmacokinetics and tolerance of pantoprazole, a proton pump inhibitor after single and multiple oral doses in healthy Japanese volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897077/),h,1.92-2.42,94602,DB00338,Omeprazole
,8897077,half-life (t1/2),The half-life (t1/2) ranged from 0.74-1.16 h.,"Pharmacokinetics and tolerance of pantoprazole, a proton pump inhibitor after single and multiple oral doses in healthy Japanese volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897077/),h,0.74-1.16,94603,DB00338,Omeprazole
,14749542,Oral clearance (CL/F),"Oral clearance (CL/F) and apparent volume of distribution (V(ss)/F) in healthy adults (Mean +/- SD: 0.62 +/- 0.27 L/h/kg and 0.76 +/- 0.26 L/kg, respectively) were not significantly different than those in children with GERD (0.51 +/- 0.34 L/h/kg and 0.66 +/- 0.25 L/kg, respectively).",Pharmacokinetics of omeprazole in healthy adults and in children with gastroesophageal reflux disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749542/),[l] / [h·kg],0.62,95094,DB00338,Omeprazole
,14749542,Oral clearance (CL/F),"Oral clearance (CL/F) and apparent volume of distribution (V(ss)/F) in healthy adults (Mean +/- SD: 0.62 +/- 0.27 L/h/kg and 0.76 +/- 0.26 L/kg, respectively) were not significantly different than those in children with GERD (0.51 +/- 0.34 L/h/kg and 0.66 +/- 0.25 L/kg, respectively).",Pharmacokinetics of omeprazole in healthy adults and in children with gastroesophageal reflux disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749542/),[l] / [h·kg],0.51,95095,DB00338,Omeprazole
,14749542,apparent volume of distribution (V(ss)/F),"Oral clearance (CL/F) and apparent volume of distribution (V(ss)/F) in healthy adults (Mean +/- SD: 0.62 +/- 0.27 L/h/kg and 0.76 +/- 0.26 L/kg, respectively) were not significantly different than those in children with GERD (0.51 +/- 0.34 L/h/kg and 0.66 +/- 0.25 L/kg, respectively).",Pharmacokinetics of omeprazole in healthy adults and in children with gastroesophageal reflux disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749542/),[l] / [kg],0.76,95096,DB00338,Omeprazole
,14749542,apparent volume of distribution (V(ss)/F),"Oral clearance (CL/F) and apparent volume of distribution (V(ss)/F) in healthy adults (Mean +/- SD: 0.62 +/- 0.27 L/h/kg and 0.76 +/- 0.26 L/kg, respectively) were not significantly different than those in children with GERD (0.51 +/- 0.34 L/h/kg and 0.66 +/- 0.25 L/kg, respectively).",Pharmacokinetics of omeprazole in healthy adults and in children with gastroesophageal reflux disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749542/),[l] / [kg],0.66,95097,DB00338,Omeprazole
,14749542,Lag time,"Healthy adults displayed a statistically significantly longer delay in drug absorption (Lag time: 0.62 +/- 0.15 hours) as compared with that observed in children with GERD (0.12 +/- 0.03 hours, P < 0.05).",Pharmacokinetics of omeprazole in healthy adults and in children with gastroesophageal reflux disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749542/),h,0.62,95098,DB00338,Omeprazole
,14749542,Lag time,"Healthy adults displayed a statistically significantly longer delay in drug absorption (Lag time: 0.62 +/- 0.15 hours) as compared with that observed in children with GERD (0.12 +/- 0.03 hours, P < 0.05).",Pharmacokinetics of omeprazole in healthy adults and in children with gastroesophageal reflux disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749542/),h,0.12,95099,DB00338,Omeprazole
,23558602,rate (C max),"Presence of food reduced the rate (C max) and extent (AUC0-t) of systemic exposure of the test and reference formulations from 1 462 to 777 ng · mL-1, 1 055 to 602 ng · mL-1, 2 597 to 1 852 ng · h · mL-1 and 2 454 to 1 873 ng · h · mL-1, respectively.",Pharmacokinetics of a new immediate-release compound omeprazole capsule and its comparison with the enteric-coated formulation under fasting and fed conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23558602/),[ng] / [ml],1,95755,DB00338,Omeprazole
,23558602,extent (,"Presence of food reduced the rate (C max) and extent (AUC0-t) of systemic exposure of the test and reference formulations from 1 462 to 777 ng · mL-1, 1 055 to 602 ng · mL-1, 2 597 to 1 852 ng · h · mL-1 and 2 454 to 1 873 ng · h · mL-1, respectively.",Pharmacokinetics of a new immediate-release compound omeprazole capsule and its comparison with the enteric-coated formulation under fasting and fed conditions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23558602/),[ng] / [ml],1,95756,DB00338,Omeprazole
,23558602,extent (,"Presence of food reduced the rate (C max) and extent (AUC0-t) of systemic exposure of the test and reference formulations from 1 462 to 777 ng · mL-1, 1 055 to 602 ng · mL-1, 2 597 to 1 852 ng · h · mL-1 and 2 454 to 1 873 ng · h · mL-1, respectively.",Pharmacokinetics of a new immediate-release compound omeprazole capsule and its comparison with the enteric-coated formulation under fasting and fed conditions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23558602/),[ng] / [ml],1 05,95757,DB00338,Omeprazole
,23558602,AUC0-t),"Presence of food reduced the rate (C max) and extent (AUC0-t) of systemic exposure of the test and reference formulations from 1 462 to 777 ng · mL-1, 1 055 to 602 ng · mL-1, 2 597 to 1 852 ng · h · mL-1 and 2 454 to 1 873 ng · h · mL-1, respectively.",Pharmacokinetics of a new immediate-release compound omeprazole capsule and its comparison with the enteric-coated formulation under fasting and fed conditions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23558602/),[ng] / [ml],1 05,95758,DB00338,Omeprazole
,23558602,AUC0-t),"Presence of food reduced the rate (C max) and extent (AUC0-t) of systemic exposure of the test and reference formulations from 1 462 to 777 ng · mL-1, 1 055 to 602 ng · mL-1, 2 597 to 1 852 ng · h · mL-1 and 2 454 to 1 873 ng · h · mL-1, respectively.",Pharmacokinetics of a new immediate-release compound omeprazole capsule and its comparison with the enteric-coated formulation under fasting and fed conditions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23558602/),[h·ng] / [ml],2 597 to 1 852,95759,DB00338,Omeprazole
,23558602,AUC0-t),"Presence of food reduced the rate (C max) and extent (AUC0-t) of systemic exposure of the test and reference formulations from 1 462 to 777 ng · mL-1, 1 055 to 602 ng · mL-1, 2 597 to 1 852 ng · h · mL-1 and 2 454 to 1 873 ng · h · mL-1, respectively.",Pharmacokinetics of a new immediate-release compound omeprazole capsule and its comparison with the enteric-coated formulation under fasting and fed conditions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23558602/),[h·ng] / [ml],2 454 to 1 873,95760,DB00338,Omeprazole
,33107158,oral bioavailability,"Rivaroxaban is a new anticoagulant option for dogs, yet its reported oral bioavailability is as low as 60%.",The influence of feeding and gastroprotectant medications on the Factor Xa inhibitory activity of orally administered rivaroxaban in normal dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107158/),%,60,95797,DB00338,Omeprazole
,15823771,C(max),"The mean (SD) values for C(max) and AUC from time 0 to infinity (AUC(0-infinity) for the lansoprazole 15-mg sachet (591.9 [242.3] ng/mL and 1614 [2065] ng.h/mL, respectively) did not differ significantly from those for the lansoprazole 15-mg capsules (578.6 [275.2] ng/mL and 1620 [2290] ng.h/mL, respectively).",Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823771/),[ng] / [ml],591.9,96782,DB00338,Omeprazole
,15823771,C(max),"The mean (SD) values for C(max) and AUC from time 0 to infinity (AUC(0-infinity) for the lansoprazole 15-mg sachet (591.9 [242.3] ng/mL and 1614 [2065] ng.h/mL, respectively) did not differ significantly from those for the lansoprazole 15-mg capsules (578.6 [275.2] ng/mL and 1620 [2290] ng.h/mL, respectively).",Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823771/),[ng] / [ml],578.6,96783,DB00338,Omeprazole
,15823771,AUC from time 0 to infinity (AUC(0-infinity),"The mean (SD) values for C(max) and AUC from time 0 to infinity (AUC(0-infinity) for the lansoprazole 15-mg sachet (591.9 [242.3] ng/mL and 1614 [2065] ng.h/mL, respectively) did not differ significantly from those for the lansoprazole 15-mg capsules (578.6 [275.2] ng/mL and 1620 [2290] ng.h/mL, respectively).",Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823771/),[h·ng] / [ml],1614,96784,DB00338,Omeprazole
,15823771,AUC from time 0 to infinity (AUC(0-infinity),"The mean (SD) values for C(max) and AUC from time 0 to infinity (AUC(0-infinity) for the lansoprazole 15-mg sachet (591.9 [242.3] ng/mL and 1614 [2065] ng.h/mL, respectively) did not differ significantly from those for the lansoprazole 15-mg capsules (578.6 [275.2] ng/mL and 1620 [2290] ng.h/mL, respectively).",Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823771/),[h·ng] / [ml],1620,96785,DB00338,Omeprazole
,15823771,C(max),"These parameters also did not differ significantly between the lansoprazole 30-mg sachet and 30-mg capsule: mean (SD) C(max), 1103 (428.3) and 1077 (465.6) ng/mL, respectively; mean (SD) AUC(0-infinity), 2655 (1338) and 2669 (1311) ng.h/mL, respectively.",Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823771/),[ng] / [ml],1103,96786,DB00338,Omeprazole
,15823771,C(max),"These parameters also did not differ significantly between the lansoprazole 30-mg sachet and 30-mg capsule: mean (SD) C(max), 1103 (428.3) and 1077 (465.6) ng/mL, respectively; mean (SD) AUC(0-infinity), 2655 (1338) and 2669 (1311) ng.h/mL, respectively.",Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823771/),[ng] / [ml],1077,96787,DB00338,Omeprazole
,15823771,AUC(0-infinity),"These parameters also did not differ significantly between the lansoprazole 30-mg sachet and 30-mg capsule: mean (SD) C(max), 1103 (428.3) and 1077 (465.6) ng/mL, respectively; mean (SD) AUC(0-infinity), 2655 (1338) and 2669 (1311) ng.h/mL, respectively.",Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823771/),[h·ng] / [ml],2655,96788,DB00338,Omeprazole
,15823771,AUC(0-infinity),"These parameters also did not differ significantly between the lansoprazole 30-mg sachet and 30-mg capsule: mean (SD) C(max), 1103 (428.3) and 1077 (465.6) ng/mL, respectively; mean (SD) AUC(0-infinity), 2655 (1338) and 2669 (1311) ng.h/mL, respectively.",Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823771/),[h·ng] / [ml],2669,96789,DB00338,Omeprazole
,32780750,injection flow,"Separation of naproxen and its major metabolic products will be performed using a Shim-Pack XR-ODS 75Lx2.0 column and C18 pre-column (Shimadzu, Kyoto, Japan) at 40°C using a mixture of methanol and 10 mM ammonium acetate (70:30, v/v) with an injection flow of 0.3 mL/min.",Simultaneous separation of naproxen and 6-O-desmethylnaproxen metabolite in saliva samples by liquid chromatography-tandem mass spectrometry: Pharmacokinetic study of naproxen alone and associated with esomeprazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32780750/),[ml] / [min],0.3,96951,DB00338,Omeprazole
,32780750,total analytical run time,The total analytical run time will be 5 min.,Simultaneous separation of naproxen and 6-O-desmethylnaproxen metabolite in saliva samples by liquid chromatography-tandem mass spectrometry: Pharmacokinetic study of naproxen alone and associated with esomeprazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32780750/),min,5,96952,DB00338,Omeprazole
,11269565,gastric ion concentration,"The predicted mean gastric ion concentration was 23.2 mM (pH 1.6) with the peak time at 12.6 hours (8:30 p.m.), and the half-time for H+ removal from the stomach averaged 1.7 hours.",Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269565/),mM,23.2,97277,DB00338,Omeprazole
,11269565,half-time,"The predicted mean gastric ion concentration was 23.2 mM (pH 1.6) with the peak time at 12.6 hours (8:30 p.m.), and the half-time for H+ removal from the stomach averaged 1.7 hours.",Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269565/),h,1.7,97278,DB00338,Omeprazole
,11269565,half-life of gastric food removal,The estimated half-life of gastric food removal was 0.8 hours.,Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269565/),h,0.8,97279,DB00338,Omeprazole
,11269565,rate constant,The rate constant for normal H+/K+-ATPase degradation was 0.045 h(-1).,Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269565/),1/[h],0.045,97280,DB00338,Omeprazole
,11269565,second-order enzyme inactivation constant,"The pharmacodynamic parameter describing lansoprazole action on gastric acid secretion was the second-order enzyme inactivation constant, which averaged 0.16 microg(-1) x L x h(-1).",Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269565/),[l] / [h·μg],0.16,97281,DB00338,Omeprazole
,33259588,flow rate,Mobile phase consisted of 0.1% formic acid in water and acetonitrile in a gradient mode at a flow rate of 0.6 mL/min.,"Quantitative Determination of AZD3264, a Selective Ikb-Kinase IKK2 Inhibitor, in Dog Plasma by Solvent-Induced Phase Transition Extraction Coupled with HPLC-MS/MS and its Application to Pharmacokinetic Study in Dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33259588/),[ml] / [min],0.6,97338,DB00338,Omeprazole
,8681489,clearance,"The mean clearance values of omeprazole in patterns G1, G2, G3, G4, and G5 were 1369.0, 332.7, 359.0, 70.8, and 89.5 ml/hr/kg, respectively.","Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8681489/),[ml] / [h·kg],1369.0,97534,DB00338,Omeprazole
,8681489,clearance,"The mean clearance values of omeprazole in patterns G1, G2, G3, G4, and G5 were 1369.0, 332.7, 359.0, 70.8, and 89.5 ml/hr/kg, respectively.","Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8681489/),[ml] / [h·kg],332.7,97535,DB00338,Omeprazole
,8681489,clearance,"The mean clearance values of omeprazole in patterns G1, G2, G3, G4, and G5 were 1369.0, 332.7, 359.0, 70.8, and 89.5 ml/hr/kg, respectively.","Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8681489/),[ml] / [h·kg],359.0,97536,DB00338,Omeprazole
,8681489,clearance,"The mean clearance values of omeprazole in patterns G1, G2, G3, G4, and G5 were 1369.0, 332.7, 359.0, 70.8, and 89.5 ml/hr/kg, respectively.","Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8681489/),[ml] / [h·kg],70.8,97537,DB00338,Omeprazole
,8681489,clearance,"The mean clearance values of omeprazole in patterns G1, G2, G3, G4, and G5 were 1369.0, 332.7, 359.0, 70.8, and 89.5 ml/hr/kg, respectively.","Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8681489/),[ml] / [h·kg],89.5,97538,DB00338,Omeprazole
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,0.58,98193,DB00338,Omeprazole
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,2.1,98194,DB00338,Omeprazole
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,1.4,98195,DB00338,Omeprazole
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,1.1,98196,DB00338,Omeprazole
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,4.4,98197,DB00338,Omeprazole
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,0.5,98198,DB00338,Omeprazole
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,0.7,98199,DB00338,Omeprazole
,23222033,tmax,"Compared with controls, the RYGB group had brisk natriuresis, with significantly lower tmax for urine sodium (1.3 ± 0.5 vs 3.1 ± 2.3 hours, P < 0.02) and correspondingly lower tmax for furosemide (1.8 ± 0.3 vs 4.2 ± 1.2 hours, P = 0.006).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,1.3,98200,DB00338,Omeprazole
,23222033,tmax,"Compared with controls, the RYGB group had brisk natriuresis, with significantly lower tmax for urine sodium (1.3 ± 0.5 vs 3.1 ± 2.3 hours, P < 0.02) and correspondingly lower tmax for furosemide (1.8 ± 0.3 vs 4.2 ± 1.2 hours, P = 0.006).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,3.1,98201,DB00338,Omeprazole
,23222033,tmax,"Compared with controls, the RYGB group had brisk natriuresis, with significantly lower tmax for urine sodium (1.3 ± 0.5 vs 3.1 ± 2.3 hours, P < 0.02) and correspondingly lower tmax for furosemide (1.8 ± 0.3 vs 4.2 ± 1.2 hours, P = 0.006).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,1.8,98202,DB00338,Omeprazole
,23222033,tmax,"Compared with controls, the RYGB group had brisk natriuresis, with significantly lower tmax for urine sodium (1.3 ± 0.5 vs 3.1 ± 2.3 hours, P < 0.02) and correspondingly lower tmax for furosemide (1.8 ± 0.3 vs 4.2 ± 1.2 hours, P = 0.006).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,4.2,98203,DB00338,Omeprazole
,11136283,terminal disposition half-life,Lansoprazole's terminal disposition half-life was 1.11 h.,Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11136283/),h,1.11,98778,DB00338,Omeprazole
,11136283,half-lives,"Mean pH and serum gastrin returned to baseline with half-lives of 22 and 19 h, respectively.",Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11136283/),h,22,98779,DB00338,Omeprazole
,11136283,half-lives,"Mean pH and serum gastrin returned to baseline with half-lives of 22 and 19 h, respectively.",Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11136283/),h,19,98780,DB00338,Omeprazole
,25795100,Absolute bioavailability,Absolute bioavailability after 24 h transdermal delivery is 37 % of the applied rotigotine dose.,"An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25795100/),%,37,99596,DB00338,Omeprazole
>,25795100,apparent volume of distribution,The drug shows a high apparent volume of distribution (>2500 L) and a total body clearance of 300-600 L/h.,"An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25795100/),l,2500,99597,DB00338,Omeprazole
,25795100,total body clearance,The drug shows a high apparent volume of distribution (>2500 L) and a total body clearance of 300-600 L/h.,"An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25795100/),[l] / [h],300-600,99598,DB00338,Omeprazole
,19203529,AUC0-t,"Several pharmacokinetic (PK) parameters were determined from the plasma samples, and data from reference and test formulations in the plasma were represented such as AUC0-t (1,223.3 vs 1,284.3 ng x h/ml), [formula in text](1,311.1 vs 1,410.0 ng x h/ml), Cmax (598.7 vs 598.1 ng/ml), tmax (1.9 vs 1.9 h), t1/2 (1.3 vs 1.4 h) and Ke (0.67 vs 0.67 h-1), respectively.",Pharmacokinetics and bioequivalence of 20 mg omeprazole capsule in 24 healthy Korean male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203529/),[h·ng] / [ml],"1,223.3",100069,DB00338,Omeprazole
,19203529,AUC0-t,"Several pharmacokinetic (PK) parameters were determined from the plasma samples, and data from reference and test formulations in the plasma were represented such as AUC0-t (1,223.3 vs 1,284.3 ng x h/ml), [formula in text](1,311.1 vs 1,410.0 ng x h/ml), Cmax (598.7 vs 598.1 ng/ml), tmax (1.9 vs 1.9 h), t1/2 (1.3 vs 1.4 h) and Ke (0.67 vs 0.67 h-1), respectively.",Pharmacokinetics and bioequivalence of 20 mg omeprazole capsule in 24 healthy Korean male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203529/),[h·ng] / [ml],"1,284.3",100070,DB00338,Omeprazole
,19203529,AUC0-t,"Several pharmacokinetic (PK) parameters were determined from the plasma samples, and data from reference and test formulations in the plasma were represented such as AUC0-t (1,223.3 vs 1,284.3 ng x h/ml), [formula in text](1,311.1 vs 1,410.0 ng x h/ml), Cmax (598.7 vs 598.1 ng/ml), tmax (1.9 vs 1.9 h), t1/2 (1.3 vs 1.4 h) and Ke (0.67 vs 0.67 h-1), respectively.",Pharmacokinetics and bioequivalence of 20 mg omeprazole capsule in 24 healthy Korean male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203529/),[h·ng] / [ml],"1,311.1",100071,DB00338,Omeprazole
,19203529,AUC0-t,"Several pharmacokinetic (PK) parameters were determined from the plasma samples, and data from reference and test formulations in the plasma were represented such as AUC0-t (1,223.3 vs 1,284.3 ng x h/ml), [formula in text](1,311.1 vs 1,410.0 ng x h/ml), Cmax (598.7 vs 598.1 ng/ml), tmax (1.9 vs 1.9 h), t1/2 (1.3 vs 1.4 h) and Ke (0.67 vs 0.67 h-1), respectively.",Pharmacokinetics and bioequivalence of 20 mg omeprazole capsule in 24 healthy Korean male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203529/),[h·ng] / [ml],"1,410.0",100072,DB00338,Omeprazole
,19203529,Cmax,"Several pharmacokinetic (PK) parameters were determined from the plasma samples, and data from reference and test formulations in the plasma were represented such as AUC0-t (1,223.3 vs 1,284.3 ng x h/ml), [formula in text](1,311.1 vs 1,410.0 ng x h/ml), Cmax (598.7 vs 598.1 ng/ml), tmax (1.9 vs 1.9 h), t1/2 (1.3 vs 1.4 h) and Ke (0.67 vs 0.67 h-1), respectively.",Pharmacokinetics and bioequivalence of 20 mg omeprazole capsule in 24 healthy Korean male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203529/),[ng] / [ml],598.7,100073,DB00338,Omeprazole
,19203529,Cmax,"Several pharmacokinetic (PK) parameters were determined from the plasma samples, and data from reference and test formulations in the plasma were represented such as AUC0-t (1,223.3 vs 1,284.3 ng x h/ml), [formula in text](1,311.1 vs 1,410.0 ng x h/ml), Cmax (598.7 vs 598.1 ng/ml), tmax (1.9 vs 1.9 h), t1/2 (1.3 vs 1.4 h) and Ke (0.67 vs 0.67 h-1), respectively.",Pharmacokinetics and bioequivalence of 20 mg omeprazole capsule in 24 healthy Korean male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203529/),[ng] / [ml],598.1,100074,DB00338,Omeprazole
,19203529,tmax,"Several pharmacokinetic (PK) parameters were determined from the plasma samples, and data from reference and test formulations in the plasma were represented such as AUC0-t (1,223.3 vs 1,284.3 ng x h/ml), [formula in text](1,311.1 vs 1,410.0 ng x h/ml), Cmax (598.7 vs 598.1 ng/ml), tmax (1.9 vs 1.9 h), t1/2 (1.3 vs 1.4 h) and Ke (0.67 vs 0.67 h-1), respectively.",Pharmacokinetics and bioequivalence of 20 mg omeprazole capsule in 24 healthy Korean male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203529/),h,1.9,100075,DB00338,Omeprazole
,19203529,t1/2,"Several pharmacokinetic (PK) parameters were determined from the plasma samples, and data from reference and test formulations in the plasma were represented such as AUC0-t (1,223.3 vs 1,284.3 ng x h/ml), [formula in text](1,311.1 vs 1,410.0 ng x h/ml), Cmax (598.7 vs 598.1 ng/ml), tmax (1.9 vs 1.9 h), t1/2 (1.3 vs 1.4 h) and Ke (0.67 vs 0.67 h-1), respectively.",Pharmacokinetics and bioequivalence of 20 mg omeprazole capsule in 24 healthy Korean male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203529/),h,1.3,100076,DB00338,Omeprazole
,19203529,t1/2,"Several pharmacokinetic (PK) parameters were determined from the plasma samples, and data from reference and test formulations in the plasma were represented such as AUC0-t (1,223.3 vs 1,284.3 ng x h/ml), [formula in text](1,311.1 vs 1,410.0 ng x h/ml), Cmax (598.7 vs 598.1 ng/ml), tmax (1.9 vs 1.9 h), t1/2 (1.3 vs 1.4 h) and Ke (0.67 vs 0.67 h-1), respectively.",Pharmacokinetics and bioequivalence of 20 mg omeprazole capsule in 24 healthy Korean male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203529/),h,1.4,100077,DB00338,Omeprazole
,19203529,Ke,"Several pharmacokinetic (PK) parameters were determined from the plasma samples, and data from reference and test formulations in the plasma were represented such as AUC0-t (1,223.3 vs 1,284.3 ng x h/ml), [formula in text](1,311.1 vs 1,410.0 ng x h/ml), Cmax (598.7 vs 598.1 ng/ml), tmax (1.9 vs 1.9 h), t1/2 (1.3 vs 1.4 h) and Ke (0.67 vs 0.67 h-1), respectively.",Pharmacokinetics and bioequivalence of 20 mg omeprazole capsule in 24 healthy Korean male volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203529/),1/[h],0.67,100078,DB00338,Omeprazole
,12562448,Tmax,"Tmax occurred at 1.8 and 2.0 h with the 15-mg and 30-mg tablets, respectively.",Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12562448/),h,1.8,100191,DB00338,Omeprazole
,12562448,Tmax,"Tmax occurred at 1.8 and 2.0 h with the 15-mg and 30-mg tablets, respectively.",Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12562448/),h,2.0,100192,DB00338,Omeprazole
,12562448,terminal elimination half-lives (t1/2),The terminal elimination half-lives (t1/2) were identical in both dose groups (1.18 h).,Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12562448/),h,1.18,100193,DB00338,Omeprazole
,20733043,C(min),"A wide variability was observed (median values [interquartile range]: 3.80 mg/liter [1.75 to 7.53 mg/liter] for C(min), 14.70 mg/liter [10.57 to 19.64] for C(max), and 196.08 mg·h/liter [144.02 to 312.10 mg·h/liter] for estimated AUC(24)).",Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20733043/),[mg] / [l],3.80,100293,DB00338,Omeprazole
,20733043,C(max),"A wide variability was observed (median values [interquartile range]: 3.80 mg/liter [1.75 to 7.53 mg/liter] for C(min), 14.70 mg/liter [10.57 to 19.64] for C(max), and 196.08 mg·h/liter [144.02 to 312.10 mg·h/liter] for estimated AUC(24)).",Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20733043/),[mg] / [l],14.70,100294,DB00338,Omeprazole
,20733043,AUC(24),"A wide variability was observed (median values [interquartile range]: 3.80 mg/liter [1.75 to 7.53 mg/liter] for C(min), 14.70 mg/liter [10.57 to 19.64] for C(max), and 196.08 mg·h/liter [144.02 to 312.10 mg·h/liter] for estimated AUC(24)).",Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20733043/),[h·mg] / [l],196.08,100295,DB00338,Omeprazole
≥,20733043,C(min),"Optimal pharmacodynamic target attainment (defined as C(min) of ≥2 mg/liter and/or AUC(24)/MIC(90) ratio of >80) was obtained in about 60 to 70% of cases, but potential overexposure (defined as C(min) of ≥10 mg/liter and/or AUC(24) of ≥400 mg·h/liter) was documented in about 12% of cases.",Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20733043/),[mg] / [l],2,100296,DB00338,Omeprazole
>,20733043,AUC(24)/MIC(90) ratio,"Optimal pharmacodynamic target attainment (defined as C(min) of ≥2 mg/liter and/or AUC(24)/MIC(90) ratio of >80) was obtained in about 60 to 70% of cases, but potential overexposure (defined as C(min) of ≥10 mg/liter and/or AUC(24) of ≥400 mg·h/liter) was documented in about 12% of cases.",Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20733043/),,80,100297,DB00338,Omeprazole
≥,20733043,C(min),"Optimal pharmacodynamic target attainment (defined as C(min) of ≥2 mg/liter and/or AUC(24)/MIC(90) ratio of >80) was obtained in about 60 to 70% of cases, but potential overexposure (defined as C(min) of ≥10 mg/liter and/or AUC(24) of ≥400 mg·h/liter) was documented in about 12% of cases.",Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20733043/),[mg] / [l],10,100298,DB00338,Omeprazole
≥,20733043,AUC(24),"Optimal pharmacodynamic target attainment (defined as C(min) of ≥2 mg/liter and/or AUC(24)/MIC(90) ratio of >80) was obtained in about 60 to 70% of cases, but potential overexposure (defined as C(min) of ≥10 mg/liter and/or AUC(24) of ≥400 mg·h/liter) was documented in about 12% of cases.",Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20733043/),[h·mg] / [l],400,100299,DB00338,Omeprazole
>,25582505,extraction efficiency,"The extraction efficiency was >90.5%, and the matrix effects ranged from 84.3 to 114.2%.","Simultaneous determination of bupropion, metroprolol, midazolam, phenacetin, omeprazole and tolbutamide in rat plasma by UPLC-MS/MS and its application to cytochrome P450 activity study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25582505/),%,90.5,101195,DB00338,Omeprazole
,19281731,Cmax,"From serum data, the obtained values for test and reference products were 593.05 +/- 84.85 and 607.92 +/- 67.07 ng/ ml for Cmax; 1756.71 +/- 287.29 and 1786.90 +/- 280.17 ng-h/ml for AUC0-24; 1889.26 +/- 286.46 and 1929.18 +/- 284.33 ng-h/ml for AUC0- yen, respectively.",Relative bioavailability and pharmacokinetic study of omeprazole 20 mg enteric-coated tablet in healthy Bangladeshi volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19281731/),[ng] / [ml],593.05,102530,DB00338,Omeprazole
,19281731,Cmax,"From serum data, the obtained values for test and reference products were 593.05 +/- 84.85 and 607.92 +/- 67.07 ng/ ml for Cmax; 1756.71 +/- 287.29 and 1786.90 +/- 280.17 ng-h/ml for AUC0-24; 1889.26 +/- 286.46 and 1929.18 +/- 284.33 ng-h/ml for AUC0- yen, respectively.",Relative bioavailability and pharmacokinetic study of omeprazole 20 mg enteric-coated tablet in healthy Bangladeshi volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19281731/),[ng] / [ml],607.92,102531,DB00338,Omeprazole
,19281731,AUC0-24,"From serum data, the obtained values for test and reference products were 593.05 +/- 84.85 and 607.92 +/- 67.07 ng/ ml for Cmax; 1756.71 +/- 287.29 and 1786.90 +/- 280.17 ng-h/ml for AUC0-24; 1889.26 +/- 286.46 and 1929.18 +/- 284.33 ng-h/ml for AUC0- yen, respectively.",Relative bioavailability and pharmacokinetic study of omeprazole 20 mg enteric-coated tablet in healthy Bangladeshi volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19281731/),[ng-h] / [ml],1756.71,102532,DB00338,Omeprazole
,19281731,AUC0-24,"From serum data, the obtained values for test and reference products were 593.05 +/- 84.85 and 607.92 +/- 67.07 ng/ ml for Cmax; 1756.71 +/- 287.29 and 1786.90 +/- 280.17 ng-h/ml for AUC0-24; 1889.26 +/- 286.46 and 1929.18 +/- 284.33 ng-h/ml for AUC0- yen, respectively.",Relative bioavailability and pharmacokinetic study of omeprazole 20 mg enteric-coated tablet in healthy Bangladeshi volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19281731/),[ng-h] / [ml],1786.90,102533,DB00338,Omeprazole
,19281731,AUC0- yen,"From serum data, the obtained values for test and reference products were 593.05 +/- 84.85 and 607.92 +/- 67.07 ng/ ml for Cmax; 1756.71 +/- 287.29 and 1786.90 +/- 280.17 ng-h/ml for AUC0-24; 1889.26 +/- 286.46 and 1929.18 +/- 284.33 ng-h/ml for AUC0- yen, respectively.",Relative bioavailability and pharmacokinetic study of omeprazole 20 mg enteric-coated tablet in healthy Bangladeshi volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19281731/),[ng-h] / [ml],1889.26,102534,DB00338,Omeprazole
,19281731,AUC0- yen,"From serum data, the obtained values for test and reference products were 593.05 +/- 84.85 and 607.92 +/- 67.07 ng/ ml for Cmax; 1756.71 +/- 287.29 and 1786.90 +/- 280.17 ng-h/ml for AUC0-24; 1889.26 +/- 286.46 and 1929.18 +/- 284.33 ng-h/ml for AUC0- yen, respectively.",Relative bioavailability and pharmacokinetic study of omeprazole 20 mg enteric-coated tablet in healthy Bangladeshi volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19281731/),[ng-h] / [ml],1929.18,102535,DB00338,Omeprazole
,19740393,area under the plasma concentration vs time curve (AUC),"PPI administration did not significantly affect the imatinib area under the plasma concentration vs time curve (AUC) (34.1 microg ml(-1) h alone vs 33.1 microg ml(-1) h with omeprazole, P= 0.64; 80% power), maximum plasma concentration (C(max)) (2.04 microg ml(-1) alone vs 2.02 microg ml(-1) with omeprazole, P= 0.97), or half-life (13.4 h alone vs 14.1 h with omeprazole, P= 0.13).",Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740393/),[h·μg] / [ml],34.1,102887,DB00338,Omeprazole
,19740393,area under the plasma concentration vs time curve (AUC),"PPI administration did not significantly affect the imatinib area under the plasma concentration vs time curve (AUC) (34.1 microg ml(-1) h alone vs 33.1 microg ml(-1) h with omeprazole, P= 0.64; 80% power), maximum plasma concentration (C(max)) (2.04 microg ml(-1) alone vs 2.02 microg ml(-1) with omeprazole, P= 0.97), or half-life (13.4 h alone vs 14.1 h with omeprazole, P= 0.13).",Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740393/),[h·μg] / [ml],33.1,102888,DB00338,Omeprazole
,19740393,maximum plasma concentration (C(max)),"PPI administration did not significantly affect the imatinib area under the plasma concentration vs time curve (AUC) (34.1 microg ml(-1) h alone vs 33.1 microg ml(-1) h with omeprazole, P= 0.64; 80% power), maximum plasma concentration (C(max)) (2.04 microg ml(-1) alone vs 2.02 microg ml(-1) with omeprazole, P= 0.97), or half-life (13.4 h alone vs 14.1 h with omeprazole, P= 0.13).",Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740393/),[μg] / [ml],2.04,102889,DB00338,Omeprazole
,19740393,maximum plasma concentration (C(max)),"PPI administration did not significantly affect the imatinib area under the plasma concentration vs time curve (AUC) (34.1 microg ml(-1) h alone vs 33.1 microg ml(-1) h with omeprazole, P= 0.64; 80% power), maximum plasma concentration (C(max)) (2.04 microg ml(-1) alone vs 2.02 microg ml(-1) with omeprazole, P= 0.97), or half-life (13.4 h alone vs 14.1 h with omeprazole, P= 0.13).",Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740393/),[μg] / [ml],2.02,102890,DB00338,Omeprazole
,19740393,half-life,"PPI administration did not significantly affect the imatinib area under the plasma concentration vs time curve (AUC) (34.1 microg ml(-1) h alone vs 33.1 microg ml(-1) h with omeprazole, P= 0.64; 80% power), maximum plasma concentration (C(max)) (2.04 microg ml(-1) alone vs 2.02 microg ml(-1) with omeprazole, P= 0.97), or half-life (13.4 h alone vs 14.1 h with omeprazole, P= 0.13).",Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740393/),h,13.4,102891,DB00338,Omeprazole
,19740393,half-life,"PPI administration did not significantly affect the imatinib area under the plasma concentration vs time curve (AUC) (34.1 microg ml(-1) h alone vs 33.1 microg ml(-1) h with omeprazole, P= 0.64; 80% power), maximum plasma concentration (C(max)) (2.04 microg ml(-1) alone vs 2.02 microg ml(-1) with omeprazole, P= 0.97), or half-life (13.4 h alone vs 14.1 h with omeprazole, P= 0.13).",Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740393/),h,14.1,102892,DB00338,Omeprazole
,22900583,metabolic ratio (MR),"Midazolam metabolic ratio (MR) dramatically decreased in presence of ritonavir (6.7 ± 2.6 versus 0.13 ± 0.07) reflecting an almost complete inhibition of CYP3A4, whereas omeprazole, flurbiprofen and bupropion MR were not affected.",Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22900583/),,6.7,104991,DB00338,Omeprazole
,22900583,metabolic ratio (MR),"Midazolam metabolic ratio (MR) dramatically decreased in presence of ritonavir (6.7 ± 2.6 versus 0.13 ± 0.07) reflecting an almost complete inhibition of CYP3A4, whereas omeprazole, flurbiprofen and bupropion MR were not affected.",Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22900583/),,0.13,104992,DB00338,Omeprazole
,16478003,terminal half live (T1/2),"After the single administrations, plasma concentrations reached a maximum between 2.5 and 4.3 h post dose, and thereafter decreased according to a terminal half live (T1/2) ranging from 4.8 to 7.7 h.","Pharmacokinetics of tenatoprazole, a newly synthesized proton pump inhibitor, in healthy male Caucasian volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16478003/),h,4.8 to 7.7,105027,DB00338,Omeprazole
,12959285,CL0,"The mean clearance and elimination half-life of lansoprazole were about 40% lower and higher, respectively, in the older subjects (CL0: 12-14 vs 20-24 1 h(-1); t1/2,z: 1.90-2.19 vs 1.26-1.44 h).",Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959285/),[1] / [h],12-14,105028,DB00338,Omeprazole
,12959285,CL0,"The mean clearance and elimination half-life of lansoprazole were about 40% lower and higher, respectively, in the older subjects (CL0: 12-14 vs 20-24 1 h(-1); t1/2,z: 1.90-2.19 vs 1.26-1.44 h).",Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959285/),[1] / [h],20-24,105029,DB00338,Omeprazole
,12959285,"t1/2,z","The mean clearance and elimination half-life of lansoprazole were about 40% lower and higher, respectively, in the older subjects (CL0: 12-14 vs 20-24 1 h(-1); t1/2,z: 1.90-2.19 vs 1.26-1.44 h).",Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959285/),h,1.90-2.19,105030,DB00338,Omeprazole
,12959285,"t1/2,z","The mean clearance and elimination half-life of lansoprazole were about 40% lower and higher, respectively, in the older subjects (CL0: 12-14 vs 20-24 1 h(-1); t1/2,z: 1.90-2.19 vs 1.26-1.44 h).",Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959285/),h,1.26-1.44,105031,DB00338,Omeprazole
,12959285,AUC,"However, the AUC associated with a 50% decrease in acid secretion was similar (849 vs 892 ng ml(-1) h) for both age groups.",Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959285/),[h·ng] / [ml],849,105032,DB00338,Omeprazole
,12959285,AUC,"However, the AUC associated with a 50% decrease in acid secretion was similar (849 vs 892 ng ml(-1) h) for both age groups.",Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959285/),[h·ng] / [ml],892,105033,DB00338,Omeprazole
,9200535,recovery,The recovery study of authentic analytes added to plasma at 0.05 to 0.25 microg/ml was 95.37+/-2.15% and the lowest amount of lansoprazole that could be detected was 20 ng/ml plasma.,High-performance thin-layer chromatographic method for the detection and determination of lansoprazole in human plasma and its use in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9200535/),%,95.37,105939,DB00338,Omeprazole
,10974394,buccal bioavailability,The buccal bioavailability of omeprazole in hamsters was 13.7+/-3.2%.,Formulation and in vivo evaluation of omeprazole buccal adhesive tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10974394/),%,13.7,107183,DB00338,Omeprazole
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],482,108437,DB00338,Omeprazole
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],206,108438,DB00338,Omeprazole
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],167,108439,DB00338,Omeprazole
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],<,108440,DB00338,Omeprazole
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],100,108441,DB00338,Omeprazole
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],3160,108442,DB00338,Omeprazole
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],2430,108443,DB00338,Omeprazole
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],937,108444,DB00338,Omeprazole
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],534,108445,DB00338,Omeprazole
,9357389,AUC(0-6),Mean omeprazole AUC(0-6) increased from 1660 to 2265 nmol/L.hr in extensive metabolizers and from 7715 to 15319 nmol/L.hr in poor metabolizers after intake of 200 mg ketoconazole.,Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],1660,108446,DB00338,Omeprazole
,9357389,AUC(0-6),Mean omeprazole AUC(0-6) increased from 1660 to 2265 nmol/L.hr in extensive metabolizers and from 7715 to 15319 nmol/L.hr in poor metabolizers after intake of 200 mg ketoconazole.,Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],7715 to 15319,108447,DB00338,Omeprazole
,2177296,percent inhibition,"Repeated once-daily infusion (15 min) of pantoprazole resulted in a rapidly increasing pharmacodynamic effect: as compared to placebo the mean percent inhibition of acid output measured from 1 to 3 h after start of infusion was 22%, 63% and 78% for the 15 mg dose, and 56%, 97% and 99% for the 30 mg dose on days 1, 4 and 5, respectively.","Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2177296/),%,22,111807,DB00338,Omeprazole
,2177296,percent inhibition,"Repeated once-daily infusion (15 min) of pantoprazole resulted in a rapidly increasing pharmacodynamic effect: as compared to placebo the mean percent inhibition of acid output measured from 1 to 3 h after start of infusion was 22%, 63% and 78% for the 15 mg dose, and 56%, 97% and 99% for the 30 mg dose on days 1, 4 and 5, respectively.","Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2177296/),%,63,111808,DB00338,Omeprazole
,2177296,percent inhibition,"Repeated once-daily infusion (15 min) of pantoprazole resulted in a rapidly increasing pharmacodynamic effect: as compared to placebo the mean percent inhibition of acid output measured from 1 to 3 h after start of infusion was 22%, 63% and 78% for the 15 mg dose, and 56%, 97% and 99% for the 30 mg dose on days 1, 4 and 5, respectively.","Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2177296/),%,78,111809,DB00338,Omeprazole
,2177296,percent inhibition,"Repeated once-daily infusion (15 min) of pantoprazole resulted in a rapidly increasing pharmacodynamic effect: as compared to placebo the mean percent inhibition of acid output measured from 1 to 3 h after start of infusion was 22%, 63% and 78% for the 15 mg dose, and 56%, 97% and 99% for the 30 mg dose on days 1, 4 and 5, respectively.","Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2177296/),%,56,111810,DB00338,Omeprazole
,2177296,percent inhibition,"Repeated once-daily infusion (15 min) of pantoprazole resulted in a rapidly increasing pharmacodynamic effect: as compared to placebo the mean percent inhibition of acid output measured from 1 to 3 h after start of infusion was 22%, 63% and 78% for the 15 mg dose, and 56%, 97% and 99% for the 30 mg dose on days 1, 4 and 5, respectively.","Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2177296/),%,97,111811,DB00338,Omeprazole
,2177296,percent inhibition,"Repeated once-daily infusion (15 min) of pantoprazole resulted in a rapidly increasing pharmacodynamic effect: as compared to placebo the mean percent inhibition of acid output measured from 1 to 3 h after start of infusion was 22%, 63% and 78% for the 15 mg dose, and 56%, 97% and 99% for the 30 mg dose on days 1, 4 and 5, respectively.","Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2177296/),%,99,111812,DB00338,Omeprazole
,15752376,"AUC0, infinity","During placebo administration, the mean AUC0, infinity of lansoprazole in homozygous EMs, heterozygous EMs and PMs were 4652 (95% CI, 2294, 7009) ng ml(-1) h, 8299 (4784, 11814) ng ml(-1) h and 25293 (17643, 32943) ng ml(-1) h (P < 0.001), respectively.",Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752376/),[h·ng] / [ml],4652,112416,DB00338,Omeprazole
,15752376,"AUC0, infinity","During placebo administration, the mean AUC0, infinity of lansoprazole in homozygous EMs, heterozygous EMs and PMs were 4652 (95% CI, 2294, 7009) ng ml(-1) h, 8299 (4784, 11814) ng ml(-1) h and 25293 (17643, 32943) ng ml(-1) h (P < 0.001), respectively.",Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752376/),[h·ng] / [ml],8299,112417,DB00338,Omeprazole
,15752376,"AUC0, infinity","During placebo administration, the mean AUC0, infinity of lansoprazole in homozygous EMs, heterozygous EMs and PMs were 4652 (95% CI, 2294, 7009) ng ml(-1) h, 8299 (4784, 11814) ng ml(-1) h and 25293 (17643, 32943) ng ml(-1) h (P < 0.001), respectively.",Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752376/),[h·ng] / [ml],25293,112418,DB00338,Omeprazole
less,19166730,limits of detection,"The limits of detection and quantification were less than 6 and 25ngmL(-1), respectively.",Analysis of omeprazole and its main metabolites by liquid chromatography using hybrid micellar mobile phases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19166730/),1/[ngml],6,112622,DB00338,Omeprazole
less,19166730,limits of detection,"The limits of detection and quantification were less than 6 and 25ngmL(-1), respectively.",Analysis of omeprazole and its main metabolites by liquid chromatography using hybrid micellar mobile phases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19166730/),1/[ngml],25,112623,DB00338,Omeprazole
,19166730,Recoveries,"Recoveries in micellar medium, plasma and urine matrices were in the 98-102% range.",Analysis of omeprazole and its main metabolites by liquid chromatography using hybrid micellar mobile phases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19166730/),%,98-102,112624,DB00338,Omeprazole
,18549670,area under the plasma concentration-time curve from time zero to infinity (AUC),"After intravenous administration of omeprazole (20 mgkg(-1)) to U-ARF rats, the area under the plasma concentration-time curve from time zero to infinity (AUC) was significantly reduced (371 vs 494 microg min mL(-1)), possibly due to the significantly faster non-renal clearance (56.6 vs 41.2 mL min(-1) kg(-1)) compared with control rats.",Faster clearance of omeprazole in rats with acute renal failure induced by uranyl nitrate: contribution of increased expression of hepatic cytochrome P450 (CYP) 3A1 and intestinal CYP1A and 3A subfamilies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18549670/),[min·μg] / [ml],371,112714,DB00338,Omeprazole
,18549670,area under the plasma concentration-time curve from time zero to infinity (AUC),"After intravenous administration of omeprazole (20 mgkg(-1)) to U-ARF rats, the area under the plasma concentration-time curve from time zero to infinity (AUC) was significantly reduced (371 vs 494 microg min mL(-1)), possibly due to the significantly faster non-renal clearance (56.6 vs 41.2 mL min(-1) kg(-1)) compared with control rats.",Faster clearance of omeprazole in rats with acute renal failure induced by uranyl nitrate: contribution of increased expression of hepatic cytochrome P450 (CYP) 3A1 and intestinal CYP1A and 3A subfamilies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18549670/),[min·μg] / [ml],494,112715,DB00338,Omeprazole
,18549670,non-renal clearance,"After intravenous administration of omeprazole (20 mgkg(-1)) to U-ARF rats, the area under the plasma concentration-time curve from time zero to infinity (AUC) was significantly reduced (371 vs 494 microg min mL(-1)), possibly due to the significantly faster non-renal clearance (56.6 vs 41.2 mL min(-1) kg(-1)) compared with control rats.",Faster clearance of omeprazole in rats with acute renal failure induced by uranyl nitrate: contribution of increased expression of hepatic cytochrome P450 (CYP) 3A1 and intestinal CYP1A and 3A subfamilies. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18549670/),[ml] / [kg·min],56.6,112716,DB00338,Omeprazole
,18549670,non-renal clearance,"After intravenous administration of omeprazole (20 mgkg(-1)) to U-ARF rats, the area under the plasma concentration-time curve from time zero to infinity (AUC) was significantly reduced (371 vs 494 microg min mL(-1)), possibly due to the significantly faster non-renal clearance (56.6 vs 41.2 mL min(-1) kg(-1)) compared with control rats.",Faster clearance of omeprazole in rats with acute renal failure induced by uranyl nitrate: contribution of increased expression of hepatic cytochrome P450 (CYP) 3A1 and intestinal CYP1A and 3A subfamilies. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18549670/),[ml] / [kg·min],41.2,112717,DB00338,Omeprazole
,18549670,AUC,"After oral administration of omeprazole (40 mgkg(-1)) to U-ARF rats, the AUC was also significantly reduced (89.3 vs 235 microg min mL(-1)) compared with control rats.",Faster clearance of omeprazole in rats with acute renal failure induced by uranyl nitrate: contribution of increased expression of hepatic cytochrome P450 (CYP) 3A1 and intestinal CYP1A and 3A subfamilies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18549670/),[min·μg] / [ml],89.3,112718,DB00338,Omeprazole
,18549670,AUC,"After oral administration of omeprazole (40 mgkg(-1)) to U-ARF rats, the AUC was also significantly reduced (89.3 vs 235 microg min mL(-1)) compared with control rats.",Faster clearance of omeprazole in rats with acute renal failure induced by uranyl nitrate: contribution of increased expression of hepatic cytochrome P450 (CYP) 3A1 and intestinal CYP1A and 3A subfamilies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18549670/),[min·μg] / [ml],235,112719,DB00338,Omeprazole
,21455427,AUC(0-24),"The decrease in AUC(0-24) (22.78 ± 4.71 to 10.46 ± 2.29), C(max) (2.76 ± 0.77 to 1.412±1.08), T(max) (2.83 ± 0.17 to 3 ± 0.40) was statistically significant (P < 0.05) when esomeprazole was given along with carbamazepine.",Effect of esomeprazole on the pharmacokinetics of carbamazepine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21455427/),,22.78,113108,DB00338,Omeprazole
,21455427,AUC(0-24),"The decrease in AUC(0-24) (22.78 ± 4.71 to 10.46 ± 2.29), C(max) (2.76 ± 0.77 to 1.412±1.08), T(max) (2.83 ± 0.17 to 3 ± 0.40) was statistically significant (P < 0.05) when esomeprazole was given along with carbamazepine.",Effect of esomeprazole on the pharmacokinetics of carbamazepine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21455427/),,10.46,113109,DB00338,Omeprazole
,21455427,C(max),"The decrease in AUC(0-24) (22.78 ± 4.71 to 10.46 ± 2.29), C(max) (2.76 ± 0.77 to 1.412±1.08), T(max) (2.83 ± 0.17 to 3 ± 0.40) was statistically significant (P < 0.05) when esomeprazole was given along with carbamazepine.",Effect of esomeprazole on the pharmacokinetics of carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21455427/),,2.76,113110,DB00338,Omeprazole
,21455427,C(max),"The decrease in AUC(0-24) (22.78 ± 4.71 to 10.46 ± 2.29), C(max) (2.76 ± 0.77 to 1.412±1.08), T(max) (2.83 ± 0.17 to 3 ± 0.40) was statistically significant (P < 0.05) when esomeprazole was given along with carbamazepine.",Effect of esomeprazole on the pharmacokinetics of carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21455427/),,1.412,113111,DB00338,Omeprazole
,21455427,T(max),"The decrease in AUC(0-24) (22.78 ± 4.71 to 10.46 ± 2.29), C(max) (2.76 ± 0.77 to 1.412±1.08), T(max) (2.83 ± 0.17 to 3 ± 0.40) was statistically significant (P < 0.05) when esomeprazole was given along with carbamazepine.",Effect of esomeprazole on the pharmacokinetics of carbamazepine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21455427/),,2.83,113112,DB00338,Omeprazole
,21455427,T(max),"The decrease in AUC(0-24) (22.78 ± 4.71 to 10.46 ± 2.29), C(max) (2.76 ± 0.77 to 1.412±1.08), T(max) (2.83 ± 0.17 to 3 ± 0.40) was statistically significant (P < 0.05) when esomeprazole was given along with carbamazepine.",Effect of esomeprazole on the pharmacokinetics of carbamazepine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21455427/),,3,113113,DB00338,Omeprazole
,10391666,AUC,"The pharmacokinetics of lansoprazole were significantly different among groups; AUC values were 1.55+/-0.20 microg x h/mL in white extensive metabolizers, 7.01+/-0.72 microg x hr/mL in Korean extensive metabolizers, and 14.34+/-2.60 microg x h/mL in poor metabolizers (P < .001).",Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391666/),[h·μg] / [ml],1.55,113122,DB00338,Omeprazole
,10391666,AUC,"The pharmacokinetics of lansoprazole were significantly different among groups; AUC values were 1.55+/-0.20 microg x h/mL in white extensive metabolizers, 7.01+/-0.72 microg x hr/mL in Korean extensive metabolizers, and 14.34+/-2.60 microg x h/mL in poor metabolizers (P < .001).",Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391666/),[h·μg] / [ml],7.01,113123,DB00338,Omeprazole
,10391666,AUC,"The pharmacokinetics of lansoprazole were significantly different among groups; AUC values were 1.55+/-0.20 microg x h/mL in white extensive metabolizers, 7.01+/-0.72 microg x hr/mL in Korean extensive metabolizers, and 14.34+/-2.60 microg x h/mL in poor metabolizers (P < .001).",Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391666/),[h·μg] / [ml],14.34,113124,DB00338,Omeprazole
,6668312,sensitivity,"Omeprazole, a substituted benzimidazole which suppresses gastric acid secretion, and its sulphone and sulphide metabolites were simultaneously measured in human plasma and urine using a selective, reversed-phase, high-performance liquid chromatographic method with a sensitivity of 5 ng/ml for omeprazole, 30 ng/ml for omeprazole sulphone, and 50 ng/ml for omeprazole sulphide.",Simultaneous high-performance liquid chromatographic analysis of omeprazole and its sulphone and sulphide metabolites in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668312/),[ng] / [ml],5,113264,DB00338,Omeprazole
,6668312,sensitivity,"Omeprazole, a substituted benzimidazole which suppresses gastric acid secretion, and its sulphone and sulphide metabolites were simultaneously measured in human plasma and urine using a selective, reversed-phase, high-performance liquid chromatographic method with a sensitivity of 5 ng/ml for omeprazole, 30 ng/ml for omeprazole sulphone, and 50 ng/ml for omeprazole sulphide.",Simultaneous high-performance liquid chromatographic analysis of omeprazole and its sulphone and sulphide metabolites in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668312/),[ng] / [ml],30,113265,DB00338,Omeprazole
,6668312,sensitivity,"Omeprazole, a substituted benzimidazole which suppresses gastric acid secretion, and its sulphone and sulphide metabolites were simultaneously measured in human plasma and urine using a selective, reversed-phase, high-performance liquid chromatographic method with a sensitivity of 5 ng/ml for omeprazole, 30 ng/ml for omeprazole sulphone, and 50 ng/ml for omeprazole sulphide.",Simultaneous high-performance liquid chromatographic analysis of omeprazole and its sulphone and sulphide metabolites in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668312/),[ng] / [ml],50,113266,DB00338,Omeprazole
,6668312,Peak plasma concentrations,"Peak plasma concentrations for omeprazole of 240 and 520 ng/ml, and for omeprazole sulphone of 320 and 400 ng/ml, were reached between 3 and 4 h post-dose.",Simultaneous high-performance liquid chromatographic analysis of omeprazole and its sulphone and sulphide metabolites in human plasma and urine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668312/),[ng] / [ml],240,113267,DB00338,Omeprazole
,6668312,Peak plasma concentrations,"Peak plasma concentrations for omeprazole of 240 and 520 ng/ml, and for omeprazole sulphone of 320 and 400 ng/ml, were reached between 3 and 4 h post-dose.",Simultaneous high-performance liquid chromatographic analysis of omeprazole and its sulphone and sulphide metabolites in human plasma and urine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668312/),[ng] / [ml],520,113268,DB00338,Omeprazole
,6668312,Peak plasma concentrations,"Peak plasma concentrations for omeprazole of 240 and 520 ng/ml, and for omeprazole sulphone of 320 and 400 ng/ml, were reached between 3 and 4 h post-dose.",Simultaneous high-performance liquid chromatographic analysis of omeprazole and its sulphone and sulphide metabolites in human plasma and urine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668312/),[ng] / [ml],320,113269,DB00338,Omeprazole
,6668312,Peak plasma concentrations,"Peak plasma concentrations for omeprazole of 240 and 520 ng/ml, and for omeprazole sulphone of 320 and 400 ng/ml, were reached between 3 and 4 h post-dose.",Simultaneous high-performance liquid chromatographic analysis of omeprazole and its sulphone and sulphide metabolites in human plasma and urine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668312/),[ng] / [ml],400,113270,DB00338,Omeprazole
,6668312,apparent half-lives,"Omeprazole concentrations fell rapidly with apparent half-lives of about 40 min, and concentrations of both omeprazole and the sulphone metabolite were below the minimal detectable level by 6-8 h.",Simultaneous high-performance liquid chromatographic analysis of omeprazole and its sulphone and sulphide metabolites in human plasma and urine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668312/),min,40,113271,DB00338,Omeprazole
,10589372,bioavailability,"Mexiletine, a class Ib antiarrhythmic agent, is rapidly and completely absorbed following oral administration with a bioavailability of about 90%.",Clinical pharmacokinetics of mexiletine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),%,90,113401,DB00338,Omeprazole
,10589372,volume of distribution,Its volume of distribution is large and varies from 5 to 9 L/kg in healthy individuals.,Clinical pharmacokinetics of mexiletine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),[l] / [kg],5 to 9,113402,DB00338,Omeprazole
,10589372,elimination half-life,Mexiletine is eliminated slowly in humans (with an elimination half-life of 10 hours).,Clinical pharmacokinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),h,10,113403,DB00338,Omeprazole
,2044903,bioavailability,"Mean (+/- SEM) bioavailability of oral omeprazole for all patients was 68% +/- 16%, which was similar to the bioavailability reported previously for normal subjects.",Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044903/),%,68,113747,DB00338,Omeprazole
,2044903,bioavailability,"Three patients had a significantly lower bioavailability (20% +/- 8%) than the others, and their basal acid outputs were significantly higher than those of the other 7 patients.",Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044903/),%,20,113748,DB00338,Omeprazole
,2044903,elimination half-lives,The mean (+/- SEM) elimination half-lives of IV and oral omeprazole were not different (2.3 +/- 0.4 vs. 2.4 +/- 0.5 hours) but were significantly longer than those reported previously for normal subjects (P less than 0.02).,Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044903/),h,2.3,113749,DB00338,Omeprazole
,2044903,elimination half-lives,The mean (+/- SEM) elimination half-lives of IV and oral omeprazole were not different (2.3 +/- 0.4 vs. 2.4 +/- 0.5 hours) but were significantly longer than those reported previously for normal subjects (P less than 0.02).,Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044903/),h,2.4,113750,DB00338,Omeprazole
,2044903,durations of action,The mean durations of action of IV and oral omeprazole were not significantly different (34 +/- 7.2 vs. 35 +/- 6.2 hours).,Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044903/),h,34,113751,DB00338,Omeprazole
,2044903,durations of action,The mean durations of action of IV and oral omeprazole were not significantly different (34 +/- 7.2 vs. 35 +/- 6.2 hours).,Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044903/),h,35,113752,DB00338,Omeprazole
,26257511,Cmax,"The Cmax (mean ± standard deviation) and AUC0-t (mean ± standard deviation) for naproxen in HCP1004 were 61.67 ± 15.16 µg/mL and 1,206.52 ± 166.46 h · µg/mL, respectively; in VIMOVO(®); these values were 61.85 ± 14.54 µg/mL and 1,211.44 ± 170.01 h · µg/mL, respectively.",Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257511/),[μg] / [ml],61.67,113794,DB00338,Omeprazole
,26257511,Cmax,"The Cmax (mean ± standard deviation) and AUC0-t (mean ± standard deviation) for naproxen in HCP1004 were 61.67 ± 15.16 µg/mL and 1,206.52 ± 166.46 h · µg/mL, respectively; in VIMOVO(®); these values were 61.85 ± 14.54 µg/mL and 1,211.44 ± 170.01 h · µg/mL, respectively.",Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257511/),[μg] / [ml],61.85,113795,DB00338,Omeprazole
,26257511,AUC0-t,"The Cmax (mean ± standard deviation) and AUC0-t (mean ± standard deviation) for naproxen in HCP1004 were 61.67 ± 15.16 µg/mL and 1,206.52 ± 166.46 h · µg/mL, respectively; in VIMOVO(®); these values were 61.85 ± 14.54 µg/mL and 1,211.44 ± 170.01 h · µg/mL, respectively.",Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257511/),[h·μg] / [ml],"1,206.52",113796,DB00338,Omeprazole
,26257511,AUC0-t,"The Cmax (mean ± standard deviation) and AUC0-t (mean ± standard deviation) for naproxen in HCP1004 were 61.67 ± 15.16 µg/mL and 1,206.52 ± 166.46 h · µg/mL, respectively; in VIMOVO(®); these values were 61.85 ± 14.54 µg/mL and 1,211.44 ± 170.01 h · µg/mL, respectively.",Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257511/),[h·μg] / [ml],"1,211.44",113797,DB00338,Omeprazole
,26257511,Cmax,"The Cmax and AUC0-t for esomeprazole in HCP1004 were 658.21 ± 510.91 ng/mL and 1,109.11 ± 1,111.59 h · ng/mL, respectively; for VIMOVO(®), these values were 595.09 ± 364.23 ng/mL and 1,015.12 ± 952.98 h · ng/mL, respectively.",Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257511/),[ng] / [ml],658.21,113798,DB00338,Omeprazole
,26257511,Cmax,"The Cmax and AUC0-t for esomeprazole in HCP1004 were 658.21 ± 510.91 ng/mL and 1,109.11 ± 1,111.59 h · ng/mL, respectively; for VIMOVO(®), these values were 595.09 ± 364.23 ng/mL and 1,015.12 ± 952.98 h · ng/mL, respectively.",Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257511/),[ng] / [ml],595.09,113799,DB00338,Omeprazole
,26257511,AUC0-t,"The Cmax and AUC0-t for esomeprazole in HCP1004 were 658.21 ± 510.91 ng/mL and 1,109.11 ± 1,111.59 h · ng/mL, respectively; for VIMOVO(®), these values were 595.09 ± 364.23 ng/mL and 1,015.12 ± 952.98 h · ng/mL, respectively.",Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257511/),[h·ng] / [ml],"1,109.11",113800,DB00338,Omeprazole
,26257511,AUC0-t,"The Cmax and AUC0-t for esomeprazole in HCP1004 were 658.21 ± 510.91 ng/mL and 1,109.11 ± 1,111.59 h · ng/mL, respectively; for VIMOVO(®), these values were 595.09 ± 364.23 ng/mL and 1,015.12 ± 952.98 h · ng/mL, respectively.",Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257511/),[h·ng] / [ml],"1,015.12",113801,DB00338,Omeprazole
,27019158,AUC0-∞,"We found geometric mean (gMean) AUC0-∞ values for faldaprevir of 48 200, 37 900 and 36 000 ng h/ml under the fed, fasted and omeprazole coadministration conditions respectively.","Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy participants. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27019158/),[h·ng] / [ml],48 200,114380,DB00338,Omeprazole
,27019158,AUC0-∞,"We found geometric mean (gMean) AUC0-∞ values for faldaprevir of 48 200, 37 900 and 36 000 ng h/ml under the fed, fasted and omeprazole coadministration conditions respectively.","Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy participants. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27019158/),[h·ng] / [ml],37 900,114381,DB00338,Omeprazole
,27019158,AUC0-∞,"We found geometric mean (gMean) AUC0-∞ values for faldaprevir of 48 200, 37 900 and 36 000 ng h/ml under the fed, fasted and omeprazole coadministration conditions respectively.","Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy participants. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27019158/),[h·ng] / [ml],36 000,114382,DB00338,Omeprazole
,27019158,Cmax,"Similarly, gMean Cmax values for faldaprevir were 2600, 2030, 1920 ng/ml under the same respective conditions.","Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy participants. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27019158/),[ng] / [ml],2600,114383,DB00338,Omeprazole
,27019158,Cmax,"Similarly, gMean Cmax values for faldaprevir were 2600, 2030, 1920 ng/ml under the same respective conditions.","Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy participants. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27019158/),[ng] / [ml],2030,114384,DB00338,Omeprazole
,27019158,Cmax,"Similarly, gMean Cmax values for faldaprevir were 2600, 2030, 1920 ng/ml under the same respective conditions.","Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy participants. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27019158/),[ng] / [ml],1920,114385,DB00338,Omeprazole
,26398674,blood concentration,"The mean omeprazole blood concentration before usage the next dose, (trough level) were 0.12±0.08 µg/ml and 0.18±0.15 µg/ml for granule and suspension groups, respectively and mean blood level after dosing (C2 peak level) were 0.68±0.61 µg/ml and 0.86±0.76 µg/ml for granule and suspension groups, respectively.","Pharmacokinetic Comparison of Omeprazole Granule and Suspension Forms in Children: A Randomized, Parallel Pilot Trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26398674/),[μg] / [ml],0.12,114792,DB00338,Omeprazole
,26398674,blood concentration,"The mean omeprazole blood concentration before usage the next dose, (trough level) were 0.12±0.08 µg/ml and 0.18±0.15 µg/ml for granule and suspension groups, respectively and mean blood level after dosing (C2 peak level) were 0.68±0.61 µg/ml and 0.86±0.76 µg/ml for granule and suspension groups, respectively.","Pharmacokinetic Comparison of Omeprazole Granule and Suspension Forms in Children: A Randomized, Parallel Pilot Trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26398674/),[μg] / [ml],0.18,114793,DB00338,Omeprazole
,26398674,blood level after dosing (C2 peak level),"The mean omeprazole blood concentration before usage the next dose, (trough level) were 0.12±0.08 µg/ml and 0.18±0.15 µg/ml for granule and suspension groups, respectively and mean blood level after dosing (C2 peak level) were 0.68±0.61 µg/ml and 0.86±0.76 µg/ml for granule and suspension groups, respectively.","Pharmacokinetic Comparison of Omeprazole Granule and Suspension Forms in Children: A Randomized, Parallel Pilot Trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26398674/),[μg] / [ml],0.68,114794,DB00338,Omeprazole
,26398674,blood level after dosing (C2 peak level),"The mean omeprazole blood concentration before usage the next dose, (trough level) were 0.12±0.08 µg/ml and 0.18±0.15 µg/ml for granule and suspension groups, respectively and mean blood level after dosing (C2 peak level) were 0.68±0.61 µg/ml and 0.86±0.76 µg/ml for granule and suspension groups, respectively.","Pharmacokinetic Comparison of Omeprazole Granule and Suspension Forms in Children: A Randomized, Parallel Pilot Trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26398674/),[μg] / [ml],0.86,114795,DB00338,Omeprazole
,9623552,AUC,"The pharmacokinetic characteristics of pantoprazole AUC, t(1/2), CL and V(d area) (geometric means) were 2.4 mgxh/l, 0.63 h, 0.227 l/h/kg and 0.206 l/kg on day A (without dialysis) and 2.3 mgxh/l, 0.8 h, 0.237 l/h/kg and 0.273 l/kg on day B (with dialysis), respectively.",Pharmacokinetics of pantoprazole in patients with end-stage renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623552/),[h·mg] / [l],2.4,115284,DB00338,Omeprazole
,9623552,t(1/2),"The pharmacokinetic characteristics of pantoprazole AUC, t(1/2), CL and V(d area) (geometric means) were 2.4 mgxh/l, 0.63 h, 0.227 l/h/kg and 0.206 l/kg on day A (without dialysis) and 2.3 mgxh/l, 0.8 h, 0.237 l/h/kg and 0.273 l/kg on day B (with dialysis), respectively.",Pharmacokinetics of pantoprazole in patients with end-stage renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623552/),h,0.63,115285,DB00338,Omeprazole
,9623552,t(1/2),"The pharmacokinetic characteristics of pantoprazole AUC, t(1/2), CL and V(d area) (geometric means) were 2.4 mgxh/l, 0.63 h, 0.227 l/h/kg and 0.206 l/kg on day A (without dialysis) and 2.3 mgxh/l, 0.8 h, 0.237 l/h/kg and 0.273 l/kg on day B (with dialysis), respectively.",Pharmacokinetics of pantoprazole in patients with end-stage renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623552/),[l] / [h·kg],0.237,115286,DB00338,Omeprazole
,9623552,CL,"The pharmacokinetic characteristics of pantoprazole AUC, t(1/2), CL and V(d area) (geometric means) were 2.4 mgxh/l, 0.63 h, 0.227 l/h/kg and 0.206 l/kg on day A (without dialysis) and 2.3 mgxh/l, 0.8 h, 0.237 l/h/kg and 0.273 l/kg on day B (with dialysis), respectively.",Pharmacokinetics of pantoprazole in patients with end-stage renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623552/),h,0.63,115287,DB00338,Omeprazole
,9623552,CL,"The pharmacokinetic characteristics of pantoprazole AUC, t(1/2), CL and V(d area) (geometric means) were 2.4 mgxh/l, 0.63 h, 0.227 l/h/kg and 0.206 l/kg on day A (without dialysis) and 2.3 mgxh/l, 0.8 h, 0.237 l/h/kg and 0.273 l/kg on day B (with dialysis), respectively.",Pharmacokinetics of pantoprazole in patients with end-stage renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623552/),[l] / [h·kg],0.227,115288,DB00338,Omeprazole
,9623552,CL,"The pharmacokinetic characteristics of pantoprazole AUC, t(1/2), CL and V(d area) (geometric means) were 2.4 mgxh/l, 0.63 h, 0.227 l/h/kg and 0.206 l/kg on day A (without dialysis) and 2.3 mgxh/l, 0.8 h, 0.237 l/h/kg and 0.273 l/kg on day B (with dialysis), respectively.",Pharmacokinetics of pantoprazole in patients with end-stage renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623552/),h,0.8,115289,DB00338,Omeprazole
,9623552,CL,"The pharmacokinetic characteristics of pantoprazole AUC, t(1/2), CL and V(d area) (geometric means) were 2.4 mgxh/l, 0.63 h, 0.227 l/h/kg and 0.206 l/kg on day A (without dialysis) and 2.3 mgxh/l, 0.8 h, 0.237 l/h/kg and 0.273 l/kg on day B (with dialysis), respectively.",Pharmacokinetics of pantoprazole in patients with end-stage renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623552/),[l] / [h·kg],0.237,115290,DB00338,Omeprazole
,9623552,V(d area),"The pharmacokinetic characteristics of pantoprazole AUC, t(1/2), CL and V(d area) (geometric means) were 2.4 mgxh/l, 0.63 h, 0.227 l/h/kg and 0.206 l/kg on day A (without dialysis) and 2.3 mgxh/l, 0.8 h, 0.237 l/h/kg and 0.273 l/kg on day B (with dialysis), respectively.",Pharmacokinetics of pantoprazole in patients with end-stage renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623552/),[l] / [kg],0.206,115291,DB00338,Omeprazole
,9623552,V(d area),"The pharmacokinetic characteristics of pantoprazole AUC, t(1/2), CL and V(d area) (geometric means) were 2.4 mgxh/l, 0.63 h, 0.227 l/h/kg and 0.206 l/kg on day A (without dialysis) and 2.3 mgxh/l, 0.8 h, 0.237 l/h/kg and 0.273 l/kg on day B (with dialysis), respectively.",Pharmacokinetics of pantoprazole in patients with end-stage renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623552/),[l] / [kg],0.273,115292,DB00338,Omeprazole
,9623552,protein binding,The protein binding was 96%.,Pharmacokinetics of pantoprazole in patients with end-stage renal failure. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623552/),%,96,115293,DB00338,Omeprazole
,31442620,AUC,"After exposure to EPP-AF®, it was observed decrease in the AUC0-∞ of fexofenadine, caffeine and losartan of approximately 18% (62.20 × 51.00 h.ng/mL), 8% (1085 × 999 h.ng/mL) and 13% (9.01 × 7.86 h.ng/mL), respectively, with all 90% CIs within the equivalence range of 0.80-1.25.",Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF®) using an in vivo cocktail approach. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31442620/),,62,116459,DB00338,Omeprazole
,31442620,AUC0-∞,"On the other hand, omeprazole and midazolam exhibited an increase in AUC0-∞ of, respectively, approximately 18% (18.90 × 22.30 h.ng/mL) and 14% (1.25 × 1.43 h.ng/mL), with the upper bounds of 90% CIs slightly above 1.25.",Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF®) using an in vivo cocktail approach. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31442620/),[h·ng] / [ml],18,116460,DB00338,Omeprazole
,31442620,AUC0-∞,"On the other hand, omeprazole and midazolam exhibited an increase in AUC0-∞ of, respectively, approximately 18% (18.90 × 22.30 h.ng/mL) and 14% (1.25 × 1.43 h.ng/mL), with the upper bounds of 90% CIs slightly above 1.25.",Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF®) using an in vivo cocktail approach. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31442620/),[h·ng] / [ml],1.,116461,DB00338,Omeprazole
,22890488,coefficient,The mean area under the concentration-time curve (AUC) from time zero to infinity (AUC(∞) ) values of omeprazole and the corresponding coefficient of variation (CV%) was 987.3 ng h/ml (65%).,Variation in omeprazole pharmacokinetics in a random Iranian population: a pilot study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22890488/),[h·ng] / [ml],987.3,117424,DB00338,Omeprazole
,22890488,metabolic ratio,"The omeprazole metabolic ratio for this subject was 2.9, while for the others it was in the range 0.12-0.56.",Variation in omeprazole pharmacokinetics in a random Iranian population: a pilot study. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22890488/),,2.9,117425,DB00338,Omeprazole
,22890488,metabolic ratio,"The omeprazole metabolic ratio for this subject was 2.9, while for the others it was in the range 0.12-0.56.",Variation in omeprazole pharmacokinetics in a random Iranian population: a pilot study. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22890488/),,0.12-0.56,117426,DB00338,Omeprazole
,8299672,t1/2,"In cirrhotics tmax was prolonged, the AUC was increased (P < 0.001) and there was prolongation of t1/2 (6.1 h in CC and 7.2 h in UCC compared to 1.4 h in healthy subjects).",Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8299672/),h,6.1,118415,DB00338,Omeprazole
,8299672,t1/2,"In cirrhotics tmax was prolonged, the AUC was increased (P < 0.001) and there was prolongation of t1/2 (6.1 h in CC and 7.2 h in UCC compared to 1.4 h in healthy subjects).",Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8299672/),h,7.2,118416,DB00338,Omeprazole
,8299672,t1/2,"In cirrhotics tmax was prolonged, the AUC was increased (P < 0.001) and there was prolongation of t1/2 (6.1 h in CC and 7.2 h in UCC compared to 1.4 h in healthy subjects).",Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8299672/),h,1.4,118417,DB00338,Omeprazole
,11421879,cure rates,"The cure rates of H. pylori infection in the PAC 250 and PAC 500 groups were, respectively, 83% and 79% (ITT analysis) and 94% and 88% (PP analysis) (P=N.S.).",Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421879/),%,83,118973,DB00338,Omeprazole
,11421879,cure rates,"The cure rates of H. pylori infection in the PAC 250 and PAC 500 groups were, respectively, 83% and 79% (ITT analysis) and 94% and 88% (PP analysis) (P=N.S.).",Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421879/),%,79,118974,DB00338,Omeprazole
,11421879,cure rates,"The cure rates of H. pylori infection in the PAC 250 and PAC 500 groups were, respectively, 83% and 79% (ITT analysis) and 94% and 88% (PP analysis) (P=N.S.).",Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421879/),%,94,118975,DB00338,Omeprazole
,11421879,cure rates,"The cure rates of H. pylori infection in the PAC 250 and PAC 500 groups were, respectively, 83% and 79% (ITT analysis) and 94% and 88% (PP analysis) (P=N.S.).",Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421879/),%,88,118976,DB00338,Omeprazole
,15568407,milk/plasma ratio,"A milk/plasma ratio of 0.022 was observed at tmax, 2 hours after dose administration.",Excretion of pantoprazole in human breast. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568407/),,0.022,119837,DB00338,Omeprazole
,15568407,maximum consumption,Infant exposure was measured as maximum concentration in milk multiplied by an estimated maximum consumption of 200 mL at this time.,Excretion of pantoprazole in human breast. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568407/),ml,200,119838,DB00338,Omeprazole
,10720166,Peak increments,Peak increments of plasma Gln concentration were 794+/-107 micromol/L (mean +/- SEM) after bolus intake of 20 g of Ala-Gln and 398+/-61 micromol/L after intermittent intake of the same cumulative dosage of the dipeptide (P<0.01).,The pharmacokinetic responses of humans to 20 g of alanyl-glutamine dipeptide differ with the dosing protocol but not with gastric acidity or in patients with acute Dengue fever. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10720166/),[μM] / [l],794,120155,DB00338,Omeprazole
,10720166,Peak increments,Peak increments of plasma Gln concentration were 794+/-107 micromol/L (mean +/- SEM) after bolus intake of 20 g of Ala-Gln and 398+/-61 micromol/L after intermittent intake of the same cumulative dosage of the dipeptide (P<0.01).,The pharmacokinetic responses of humans to 20 g of alanyl-glutamine dipeptide differ with the dosing protocol but not with gastric acidity or in patients with acute Dengue fever. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10720166/),[μM] / [l],398,120156,DB00338,Omeprazole
,7756094,% time of pH > 5,3. Study A: the median % time of pH > 5 was 71.2 (total range: 48.9-83.2) with feedback infusions and 57.9 (28.0-95.3) with fixed-dose infusions (P = 0.06).,Individual and group dose-responses to intravenous omeprazole in the first 24 h: pH-feedback-controlled and fixed-dose infusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756094/),,71.2,120259,DB00338,Omeprazole
,7756094,% time of pH > 5,3. Study A: the median % time of pH > 5 was 71.2 (total range: 48.9-83.2) with feedback infusions and 57.9 (28.0-95.3) with fixed-dose infusions (P = 0.06).,Individual and group dose-responses to intravenous omeprazole in the first 24 h: pH-feedback-controlled and fixed-dose infusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756094/),,57.9,120260,DB00338,Omeprazole
,12222996,total area under the plasma concentration-time curve (AUC),"For omeprazole, the mean total area under the plasma concentration-time curve (AUC) was 286.5 micromol x h/L, peak plasma concentration was 14.9 micromol/L and terminal elimination half-life was 4.1 hours; these values were higher than those observed historically in control patient populations.",Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12222996/),[h·μM] / [l],286.5,124203,DB00338,Omeprazole
,12222996,peak plasma concentration,"For omeprazole, the mean total area under the plasma concentration-time curve (AUC) was 286.5 micromol x h/L, peak plasma concentration was 14.9 micromol/L and terminal elimination half-life was 4.1 hours; these values were higher than those observed historically in control patient populations.",Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12222996/),[μM] / [l],14.9,124204,DB00338,Omeprazole
,12222996,terminal elimination half-life,"For omeprazole, the mean total area under the plasma concentration-time curve (AUC) was 286.5 micromol x h/L, peak plasma concentration was 14.9 micromol/L and terminal elimination half-life was 4.1 hours; these values were higher than those observed historically in control patient populations.",Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12222996/),h,4.1,124205,DB00338,Omeprazole
,12222996,AUC(48 ),"For example, in patients with liver dysfunction of Child-Pugh categories A, B and C, AUC(48 )was 240.8, 280.4 and 323.3 micromol x h/L compared with 151.3 micromol x h/L in the historical control population.",Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12222996/),[h·μM] / [l],240.8,124206,DB00338,Omeprazole
,12222996,AUC(48 ),"For example, in patients with liver dysfunction of Child-Pugh categories A, B and C, AUC(48 )was 240.8, 280.4 and 323.3 micromol x h/L compared with 151.3 micromol x h/L in the historical control population.",Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12222996/),[h·μM] / [l],280.4,124207,DB00338,Omeprazole
,12222996,AUC(48 ),"For example, in patients with liver dysfunction of Child-Pugh categories A, B and C, AUC(48 )was 240.8, 280.4 and 323.3 micromol x h/L compared with 151.3 micromol x h/L in the historical control population.",Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12222996/),[h·μM] / [l],323.3,124208,DB00338,Omeprazole
,12222996,AUC(48 ),"For example, in patients with liver dysfunction of Child-Pugh categories A, B and C, AUC(48 )was 240.8, 280.4 and 323.3 micromol x h/L compared with 151.3 micromol x h/L in the historical control population.",Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12222996/),[h·μM] / [l],151.3,124209,DB00338,Omeprazole
,17203292,"AUC (0,infinity)","Mean omeprazole AUC (0,infinity) was 1164, 3093 and 10511 ng h/mL after PO, and 1435, 2495 and 6222 ng h/mL after IV in hmEMs, htEMs and PMs, respectively.",Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17203292/),[h·ng] / [ml],1164,124782,DB00338,Omeprazole
,17203292,"AUC (0,infinity)","Mean omeprazole AUC (0,infinity) was 1164, 3093 and 10511 ng h/mL after PO, and 1435, 2495 and 6222 ng h/mL after IV in hmEMs, htEMs and PMs, respectively.",Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17203292/),[h·ng] / [ml],3093,124783,DB00338,Omeprazole
,17203292,"AUC (0,infinity)","Mean omeprazole AUC (0,infinity) was 1164, 3093 and 10511 ng h/mL after PO, and 1435, 2495 and 6222 ng h/mL after IV in hmEMs, htEMs and PMs, respectively.",Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17203292/),[h·ng] / [ml],10511,124784,DB00338,Omeprazole
,17203292,"AUC (0,infinity)","Mean omeprazole AUC (0,infinity) was 1164, 3093 and 10511 ng h/mL after PO, and 1435, 2495 and 6222 ng h/mL after IV in hmEMs, htEMs and PMs, respectively.",Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17203292/),[h·ng] / [ml],1435,124785,DB00338,Omeprazole
,17203292,"AUC (0,infinity)","Mean omeprazole AUC (0,infinity) was 1164, 3093 and 10511 ng h/mL after PO, and 1435, 2495 and 6222 ng h/mL after IV in hmEMs, htEMs and PMs, respectively.",Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17203292/),[h·ng] / [ml],2495,124786,DB00338,Omeprazole
,17203292,"AUC (0,infinity)","Mean omeprazole AUC (0,infinity) was 1164, 3093 and 10511 ng h/mL after PO, and 1435, 2495 and 6222 ng h/mL after IV in hmEMs, htEMs and PMs, respectively.",Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17203292/),[h·ng] / [ml],6222,124787,DB00338,Omeprazole
,15664363,total time,"The peak was detected by a ultraviolet detector set at a wavelength of 285 nm, and the total time for a chromatographic separation was approximately 25 min.",Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664363/),min,25,125043,DB00338,Omeprazole
,15664363,recoveries,"Mean recoveries were 74.0% for lansoprazole, 68.3% for 5-hydroxylansoprazole, and 79.4% for lansoprazole sulfone.",Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664363/),%,74.0,125044,DB00338,Omeprazole
,15664363,recoveries,"Mean recoveries were 74.0% for lansoprazole, 68.3% for 5-hydroxylansoprazole, and 79.4% for lansoprazole sulfone.",Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664363/),%,68.3,125045,DB00338,Omeprazole
,15664363,recoveries,"Mean recoveries were 74.0% for lansoprazole, 68.3% for 5-hydroxylansoprazole, and 79.4% for lansoprazole sulfone.",Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664363/),%,79.4,125046,DB00338,Omeprazole
,15704613,absolute bioavailability,The absolute bioavailability of rabeprazole was 51.8%.,Pharmacokinetics of rabeprazole following single intravenous and oral administration to healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15704613/),%,51.8,125091,DB00338,Omeprazole
,15704613,elimination half-life,"The elimination half-life of rabeprazole sodium (1.47 +/- 0.82 h) after oral administration was significantly longer than the elimination half-life after intravenous administration (1.02 +/- 0.63 h), probably due to slower rate of absorption than that of elimination.",Pharmacokinetics of rabeprazole following single intravenous and oral administration to healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15704613/),h,1.47,125092,DB00338,Omeprazole
,15704613,elimination half-life,"The elimination half-life of rabeprazole sodium (1.47 +/- 0.82 h) after oral administration was significantly longer than the elimination half-life after intravenous administration (1.02 +/- 0.63 h), probably due to slower rate of absorption than that of elimination.",Pharmacokinetics of rabeprazole following single intravenous and oral administration to healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15704613/),h,1.02,125093,DB00338,Omeprazole
,15704613,total body clearance,The mean total body clearance was 283 +/- 98 ml/minutes following a 20 mg intravenous dose.,Pharmacokinetics of rabeprazole following single intravenous and oral administration to healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15704613/),[ml] / [min],283,125094,DB00338,Omeprazole
,14671680,elimination half-life,"The elimination half-life was significantly (p < 0.05) increased to 2.38 +/- 0.16, 3.26 +/- 0,12, 3.58 +/- 0.31 and 2.59 +/- 0.22 h in patients with different grades of cirrhosis (A, B and C) and also in patients with EHPVO, respectively, compared with 1.054 + 0.10 h in healthy volunteers.",Pharmacokinetics of omeprazole in patients with liver cirrhosis and extrahepatic portal venous obstruction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671680/),h,2.38,126319,DB00338,Omeprazole
,14671680,elimination half-life,"The elimination half-life was significantly (p < 0.05) increased to 2.38 +/- 0.16, 3.26 +/- 0,12, 3.58 +/- 0.31 and 2.59 +/- 0.22 h in patients with different grades of cirrhosis (A, B and C) and also in patients with EHPVO, respectively, compared with 1.054 + 0.10 h in healthy volunteers.",Pharmacokinetics of omeprazole in patients with liver cirrhosis and extrahepatic portal venous obstruction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671680/),h,3.26,126320,DB00338,Omeprazole
,14671680,elimination half-life,"The elimination half-life was significantly (p < 0.05) increased to 2.38 +/- 0.16, 3.26 +/- 0,12, 3.58 +/- 0.31 and 2.59 +/- 0.22 h in patients with different grades of cirrhosis (A, B and C) and also in patients with EHPVO, respectively, compared with 1.054 + 0.10 h in healthy volunteers.",Pharmacokinetics of omeprazole in patients with liver cirrhosis and extrahepatic portal venous obstruction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671680/),h,12,126321,DB00338,Omeprazole
,14671680,elimination half-life,"The elimination half-life was significantly (p < 0.05) increased to 2.38 +/- 0.16, 3.26 +/- 0,12, 3.58 +/- 0.31 and 2.59 +/- 0.22 h in patients with different grades of cirrhosis (A, B and C) and also in patients with EHPVO, respectively, compared with 1.054 + 0.10 h in healthy volunteers.",Pharmacokinetics of omeprazole in patients with liver cirrhosis and extrahepatic portal venous obstruction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671680/),h,3.58,126322,DB00338,Omeprazole
,14671680,elimination half-life,"The elimination half-life was significantly (p < 0.05) increased to 2.38 +/- 0.16, 3.26 +/- 0,12, 3.58 +/- 0.31 and 2.59 +/- 0.22 h in patients with different grades of cirrhosis (A, B and C) and also in patients with EHPVO, respectively, compared with 1.054 + 0.10 h in healthy volunteers.",Pharmacokinetics of omeprazole in patients with liver cirrhosis and extrahepatic portal venous obstruction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671680/),h,2.59,126323,DB00338,Omeprazole
,14671680,elimination half-life,"The elimination half-life was significantly (p < 0.05) increased to 2.38 +/- 0.16, 3.26 +/- 0,12, 3.58 +/- 0.31 and 2.59 +/- 0.22 h in patients with different grades of cirrhosis (A, B and C) and also in patients with EHPVO, respectively, compared with 1.054 + 0.10 h in healthy volunteers.",Pharmacokinetics of omeprazole in patients with liver cirrhosis and extrahepatic portal venous obstruction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671680/),h,1.054,126324,DB00338,Omeprazole
,14671680,AUC(0alpha),"A similar significant increase (p < 0.05) was observed in the AUC(0alpha), while C(max) was significantly increased to 400.40 +/- 27.89 and 602 +/- 55.13 ng/ml in only grade C cirrhosis patients and EHPVO patients, compared with 303.5 +/- 36.42 ng/ml in healthy volunteers.",Pharmacokinetics of omeprazole in patients with liver cirrhosis and extrahepatic portal venous obstruction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671680/),[ng] / [ml],400.40,126325,DB00338,Omeprazole
,14671680,C(max),"A similar significant increase (p < 0.05) was observed in the AUC(0alpha), while C(max) was significantly increased to 400.40 +/- 27.89 and 602 +/- 55.13 ng/ml in only grade C cirrhosis patients and EHPVO patients, compared with 303.5 +/- 36.42 ng/ml in healthy volunteers.",Pharmacokinetics of omeprazole in patients with liver cirrhosis and extrahepatic portal venous obstruction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671680/),[ng] / [ml],400.40,126326,DB00338,Omeprazole
,14671680,C(max),"A similar significant increase (p < 0.05) was observed in the AUC(0alpha), while C(max) was significantly increased to 400.40 +/- 27.89 and 602 +/- 55.13 ng/ml in only grade C cirrhosis patients and EHPVO patients, compared with 303.5 +/- 36.42 ng/ml in healthy volunteers.",Pharmacokinetics of omeprazole in patients with liver cirrhosis and extrahepatic portal venous obstruction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671680/),[ng] / [ml],602,126327,DB00338,Omeprazole
,14671680,C(max),"A similar significant increase (p < 0.05) was observed in the AUC(0alpha), while C(max) was significantly increased to 400.40 +/- 27.89 and 602 +/- 55.13 ng/ml in only grade C cirrhosis patients and EHPVO patients, compared with 303.5 +/- 36.42 ng/ml in healthy volunteers.",Pharmacokinetics of omeprazole in patients with liver cirrhosis and extrahepatic portal venous obstruction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671680/),[ng] / [ml],303.5,126328,DB00338,Omeprazole
,8738854,absolute bioavailability,Its absolute bioavailability is 77% and does not change upon multiple dosing.,Pharmacokinetics of pantoprazole in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),%,77,126641,DB00338,Omeprazole
,8738854,Cmax,"Following a single oral dose of 40 mg, Cmax is approximately 2.5 mg/l, with a tmax of 2-3 h.",Pharmacokinetics of pantoprazole in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),[mg] / [l],2.5,126642,DB00338,Omeprazole
,8738854,tmax,"Following a single oral dose of 40 mg, Cmax is approximately 2.5 mg/l, with a tmax of 2-3 h.",Pharmacokinetics of pantoprazole in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),h,2-3,126643,DB00338,Omeprazole
,8738854,AUC(O,"The AUC(O,inf.) is approximately 5 mgxh/l.",Pharmacokinetics of pantoprazole in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),[h·mg] / [l],5,126644,DB00338,Omeprazole
,8738854,total serum clearance,"Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination halflife of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins.",Pharmacokinetics of pantoprazole in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),[l] / [h·kg],0.1,126645,DB00338,Omeprazole
,8738854,serum elimination halflife,"Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination halflife of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins.",Pharmacokinetics of pantoprazole in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),h,1.1,126646,DB00338,Omeprazole
,8738854,apparent volume of distribution,"Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination halflife of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins.",Pharmacokinetics of pantoprazole in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),[l] / [kg],0.15,126647,DB00338,Omeprazole
,8738854,half-life,"In patients with severe liver cirrhosis, the decreased rate of metabolism results in a half-life of 7-9 h.",Pharmacokinetics of pantoprazole in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),h,7-9,126648,DB00338,Omeprazole
,8738854,half-life,"The clearance of pantoprazole is only slightly affected by age, its half-life being approximately 1.25 h in the elderly.",Pharmacokinetics of pantoprazole in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),h,1.25,126649,DB00338,Omeprazole
,19394048,area under the plasma concentration time curve,"The estimated geometric mean of area under the plasma concentration time curve during the dosing interval and observed maximum plasma concentration was 2.5 micromol x h/L and 0.74 micromol/L, respectively.",Pharmacodynamics and systemic exposure of esomeprazole in preterm infants and term neonates with gastroesophageal reflux disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19394048/),[h·μM] / [l],2.5,128679,DB00338,Omeprazole
,19394048,observed maximum plasma concentration,"The estimated geometric mean of area under the plasma concentration time curve during the dosing interval and observed maximum plasma concentration was 2.5 micromol x h/L and 0.74 micromol/L, respectively.",Pharmacodynamics and systemic exposure of esomeprazole in preterm infants and term neonates with gastroesophageal reflux disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19394048/),[h·μM] / [l],2.5,128680,DB00338,Omeprazole
,19394048,observed maximum plasma concentration,"The estimated geometric mean of area under the plasma concentration time curve during the dosing interval and observed maximum plasma concentration was 2.5 micromol x h/L and 0.74 micromol/L, respectively.",Pharmacodynamics and systemic exposure of esomeprazole in preterm infants and term neonates with gastroesophageal reflux disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19394048/),[μM] / [l],0.74,128681,DB00338,Omeprazole
,23719968,total clearance (CL),"The mean values (% relative standard error) for total clearance (CL) and for central volume of distribution (Vd) in patients with and without concomitant esomeprazole were 5.3 L/h (9.2 %) and 256.1 (6.4 %) and 153.2 l (19.2 %), respectively.",Interaction of thiopental with esomeprazole in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719968/),[l] / [h],5.3,129978,DB00338,Omeprazole
,23719968,central volume of distribution (Vd),"The mean values (% relative standard error) for total clearance (CL) and for central volume of distribution (Vd) in patients with and without concomitant esomeprazole were 5.3 L/h (9.2 %) and 256.1 (6.4 %) and 153.2 l (19.2 %), respectively.",Interaction of thiopental with esomeprazole in critically ill patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719968/),l,153.2,129979,DB00338,Omeprazole
,9604487,AUC ratios,The AUC ratios (Omeraz/Losec) for 24 hours and for infinity were respectively 1.02 with a 90% C.L. of 0.88-1.16 and 1.00 with a 90% C.L. of 0.88-1.14.,Bioequivalence study of two capsule formulations of omeprazole. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9604487/),,1.02,132432,DB00338,Omeprazole
,9604487,AUC ratios,The AUC ratios (Omeraz/Losec) for 24 hours and for infinity were respectively 1.02 with a 90% C.L. of 0.88-1.16 and 1.00 with a 90% C.L. of 0.88-1.14.,Bioequivalence study of two capsule formulations of omeprazole. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9604487/),,1.00,132433,DB00338,Omeprazole
,24009966,apparent plasma clearance (CL/F),The mean value for apparent plasma clearance (CL/F) was 20.8±6.9 (L.h(-1)).,Population pharmacokinetics of omeprazole in a random Iranian population. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24009966/),[l] / [h],20.8,132648,DB00338,Omeprazole
,24009966,apparent volume of distribution (V/F),"The corresponding value for apparent volume of distribution (V/F), and t 1/2 beta were 21.6±7.5 (L) and 0.8±0.3 (h), respectively.",Population pharmacokinetics of omeprazole in a random Iranian population. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24009966/),l,21.6,132649,DB00338,Omeprazole
,24009966,t 1/2 beta,"The corresponding value for apparent volume of distribution (V/F), and t 1/2 beta were 21.6±7.5 (L) and 0.8±0.3 (h), respectively.",Population pharmacokinetics of omeprazole in a random Iranian population. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24009966/),h,0.8,132650,DB00338,Omeprazole
,25920292,plasma,"Patients with PPI use had no difference in plasma voriconazole concentration, when compared with those without PPI use, at day 3 (5.89 vs. 5.44 mg/L, p = 0.744), day 7 (5.4 vs. 5.29 mg/L, p = 0.471), day 14 (2.40 vs. 3.13 mg/L, p = 0.372) and day 28 (1.77 vs. 3.23 mg/L, p = 0.314).",Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25920292/),[mg] / [l],5.89,132790,DB00338,Omeprazole
,25920292,plasma,"Patients with PPI use had no difference in plasma voriconazole concentration, when compared with those without PPI use, at day 3 (5.89 vs. 5.44 mg/L, p = 0.744), day 7 (5.4 vs. 5.29 mg/L, p = 0.471), day 14 (2.40 vs. 3.13 mg/L, p = 0.372) and day 28 (1.77 vs. 3.23 mg/L, p = 0.314).",Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25920292/),[mg] / [l],5.44,132791,DB00338,Omeprazole
,25920292,plasma,"Patients with PPI use had no difference in plasma voriconazole concentration, when compared with those without PPI use, at day 3 (5.89 vs. 5.44 mg/L, p = 0.744), day 7 (5.4 vs. 5.29 mg/L, p = 0.471), day 14 (2.40 vs. 3.13 mg/L, p = 0.372) and day 28 (1.77 vs. 3.23 mg/L, p = 0.314).",Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25920292/),[mg] / [l],5.4,132792,DB00338,Omeprazole
,25920292,plasma,"Patients with PPI use had no difference in plasma voriconazole concentration, when compared with those without PPI use, at day 3 (5.89 vs. 5.44 mg/L, p = 0.744), day 7 (5.4 vs. 5.29 mg/L, p = 0.471), day 14 (2.40 vs. 3.13 mg/L, p = 0.372) and day 28 (1.77 vs. 3.23 mg/L, p = 0.314).",Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25920292/),[mg] / [l],5.29,132793,DB00338,Omeprazole
,25920292,plasma,"Patients with PPI use had no difference in plasma voriconazole concentration, when compared with those without PPI use, at day 3 (5.89 vs. 5.44 mg/L, p = 0.744), day 7 (5.4 vs. 5.29 mg/L, p = 0.471), day 14 (2.40 vs. 3.13 mg/L, p = 0.372) and day 28 (1.77 vs. 3.23 mg/L, p = 0.314).",Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25920292/),[mg] / [l],2.40,132794,DB00338,Omeprazole
,25920292,plasma,"Patients with PPI use had no difference in plasma voriconazole concentration, when compared with those without PPI use, at day 3 (5.89 vs. 5.44 mg/L, p = 0.744), day 7 (5.4 vs. 5.29 mg/L, p = 0.471), day 14 (2.40 vs. 3.13 mg/L, p = 0.372) and day 28 (1.77 vs. 3.23 mg/L, p = 0.314).",Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25920292/),[mg] / [l],3.13,132795,DB00338,Omeprazole
,25920292,plasma,"Patients with PPI use had no difference in plasma voriconazole concentration, when compared with those without PPI use, at day 3 (5.89 vs. 5.44 mg/L, p = 0.744), day 7 (5.4 vs. 5.29 mg/L, p = 0.471), day 14 (2.40 vs. 3.13 mg/L, p = 0.372) and day 28 (1.77 vs. 3.23 mg/L, p = 0.314).",Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25920292/),[mg] / [l],1.77,132796,DB00338,Omeprazole
,25920292,plasma,"Patients with PPI use had no difference in plasma voriconazole concentration, when compared with those without PPI use, at day 3 (5.89 vs. 5.44 mg/L, p = 0.744), day 7 (5.4 vs. 5.29 mg/L, p = 0.471), day 14 (2.40 vs. 3.13 mg/L, p = 0.372) and day 28 (1.77 vs. 3.23 mg/L, p = 0.314).",Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25920292/),[mg] / [l],3.23,132797,DB00338,Omeprazole
,25920292,concentration,"Patients with PPI use had no difference in plasma voriconazole concentration, when compared with those without PPI use, at day 3 (5.89 vs. 5.44 mg/L, p = 0.744), day 7 (5.4 vs. 5.29 mg/L, p = 0.471), day 14 (2.40 vs. 3.13 mg/L, p = 0.372) and day 28 (1.77 vs. 3.23 mg/L, p = 0.314).",Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25920292/),[mg] / [l],5.89,132798,DB00338,Omeprazole
,25920292,concentration,"Patients with PPI use had no difference in plasma voriconazole concentration, when compared with those without PPI use, at day 3 (5.89 vs. 5.44 mg/L, p = 0.744), day 7 (5.4 vs. 5.29 mg/L, p = 0.471), day 14 (2.40 vs. 3.13 mg/L, p = 0.372) and day 28 (1.77 vs. 3.23 mg/L, p = 0.314).",Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25920292/),[mg] / [l],5.44,132799,DB00338,Omeprazole
,25920292,concentration,"Patients with PPI use had no difference in plasma voriconazole concentration, when compared with those without PPI use, at day 3 (5.89 vs. 5.44 mg/L, p = 0.744), day 7 (5.4 vs. 5.29 mg/L, p = 0.471), day 14 (2.40 vs. 3.13 mg/L, p = 0.372) and day 28 (1.77 vs. 3.23 mg/L, p = 0.314).",Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25920292/),[mg] / [l],5.4,132800,DB00338,Omeprazole
,25920292,concentration,"Patients with PPI use had no difference in plasma voriconazole concentration, when compared with those without PPI use, at day 3 (5.89 vs. 5.44 mg/L, p = 0.744), day 7 (5.4 vs. 5.29 mg/L, p = 0.471), day 14 (2.40 vs. 3.13 mg/L, p = 0.372) and day 28 (1.77 vs. 3.23 mg/L, p = 0.314).",Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25920292/),[mg] / [l],5.29,132801,DB00338,Omeprazole
,25920292,concentration,"Patients with PPI use had no difference in plasma voriconazole concentration, when compared with those without PPI use, at day 3 (5.89 vs. 5.44 mg/L, p = 0.744), day 7 (5.4 vs. 5.29 mg/L, p = 0.471), day 14 (2.40 vs. 3.13 mg/L, p = 0.372) and day 28 (1.77 vs. 3.23 mg/L, p = 0.314).",Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25920292/),[mg] / [l],2.40,132802,DB00338,Omeprazole
,25920292,concentration,"Patients with PPI use had no difference in plasma voriconazole concentration, when compared with those without PPI use, at day 3 (5.89 vs. 5.44 mg/L, p = 0.744), day 7 (5.4 vs. 5.29 mg/L, p = 0.471), day 14 (2.40 vs. 3.13 mg/L, p = 0.372) and day 28 (1.77 vs. 3.23 mg/L, p = 0.314).",Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25920292/),[mg] / [l],3.13,132803,DB00338,Omeprazole
,25920292,concentration,"Patients with PPI use had no difference in plasma voriconazole concentration, when compared with those without PPI use, at day 3 (5.89 vs. 5.44 mg/L, p = 0.744), day 7 (5.4 vs. 5.29 mg/L, p = 0.471), day 14 (2.40 vs. 3.13 mg/L, p = 0.372) and day 28 (1.77 vs. 3.23 mg/L, p = 0.314).",Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25920292/),[mg] / [l],1.77,132804,DB00338,Omeprazole
,25920292,concentration,"Patients with PPI use had no difference in plasma voriconazole concentration, when compared with those without PPI use, at day 3 (5.89 vs. 5.44 mg/L, p = 0.744), day 7 (5.4 vs. 5.29 mg/L, p = 0.471), day 14 (2.40 vs. 3.13 mg/L, p = 0.372) and day 28 (1.77 vs. 3.23 mg/L, p = 0.314).",Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25920292/),[mg] / [l],3.23,132805,DB00338,Omeprazole
,9459044,time to reach Cmax (tmax),"The time to reach Cmax (tmax) with the tablet was, on average, about 0.5 h longer than to reach the tmax of the capsule.",Pharmacokinetics and pharmacodynamics during treatment with the omeprazole 20 mg enteric-coated tablet and 20 mg capsule in asymptomatic duodenal ulcer patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459044/),h,0.5,133380,DB00338,Omeprazole
,32899425,apparent oral clearance (CL/F),"The apparent oral clearance (CL/F) was 3.43 L/h, the apparent volume of distribution (V/F) was 47.6 L, and the absorption rate constant (Ka) was fixed at 1.1 h-1.",Impact of Albumin and Omeprazole on Steady-State Population Pharmacokinetics of Voriconazole and Development of a Voriconazole Dosing Optimization Model in Thai Patients with Hematologic Diseases. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32899425/),[l] / [h],3.43,134361,DB00338,Omeprazole
,32899425,apparent volume of distribution (V/F),"The apparent oral clearance (CL/F) was 3.43 L/h, the apparent volume of distribution (V/F) was 47.6 L, and the absorption rate constant (Ka) was fixed at 1.1 h-1.",Impact of Albumin and Omeprazole on Steady-State Population Pharmacokinetics of Voriconazole and Development of a Voriconazole Dosing Optimization Model in Thai Patients with Hematologic Diseases. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32899425/),l,47.6,134362,DB00338,Omeprazole
,32899425,absorption rate constant (Ka),"The apparent oral clearance (CL/F) was 3.43 L/h, the apparent volume of distribution (V/F) was 47.6 L, and the absorption rate constant (Ka) was fixed at 1.1 h-1.",Impact of Albumin and Omeprazole on Steady-State Population Pharmacokinetics of Voriconazole and Development of a Voriconazole Dosing Optimization Model in Thai Patients with Hematologic Diseases. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32899425/),1/[h],1.1,134363,DB00338,Omeprazole
,30520273,clearance (CL) ratio,The predicted-to-observed pantoprazole clearance (CL) ratio ranged from 0.96-1.35 in children 1-17 years of age and 0.43-0.70 in term infants.,Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520273/),,0.96-1.35,135347,DB00338,Omeprazole
,30520273,clearance (CL) ratio,The predicted-to-observed pantoprazole clearance (CL) ratio ranged from 0.96-1.35 in children 1-17 years of age and 0.43-0.70 in term infants.,Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520273/),,0.43-0.70,135348,DB00338,Omeprazole
,30520273,CL ratio,"The predicted-to-observed esomeprazole CL ratio ranged from 1.08-1.50 for children 6-17 years of age, and 0.15-0.33 for infants.",Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520273/),,1.08-1.50,135349,DB00338,Omeprazole
,30520273,CL ratio,"The predicted-to-observed esomeprazole CL ratio ranged from 1.08-1.50 for children 6-17 years of age, and 0.15-0.33 for infants.",Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520273/),,0.15-0.33,135350,DB00338,Omeprazole
greater,25720462,AUC ratios,"The AUC ratios of omeprazole and erythromycin, which are administered orally to humans, as enteric-coated tablets, were greater than 1.9 in the rats and dogs controlled for gastric acid secretion.",Evaluation of Acid Tolerance of Drugs Using Rats and Dogs Controlled for Gastric Acid Secretion. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25720462/),,1.9,135783,DB00338,Omeprazole
less,25720462,AUC ratios,"On the contrary, the AUC ratios of clarithromycin, azithromycin, and etoposide (commercially available as a standard immediate-release form) were less than 1.3 each.",Evaluation of Acid Tolerance of Drugs Using Rats and Dogs Controlled for Gastric Acid Secretion. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25720462/),,1.3,135784,DB00338,Omeprazole
,9725501,retention time,The retention time was 5.2 min for niflumic acid and 6.7 min for lansoprazole.,Determination of lansoprazole in biological fluids and pharmaceutical dosage by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725501/),min,5.2,135848,DB00338,Omeprazole
,9725501,retention time,The retention time was 5.2 min for niflumic acid and 6.7 min for lansoprazole.,Determination of lansoprazole in biological fluids and pharmaceutical dosage by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725501/),min,6.7,135849,DB00338,Omeprazole
,9725501,detection limit,The detection limit was 20 ng/ml using a 100 microl loop.,Determination of lansoprazole in biological fluids and pharmaceutical dosage by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725501/),[ng] / [ml],20,135850,DB00338,Omeprazole
,16098001,eradication rates,"On an intention-to-treat basis, eradication rates were 91 and 76% for the RCM and OCM groups respectively (P < 0.02).","Is a long-term ranitidine-based triple therapy against Helicobacter pylori only a heritage of the past? A prospective, randomized clinicopharmacological study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16098001/),%,91,136422,DB00338,Omeprazole
,16098001,eradication rates,"On an intention-to-treat basis, eradication rates were 91 and 76% for the RCM and OCM groups respectively (P < 0.02).","Is a long-term ranitidine-based triple therapy against Helicobacter pylori only a heritage of the past? A prospective, randomized clinicopharmacological study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16098001/),%,76,136423,DB00338,Omeprazole
,9296318,AUC,"Following intravenous administration of metronidazole to the placebo group and omeprazole treated group respectively, the gastric transfer of metronidazole was significantly reduced from 15.5 +/- 10.4% to 2.6 +/- 1.0% of the dose (P = 0.007; 95% CI of difference 4.8 to 21.0) with concomitant changes in the metronidazole AUC (from 77.5 +/- 18.0 mumol l-1 h to 352.6 +/- 182.1 mumol l-1 h; P = 0.0003; 95% CI of difference 127.6 to 422.7), Cmax (from 61.4 +/- 26.5 mumol l-1 to 271.8 +/- 104.3 mumol l-1; p = 0.0001; 95% CI of difference 118.6 to 302.1).","The effect of omeprazole on the pharmacokinetics of metronidazole and hydroxymetronidazole in human plasma, saliva and gastric juice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296318/),[h·μM] / [l],77.5,136613,DB00338,Omeprazole
,9296318,AUC,"Following intravenous administration of metronidazole to the placebo group and omeprazole treated group respectively, the gastric transfer of metronidazole was significantly reduced from 15.5 +/- 10.4% to 2.6 +/- 1.0% of the dose (P = 0.007; 95% CI of difference 4.8 to 21.0) with concomitant changes in the metronidazole AUC (from 77.5 +/- 18.0 mumol l-1 h to 352.6 +/- 182.1 mumol l-1 h; P = 0.0003; 95% CI of difference 127.6 to 422.7), Cmax (from 61.4 +/- 26.5 mumol l-1 to 271.8 +/- 104.3 mumol l-1; p = 0.0001; 95% CI of difference 118.6 to 302.1).","The effect of omeprazole on the pharmacokinetics of metronidazole and hydroxymetronidazole in human plasma, saliva and gastric juice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296318/),[h·μM] / [l],352.6,136614,DB00338,Omeprazole
,9296318,Cmax,"Following intravenous administration of metronidazole to the placebo group and omeprazole treated group respectively, the gastric transfer of metronidazole was significantly reduced from 15.5 +/- 10.4% to 2.6 +/- 1.0% of the dose (P = 0.007; 95% CI of difference 4.8 to 21.0) with concomitant changes in the metronidazole AUC (from 77.5 +/- 18.0 mumol l-1 h to 352.6 +/- 182.1 mumol l-1 h; P = 0.0003; 95% CI of difference 127.6 to 422.7), Cmax (from 61.4 +/- 26.5 mumol l-1 to 271.8 +/- 104.3 mumol l-1; p = 0.0001; 95% CI of difference 118.6 to 302.1).","The effect of omeprazole on the pharmacokinetics of metronidazole and hydroxymetronidazole in human plasma, saliva and gastric juice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296318/),[μM] / [l],61.4,136615,DB00338,Omeprazole
,9296318,Cmax,"Following intravenous administration of metronidazole to the placebo group and omeprazole treated group respectively, the gastric transfer of metronidazole was significantly reduced from 15.5 +/- 10.4% to 2.6 +/- 1.0% of the dose (P = 0.007; 95% CI of difference 4.8 to 21.0) with concomitant changes in the metronidazole AUC (from 77.5 +/- 18.0 mumol l-1 h to 352.6 +/- 182.1 mumol l-1 h; P = 0.0003; 95% CI of difference 127.6 to 422.7), Cmax (from 61.4 +/- 26.5 mumol l-1 to 271.8 +/- 104.3 mumol l-1; p = 0.0001; 95% CI of difference 118.6 to 302.1).","The effect of omeprazole on the pharmacokinetics of metronidazole and hydroxymetronidazole in human plasma, saliva and gastric juice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296318/),[μM] / [l],271.8,136616,DB00338,Omeprazole
,9296318,AUC,"Similarly, the gastric juice AUC of hydroxymetronidazole was significantly reduced from 3.2 +/- 1.9 mumol l-1 h to 1.5 +/- 0.8 mumol l-1 h of the dose (P = 0.0043; 95% CI of difference 0.4 to 3.0) with a concomitant change in Cmax (from 5.0 +/- 2.5 mumol l-1 to 3.0 +/- 1.2 mumol l-1; P = 0.0007; 95% CI of difference 0.7 to 3.4).","The effect of omeprazole on the pharmacokinetics of metronidazole and hydroxymetronidazole in human plasma, saliva and gastric juice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296318/),[h·μM] / [l],3.2,136617,DB00338,Omeprazole
,9296318,AUC,"Similarly, the gastric juice AUC of hydroxymetronidazole was significantly reduced from 3.2 +/- 1.9 mumol l-1 h to 1.5 +/- 0.8 mumol l-1 h of the dose (P = 0.0043; 95% CI of difference 0.4 to 3.0) with a concomitant change in Cmax (from 5.0 +/- 2.5 mumol l-1 to 3.0 +/- 1.2 mumol l-1; P = 0.0007; 95% CI of difference 0.7 to 3.4).","The effect of omeprazole on the pharmacokinetics of metronidazole and hydroxymetronidazole in human plasma, saliva and gastric juice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296318/),[h·μM] / [l],1.5,136618,DB00338,Omeprazole
,9296318,Cmax,"Similarly, the gastric juice AUC of hydroxymetronidazole was significantly reduced from 3.2 +/- 1.9 mumol l-1 h to 1.5 +/- 0.8 mumol l-1 h of the dose (P = 0.0043; 95% CI of difference 0.4 to 3.0) with a concomitant change in Cmax (from 5.0 +/- 2.5 mumol l-1 to 3.0 +/- 1.2 mumol l-1; P = 0.0007; 95% CI of difference 0.7 to 3.4).","The effect of omeprazole on the pharmacokinetics of metronidazole and hydroxymetronidazole in human plasma, saliva and gastric juice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296318/),[μM] / [l],5.0,136619,DB00338,Omeprazole
,9296318,Cmax,"Similarly, the gastric juice AUC of hydroxymetronidazole was significantly reduced from 3.2 +/- 1.9 mumol l-1 h to 1.5 +/- 0.8 mumol l-1 h of the dose (P = 0.0043; 95% CI of difference 0.4 to 3.0) with a concomitant change in Cmax (from 5.0 +/- 2.5 mumol l-1 to 3.0 +/- 1.2 mumol l-1; P = 0.0007; 95% CI of difference 0.7 to 3.4).","The effect of omeprazole on the pharmacokinetics of metronidazole and hydroxymetronidazole in human plasma, saliva and gastric juice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296318/),[μM] / [l],3.0,136620,DB00338,Omeprazole
,1505152,percentage exhalation,"The mean percentage exhalation of the 13C test dose, as determined by 13CO2 in breath during 8 hours, was 23.0% +/- 8.0% (n = 18) before treatment.",Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505152/),%,23.0,137108,DB00338,Omeprazole
,1505152,exhalation rates,In both groups exhalation rates of 13CO2 returned to near pretreatment values within the 7-day washout period (24.2% +/- 7.8%; n = 17).,Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505152/),%,24.2,137109,DB00338,Omeprazole
,23208431,Bioavailabilities,"Bioavailabilities were approximately 80% for caffeine and warfarin, but less than 10% for omeprazole, metoprolol, and midazolam.","Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23208431/),%,80,137185,DB00338,Omeprazole
less,23208431,Bioavailabilities,"Bioavailabilities were approximately 80% for caffeine and warfarin, but less than 10% for omeprazole, metoprolol, and midazolam.","Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23208431/),%,10,137186,DB00338,Omeprazole
,15831779,AUC(0-infinity),A decrease in the mean dabigatran AUC(0-infinity) (904 to 705 ng*h/mL) occurred with coadministration of pantoprazole.,Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831779/),[h·ng] / [ml],904 to 705,140325,DB00338,Omeprazole
,18281734,area under the concentration-versus-time curve (AUC),"The coadministration of 20 or 40 mg of omeprazole with indinavir significantly reduced the mean indinavir area under the concentration-versus-time curve (AUC) from 30.0 mg x hr/L (95% confidence interval [CI], 21.9-41.1 mg x hr/L) to 19.7 mg x hr/L (95% CI, 14.6-26.8 mg x hr/L) or 16.0 mg x hr/L (95% CI, 11.8-21.7 mg x hr/L), respectively (p < 0.002).",Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18281734/),[h·mg] / [l],30.0,140530,DB00338,Omeprazole
,18281734,area under the concentration-versus-time curve (AUC),"The coadministration of 20 or 40 mg of omeprazole with indinavir significantly reduced the mean indinavir area under the concentration-versus-time curve (AUC) from 30.0 mg x hr/L (95% confidence interval [CI], 21.9-41.1 mg x hr/L) to 19.7 mg x hr/L (95% CI, 14.6-26.8 mg x hr/L) or 16.0 mg x hr/L (95% CI, 11.8-21.7 mg x hr/L), respectively (p < 0.002).",Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18281734/),[h·mg] / [l],19.7,140531,DB00338,Omeprazole
,18281734,area under the concentration-versus-time curve (AUC),"The coadministration of 20 or 40 mg of omeprazole with indinavir significantly reduced the mean indinavir area under the concentration-versus-time curve (AUC) from 30.0 mg x hr/L (95% confidence interval [CI], 21.9-41.1 mg x hr/L) to 19.7 mg x hr/L (95% CI, 14.6-26.8 mg x hr/L) or 16.0 mg x hr/L (95% CI, 11.8-21.7 mg x hr/L), respectively (p < 0.002).",Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18281734/),[h·mg] / [l],16.0,140532,DB00338,Omeprazole
,18281734,AUC,"The addition of 200 mg of ritonavir to 800 mg of indinavir in combination with 40 mg of omeprazole significantly increased the mean indinavir AUC from 30.0 mg x hr/L (95% CI, 21.9-41.1 mg x hr/L) to 46.6 mg x hr/L (95% CI, 34.0-63.8 mg x hr/L), but it did not significantly affect mean omeprazole concentrations (p < or = 0.02).",Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18281734/),[h·mg] / [l],30.0,140533,DB00338,Omeprazole
,18281734,AUC,"The addition of 200 mg of ritonavir to 800 mg of indinavir in combination with 40 mg of omeprazole significantly increased the mean indinavir AUC from 30.0 mg x hr/L (95% CI, 21.9-41.1 mg x hr/L) to 46.6 mg x hr/L (95% CI, 34.0-63.8 mg x hr/L), but it did not significantly affect mean omeprazole concentrations (p < or = 0.02).",Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18281734/),[h·mg] / [l],46.6,140534,DB00338,Omeprazole
,10763943,AO,"During omeprazole, median AO were 0.0 mmol/h before, 0.86 mmol/h (p = 0.003 vs before cure) at 1 month, and 0.34 mmol/h (p = 0.02) at 6 months after cure; median NH3 output was 0.17 mmol/h before, 0.03 mmol/h (p = 0.002) at 1 month, and 0.02 mmol/h (p = 0.005) at 6 months after cure.",The effect of ammonia on omeprazole-induced reduction of gastric acidity in subjects with Helicobacter pylori infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763943/),[mM] / [h],0.0,140619,DB00338,Omeprazole
,10763943,AO,"During omeprazole, median AO were 0.0 mmol/h before, 0.86 mmol/h (p = 0.003 vs before cure) at 1 month, and 0.34 mmol/h (p = 0.02) at 6 months after cure; median NH3 output was 0.17 mmol/h before, 0.03 mmol/h (p = 0.002) at 1 month, and 0.02 mmol/h (p = 0.005) at 6 months after cure.",The effect of ammonia on omeprazole-induced reduction of gastric acidity in subjects with Helicobacter pylori infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763943/),[mM] / [h],0.86,140620,DB00338,Omeprazole
,10763943,AO,"During omeprazole, median AO were 0.0 mmol/h before, 0.86 mmol/h (p = 0.003 vs before cure) at 1 month, and 0.34 mmol/h (p = 0.02) at 6 months after cure; median NH3 output was 0.17 mmol/h before, 0.03 mmol/h (p = 0.002) at 1 month, and 0.02 mmol/h (p = 0.005) at 6 months after cure.",The effect of ammonia on omeprazole-induced reduction of gastric acidity in subjects with Helicobacter pylori infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763943/),[mM] / [h],0.34,140621,DB00338,Omeprazole
,10763943,NH3 output,"During omeprazole, median AO were 0.0 mmol/h before, 0.86 mmol/h (p = 0.003 vs before cure) at 1 month, and 0.34 mmol/h (p = 0.02) at 6 months after cure; median NH3 output was 0.17 mmol/h before, 0.03 mmol/h (p = 0.002) at 1 month, and 0.02 mmol/h (p = 0.005) at 6 months after cure.",The effect of ammonia on omeprazole-induced reduction of gastric acidity in subjects with Helicobacter pylori infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763943/),[mM] / [h],0.17,140622,DB00338,Omeprazole
,10763943,NH3 output,"During omeprazole, median AO were 0.0 mmol/h before, 0.86 mmol/h (p = 0.003 vs before cure) at 1 month, and 0.34 mmol/h (p = 0.02) at 6 months after cure; median NH3 output was 0.17 mmol/h before, 0.03 mmol/h (p = 0.002) at 1 month, and 0.02 mmol/h (p = 0.005) at 6 months after cure.",The effect of ammonia on omeprazole-induced reduction of gastric acidity in subjects with Helicobacter pylori infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763943/),[mM] / [h],0.03,140623,DB00338,Omeprazole
,10763943,NH3 output,"During omeprazole, median AO were 0.0 mmol/h before, 0.86 mmol/h (p = 0.003 vs before cure) at 1 month, and 0.34 mmol/h (p = 0.02) at 6 months after cure; median NH3 output was 0.17 mmol/h before, 0.03 mmol/h (p = 0.002) at 1 month, and 0.02 mmol/h (p = 0.005) at 6 months after cure.",The effect of ammonia on omeprazole-induced reduction of gastric acidity in subjects with Helicobacter pylori infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763943/),[mM] / [h],0.02,140624,DB00338,Omeprazole
,9494064,serum AUC,"Actually, although 40 mg pantoprazole (steady state) gave a slightly higher serum AUC of the total parent compound than 40 mg omeprazole (10.5 vs.",Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9494064/),,10.5,141509,DB00338,Omeprazole
,9494064,serum protein binding,"7.1 micromol x h x l[-1]), a higher serum protein binding of pantoprazole versus omeprazole (98 vs. 96%) reversed the AUC values for the free drug in favor of a lower value for pantoprazole (0.19 vs. 0.28 micromol x h x l[-1]).",Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9494064/),,96,141510,DB00338,Omeprazole
,9494064,AUC,"7.1 micromol x h x l[-1]), a higher serum protein binding of pantoprazole versus omeprazole (98 vs. 96%) reversed the AUC values for the free drug in favor of a lower value for pantoprazole (0.19 vs. 0.28 micromol x h x l[-1]).",Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9494064/),[h·μM] / [l],0.19,141511,DB00338,Omeprazole
,9494064,AUC,"7.1 micromol x h x l[-1]), a higher serum protein binding of pantoprazole versus omeprazole (98 vs. 96%) reversed the AUC values for the free drug in favor of a lower value for pantoprazole (0.19 vs. 0.28 micromol x h x l[-1]).",Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9494064/),[h·μM] / [l],0.28,141512,DB00338,Omeprazole
,9494064,activation half-life,"At pH 5.1, the activation half-life of pantoprazole was 4.7 versus 1.4 h for omeprazole, the latter being in the order of the common serum elimination half-life determined in an intraindividual comparison (1.24 vs. 1.25 h).",Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9494064/),h,4.7,141513,DB00338,Omeprazole
,9494064,activation half-life,"At pH 5.1, the activation half-life of pantoprazole was 4.7 versus 1.4 h for omeprazole, the latter being in the order of the common serum elimination half-life determined in an intraindividual comparison (1.24 vs. 1.25 h).",Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9494064/),h,1.4,141514,DB00338,Omeprazole
,9494064,serum elimination half-life,"At pH 5.1, the activation half-life of pantoprazole was 4.7 versus 1.4 h for omeprazole, the latter being in the order of the common serum elimination half-life determined in an intraindividual comparison (1.24 vs. 1.25 h).",Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9494064/),h,1.24,141515,DB00338,Omeprazole
,9494064,serum elimination half-life,"At pH 5.1, the activation half-life of pantoprazole was 4.7 versus 1.4 h for omeprazole, the latter being in the order of the common serum elimination half-life determined in an intraindividual comparison (1.24 vs. 1.25 h).",Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9494064/),h,1.25,141516,DB00338,Omeprazole
,19182399,bioavailability (AUC),"The bioavailability (AUC) of the multi-layer coated drug-layered and drug-containing pellets was 3.48+/-0.86 and 2.97+/-0.57 microg*h/ml, respectively.",Design and in vitro/in vivo evaluation of multi-layer film coated pellets for omeprazole. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182399/),[h·μg] / [ml],3.48,141891,DB00338,Omeprazole
,19182399,bioavailability (AUC),"The bioavailability (AUC) of the multi-layer coated drug-layered and drug-containing pellets was 3.48+/-0.86 and 2.97+/-0.57 microg*h/ml, respectively.",Design and in vitro/in vivo evaluation of multi-layer film coated pellets for omeprazole. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182399/),[h·μg] / [ml],2.97,141892,DB00338,Omeprazole
,1793783,area under the time-plasma quinidine concentration curve,"During placebo and omeprazole treatment, there was no significant difference in area under the time-plasma quinidine concentration curve, (17.0 +/- 4.83 micrograms.h/ml, 18.6 +/- 4.43 micrograms.h/ml, respectively; P greater than 0.2) or renal clearance of quinidine (56.2 +/- 26.0 ml/min, 55.6 +/- 12.7 ml/min, respectively; P greater than 0.5).",Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1793783/),[h·μg] / [ml],17.0,142357,DB00338,Omeprazole
,1793783,area under the time-plasma quinidine concentration curve,"During placebo and omeprazole treatment, there was no significant difference in area under the time-plasma quinidine concentration curve, (17.0 +/- 4.83 micrograms.h/ml, 18.6 +/- 4.43 micrograms.h/ml, respectively; P greater than 0.2) or renal clearance of quinidine (56.2 +/- 26.0 ml/min, 55.6 +/- 12.7 ml/min, respectively; P greater than 0.5).",Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1793783/),[h·μg] / [ml],18.6,142358,DB00338,Omeprazole
,1793783,renal clearance,"During placebo and omeprazole treatment, there was no significant difference in area under the time-plasma quinidine concentration curve, (17.0 +/- 4.83 micrograms.h/ml, 18.6 +/- 4.43 micrograms.h/ml, respectively; P greater than 0.2) or renal clearance of quinidine (56.2 +/- 26.0 ml/min, 55.6 +/- 12.7 ml/min, respectively; P greater than 0.5).",Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1793783/),[ml] / [min],56.2,142359,DB00338,Omeprazole
,1793783,renal clearance,"During placebo and omeprazole treatment, there was no significant difference in area under the time-plasma quinidine concentration curve, (17.0 +/- 4.83 micrograms.h/ml, 18.6 +/- 4.43 micrograms.h/ml, respectively; P greater than 0.2) or renal clearance of quinidine (56.2 +/- 26.0 ml/min, 55.6 +/- 12.7 ml/min, respectively; P greater than 0.5).",Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1793783/),[ml] / [min],55.6,142360,DB00338,Omeprazole
,1793783,unbound fraction,Quinidine unbound fraction in plasma (0.170 +/- 0.041 vs. 0.166 +/- 0.041 in the presence of omeprazole; P greater than 0.5) was not altered by omeprazole.,Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1793783/),,0.170,142361,DB00338,Omeprazole
,1793783,unbound fraction,Quinidine unbound fraction in plasma (0.170 +/- 0.041 vs. 0.166 +/- 0.041 in the presence of omeprazole; P greater than 0.5) was not altered by omeprazole.,Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1793783/),,0.166,142362,DB00338,Omeprazole
,1793783,area under the time versus delta Q-Tc curve,"There was no significant difference in the change in the corrected Q-T interval on the electrocardiogram due to quinidine (mean area under the time versus delta Q-Tc curve = 351 +/- 192 ms.h, placebo; 414 +/- 303 ms.h, omeprazole) showing that quinidine pharmacodynamics were unaltered by omeprazole.",Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1793783/),h·ms,351,142363,DB00338,Omeprazole
,1793783,area under the time versus delta Q-Tc curve,"There was no significant difference in the change in the corrected Q-T interval on the electrocardiogram due to quinidine (mean area under the time versus delta Q-Tc curve = 351 +/- 192 ms.h, placebo; 414 +/- 303 ms.h, omeprazole) showing that quinidine pharmacodynamics were unaltered by omeprazole.",Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1793783/),h·ms,414,142364,DB00338,Omeprazole
,1820900,limit of detection,"Lansoprazole and metabolite (sulfone (AG 1813), sulfide (AG 1777) and hydroxylated (AG 1908) metabolites) plasma concentrations were determined using a specific high pressure liquid chromatographic assay procedure, with a limit of detection of 2 ng/ml.",The effect of food and antacids on lansoprazole absorption and disposition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820900/),[ng] / [ml],2,145096,DB00338,Omeprazole
,1820900,time to peak,"The time to peak was significantly later with food (p less than 0.001) and its magnitude was significantly decreased (600 +/- 330 ng/ml vs 1151 +/- 344 ng/ml, p less than 0.001).",The effect of food and antacids on lansoprazole absorption and disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820900/),[ng] / [ml],600,145097,DB00338,Omeprazole
,1820900,time to peak,"The time to peak was significantly later with food (p less than 0.001) and its magnitude was significantly decreased (600 +/- 330 ng/ml vs 1151 +/- 344 ng/ml, p less than 0.001).",The effect of food and antacids on lansoprazole absorption and disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820900/),[ng] / [ml],1151,145098,DB00338,Omeprazole
,1820900,bioavailability,"The bioavailability of lansoprazole was significantly decreased by food, about 27%, (p less than 0.05) and slightly decreased by concomitant administration of antacids (NS), the effect was more pronounced in male subjects (p less than 0.05).",The effect of food and antacids on lansoprazole absorption and disposition. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820900/),%,27,145099,DB00338,Omeprazole
,15313923,IC50,"In Sf9-BCRP vesicles, pantoprazole and omeprazole inhibited MTX transport (IC50 13 microm and 36 microm, respectively).",Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15313923/),μm,13,145395,DB00338,Omeprazole
,15313923,IC50,"In Sf9-BCRP vesicles, pantoprazole and omeprazole inhibited MTX transport (IC50 13 microm and 36 microm, respectively).",Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15313923/),μm,36,145396,DB00338,Omeprazole
,26422094,AUC0-t,"The geometric mean AUC0-t of esomeprazole were 0.24 and 1.79 μmol · h/L for the 0.25 mg/kg and 1 mg/kg dosages of esomeprazole, respectively.",Pharmacokinetics and Acid-suppressive Effects of Esomeprazole in Infants 1-24 Months Old With Symptoms of Gastroesophageal Reflux Disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26422094/),[h·μM] / [l],0.24,145889,DB00338,Omeprazole
,26422094,AUC0-t,"The geometric mean AUC0-t of esomeprazole were 0.24 and 1.79 μmol · h/L for the 0.25 mg/kg and 1 mg/kg dosages of esomeprazole, respectively.",Pharmacokinetics and Acid-suppressive Effects of Esomeprazole in Infants 1-24 Months Old With Symptoms of Gastroesophageal Reflux Disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26422094/),[h·μM] / [l],1.79,145890,DB00338,Omeprazole
,25271390,Bioavailability,Bioavailability was higher (P = 0.038) in the ECO-Fasted group (21.5 [9.0-27.7]%) than the PL-Fasted group (10.1 [7.7-13.3]%).,"Pharmacokinetics of intravenous, plain oral and enteric-coated oral omeprazole in the horse. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25271390/),%,21.5,145961,DB00338,Omeprazole
,25271390,Bioavailability,Bioavailability was higher (P = 0.038) in the ECO-Fasted group (21.5 [9.0-27.7]%) than the PL-Fasted group (10.1 [7.7-13.3]%).,"Pharmacokinetics of intravenous, plain oral and enteric-coated oral omeprazole in the horse. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25271390/),%,10.1,145962,DB00338,Omeprazole
,25271390,half-life,"When the half-life data from the oral formulations was pooled, it was longer than that observed in the IV-Fasted group (100 [73-118] min) and 35 [34-39] min, respectively; P < 0.0001).","Pharmacokinetics of intravenous, plain oral and enteric-coated oral omeprazole in the horse. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25271390/),min,100,145963,DB00338,Omeprazole
,25271390,half-life,"When the half-life data from the oral formulations was pooled, it was longer than that observed in the IV-Fasted group (100 [73-118] min) and 35 [34-39] min, respectively; P < 0.0001).","Pharmacokinetics of intravenous, plain oral and enteric-coated oral omeprazole in the horse. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25271390/),min,35,145964,DB00338,Omeprazole
,25767373,area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞),"The mean area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞) was 23.3 ng · h/mL (standard deviation [SD]: 6.33 ng · h/mL) versus 24.6 ng · h/mL (SD: 6.31 ng · h/mL), and maximum plasma concentrations (Cmax) were 3.89 ng/mL (SD: 1.30 ng/mL) and 4.12 ng/mL (SD: 1.29 ng/mL) in participants without and with omeprazole, respectively.","A phase 1 randomized study evaluating the effect of omeprazole on the pharmacokinetics of a novel 5-hydroxytryptamine receptor 4 agonist, revexepride (SSP-002358), in healthy adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25767373/),[h·ng] / [ml],23.3,146652,DB00338,Omeprazole
,25767373,area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞),"The mean area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞) was 23.3 ng · h/mL (standard deviation [SD]: 6.33 ng · h/mL) versus 24.6 ng · h/mL (SD: 6.31 ng · h/mL), and maximum plasma concentrations (Cmax) were 3.89 ng/mL (SD: 1.30 ng/mL) and 4.12 ng/mL (SD: 1.29 ng/mL) in participants without and with omeprazole, respectively.","A phase 1 randomized study evaluating the effect of omeprazole on the pharmacokinetics of a novel 5-hydroxytryptamine receptor 4 agonist, revexepride (SSP-002358), in healthy adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25767373/),[h·ng] / [ml],24.6,146653,DB00338,Omeprazole
,25767373,maximum plasma concentrations (Cmax),"The mean area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞) was 23.3 ng · h/mL (standard deviation [SD]: 6.33 ng · h/mL) versus 24.6 ng · h/mL (SD: 6.31 ng · h/mL), and maximum plasma concentrations (Cmax) were 3.89 ng/mL (SD: 1.30 ng/mL) and 4.12 ng/mL (SD: 1.29 ng/mL) in participants without and with omeprazole, respectively.","A phase 1 randomized study evaluating the effect of omeprazole on the pharmacokinetics of a novel 5-hydroxytryptamine receptor 4 agonist, revexepride (SSP-002358), in healthy adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25767373/),[ng] / [ml],3.89,146654,DB00338,Omeprazole
,25767373,maximum plasma concentrations (Cmax),"The mean area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞) was 23.3 ng · h/mL (standard deviation [SD]: 6.33 ng · h/mL) versus 24.6 ng · h/mL (SD: 6.31 ng · h/mL), and maximum plasma concentrations (Cmax) were 3.89 ng/mL (SD: 1.30 ng/mL) and 4.12 ng/mL (SD: 1.29 ng/mL) in participants without and with omeprazole, respectively.","A phase 1 randomized study evaluating the effect of omeprazole on the pharmacokinetics of a novel 5-hydroxytryptamine receptor 4 agonist, revexepride (SSP-002358), in healthy adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25767373/),[ng] / [ml],4.12,146655,DB00338,Omeprazole
,25767373,apparent terminal phase half-life,"Mean apparent terminal phase half-life was 9.95 hours (SD: 2.06 hours) without omeprazole, and 11.0 hours (SD: 3.25 hours) with omeprazole.","A phase 1 randomized study evaluating the effect of omeprazole on the pharmacokinetics of a novel 5-hydroxytryptamine receptor 4 agonist, revexepride (SSP-002358), in healthy adults. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25767373/),h,9.95,146656,DB00338,Omeprazole
,25767373,apparent terminal phase half-life,"Mean apparent terminal phase half-life was 9.95 hours (SD: 2.06 hours) without omeprazole, and 11.0 hours (SD: 3.25 hours) with omeprazole.","A phase 1 randomized study evaluating the effect of omeprazole on the pharmacokinetics of a novel 5-hydroxytryptamine receptor 4 agonist, revexepride (SSP-002358), in healthy adults. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25767373/),h,11.0,146657,DB00338,Omeprazole
,8097364,durations of action,"The durations of action of cimetidine, ranitidine, and famotidine are similar to the dosage intervals usually chosen (6, 8, and 12 hours, respectively).",Pharmacokinetics and pharmacodynamics of acid-suppressive agents in patients with gastroesophageal reflux disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097364/),h,6,146832,DB00338,Omeprazole
,8097364,durations of action,"The durations of action of cimetidine, ranitidine, and famotidine are similar to the dosage intervals usually chosen (6, 8, and 12 hours, respectively).",Pharmacokinetics and pharmacodynamics of acid-suppressive agents in patients with gastroesophageal reflux disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097364/),h,8,146833,DB00338,Omeprazole
,8097364,durations of action,"The durations of action of cimetidine, ranitidine, and famotidine are similar to the dosage intervals usually chosen (6, 8, and 12 hours, respectively).",Pharmacokinetics and pharmacodynamics of acid-suppressive agents in patients with gastroesophageal reflux disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097364/),h,12,146834,DB00338,Omeprazole
,17375980,elimination half-life,The elimination half-life of escitalopram is about 27-33 hours and is consistent with once-daily administration.,The clinical pharmacokinetics of escitalopram. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17375980/),h,27-33,147053,DB00338,Omeprazole
,17375980,protein binding,Escitalopram has low protein binding (56%) and is not likely to cause interactions with highly protein-bound drugs.,The clinical pharmacokinetics of escitalopram. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17375980/),%,56,147054,DB00338,Omeprazole
,17375980,apparent volume of distribution during the terminal phase after oral administration (V(z)/F),"It is widely distributed throughout tissues, with an apparent volume of distribution during the terminal phase after oral administration (V(z)/F) of about 1100L.",The clinical pharmacokinetics of escitalopram. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17375980/),l,1100,147055,DB00338,Omeprazole
,24628650,AUCGG,"Plasma omeprazole concentrations were significantly higher after GastroGard compared with Gastrozol administration (AUCGG = 2856 (1405-4576) ng/mL × h, AUCGZ = 604 (430-1609) ng/mL × h; P = .03).",Efficacy of omeprazole powder paste or enteric-coated formulation in healing of gastric ulcers in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628650/),[ng] / [h·ml],2856,147343,DB00338,Omeprazole
,24628650,AUCGZ,"Plasma omeprazole concentrations were significantly higher after GastroGard compared with Gastrozol administration (AUCGG = 2856 (1405-4576) ng/mL × h, AUCGZ = 604 (430-1609) ng/mL × h; P = .03).",Efficacy of omeprazole powder paste or enteric-coated formulation in healing of gastric ulcers in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628650/),[ng] / [h·ml],604,147344,DB00338,Omeprazole
,7820329,plasma half-life,The mean plasma half-life was about 1.0 hour and was dose-independent.,"Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7820329/),h,1.0,148139,DB00338,Omeprazole
,7820329,apparent oral clearance,The apparent oral clearance of E3810 ranged from 4.37 to 8.40 ml/min/kg.,"Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7820329/),[ml] / [kg·min],4.37 to 8.40,148140,DB00338,Omeprazole
,7820329,serum protein binding,The mean serum protein binding was 96.3%.,"Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7820329/),%,96.3,148141,DB00338,Omeprazole
,10511062,area under the plasma concentration-time curves from 0 to 24 hours (AUC),"Mean area under the plasma concentration-time curves from 0 to 24 hours (AUC) of omeprazole in the homozygous extensive metabolizer, heterozygous extensive metabolizer, and poor metabolizer groups were significantly increased by clarithromycin from 383.9 to 813.1, from 1001.9 to 2110.4, and from 5589.7 to 13098.6 ng x h/mL, respectively.",Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511062/),[h·ng] / [ml],383.9,149036,DB00338,Omeprazole
,10511062,area under the plasma concentration-time curves from 0 to 24 hours (AUC),"Mean area under the plasma concentration-time curves from 0 to 24 hours (AUC) of omeprazole in the homozygous extensive metabolizer, heterozygous extensive metabolizer, and poor metabolizer groups were significantly increased by clarithromycin from 383.9 to 813.1, from 1001.9 to 2110.4, and from 5589.7 to 13098.6 ng x h/mL, respectively.",Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511062/),[h·ng] / [ml],813.1,149037,DB00338,Omeprazole
,10511062,area under the plasma concentration-time curves from 0 to 24 hours (AUC),"Mean area under the plasma concentration-time curves from 0 to 24 hours (AUC) of omeprazole in the homozygous extensive metabolizer, heterozygous extensive metabolizer, and poor metabolizer groups were significantly increased by clarithromycin from 383.9 to 813.1, from 1001.9 to 2110.4, and from 5589.7 to 13098.6 ng x h/mL, respectively.",Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511062/),[h·ng] / [ml],1001.9,149038,DB00338,Omeprazole
,10511062,area under the plasma concentration-time curves from 0 to 24 hours (AUC),"Mean area under the plasma concentration-time curves from 0 to 24 hours (AUC) of omeprazole in the homozygous extensive metabolizer, heterozygous extensive metabolizer, and poor metabolizer groups were significantly increased by clarithromycin from 383.9 to 813.1, from 1001.9 to 2110.4, and from 5589.7 to 13098.6 ng x h/mL, respectively.",Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511062/),[h·ng] / [ml],2110.4,149039,DB00338,Omeprazole
,10511062,area under the plasma concentration-time curves from 0 to 24 hours (AUC),"Mean area under the plasma concentration-time curves from 0 to 24 hours (AUC) of omeprazole in the homozygous extensive metabolizer, heterozygous extensive metabolizer, and poor metabolizer groups were significantly increased by clarithromycin from 383.9 to 813.1, from 1001.9 to 2110.4, and from 5589.7 to 13098.6 ng x h/mL, respectively.",Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511062/),[h·ng] / [ml],5589.7,149040,DB00338,Omeprazole
,10511062,area under the plasma concentration-time curves from 0 to 24 hours (AUC),"Mean area under the plasma concentration-time curves from 0 to 24 hours (AUC) of omeprazole in the homozygous extensive metabolizer, heterozygous extensive metabolizer, and poor metabolizer groups were significantly increased by clarithromycin from 383.9 to 813.1, from 1001.9 to 2110.4, and from 5589.7 to 13098.6 ng x h/mL, respectively.",Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511062/),[h·ng] / [ml],13098.6,149041,DB00338,Omeprazole
,33214342,AUC (0-12),"The median AUC (0-12) and C0 results were 62.2 mg·h/L and 2.0 mg/L for the MMF group and 71.9 mg·h/L and 1.8 mg/L for the EC-MPS group (P = 0.160 and 0.225, respectively).",The impact of omeprazole on mycophenolate pharmacokinetics in kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214342/),[h·mg] / [l],62.2,151414,DB00338,Omeprazole
,33214342,AUC (0-12),"The median AUC (0-12) and C0 results were 62.2 mg·h/L and 2.0 mg/L for the MMF group and 71.9 mg·h/L and 1.8 mg/L for the EC-MPS group (P = 0.160 and 0.225, respectively).",The impact of omeprazole on mycophenolate pharmacokinetics in kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214342/),[h·mg] / [l],71.9,151415,DB00338,Omeprazole
,33214342,C0,"The median AUC (0-12) and C0 results were 62.2 mg·h/L and 2.0 mg/L for the MMF group and 71.9 mg·h/L and 1.8 mg/L for the EC-MPS group (P = 0.160 and 0.225, respectively).",The impact of omeprazole on mycophenolate pharmacokinetics in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214342/),[mg] / [l],2.0,151416,DB00338,Omeprazole
,33214342,C0,"The median AUC (0-12) and C0 results were 62.2 mg·h/L and 2.0 mg/L for the MMF group and 71.9 mg·h/L and 1.8 mg/L for the EC-MPS group (P = 0.160 and 0.225, respectively).",The impact of omeprazole on mycophenolate pharmacokinetics in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214342/),[mg] / [l],1.8,151417,DB00338,Omeprazole
,12607793,T(max),"After lansoprazole administration, T(max) occurred at 1.6 hours in those treated with lansoprazole 15 mg and at 1.7 hours in those treated with lansoprazole 30 mg.","Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12607793/),h,1.6,151641,DB00338,Omeprazole
,12607793,T(max),"After lansoprazole administration, T(max) occurred at 1.6 hours in those treated with lansoprazole 15 mg and at 1.7 hours in those treated with lansoprazole 30 mg.","Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12607793/),h,1.7,151642,DB00338,Omeprazole
,8039533,bioavailability,"The two formulations were bioequivalent (rate and extent) during fasting without omeprazole pre-treatment, whereas after omeprazole, the monohydrate showed a highly significant decrease in bioavailability (38% for AUC and 45% for Cmax) compared to the carrageenate formulation, which was not affected by prior administration of omeprazole.",Doxycycline carrageenate--an improved formulation providing more reliable absorption and plasma concentrations at high gastric pH than doxycycline monohydrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8039533/),%,38,151661,DB00338,Omeprazole
,8039533,bioavailability,"The two formulations were bioequivalent (rate and extent) during fasting without omeprazole pre-treatment, whereas after omeprazole, the monohydrate showed a highly significant decrease in bioavailability (38% for AUC and 45% for Cmax) compared to the carrageenate formulation, which was not affected by prior administration of omeprazole.",Doxycycline carrageenate--an improved formulation providing more reliable absorption and plasma concentrations at high gastric pH than doxycycline monohydrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8039533/),%,45,151662,DB00338,Omeprazole
,31564831,Time to peak concentration,Time to peak concentration of IR-ESO (0.50-0.75 hr) was shorter than that of ESO (1.25-1.50 hr).,"The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31564831/),h,0.50-0.75,151663,DB00338,Omeprazole
,31564831,Time to peak concentration,Time to peak concentration of IR-ESO (0.50-0.75 hr) was shorter than that of ESO (1.25-1.50 hr).,"The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31564831/),h,1.25-1.50,151664,DB00338,Omeprazole
,31564831,time to maintain gastric pH >4,"In addition, mean time to maintain gastric pH >4 for 24 hr was similar for both drugs (IR-ESO 55.5-69.9% vs ESO 56.8-70.2%).","The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31564831/),,24,151665,DB00338,Omeprazole
,16343286,Cmax,"On day 6, plasma omeprazole concentrations reached a Cmax of 0.12 microg/mL at a Tmax of 45 min.",Pharmacokinetics of oral omeprazole in llamas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343286/),[μg] / [ml],0.12,152616,DB00338,Omeprazole
,16343286,Tmax,"On day 6, plasma omeprazole concentrations reached a Cmax of 0.12 microg/mL at a Tmax of 45 min.",Pharmacokinetics of oral omeprazole in llamas. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343286/),min,45,152617,DB00338,Omeprazole
,16343286,t(1/2),The t(1/2) of omeprazole was 2.3 h and the AUC(0-infinity) was 0.38 h x microg/mL.,Pharmacokinetics of oral omeprazole in llamas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343286/),h,2.3,152618,DB00338,Omeprazole
,16343286,AUC(0-infinity),The t(1/2) of omeprazole was 2.3 h and the AUC(0-infinity) was 0.38 h x microg/mL.,Pharmacokinetics of oral omeprazole in llamas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343286/),[h·μg] / [ml],0.38,152619,DB00338,Omeprazole
,16343286,oral absorption,"However, using data published on the i.v. pharmacokinetics of omeprazole in llamas, oral absorption was estimated to be only 2.95%.",Pharmacokinetics of oral omeprazole in llamas. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343286/),%,2.95,152620,DB00338,Omeprazole
,10886044,Relative bioavailability,Relative bioavailability of omeprazole from simplified omeprazole suspension compared to the capsule was 58.4% on day 5.,Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10886044/),%,58.4,153864,DB00338,Omeprazole
>,24186263,AUC ratio,The static model predicted in vivo interaction with predicted AUC ratio values of >1.1 for all CYP (except CYP3A4).,"Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24186263/),,1.1,154701,DB00338,Omeprazole
,1577056,oral clearance,The oral clearance of theophylline remained unchanged whether it was administered alone or with omeprazole (54.2 ml.min-1).,Theophylline steady state pharmacokinetics is not altered by omeprazole. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577056/),[ml] / [min],54.2,155146,DB00338,Omeprazole
,1577056,urinary excretion,"The average urinary excretion of theophylline and its metabolites, 1,3 dimethyluric acid (1,3-DMU), 3-methylxanthine (3-MX), 1-methyluric acid (1-MU) amounted to 9%, 32%, 12% and 22% of the administered dose, respectively, and no significant change occurred during concomitant treatment with omeprazole.",Theophylline steady state pharmacokinetics is not altered by omeprazole. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577056/),%,9,155147,DB00338,Omeprazole
,1577056,urinary excretion,"The average urinary excretion of theophylline and its metabolites, 1,3 dimethyluric acid (1,3-DMU), 3-methylxanthine (3-MX), 1-methyluric acid (1-MU) amounted to 9%, 32%, 12% and 22% of the administered dose, respectively, and no significant change occurred during concomitant treatment with omeprazole.",Theophylline steady state pharmacokinetics is not altered by omeprazole. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577056/),%,32,155148,DB00338,Omeprazole
,1577056,urinary excretion,"The average urinary excretion of theophylline and its metabolites, 1,3 dimethyluric acid (1,3-DMU), 3-methylxanthine (3-MX), 1-methyluric acid (1-MU) amounted to 9%, 32%, 12% and 22% of the administered dose, respectively, and no significant change occurred during concomitant treatment with omeprazole.",Theophylline steady state pharmacokinetics is not altered by omeprazole. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577056/),%,12,155149,DB00338,Omeprazole
,1577056,urinary excretion,"The average urinary excretion of theophylline and its metabolites, 1,3 dimethyluric acid (1,3-DMU), 3-methylxanthine (3-MX), 1-methyluric acid (1-MU) amounted to 9%, 32%, 12% and 22% of the administered dose, respectively, and no significant change occurred during concomitant treatment with omeprazole.",Theophylline steady state pharmacokinetics is not altered by omeprazole. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577056/),%,22,155150,DB00338,Omeprazole
,10471987,peak concentration (Cmax),"For cisapride alone, mean parameter values were the following: peak concentration (Cmax), 56 ng/mL; time to Cmax (tmax), 1.7 hours; area under the concentration-time curve (AUC), 426 ng x h/mL; and terminal half-life (t1/2), 5.8 hours.",Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10471987/),[ng] / [ml],56,155744,DB00338,Omeprazole
,10471987,time to Cmax (tmax),"For cisapride alone, mean parameter values were the following: peak concentration (Cmax), 56 ng/mL; time to Cmax (tmax), 1.7 hours; area under the concentration-time curve (AUC), 426 ng x h/mL; and terminal half-life (t1/2), 5.8 hours.",Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10471987/),h,1.7,155745,DB00338,Omeprazole
,10471987,area under the concentration-time curve (AUC),"For cisapride alone, mean parameter values were the following: peak concentration (Cmax), 56 ng/mL; time to Cmax (tmax), 1.7 hours; area under the concentration-time curve (AUC), 426 ng x h/mL; and terminal half-life (t1/2), 5.8 hours.",Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10471987/),[h·ng] / [ml],426,155746,DB00338,Omeprazole
,10471987,terminal half-life (t1/2),"For cisapride alone, mean parameter values were the following: peak concentration (Cmax), 56 ng/mL; time to Cmax (tmax), 1.7 hours; area under the concentration-time curve (AUC), 426 ng x h/mL; and terminal half-life (t1/2), 5.8 hours.",Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10471987/),h,5.8,155747,DB00338,Omeprazole
,20497746,clearance,"Typical mean value of tacrolimus clearance, estimated by the base model (without covariates), in our population was 1.03 l h-1.",Population pharmacokinetics of tacrolimus in kidney transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20497746/),[l] / [h],1.03,155926,DB00338,Omeprazole
,16750456,AUC(0-infinity),Geometric mean AUC(0-infinity) values (overall drug exposure) were 1.58 and 5.57 micromol .,"Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16750456/),μM,1.58,155992,DB00338,Omeprazole
,16750456,AUC(0-infinity),Geometric mean AUC(0-infinity) values (overall drug exposure) were 1.58 and 5.57 micromol .,"Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16750456/),μM,5.57,155993,DB00338,Omeprazole
,16750456,Cmax,"Geometric mean Cmax values were 0.67 and 2.78 micromol/L (0.012 and 0.041 micromol/L x kg(-1)) with single-dose administration of esomeprazole 20 and 40 mg, respectively, and 1.45 and 5.13 micromol/L (0.026 and 0.075 micromol/L x kg(-1)), respectively, with repeated doses (day 8).","Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16750456/),[μM] / [l],0.67,155994,DB00338,Omeprazole
,16750456,Cmax,"Geometric mean Cmax values were 0.67 and 2.78 micromol/L (0.012 and 0.041 micromol/L x kg(-1)) with single-dose administration of esomeprazole 20 and 40 mg, respectively, and 1.45 and 5.13 micromol/L (0.026 and 0.075 micromol/L x kg(-1)), respectively, with repeated doses (day 8).","Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16750456/),[μM] / [l],2.78,155995,DB00338,Omeprazole
,16750456,Cmax,"Geometric mean Cmax values were 0.67 and 2.78 micromol/L (0.012 and 0.041 micromol/L x kg(-1)) with single-dose administration of esomeprazole 20 and 40 mg, respectively, and 1.45 and 5.13 micromol/L (0.026 and 0.075 micromol/L x kg(-1)), respectively, with repeated doses (day 8).","Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16750456/),[l·μM] / [kg],0.012,155996,DB00338,Omeprazole
,16750456,Cmax,"Geometric mean Cmax values were 0.67 and 2.78 micromol/L (0.012 and 0.041 micromol/L x kg(-1)) with single-dose administration of esomeprazole 20 and 40 mg, respectively, and 1.45 and 5.13 micromol/L (0.026 and 0.075 micromol/L x kg(-1)), respectively, with repeated doses (day 8).","Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16750456/),[l·μM] / [kg],0.041,155997,DB00338,Omeprazole
,16750456,Cmax,"Geometric mean Cmax values were 0.67 and 2.78 micromol/L (0.012 and 0.041 micromol/L x kg(-1)) with single-dose administration of esomeprazole 20 and 40 mg, respectively, and 1.45 and 5.13 micromol/L (0.026 and 0.075 micromol/L x kg(-1)), respectively, with repeated doses (day 8).","Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16750456/),[μM] / [l],1.45,155998,DB00338,Omeprazole
,16750456,Cmax,"Geometric mean Cmax values were 0.67 and 2.78 micromol/L (0.012 and 0.041 micromol/L x kg(-1)) with single-dose administration of esomeprazole 20 and 40 mg, respectively, and 1.45 and 5.13 micromol/L (0.026 and 0.075 micromol/L x kg(-1)), respectively, with repeated doses (day 8).","Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16750456/),[μM] / [l],5.13,155999,DB00338,Omeprazole
,16750456,Cmax,"Geometric mean Cmax values were 0.67 and 2.78 micromol/L (0.012 and 0.041 micromol/L x kg(-1)) with single-dose administration of esomeprazole 20 and 40 mg, respectively, and 1.45 and 5.13 micromol/L (0.026 and 0.075 micromol/L x kg(-1)), respectively, with repeated doses (day 8).","Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16750456/),[l·μM] / [kg],0.026,156000,DB00338,Omeprazole
,16750456,Cmax,"Geometric mean Cmax values were 0.67 and 2.78 micromol/L (0.012 and 0.041 micromol/L x kg(-1)) with single-dose administration of esomeprazole 20 and 40 mg, respectively, and 1.45 and 5.13 micromol/L (0.026 and 0.075 micromol/L x kg(-1)), respectively, with repeated doses (day 8).","Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16750456/),[l·μM] / [kg],0.075,156001,DB00338,Omeprazole
,8622049,F,"The F value of oral 2-CdA measured on days 1 and 5 was 37.2% and 36.7%, respectively.",Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622049/),%,37.2,156078,DB00338,Omeprazole
,8622049,F,"The F value of oral 2-CdA measured on days 1 and 5 was 37.2% and 36.7%, respectively.",Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622049/),%,36.7,156079,DB00338,Omeprazole
,8622049,F,The F value of 2-CdA after oral administration was approximately 37% and there were no cumulative differences in bioavailability observed on multiple dosing of the drug.,Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622049/),%,37,156080,DB00338,Omeprazole
,19385713,maximum plasma concentration,Bortezomib pharmacokinetic parameters were similar when bortezomib was administered alone or with omeprazole (maximum plasma concentration 120 vs 123 ng/mL; area under the plasma concentration-time curve from 0 to 72 hours 129 vs 135 ng . h/mL).,"Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19385713/),[ng] / [ml],120,156123,DB00338,Omeprazole
,19385713,maximum plasma concentration,Bortezomib pharmacokinetic parameters were similar when bortezomib was administered alone or with omeprazole (maximum plasma concentration 120 vs 123 ng/mL; area under the plasma concentration-time curve from 0 to 72 hours 129 vs 135 ng . h/mL).,"Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19385713/),[ng] / [ml],123,156124,DB00338,Omeprazole
,19385713,area under the plasma concentration-time curve from 0 to 72 hours,Bortezomib pharmacokinetic parameters were similar when bortezomib was administered alone or with omeprazole (maximum plasma concentration 120 vs 123 ng/mL; area under the plasma concentration-time curve from 0 to 72 hours 129 vs 135 ng . h/mL).,"Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19385713/),[h·ng] / [ml],129,156125,DB00338,Omeprazole
,19385713,area under the plasma concentration-time curve from 0 to 72 hours,Bortezomib pharmacokinetic parameters were similar when bortezomib was administered alone or with omeprazole (maximum plasma concentration 120 vs 123 ng/mL; area under the plasma concentration-time curve from 0 to 72 hours 129 vs 135 ng . h/mL).,"Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19385713/),[h·ng] / [ml],135,156126,DB00338,Omeprazole
,19385713,area under the percent inhibition-time curve over 72 hours,The pharmacodynamic parameters were also similar (maximum effect 85.8% vs 93.7%; area under the percent inhibition-time curve over 72 hours 4052 vs 3910 % x h); the differences were not statistically significant.,"Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19385713/),%·h,4052,156127,DB00338,Omeprazole
,19385713,area under the percent inhibition-time curve over 72 hours,The pharmacodynamic parameters were also similar (maximum effect 85.8% vs 93.7%; area under the percent inhibition-time curve over 72 hours 4052 vs 3910 % x h); the differences were not statistically significant.,"Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19385713/),%·h,3910,156128,DB00338,Omeprazole
,29411268,Peak mean plasma cysteamine concentrations,Peak mean plasma cysteamine concentrations following co-administration of CBDR capsules with orange juice (1892 ng/mL) were higher compared with co-administration with water (1663 ng/mL) or omeprazole 20 mg and water (1712 ng/mL).,"A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29411268/),[ng] / [ml],1892,159177,DB00338,Omeprazole
,29411268,Peak mean plasma cysteamine concentrations,Peak mean plasma cysteamine concentrations following co-administration of CBDR capsules with orange juice (1892 ng/mL) were higher compared with co-administration with water (1663 ng/mL) or omeprazole 20 mg and water (1712 ng/mL).,"A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29411268/),[ng] / [ml],1663,159178,DB00338,Omeprazole
,29411268,Peak mean plasma cysteamine concentrations,Peak mean plasma cysteamine concentrations following co-administration of CBDR capsules with orange juice (1892 ng/mL) were higher compared with co-administration with water (1663 ng/mL) or omeprazole 20 mg and water (1712 ng/mL).,"A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29411268/),[ng] / [ml],1712,159179,DB00338,Omeprazole
,29411268,time to peak plasma concentration,Mean time to peak plasma concentration was shorter with omeprazole co-administration (2.5 h) compared with orange juice (3.5 h) or water (3.0 h).,"A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29411268/),h,2.5,159180,DB00338,Omeprazole
,29411268,time to peak plasma concentration,Mean time to peak plasma concentration was shorter with omeprazole co-administration (2.5 h) compared with orange juice (3.5 h) or water (3.0 h).,"A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29411268/),h,3.5,159181,DB00338,Omeprazole
,29411268,time to peak plasma concentration,Mean time to peak plasma concentration was shorter with omeprazole co-administration (2.5 h) compared with orange juice (3.5 h) or water (3.0 h).,"A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29411268/),h,3.0,159182,DB00338,Omeprazole
,32558923,turnover half-life,"Based on the recovery of R-pantoprazole oral clearance, the turnover half-life of CYP2C19 was estimated to average 53 hours.","Effect of High-Dose Esomeprazole on CYP1A2, CYP2C19, and CYP3A4 Activities in Humans: Evidence for Substantial and Long-lasting Inhibition of CYP2C19. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32558923/),h,53,159396,DB00338,Omeprazole
,11210394,half-lives,Pantoprazole has short half-lives of 0.5 hours in rats and 0.8 hours in humans.,Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210394/),h,0.5,160213,DB00338,Omeprazole
,11210394,half-lives,Pantoprazole has short half-lives of 0.5 hours in rats and 0.8 hours in humans.,Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210394/),h,0.8,160214,DB00338,Omeprazole
,11210394,apparent reaction rate constants,"The apparent reaction rate constants of pantoprazole with the proton pumps were 0.691 L/mg/h in rats and 0.751 L/mg/h in humans, and the apparent recovery rates of the pumps were 0.053 h-1 and 0.031 h-1, respectively.",Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210394/),[l] / [h·mg],0.691,160215,DB00338,Omeprazole
,11210394,apparent reaction rate constants,"The apparent reaction rate constants of pantoprazole with the proton pumps were 0.691 L/mg/h in rats and 0.751 L/mg/h in humans, and the apparent recovery rates of the pumps were 0.053 h-1 and 0.031 h-1, respectively.",Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210394/),[l] / [h·mg],0.751,160216,DB00338,Omeprazole
,11210394,apparent recovery rates,"The apparent reaction rate constants of pantoprazole with the proton pumps were 0.691 L/mg/h in rats and 0.751 L/mg/h in humans, and the apparent recovery rates of the pumps were 0.053 h-1 and 0.031 h-1, respectively.",Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210394/),1/[h],0.053,160217,DB00338,Omeprazole
,11210394,apparent recovery rates,"The apparent reaction rate constants of pantoprazole with the proton pumps were 0.691 L/mg/h in rats and 0.751 L/mg/h in humans, and the apparent recovery rates of the pumps were 0.053 h-1 and 0.031 h-1, respectively.",Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210394/),1/[h],0.031,160218,DB00338,Omeprazole
,21628602,t(max),"Naproxen plasma profiles were similar between the NAP/ESO tablet and EC naproxen, although median t(max) was longest for the NAP/ESO tablet (5.3 vs 3.5-4.0 hours).",Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21628602/),h,5.3,160356,DB00338,Omeprazole
,21628602,t(max),"Naproxen plasma profiles were similar between the NAP/ESO tablet and EC naproxen, although median t(max) was longest for the NAP/ESO tablet (5.3 vs 3.5-4.0 hours).",Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21628602/),h,3.5-4.0,160357,DB00338,Omeprazole
,21628602,t(max),The NAP/ESO tablet produced much shorter esomeprazole t(max) than the EC esomeprazole formulation (0.45 vs 2.5 hours).,Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21628602/),h,0.45,160358,DB00338,Omeprazole
,21628602,t(max),The NAP/ESO tablet produced much shorter esomeprazole t(max) than the EC esomeprazole formulation (0.45 vs 2.5 hours).,Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21628602/),h,2.5,160359,DB00338,Omeprazole
,19517893,Cmax,"From serum data, the obtained values for test and reference products were 648.07 +/- 216.27 and 632.69 +/- 257.01 ng/ml for Cmax; 2012.24 +/- 634.48 and 1907.86 +/- 761.91 ng x h/ml for AUC0-24; 2105.21 +/- 623.79 and 1979.18 +/- 748.12 ng x h/ml for AUC0-infinity respectively.",Bioequivalence and pharmacokinetic study of two different omeprazole capsule formulations in healthy Bangladeshi volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19517893/),[ng] / [ml],648.07,160406,DB00338,Omeprazole
,19517893,Cmax,"From serum data, the obtained values for test and reference products were 648.07 +/- 216.27 and 632.69 +/- 257.01 ng/ml for Cmax; 2012.24 +/- 634.48 and 1907.86 +/- 761.91 ng x h/ml for AUC0-24; 2105.21 +/- 623.79 and 1979.18 +/- 748.12 ng x h/ml for AUC0-infinity respectively.",Bioequivalence and pharmacokinetic study of two different omeprazole capsule formulations in healthy Bangladeshi volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19517893/),[ng] / [ml],632.69,160407,DB00338,Omeprazole
,19517893,AUC0-24,"From serum data, the obtained values for test and reference products were 648.07 +/- 216.27 and 632.69 +/- 257.01 ng/ml for Cmax; 2012.24 +/- 634.48 and 1907.86 +/- 761.91 ng x h/ml for AUC0-24; 2105.21 +/- 623.79 and 1979.18 +/- 748.12 ng x h/ml for AUC0-infinity respectively.",Bioequivalence and pharmacokinetic study of two different omeprazole capsule formulations in healthy Bangladeshi volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19517893/),[h·ng] / [ml],2012.24,160408,DB00338,Omeprazole
,19517893,AUC0-24,"From serum data, the obtained values for test and reference products were 648.07 +/- 216.27 and 632.69 +/- 257.01 ng/ml for Cmax; 2012.24 +/- 634.48 and 1907.86 +/- 761.91 ng x h/ml for AUC0-24; 2105.21 +/- 623.79 and 1979.18 +/- 748.12 ng x h/ml for AUC0-infinity respectively.",Bioequivalence and pharmacokinetic study of two different omeprazole capsule formulations in healthy Bangladeshi volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19517893/),[h·ng] / [ml],1907.86,160409,DB00338,Omeprazole
,19517893,AUC0-infinity,"From serum data, the obtained values for test and reference products were 648.07 +/- 216.27 and 632.69 +/- 257.01 ng/ml for Cmax; 2012.24 +/- 634.48 and 1907.86 +/- 761.91 ng x h/ml for AUC0-24; 2105.21 +/- 623.79 and 1979.18 +/- 748.12 ng x h/ml for AUC0-infinity respectively.",Bioequivalence and pharmacokinetic study of two different omeprazole capsule formulations in healthy Bangladeshi volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19517893/),[h·ng] / [ml],2105.21,160410,DB00338,Omeprazole
,19517893,AUC0-infinity,"From serum data, the obtained values for test and reference products were 648.07 +/- 216.27 and 632.69 +/- 257.01 ng/ml for Cmax; 2012.24 +/- 634.48 and 1907.86 +/- 761.91 ng x h/ml for AUC0-24; 2105.21 +/- 623.79 and 1979.18 +/- 748.12 ng x h/ml for AUC0-infinity respectively.",Bioequivalence and pharmacokinetic study of two different omeprazole capsule formulations in healthy Bangladeshi volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19517893/),[h·ng] / [ml],1979.18,160411,DB00338,Omeprazole
,10807427,cure rate,"The cure rate for the peptic ulcer patients was 84% on a per protocol analysis (95% CI: 80%-88%) and 81% on an intention-to-treat analysis (95% CI: 77%-85%), while in the liver cirrhosis patients it was 89% in a per protocol analysis (95% CI: 78%-99%) and 83% in an intention-to-treat analysis (95% CI: 70%-97%).",Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10807427/),%,84,161396,DB00338,Omeprazole
,10807427,cure rate,"The cure rate for the peptic ulcer patients was 84% on a per protocol analysis (95% CI: 80%-88%) and 81% on an intention-to-treat analysis (95% CI: 77%-85%), while in the liver cirrhosis patients it was 89% in a per protocol analysis (95% CI: 78%-99%) and 83% in an intention-to-treat analysis (95% CI: 70%-97%).",Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10807427/),%,81,161397,DB00338,Omeprazole
,10807427,cure rate,"The cure rate for the peptic ulcer patients was 84% on a per protocol analysis (95% CI: 80%-88%) and 81% on an intention-to-treat analysis (95% CI: 77%-85%), while in the liver cirrhosis patients it was 89% in a per protocol analysis (95% CI: 78%-99%) and 83% in an intention-to-treat analysis (95% CI: 70%-97%).",Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10807427/),%,89,161398,DB00338,Omeprazole
,10807427,cure rate,"The cure rate for the peptic ulcer patients was 84% on a per protocol analysis (95% CI: 80%-88%) and 81% on an intention-to-treat analysis (95% CI: 77%-85%), while in the liver cirrhosis patients it was 89% in a per protocol analysis (95% CI: 78%-99%) and 83% in an intention-to-treat analysis (95% CI: 70%-97%).",Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10807427/),%,83,161399,DB00338,Omeprazole
,28649076,diuresis,The results indicate that mean diuresis was 0.0172±0.0029 ml/min/kg.,Renal clearance and urinary excretion of omeprazole in healthy female volunteers in Pakistan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28649076/),[ml] / [kg·min],0.0172,161681,DB00338,Omeprazole
,28649076,renal clearance,While the mean values of renal clearance of creatinine and omeprazole were 1.315±0.103 and 0.066±0.0042 ml/min.,Renal clearance and urinary excretion of omeprazole in healthy female volunteers in Pakistan. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28649076/),[ml] / [min],1.315,161682,DB00338,Omeprazole
,28649076,renal clearance,While the mean values of renal clearance of creatinine and omeprazole were 1.315±0.103 and 0.066±0.0042 ml/min.,Renal clearance and urinary excretion of omeprazole in healthy female volunteers in Pakistan. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28649076/),[ml] / [min],0.066,161683,DB00338,Omeprazole
,28649076,clearance ratio,"Whereas, clearance ratio was 0.055±0.007 which indicates back diffusion.",Renal clearance and urinary excretion of omeprazole in healthy female volunteers in Pakistan. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28649076/),,0.055,161684,DB00338,Omeprazole
,28649076,percentage of dose excreted,The cumulative percentage of dose excreted was 6.71±0.358.,Renal clearance and urinary excretion of omeprazole in healthy female volunteers in Pakistan. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28649076/),,6.71,161685,DB00338,Omeprazole
,2690330,volume of distribution,The volume of distribution is 0.3 litres/kg corresponding to the volume of extracellular water.,Omeprazole: pharmacokinetics and metabolism in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2690330/),[l] / [kg],0.3,161885,DB00338,Omeprazole
less,2690330,half-life,"The half-life is less than 1 hour, and omeprazole is almost entirely cleared from plasma within 3-4 hours.",Omeprazole: pharmacokinetics and metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2690330/),h,1,161886,DB00338,Omeprazole
,2690330,Bioavailability,Bioavailability after a single dose is 35% and increases during repeated once-daily dosing to 60%.,Omeprazole: pharmacokinetics and metabolism in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2690330/),%,35,161887,DB00338,Omeprazole
,2690330,Bioavailability,Bioavailability after a single dose is 35% and increases during repeated once-daily dosing to 60%.,Omeprazole: pharmacokinetics and metabolism in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2690330/),%,60,161888,DB00338,Omeprazole
,10589373,oral bioavailability,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),%,52 to 55,162570,DB00338,Omeprazole
,10589373,maximum concentrations,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[mg] / [l],1.01 to 1.52,162571,DB00338,Omeprazole
,10589373,maximum concentrations,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[mg] / [l],2.41 to 2.85,162572,DB00338,Omeprazole
,10589373,elimination half-life,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),h,3.3 to 4.9,162573,DB00338,Omeprazole
,10589373,total body clearance,"The reported mean values of total body clearance and renal clearance in adults have ranged from 29.2 to 58.1 L/h and 6.7 to 12.8 L/h, respectively.",Clinical pharmacokinetics of clarithromycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[l] / [h],29.2 to 58.1,162574,DB00338,Omeprazole
,10589373,renal clearance,"The reported mean values of total body clearance and renal clearance in adults have ranged from 29.2 to 58.1 L/h and 6.7 to 12.8 L/h, respectively.",Clinical pharmacokinetics of clarithromycin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[l] / [h],6.7 to 12.8,162575,DB00338,Omeprazole
,20063355,LOQ,The LOQ was established at 1.5 and 5 ng/mL for the two concentration ranges.,A bio-analytical hydrophilic interaction LC-MS/MS method for the simultaneous quantification of omeprazole and lansoprazole in human plasma in support of a pharmacokinetic omeprazole study in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20063355/),[ng] / [ml],1.5,163432,DB00338,Omeprazole
,20063355,LOQ,The LOQ was established at 1.5 and 5 ng/mL for the two concentration ranges.,A bio-analytical hydrophilic interaction LC-MS/MS method for the simultaneous quantification of omeprazole and lansoprazole in human plasma in support of a pharmacokinetic omeprazole study in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20063355/),[ng] / [ml],5,163433,DB00338,Omeprazole
,20063355,extraction recovery,"Lack of variability in matrix effects was demonstrated and mean extraction recovery for omeprazole and lansoprazole was determined in the low (56.3-67.7%) and high (45.3-44.3%) concentration range, respectively.",A bio-analytical hydrophilic interaction LC-MS/MS method for the simultaneous quantification of omeprazole and lansoprazole in human plasma in support of a pharmacokinetic omeprazole study in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20063355/),%,56.3-67.7,163434,DB00338,Omeprazole
,20063355,extraction recovery,"Lack of variability in matrix effects was demonstrated and mean extraction recovery for omeprazole and lansoprazole was determined in the low (56.3-67.7%) and high (45.3-44.3%) concentration range, respectively.",A bio-analytical hydrophilic interaction LC-MS/MS method for the simultaneous quantification of omeprazole and lansoprazole in human plasma in support of a pharmacokinetic omeprazole study in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20063355/),%,45.3-44.3,163435,DB00338,Omeprazole
,11214773,Plasma clearance (CL),"Plasma clearance (CL) of esomeprazole decreased from 22 l/h to 16 l/h and from 17 l/h to 9 l/h following repeated dosing of 20 mg and 40 mg, respectively.",Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214773/),[l] / [h],22,163709,DB00338,Omeprazole
,11214773,Plasma clearance (CL),"Plasma clearance (CL) of esomeprazole decreased from 22 l/h to 16 l/h and from 17 l/h to 9 l/h following repeated dosing of 20 mg and 40 mg, respectively.",Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214773/),[l] / [h],16,163710,DB00338,Omeprazole
,11214773,Plasma clearance (CL),"Plasma clearance (CL) of esomeprazole decreased from 22 l/h to 16 l/h and from 17 l/h to 9 l/h following repeated dosing of 20 mg and 40 mg, respectively.",Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214773/),[l] / [h],17,163711,DB00338,Omeprazole
,11214773,Plasma clearance (CL),"Plasma clearance (CL) of esomeprazole decreased from 22 l/h to 16 l/h and from 17 l/h to 9 l/h following repeated dosing of 20 mg and 40 mg, respectively.",Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214773/),[l] / [h],9,163712,DB00338,Omeprazole
,11214773,Total area under the plasma concentration-time curve (AUC),Total area under the plasma concentration-time curve (AUC) increased (from 1.34 micromol x h/l to 2.55 micromol x h/l) with absolute bioavailability (F) being 50% on day 1 and 68% on day 5 after the 20-mg oral dose.,Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214773/),[h·μM] / [l],1.34,163713,DB00338,Omeprazole
,11214773,Total area under the plasma concentration-time curve (AUC),Total area under the plasma concentration-time curve (AUC) increased (from 1.34 micromol x h/l to 2.55 micromol x h/l) with absolute bioavailability (F) being 50% on day 1 and 68% on day 5 after the 20-mg oral dose.,Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214773/),[h·μM] / [l],2.55,163714,DB00338,Omeprazole
,11214773,absolute bioavailability (F),Total area under the plasma concentration-time curve (AUC) increased (from 1.34 micromol x h/l to 2.55 micromol x h/l) with absolute bioavailability (F) being 50% on day 1 and 68% on day 5 after the 20-mg oral dose.,Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214773/),%,50,163715,DB00338,Omeprazole
,11214773,absolute bioavailability (F),Total area under the plasma concentration-time curve (AUC) increased (from 1.34 micromol x h/l to 2.55 micromol x h/l) with absolute bioavailability (F) being 50% on day 1 and 68% on day 5 after the 20-mg oral dose.,Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214773/),%,68,163716,DB00338,Omeprazole
,11214773,AUC,AUC increased (from 4.32 micromol x h/l to 11.21 micromol x h/l) with F being 64% on day 1 and 89% on day 5 after the 40-mg oral dose.,Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214773/),[h·μM] / [l],4.32,163717,DB00338,Omeprazole
,11214773,AUC,AUC increased (from 4.32 micromol x h/l to 11.21 micromol x h/l) with F being 64% on day 1 and 89% on day 5 after the 40-mg oral dose.,Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214773/),[h·μM] / [l],11.21,163718,DB00338,Omeprazole
,16791583,log10,The mean log10(omeprazole/omeprazole sulfone) ratio was 0.18 3 h after intake of omeprazole alone.,Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791583/),,0.18,164111,DB00338,Omeprazole
,15195855,minimum quantifiable concentration,The minimum quantifiable concentration was set at 10 ng/ml [co-efficient of variance (CV) < 10%].,Bioequivalence study of rabeprazole sodium on healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15195855/),[ng] / [ml],10,164232,DB00338,Omeprazole
,15195855,relative bioavailability,By comparing AUC(o-t) the relative bioavailability of test preparation has been found to be 100.88% of that of reference preparation.,Bioequivalence study of rabeprazole sodium on healthy human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15195855/),%,100.88,164233,DB00338,Omeprazole
,21696537,area under the,"Vasodilator stimulated phosphoprotein (VASP), platelet aggregometry (area under the curve (AUC)) and VerifyNow results were 54.7% ± 2.8 platelet reactivity index (PRI), 66.3 ± 2.6 AUC units and 213.1 ± 14.1 platelet reactivity units (PRU) with esomeprazole vs. 47% ± 2.7 PRI, 59.7 ± 3.7 AUC units and 181.4 ± 14.6 PRU with placebo (P < 0.01 esomeprazole vs. placebo for all measures).",Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),,54,166599,DB00338,Omeprazole
,21696537,AUC,"Vasodilator stimulated phosphoprotein (VASP), platelet aggregometry (area under the curve (AUC)) and VerifyNow results were 54.7% ± 2.8 platelet reactivity index (PRI), 66.3 ± 2.6 AUC units and 213.1 ± 14.1 platelet reactivity units (PRU) with esomeprazole vs. 47% ± 2.7 PRI, 59.7 ± 3.7 AUC units and 181.4 ± 14.6 PRU with placebo (P < 0.01 esomeprazole vs. placebo for all measures).",Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),,66.3,166600,DB00338,Omeprazole
,21696537,AUC,"Vasodilator stimulated phosphoprotein (VASP), platelet aggregometry (area under the curve (AUC)) and VerifyNow results were 54.7% ± 2.8 platelet reactivity index (PRI), 66.3 ± 2.6 AUC units and 213.1 ± 14.1 platelet reactivity units (PRU) with esomeprazole vs. 47% ± 2.7 PRI, 59.7 ± 3.7 AUC units and 181.4 ± 14.6 PRU with placebo (P < 0.01 esomeprazole vs. placebo for all measures).",Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),%,47,166601,DB00338,Omeprazole
,21696537,AUC,"Vasodilator stimulated phosphoprotein (VASP), platelet aggregometry (area under the curve (AUC)) and VerifyNow results were 54.7% ± 2.8 platelet reactivity index (PRI), 66.3 ± 2.6 AUC units and 213.1 ± 14.1 platelet reactivity units (PRU) with esomeprazole vs. 47% ± 2.7 PRI, 59.7 ± 3.7 AUC units and 181.4 ± 14.6 PRU with placebo (P < 0.01 esomeprazole vs. placebo for all measures).",Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),,59.7,166602,DB00338,Omeprazole
,21696537,maximal aggregation,There was no significant difference in platelet aggregometry (maximal aggregation) between the esomeprazole group (68.9% ± 2.7 units) and placebo-treated group (64.5% ± 4.1 units; P > 0.05).,Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),%,68.9,166603,DB00338,Omeprazole
,21696537,maximal aggregation,There was no significant difference in platelet aggregometry (maximal aggregation) between the esomeprazole group (68.9% ± 2.7 units) and placebo-treated group (64.5% ± 4.1 units; P > 0.05).,Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),%,64.5,166604,DB00338,Omeprazole
,17293174,total run time,"Omeprazole and flunitrazepam, the internal standard, elute at 0.80+/-0.10 min with a total run time 1.35 min.",Rapid determination of omeprazole in human plasma by protein precipitation and liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17293174/),min,1.35,166723,DB00338,Omeprazole
,17293174,m/z,"Quantification was through positive ion mode and selected reaction monitoring mode at m/z 346.1-->197.9 for omeprazole and m/z 314.0-->268.0 for flunitrazepam, respectively.",Rapid determination of omeprazole in human plasma by protein precipitation and liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17293174/),,346.1,166724,DB00338,Omeprazole
,17293174,m/z,"Quantification was through positive ion mode and selected reaction monitoring mode at m/z 346.1-->197.9 for omeprazole and m/z 314.0-->268.0 for flunitrazepam, respectively.",Rapid determination of omeprazole in human plasma by protein precipitation and liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17293174/),,197.9,166725,DB00338,Omeprazole
,17293174,m/z,"Quantification was through positive ion mode and selected reaction monitoring mode at m/z 346.1-->197.9 for omeprazole and m/z 314.0-->268.0 for flunitrazepam, respectively.",Rapid determination of omeprazole in human plasma by protein precipitation and liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17293174/),,314.0,166726,DB00338,Omeprazole
,17293174,m/z,"Quantification was through positive ion mode and selected reaction monitoring mode at m/z 346.1-->197.9 for omeprazole and m/z 314.0-->268.0 for flunitrazepam, respectively.",Rapid determination of omeprazole in human plasma by protein precipitation and liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17293174/),,268.0,166727,DB00338,Omeprazole
,24899600,AUC(0-t),"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[mg] / [h·l],15.371,167278,DB00338,Omeprazole
,24899600,AUC(0-t),"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[mg] / [h·l],6.901,167279,DB00338,Omeprazole
,24899600,MRT(0-t),"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),h,8.751,167280,DB00338,Omeprazole
,24899600,MRT(0-t),"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),h,6.032,167281,DB00338,Omeprazole
,24899600,t1/2,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),h,3.88,167282,DB00338,Omeprazole
,24899600,t1/2,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),h,3.602,167283,DB00338,Omeprazole
,24899600,Tmax,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),h,6.2,167284,DB00338,Omeprazole
,24899600,Tmax,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),h,1.95,167285,DB00338,Omeprazole
,24899600,CL/F,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[l] / [h·kg],0.038,167286,DB00338,Omeprazole
,24899600,CL/F,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[l] / [h·kg],0.107,167287,DB00338,Omeprazole
,24899600,V/F,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[l] / [kg],0.212,167288,DB00338,Omeprazole
,24899600,V/F,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[l] / [kg],0.567,167289,DB00338,Omeprazole
,24899600,Cmax,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[mg] / [l],1.853,167290,DB00338,Omeprazole
,24899600,Cmax,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[mg] / [l],1.422,167291,DB00338,Omeprazole
,10829049,maximum dose,"At higher doses, BR96-Dox was associated with nausea, vomiting, and endoscopically documented exudative gastritis of the upper GI tract, which was dose-limiting at a maximum dose of 875 mg/m(2) (doxorubicin equivalent, 25 mg/m(2)) administered every 3 weeks.",Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829049/),[mg] / [m(2],875,168140,DB00338,Omeprazole
,10829049,half-life,"At the 550-mg/m(2) dose, the half-life (mean +/- SD) of BR96 and doxorubicin was 300 +/- 95 hours and 43 +/- 4 hours, respectively.",Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829049/),h,300,168141,DB00338,Omeprazole
,10829049,half-life,"At the 550-mg/m(2) dose, the half-life (mean +/- SD) of BR96 and doxorubicin was 300 +/- 95 hours and 43 +/- 4 hours, respectively.",Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829049/),h,43,168142,DB00338,Omeprazole
,22318618,AUC(0-∞) metabolic ratio (MR),"Relative to single-dose treatment, multiple doses of efavirenz significantly decreased (P < 0.0001) the area under the plasma concentration-time curve from 0 to infinity (AUC(0-∞)) of racemic-, R- and S-omeprazole (2.01- to 2.15-fold) and the corresponding AUC(0-∞) metabolic ratio (MR) for 5-hydroxyomeprazole (1.36- to 1.44-fold) as well as the MR for omeprazole sulfone (∼2.0) (P < 0.0001).",Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22318618/),,∼2.0,168709,DB00338,Omeprazole
,25364857,maximum concentrations,"3. The mean maximum concentrations of R- and S-warfarin (4.6 and 3.7 µg/mL, respectively) in aged monkeys after oral administration were significantly higher than those in young monkeys (3.3 and 2.7 µg/mL).","Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[μg] / [ml],4.6,168775,DB00338,Omeprazole
,25364857,maximum concentrations,"3. The mean maximum concentrations of R- and S-warfarin (4.6 and 3.7 µg/mL, respectively) in aged monkeys after oral administration were significantly higher than those in young monkeys (3.3 and 2.7 µg/mL).","Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[μg] / [ml],3.7,168776,DB00338,Omeprazole
,25364857,maximum concentrations,"3. The mean maximum concentrations of R- and S-warfarin (4.6 and 3.7 µg/mL, respectively) in aged monkeys after oral administration were significantly higher than those in young monkeys (3.3 and 2.7 µg/mL).","Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[μg] / [ml],3.3,168777,DB00338,Omeprazole
,25364857,maximum concentrations,"3. The mean maximum concentrations of R- and S-warfarin (4.6 and 3.7 µg/mL, respectively) in aged monkeys after oral administration were significantly higher than those in young monkeys (3.3 and 2.7 µg/mL).","Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[μg] / [ml],2.7,168778,DB00338,Omeprazole
,25364857,clearance (CL),The mean clearance (CL) values of midazolam in aged monkeys (9.5 mL/min/kg) were significantly lower than those in young monkeys (13 mL/min/kg).,"Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[ml] / [kg·min],9.5,168779,DB00338,Omeprazole
,25364857,clearance (CL),The mean clearance (CL) values of midazolam in aged monkeys (9.5 mL/min/kg) were significantly lower than those in young monkeys (13 mL/min/kg).,"Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[ml] / [kg·min],13,168780,DB00338,Omeprazole
,20562093,t(max),"t(max) of NA were on average 0.75 h in dialysis patients and 3.0 h in CKD patients and, therefore, especially for dialysis patients, clearly shorter than expected for extended-release formulations.",Pharmacokinetics and dose recommendations of Niaspan® in chronic kidney disease and dialysis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20562093/),h,0.75,170185,DB00338,Omeprazole
,20562093,t(max),"t(max) of NA were on average 0.75 h in dialysis patients and 3.0 h in CKD patients and, therefore, especially for dialysis patients, clearly shorter than expected for extended-release formulations.",Pharmacokinetics and dose recommendations of Niaspan® in chronic kidney disease and dialysis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20562093/),h,3.0,170186,DB00338,Omeprazole
,11966672,AUC,"The coadministration of moclobemide in EMs approximately doubled the mean AUC (from 1834 to 3760 ng ml(-1) h) and C(max) (from 987 to 1649 ng ml(-1)) of omeprazole, and increased the AUC of omeprazole sulphone without changing AUC ratio of omeprazole to omeprazole sulphone.",Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11966672/),[h·ng] / [ml],1834,170216,DB00338,Omeprazole
,11966672,C(max),"The coadministration of moclobemide in EMs approximately doubled the mean AUC (from 1834 to 3760 ng ml(-1) h) and C(max) (from 987 to 1649 ng ml(-1)) of omeprazole, and increased the AUC of omeprazole sulphone without changing AUC ratio of omeprazole to omeprazole sulphone.",Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11966672/),[ng] / [ml],987 to 1649,170217,DB00338,Omeprazole
,11966672,AUC ratio,"Moclobemide coadministration more than doubled the AUC ratio of omeprazole to 5-hydroxyomeprazole (from 2.5 to 5.3) in EMs, too.",Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11966672/),,2.5,170218,DB00338,Omeprazole
,11966672,AUC ratio,"Moclobemide coadministration more than doubled the AUC ratio of omeprazole to 5-hydroxyomeprazole (from 2.5 to 5.3) in EMs, too.",Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11966672/),,5.3,170219,DB00338,Omeprazole
,16028623,Bioavailability,Bioavailability of intragastric-administered pantoprazole was 41%.,Pharmacokinetics and pharmacodynamics of pantoprazole in clinically normal neonatal foals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028623/),%,41,170384,DB00338,Omeprazole
<,22549498,AUC,"Similarly, the number of patients underexposed to MPA (AUC < 30 ng·h/mL) was higher at most periods in the PPI group but again not statistically significant.",Diminished mycophenolic acid exposure caused by omeprazole may be clinically relevant in the first week posttransplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22549498/),[h·ng] / [ml],30,171979,DB00338,Omeprazole
,15319328,terminal half-life,The mean terminal half-life of approximately 6 min was found across genotype and gender groups.,Altered pharmacokinetics of omeprazole in cystic fibrosis knockout mice relative to wild-type mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319328/),min,6,173695,DB00338,Omeprazole
,15319328,blood clearance (Cl(b)),Omeprazole blood clearance (Cl(b)) was significantly higher in both male (190 ml/min/kg) and female (168 ml/min/kg) CF-KO mice compared with wild-type controls of the same gender (73 ml/min/kg for males and 100 ml/min/kg for females).,Altered pharmacokinetics of omeprazole in cystic fibrosis knockout mice relative to wild-type mice. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319328/),[ml] / [kg·min],190,173696,DB00338,Omeprazole
,15319328,blood clearance (Cl(b)),Omeprazole blood clearance (Cl(b)) was significantly higher in both male (190 ml/min/kg) and female (168 ml/min/kg) CF-KO mice compared with wild-type controls of the same gender (73 ml/min/kg for males and 100 ml/min/kg for females).,Altered pharmacokinetics of omeprazole in cystic fibrosis knockout mice relative to wild-type mice. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319328/),[ml] / [kg·min],168,173697,DB00338,Omeprazole
,15319328,blood clearance (Cl(b)),Omeprazole blood clearance (Cl(b)) was significantly higher in both male (190 ml/min/kg) and female (168 ml/min/kg) CF-KO mice compared with wild-type controls of the same gender (73 ml/min/kg for males and 100 ml/min/kg for females).,Altered pharmacokinetics of omeprazole in cystic fibrosis knockout mice relative to wild-type mice. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319328/),[ml] / [kg·min],73,173698,DB00338,Omeprazole
,15319328,blood clearance (Cl(b)),Omeprazole blood clearance (Cl(b)) was significantly higher in both male (190 ml/min/kg) and female (168 ml/min/kg) CF-KO mice compared with wild-type controls of the same gender (73 ml/min/kg for males and 100 ml/min/kg for females).,Altered pharmacokinetics of omeprazole in cystic fibrosis knockout mice relative to wild-type mice. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319328/),[ml] / [kg·min],100,173699,DB00338,Omeprazole
,31251331,flow rate,The flow rate was 1 mL/min and maximum absorption was measured using Diode Array (DAD) detector at 285 nm.,"Developing a High-Performance Liquid Chromatography (HPLC) Method for Simultaneous Determination of Oxytetracycline, Tinidazole and Esomeprazole in Human Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31251331/),[ml] / [min],1,174358,DB00338,Omeprazole
,31251331,retention times,"The retention times of OXY, TIN and ESM were recorded to be 2.68, 3.52 and 5.17 minutes, respectively, indicating a shorter analysis time.","Developing a High-Performance Liquid Chromatography (HPLC) Method for Simultaneous Determination of Oxytetracycline, Tinidazole and Esomeprazole in Human Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31251331/),min,2.68,174359,DB00338,Omeprazole
,31251331,retention times,"The retention times of OXY, TIN and ESM were recorded to be 2.68, 3.52 and 5.17 minutes, respectively, indicating a shorter analysis time.","Developing a High-Performance Liquid Chromatography (HPLC) Method for Simultaneous Determination of Oxytetracycline, Tinidazole and Esomeprazole in Human Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31251331/),min,3.52,174360,DB00338,Omeprazole
,31251331,retention times,"The retention times of OXY, TIN and ESM were recorded to be 2.68, 3.52 and 5.17 minutes, respectively, indicating a shorter analysis time.","Developing a High-Performance Liquid Chromatography (HPLC) Method for Simultaneous Determination of Oxytetracycline, Tinidazole and Esomeprazole in Human Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31251331/),min,5.17,174361,DB00338,Omeprazole
,31251331,Limits of detection,"Limits of detection were also reported to be 0.10, 0.07 and 0.04 μg/mL for OXY, TIN and ESM, respectively, showing a high degree of the method sensitivity.","Developing a High-Performance Liquid Chromatography (HPLC) Method for Simultaneous Determination of Oxytetracycline, Tinidazole and Esomeprazole in Human Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31251331/),[μg] / [ml],0.10,174362,DB00338,Omeprazole
,31251331,Limits of detection,"Limits of detection were also reported to be 0.10, 0.07 and 0.04 μg/mL for OXY, TIN and ESM, respectively, showing a high degree of the method sensitivity.","Developing a High-Performance Liquid Chromatography (HPLC) Method for Simultaneous Determination of Oxytetracycline, Tinidazole and Esomeprazole in Human Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31251331/),[μg] / [ml],0.07,174363,DB00338,Omeprazole
,31251331,Limits of detection,"Limits of detection were also reported to be 0.10, 0.07 and 0.04 μg/mL for OXY, TIN and ESM, respectively, showing a high degree of the method sensitivity.","Developing a High-Performance Liquid Chromatography (HPLC) Method for Simultaneous Determination of Oxytetracycline, Tinidazole and Esomeprazole in Human Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31251331/),[μg] / [ml],0.04,174364,DB00338,Omeprazole
,11768559,half-life,"Actually, all PPIs display chemical activation half-lives at pH 1.0 of a few minutes at the most, while being eliminated from serum with a half-life of about 1 h.",Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11768559/),h,1,175782,DB00338,Omeprazole
,11999751,blood-to-brain coefficient of distribution,"Following omeprazole administration, the blood-to-brain coefficient of distribution was 0.15, which was calculated as the area under the concentration versus time curve (AUC) in the brain divided by the AUC in blood (k=AUCbrain/AUCblood).","Determination and pharmacokinetic profile of omeprazole in rat blood, brain and bile by microdialysis and high-performance liquid chromatography. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999751/),,0.15,175828,DB00338,Omeprazole
,11999751,blood-to-bile,The blood-to-bile coefficient of distribution (k=AUCbile/AUCblood) was 0.58.,"Determination and pharmacokinetic profile of omeprazole in rat blood, brain and bile by microdialysis and high-performance liquid chromatography. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999751/),,0.58,175829,DB00338,Omeprazole
,11999751,coefficient of distribution (k,The blood-to-bile coefficient of distribution (k=AUCbile/AUCblood) was 0.58.,"Determination and pharmacokinetic profile of omeprazole in rat blood, brain and bile by microdialysis and high-performance liquid chromatography. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999751/),,0.58,175830,DB00338,Omeprazole
,30422368,time to reach maximum plasma concentration,"Esomeprazole was absorbed and eliminated rapidly in all groups, with a median time to reach maximum plasma concentration of 1.47-1.75 h, an arithmetic mean terminal elimination half-life of 0.80-1.37 h, and a weight-correlated apparent total body clearance of 0.216-0.343 L/h/kg.","Oral esomeprazole in Japanese pediatric patients with gastric acid-related disease: Safety, efficacy, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30422368/),h,1.47-1.75,176105,DB00338,Omeprazole
,30422368,terminal elimination half-life,"Esomeprazole was absorbed and eliminated rapidly in all groups, with a median time to reach maximum plasma concentration of 1.47-1.75 h, an arithmetic mean terminal elimination half-life of 0.80-1.37 h, and a weight-correlated apparent total body clearance of 0.216-0.343 L/h/kg.","Oral esomeprazole in Japanese pediatric patients with gastric acid-related disease: Safety, efficacy, and pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30422368/),h,0.80-1.37,176106,DB00338,Omeprazole
,30422368,weight-correlated apparent total body clearance,"Esomeprazole was absorbed and eliminated rapidly in all groups, with a median time to reach maximum plasma concentration of 1.47-1.75 h, an arithmetic mean terminal elimination half-life of 0.80-1.37 h, and a weight-correlated apparent total body clearance of 0.216-0.343 L/h/kg.","Oral esomeprazole in Japanese pediatric patients with gastric acid-related disease: Safety, efficacy, and pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30422368/),[l] / [h·kg],0.216-0.343,176107,DB00338,Omeprazole
,30297369,area under the concentration-time curve,"In the fed and fasted states, SUBA itraconazole demonstrated similar concentrations at the end of the dosing interval, with modestly lower total and peak ITZ exposure being shown when it was administered under fed conditions than when it was administered in the fasted state, with fed state/fasted state ratios of 78.09% (90% confidence interval [CI], 74.49 to 81.86%) for the area under the concentration-time curve over the dosing interval (14,183.2 versus 18,479.8 ng · h/ml), 73.05% (90% CI, 69.01 to 77.33%) for the maximum concentration at steady state (1,519.1 versus 2,085.2 ng/ml), and 91.53% (90% CI, 86.41 to 96.96%) for the trough concentration (1,071.5 versus 1,218.5 ng/ml) being found.",Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30297369/),[h·ng] / [ml],"14,183.2",176680,DB00338,Omeprazole
,30297369,area under the concentration-time curve,"In the fed and fasted states, SUBA itraconazole demonstrated similar concentrations at the end of the dosing interval, with modestly lower total and peak ITZ exposure being shown when it was administered under fed conditions than when it was administered in the fasted state, with fed state/fasted state ratios of 78.09% (90% confidence interval [CI], 74.49 to 81.86%) for the area under the concentration-time curve over the dosing interval (14,183.2 versus 18,479.8 ng · h/ml), 73.05% (90% CI, 69.01 to 77.33%) for the maximum concentration at steady state (1,519.1 versus 2,085.2 ng/ml), and 91.53% (90% CI, 86.41 to 96.96%) for the trough concentration (1,071.5 versus 1,218.5 ng/ml) being found.",Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30297369/),[h·ng] / [ml],"18,479.8",176681,DB00338,Omeprazole
,30297369,maximum concentration at steady state,"In the fed and fasted states, SUBA itraconazole demonstrated similar concentrations at the end of the dosing interval, with modestly lower total and peak ITZ exposure being shown when it was administered under fed conditions than when it was administered in the fasted state, with fed state/fasted state ratios of 78.09% (90% confidence interval [CI], 74.49 to 81.86%) for the area under the concentration-time curve over the dosing interval (14,183.2 versus 18,479.8 ng · h/ml), 73.05% (90% CI, 69.01 to 77.33%) for the maximum concentration at steady state (1,519.1 versus 2,085.2 ng/ml), and 91.53% (90% CI, 86.41 to 96.96%) for the trough concentration (1,071.5 versus 1,218.5 ng/ml) being found.",Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30297369/),ng,"1,519.1",176682,DB00338,Omeprazole
,30297369,maximum concentration at steady state,"In the fed and fasted states, SUBA itraconazole demonstrated similar concentrations at the end of the dosing interval, with modestly lower total and peak ITZ exposure being shown when it was administered under fed conditions than when it was administered in the fasted state, with fed state/fasted state ratios of 78.09% (90% confidence interval [CI], 74.49 to 81.86%) for the area under the concentration-time curve over the dosing interval (14,183.2 versus 18,479.8 ng · h/ml), 73.05% (90% CI, 69.01 to 77.33%) for the maximum concentration at steady state (1,519.1 versus 2,085.2 ng/ml), and 91.53% (90% CI, 86.41 to 96.96%) for the trough concentration (1,071.5 versus 1,218.5 ng/ml) being found.",Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30297369/),ng,"2,085.2",176683,DB00338,Omeprazole
,30297369,trough concentration,"In the fed and fasted states, SUBA itraconazole demonstrated similar concentrations at the end of the dosing interval, with modestly lower total and peak ITZ exposure being shown when it was administered under fed conditions than when it was administered in the fasted state, with fed state/fasted state ratios of 78.09% (90% confidence interval [CI], 74.49 to 81.86%) for the area under the concentration-time curve over the dosing interval (14,183.2 versus 18,479.8 ng · h/ml), 73.05% (90% CI, 69.01 to 77.33%) for the maximum concentration at steady state (1,519.1 versus 2,085.2 ng/ml), and 91.53% (90% CI, 86.41 to 96.96%) for the trough concentration (1,071.5 versus 1,218.5 ng/ml) being found.",Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30297369/),[ng] / [ml],"1,071.5",176684,DB00338,Omeprazole
,30297369,trough concentration,"In the fed and fasted states, SUBA itraconazole demonstrated similar concentrations at the end of the dosing interval, with modestly lower total and peak ITZ exposure being shown when it was administered under fed conditions than when it was administered in the fasted state, with fed state/fasted state ratios of 78.09% (90% confidence interval [CI], 74.49 to 81.86%) for the area under the concentration-time curve over the dosing interval (14,183.2 versus 18,479.8 ng · h/ml), 73.05% (90% CI, 69.01 to 77.33%) for the maximum concentration at steady state (1,519.1 versus 2,085.2 ng/ml), and 91.53% (90% CI, 86.41 to 96.96%) for the trough concentration (1,071.5 versus 1,218.5 ng/ml) being found.",Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30297369/),[ng] / [ml],"1,218.5",176685,DB00338,Omeprazole
,8823233,area under the plasma concentration time curve extrapolated to infinity [AUCO-infinity],"Omeprazole concentrations were significantly lower (mean area under the plasma concentration time curve extrapolated to infinity [AUCO-infinity] +/- SEM; 7.53 +/- 1.21 versus 12.80 +/- 2.13 mumol.hr.L-1, respectively; p < 0.05) and its oral clearance greater (319 +/- 60 versus 183 +/- 35 ml/min, respectively; p < 0.05) in the white subjects than in the Chinese subjects.",Ethnic and genetic determinants of omeprazole disposition and effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823233/),[h·μM] / [l],7.53,176901,DB00338,Omeprazole
,8823233,area under the plasma concentration time curve extrapolated to infinity [AUCO-infinity],"Omeprazole concentrations were significantly lower (mean area under the plasma concentration time curve extrapolated to infinity [AUCO-infinity] +/- SEM; 7.53 +/- 1.21 versus 12.80 +/- 2.13 mumol.hr.L-1, respectively; p < 0.05) and its oral clearance greater (319 +/- 60 versus 183 +/- 35 ml/min, respectively; p < 0.05) in the white subjects than in the Chinese subjects.",Ethnic and genetic determinants of omeprazole disposition and effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823233/),[h·μM] / [l],12.80,176902,DB00338,Omeprazole
,8823233,oral clearance,"Omeprazole concentrations were significantly lower (mean area under the plasma concentration time curve extrapolated to infinity [AUCO-infinity] +/- SEM; 7.53 +/- 1.21 versus 12.80 +/- 2.13 mumol.hr.L-1, respectively; p < 0.05) and its oral clearance greater (319 +/- 60 versus 183 +/- 35 ml/min, respectively; p < 0.05) in the white subjects than in the Chinese subjects.",Ethnic and genetic determinants of omeprazole disposition and effect. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823233/),[ml] / [min],319,176903,DB00338,Omeprazole
,8823233,oral clearance,"Omeprazole concentrations were significantly lower (mean area under the plasma concentration time curve extrapolated to infinity [AUCO-infinity] +/- SEM; 7.53 +/- 1.21 versus 12.80 +/- 2.13 mumol.hr.L-1, respectively; p < 0.05) and its oral clearance greater (319 +/- 60 versus 183 +/- 35 ml/min, respectively; p < 0.05) in the white subjects than in the Chinese subjects.",Ethnic and genetic determinants of omeprazole disposition and effect. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823233/),[ml] / [min],183,176904,DB00338,Omeprazole
,8823233,AUCgas24,"Fasting gastrin, AUCgas12, and AUCgas24 were significantly greater in the Chinese subjects than in the white subjects (30.0 +/- 6.4 versus 14.4 +/- 1.2 pmol, respectively [p < 0.02]; 661 +/- 114 versus 334 +/- 38 pmol.hr.L-1, respectively [p < 0.002]; and 1414 +/- 228 versus 747 +/- 99 pmol.hr.L-1, respectively [p < 0.004]).",Ethnic and genetic determinants of omeprazole disposition and effect. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823233/),[h·pM] / [l],334,176905,DB00338,Omeprazole
,8823233,AUCgas24,"Fasting gastrin, AUCgas12, and AUCgas24 were significantly greater in the Chinese subjects than in the white subjects (30.0 +/- 6.4 versus 14.4 +/- 1.2 pmol, respectively [p < 0.02]; 661 +/- 114 versus 334 +/- 38 pmol.hr.L-1, respectively [p < 0.002]; and 1414 +/- 228 versus 747 +/- 99 pmol.hr.L-1, respectively [p < 0.004]).",Ethnic and genetic determinants of omeprazole disposition and effect. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823233/),[h·pM] / [l],1414,176906,DB00338,Omeprazole
,8823233,AUCgas24,"Fasting gastrin, AUCgas12, and AUCgas24 were significantly greater in the Chinese subjects than in the white subjects (30.0 +/- 6.4 versus 14.4 +/- 1.2 pmol, respectively [p < 0.02]; 661 +/- 114 versus 334 +/- 38 pmol.hr.L-1, respectively [p < 0.002]; and 1414 +/- 228 versus 747 +/- 99 pmol.hr.L-1, respectively [p < 0.004]).",Ethnic and genetic determinants of omeprazole disposition and effect. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823233/),[h·pM] / [l],747,176907,DB00338,Omeprazole
,11467632,time to the maximum observed concentration,"Lansoprazole's time to the maximum observed concentration and area under the plasma concentration-time curve over the 24-h time interval increased significantly from day I to day 5 (1.7 h vs 2.0 h and 1865 ng x h/ml vs 2091 ng x h/ml, respectively), and a significant increase in half-life relative to day 1 (0.96 h) was observed on day 5 (1.03 h) during pantoprazole treatment.",Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11467632/),h,1.7,177294,DB00338,Omeprazole
,11467632,time to the maximum observed concentration,"Lansoprazole's time to the maximum observed concentration and area under the plasma concentration-time curve over the 24-h time interval increased significantly from day I to day 5 (1.7 h vs 2.0 h and 1865 ng x h/ml vs 2091 ng x h/ml, respectively), and a significant increase in half-life relative to day 1 (0.96 h) was observed on day 5 (1.03 h) during pantoprazole treatment.",Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11467632/),h,2.0,177295,DB00338,Omeprazole
,11467632,area under the plasma concentration-time curve,"Lansoprazole's time to the maximum observed concentration and area under the plasma concentration-time curve over the 24-h time interval increased significantly from day I to day 5 (1.7 h vs 2.0 h and 1865 ng x h/ml vs 2091 ng x h/ml, respectively), and a significant increase in half-life relative to day 1 (0.96 h) was observed on day 5 (1.03 h) during pantoprazole treatment.",Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11467632/),[h·ng] / [ml],1865,177296,DB00338,Omeprazole
,11467632,area under the plasma concentration-time curve,"Lansoprazole's time to the maximum observed concentration and area under the plasma concentration-time curve over the 24-h time interval increased significantly from day I to day 5 (1.7 h vs 2.0 h and 1865 ng x h/ml vs 2091 ng x h/ml, respectively), and a significant increase in half-life relative to day 1 (0.96 h) was observed on day 5 (1.03 h) during pantoprazole treatment.",Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11467632/),[h·ng] / [ml],2091,177297,DB00338,Omeprazole
,11467632,half-life,"Lansoprazole's time to the maximum observed concentration and area under the plasma concentration-time curve over the 24-h time interval increased significantly from day I to day 5 (1.7 h vs 2.0 h and 1865 ng x h/ml vs 2091 ng x h/ml, respectively), and a significant increase in half-life relative to day 1 (0.96 h) was observed on day 5 (1.03 h) during pantoprazole treatment.",Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11467632/),h,0.96,177298,DB00338,Omeprazole
,11467632,half-life,"Lansoprazole's time to the maximum observed concentration and area under the plasma concentration-time curve over the 24-h time interval increased significantly from day I to day 5 (1.7 h vs 2.0 h and 1865 ng x h/ml vs 2091 ng x h/ml, respectively), and a significant increase in half-life relative to day 1 (0.96 h) was observed on day 5 (1.03 h) during pantoprazole treatment.",Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11467632/),h,1.03,177299,DB00338,Omeprazole
,8803522,total clearance,"The total clearance was 517 ml.min-1, and the absolute bioavailability was 91% for the 30-mg and 81% for the 15-mg enteric-coated formulation.",Pharmacokinetics and absolute bioavailability of lansoprazole. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803522/),[ml] / [min],517,177431,DB00338,Omeprazole
,8803522,absolute bioavailability,"The total clearance was 517 ml.min-1, and the absolute bioavailability was 91% for the 30-mg and 81% for the 15-mg enteric-coated formulation.",Pharmacokinetics and absolute bioavailability of lansoprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803522/),%,91,177432,DB00338,Omeprazole
,8803522,absolute bioavailability,"The total clearance was 517 ml.min-1, and the absolute bioavailability was 91% for the 30-mg and 81% for the 15-mg enteric-coated formulation.",Pharmacokinetics and absolute bioavailability of lansoprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803522/),%,81,177433,DB00338,Omeprazole
,8803522,elimination half-life,The elimination half-life was about 1 h.,Pharmacokinetics and absolute bioavailability of lansoprazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803522/),h,1,177434,DB00338,Omeprazole
,16715780,E0,"The final PK-PD model incorporated a one-compartment PK model with one-order absorption from the gastroenteric trace, first-order elimination pathway with one fixed-effect genotype modeling, and a full sigmoidal Emax PD model (X +/- SE: E0 = 2.30 +/- 0.189; Emax = 7.32 +/- 0.662; EC50 = 51.3 +/- 2.142 ng/ml; Hill coefficient = 5.00 +/- 0.556).",Pharmacokinetic and pharmacodynamic population modeling of orally administered rabeprazole in healthy Chinese volunteers by the NONMEM method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715780/),,2.30,177872,DB00338,Omeprazole
,16715780,Emax,"The final PK-PD model incorporated a one-compartment PK model with one-order absorption from the gastroenteric trace, first-order elimination pathway with one fixed-effect genotype modeling, and a full sigmoidal Emax PD model (X +/- SE: E0 = 2.30 +/- 0.189; Emax = 7.32 +/- 0.662; EC50 = 51.3 +/- 2.142 ng/ml; Hill coefficient = 5.00 +/- 0.556).",Pharmacokinetic and pharmacodynamic population modeling of orally administered rabeprazole in healthy Chinese volunteers by the NONMEM method. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715780/),,7.32,177873,DB00338,Omeprazole
,16715780,EC50,"The final PK-PD model incorporated a one-compartment PK model with one-order absorption from the gastroenteric trace, first-order elimination pathway with one fixed-effect genotype modeling, and a full sigmoidal Emax PD model (X +/- SE: E0 = 2.30 +/- 0.189; Emax = 7.32 +/- 0.662; EC50 = 51.3 +/- 2.142 ng/ml; Hill coefficient = 5.00 +/- 0.556).",Pharmacokinetic and pharmacodynamic population modeling of orally administered rabeprazole in healthy Chinese volunteers by the NONMEM method. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715780/),[ng] / [ml],51.3,177874,DB00338,Omeprazole
,16715780,Hill coefficient,"The final PK-PD model incorporated a one-compartment PK model with one-order absorption from the gastroenteric trace, first-order elimination pathway with one fixed-effect genotype modeling, and a full sigmoidal Emax PD model (X +/- SE: E0 = 2.30 +/- 0.189; Emax = 7.32 +/- 0.662; EC50 = 51.3 +/- 2.142 ng/ml; Hill coefficient = 5.00 +/- 0.556).",Pharmacokinetic and pharmacodynamic population modeling of orally administered rabeprazole in healthy Chinese volunteers by the NONMEM method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715780/),,5.00,177875,DB00338,Omeprazole
,16180125,CLint,"The sum of the CLint of the formation of all three metabolites was 3.06 and 4.82 mL/min/mg protein for S- and R-pantoprazole, respectively.",Pharmacokinetic differences between pantoprazole enantiomers in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16180125/),[ml] / [mg·min],3.06,179016,DB00338,Omeprazole
,16180125,CLint,"The sum of the CLint of the formation of all three metabolites was 3.06 and 4.82 mL/min/mg protein for S- and R-pantoprazole, respectively.",Pharmacokinetic differences between pantoprazole enantiomers in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16180125/),[ml] / [mg·min],4.82,179017,DB00338,Omeprazole
,8448974,elimination half-life,The mean elimination half-life of omeprazole in the patients with cirrhosis was 2.8h and the mean total plasma clearance was 67 ml/min (4.02 L/h); corresponding values from separate studies in young healthy volunteers were 0.7h and 594 ml/min (35.64 L/h).,Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8448974/),h,2.8,179759,DB00338,Omeprazole
,8448974,total plasma clearance,The mean elimination half-life of omeprazole in the patients with cirrhosis was 2.8h and the mean total plasma clearance was 67 ml/min (4.02 L/h); corresponding values from separate studies in young healthy volunteers were 0.7h and 594 ml/min (35.64 L/h).,Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8448974/),[ml] / [min],67,179760,DB00338,Omeprazole
,8448974,total plasma clearance,The mean elimination half-life of omeprazole in the patients with cirrhosis was 2.8h and the mean total plasma clearance was 67 ml/min (4.02 L/h); corresponding values from separate studies in young healthy volunteers were 0.7h and 594 ml/min (35.64 L/h).,Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8448974/),h,0.7,179761,DB00338,Omeprazole
,8448974,total plasma clearance,The mean elimination half-life of omeprazole in the patients with cirrhosis was 2.8h and the mean total plasma clearance was 67 ml/min (4.02 L/h); corresponding values from separate studies in young healthy volunteers were 0.7h and 594 ml/min (35.64 L/h).,Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8448974/),[ml] / [min],594,179762,DB00338,Omeprazole
,8448974,systemic availability,The mean systemic availability was nearly 100% in the patients with cirrhosis whereas the previously reported value in young volunteers was only 56%.,Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8448974/),%,100,179763,DB00338,Omeprazole
,8448974,systemic availability,The mean systemic availability was nearly 100% in the patients with cirrhosis whereas the previously reported value in young volunteers was only 56%.,Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8448974/),%,56,179764,DB00338,Omeprazole
,1357107,bioavailability,"The bioavailability of SC CdA was 102% +/- 28% (mean +/- SD), and the bioavailability of CdA administered in enteric-coated capsules was 19%, 24%, and 60%.",On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357107/),%,102,179814,DB00338,Omeprazole
,1357107,bioavailability,"The bioavailability of SC CdA was 102% +/- 28% (mean +/- SD), and the bioavailability of CdA administered in enteric-coated capsules was 19%, 24%, and 60%.",On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357107/),%,19,179815,DB00338,Omeprazole
,1357107,bioavailability,"The bioavailability of SC CdA was 102% +/- 28% (mean +/- SD), and the bioavailability of CdA administered in enteric-coated capsules was 19%, 24%, and 60%.",On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357107/),%,24,179816,DB00338,Omeprazole
,1357107,bioavailability,"The bioavailability of SC CdA was 102% +/- 28% (mean +/- SD), and the bioavailability of CdA administered in enteric-coated capsules was 19%, 24%, and 60%.",On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357107/),%,60,179817,DB00338,Omeprazole
,1357107,bioavailability,"In the three patients who were given 0.14 mg/kg orally dissolved in PBS, the bioavailability was 48% +/- 8%, whereas in the seven patients who received 0.28 mg/kg, the bioavailability was 55% +/- 17%.",On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357107/),%,48,179818,DB00338,Omeprazole
,1357107,bioavailability,"In the three patients who were given 0.14 mg/kg orally dissolved in PBS, the bioavailability was 48% +/- 8%, whereas in the seven patients who received 0.28 mg/kg, the bioavailability was 55% +/- 17%.",On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357107/),%,55,179819,DB00338,Omeprazole
,7863246,bioavailability,"Antacid ingestion decreased the bioavailability of famotidine, ranitidine and cimetidine by 20-25%, and the bioavailability of nizatidine by 12%.",Drug interactions of H2-receptor antagonists. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7863246/),,12,179873,DB00338,Omeprazole
,9803530,AUCs,"The AUCs of (-)-PAN after intravenous and oral dosing of (+)-PAN were 36.3 and 28.1%, respectively of those of total [(+) + (-)] PAN.",Stereoselective chiral inversion of pantoprazole enantiomers after separate doses to rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9803530/),%,36.3,180478,DB00338,Omeprazole
,9803530,AUCs,"The AUCs of (-)-PAN after intravenous and oral dosing of (+)-PAN were 36.3 and 28.1%, respectively of those of total [(+) + (-)] PAN.",Stereoselective chiral inversion of pantoprazole enantiomers after separate doses to rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9803530/),%,28.1,180479,DB00338,Omeprazole
,17213007,AUC(0-infinity),"In the younger group, the geometric mean AUC(0-infinity) and Cmax values in the esomeprazole 10-mg group were >2-fold that in the 5-mg group (AUC(0-infinity), 4.83 and 0.74 pmol x h/L [0.32 and 0.04 micromol x h x L(-1)/kg], respectively; Cmax, 2.98 and 0.62 micromol/L [0.19 and 0.03 micromol/L x kg(-1)], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[h·pM] / [l],4.83,182691,DB00338,Omeprazole
,17213007,AUC(0-infinity),"In the younger group, the geometric mean AUC(0-infinity) and Cmax values in the esomeprazole 10-mg group were >2-fold that in the 5-mg group (AUC(0-infinity), 4.83 and 0.74 pmol x h/L [0.32 and 0.04 micromol x h x L(-1)/kg], respectively; Cmax, 2.98 and 0.62 micromol/L [0.19 and 0.03 micromol/L x kg(-1)], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[h·pM] / [l],0.74,182692,DB00338,Omeprazole
,17213007,AUC(0-infinity),"In the younger group, the geometric mean AUC(0-infinity) and Cmax values in the esomeprazole 10-mg group were >2-fold that in the 5-mg group (AUC(0-infinity), 4.83 and 0.74 pmol x h/L [0.32 and 0.04 micromol x h x L(-1)/kg], respectively; Cmax, 2.98 and 0.62 micromol/L [0.19 and 0.03 micromol/L x kg(-1)], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[h·μM] / [kg·l],0.32,182693,DB00338,Omeprazole
,17213007,AUC(0-infinity),"In the younger group, the geometric mean AUC(0-infinity) and Cmax values in the esomeprazole 10-mg group were >2-fold that in the 5-mg group (AUC(0-infinity), 4.83 and 0.74 pmol x h/L [0.32 and 0.04 micromol x h x L(-1)/kg], respectively; Cmax, 2.98 and 0.62 micromol/L [0.19 and 0.03 micromol/L x kg(-1)], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[h·μM] / [kg·l],0.04,182694,DB00338,Omeprazole
,17213007,Cmax,"In the younger group, the geometric mean AUC(0-infinity) and Cmax values in the esomeprazole 10-mg group were >2-fold that in the 5-mg group (AUC(0-infinity), 4.83 and 0.74 pmol x h/L [0.32 and 0.04 micromol x h x L(-1)/kg], respectively; Cmax, 2.98 and 0.62 micromol/L [0.19 and 0.03 micromol/L x kg(-1)], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[μM] / [l],2.98,182695,DB00338,Omeprazole
,17213007,Cmax,"In the younger group, the geometric mean AUC(0-infinity) and Cmax values in the esomeprazole 10-mg group were >2-fold that in the 5-mg group (AUC(0-infinity), 4.83 and 0.74 pmol x h/L [0.32 and 0.04 micromol x h x L(-1)/kg], respectively; Cmax, 2.98 and 0.62 micromol/L [0.19 and 0.03 micromol/L x kg(-1)], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[μM] / [l],0.62,182696,DB00338,Omeprazole
,17213007,Cmax,"In the younger group, the geometric mean AUC(0-infinity) and Cmax values in the esomeprazole 10-mg group were >2-fold that in the 5-mg group (AUC(0-infinity), 4.83 and 0.74 pmol x h/L [0.32 and 0.04 micromol x h x L(-1)/kg], respectively; Cmax, 2.98 and 0.62 micromol/L [0.19 and 0.03 micromol/L x kg(-1)], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[l·μM] / [kg],0.19,182697,DB00338,Omeprazole
,17213007,Cmax,"In the younger group, the geometric mean AUC(0-infinity) and Cmax values in the esomeprazole 10-mg group were >2-fold that in the 5-mg group (AUC(0-infinity), 4.83 and 0.74 pmol x h/L [0.32 and 0.04 micromol x h x L(-1)/kg], respectively; Cmax, 2.98 and 0.62 micromol/L [0.19 and 0.03 micromol/L x kg(-1)], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[l·μM] / [kg],0.03,182698,DB00338,Omeprazole
,17213007,AUC(0-infinity),"In the older group, the geometric mean AUC(0-infinity) and Cmax values for the 20-mg dose group were approximately 2-fold those for the 10-mg dose group (AUC(0-infinity), 6.28 and 3.70 micromol x h/L [0.21 and 0.12 pmol x h x L(-1)/kg], respectively; Cmax, 3.73 and 1.77 micromol/L [0.13 and 0.06 micromol/L x kg 1], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[h·μM] / [l],6.28,182699,DB00338,Omeprazole
,17213007,AUC(0-infinity),"In the older group, the geometric mean AUC(0-infinity) and Cmax values for the 20-mg dose group were approximately 2-fold those for the 10-mg dose group (AUC(0-infinity), 6.28 and 3.70 micromol x h/L [0.21 and 0.12 pmol x h x L(-1)/kg], respectively; Cmax, 3.73 and 1.77 micromol/L [0.13 and 0.06 micromol/L x kg 1], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[h·μM] / [l],3.70,182700,DB00338,Omeprazole
,17213007,AUC(0-infinity),"In the older group, the geometric mean AUC(0-infinity) and Cmax values for the 20-mg dose group were approximately 2-fold those for the 10-mg dose group (AUC(0-infinity), 6.28 and 3.70 micromol x h/L [0.21 and 0.12 pmol x h x L(-1)/kg], respectively; Cmax, 3.73 and 1.77 micromol/L [0.13 and 0.06 micromol/L x kg 1], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[h·pM] / [kg·l],0.21,182701,DB00338,Omeprazole
,17213007,AUC(0-infinity),"In the older group, the geometric mean AUC(0-infinity) and Cmax values for the 20-mg dose group were approximately 2-fold those for the 10-mg dose group (AUC(0-infinity), 6.28 and 3.70 micromol x h/L [0.21 and 0.12 pmol x h x L(-1)/kg], respectively; Cmax, 3.73 and 1.77 micromol/L [0.13 and 0.06 micromol/L x kg 1], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[h·pM] / [kg·l],0.12,182702,DB00338,Omeprazole
,17213007,Cmax,"In the older group, the geometric mean AUC(0-infinity) and Cmax values for the 20-mg dose group were approximately 2-fold those for the 10-mg dose group (AUC(0-infinity), 6.28 and 3.70 micromol x h/L [0.21 and 0.12 pmol x h x L(-1)/kg], respectively; Cmax, 3.73 and 1.77 micromol/L [0.13 and 0.06 micromol/L x kg 1], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[μM] / [l],3.73,182703,DB00338,Omeprazole
,17213007,Cmax,"In the older group, the geometric mean AUC(0-infinity) and Cmax values for the 20-mg dose group were approximately 2-fold those for the 10-mg dose group (AUC(0-infinity), 6.28 and 3.70 micromol x h/L [0.21 and 0.12 pmol x h x L(-1)/kg], respectively; Cmax, 3.73 and 1.77 micromol/L [0.13 and 0.06 micromol/L x kg 1], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[μM] / [l],1.77,182704,DB00338,Omeprazole
,17213007,Cmax,"In the older group, the geometric mean AUC(0-infinity) and Cmax values for the 20-mg dose group were approximately 2-fold those for the 10-mg dose group (AUC(0-infinity), 6.28 and 3.70 micromol x h/L [0.21 and 0.12 pmol x h x L(-1)/kg], respectively; Cmax, 3.73 and 1.77 micromol/L [0.13 and 0.06 micromol/L x kg 1], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[μM] / [1·kg·l],0.13,182705,DB00338,Omeprazole
,17213007,Cmax,"In the older group, the geometric mean AUC(0-infinity) and Cmax values for the 20-mg dose group were approximately 2-fold those for the 10-mg dose group (AUC(0-infinity), 6.28 and 3.70 micromol x h/L [0.21 and 0.12 pmol x h x L(-1)/kg], respectively; Cmax, 3.73 and 1.77 micromol/L [0.13 and 0.06 micromol/L x kg 1], respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[μM] / [1·kg·l],0.06,182706,DB00338,Omeprazole
,17213007,body-weight-normalized apparent oral clearance,"For the 10-mg esomeprazole dose, the geometric mean body-weight-normalized apparent oral clearance was approximately 50% higher in the younger group compared with the older group (0.40 and 0.25 L/h x kg(-1), respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[h·l] / [kg],0.40,182707,DB00338,Omeprazole
,17213007,body-weight-normalized apparent oral clearance,"For the 10-mg esomeprazole dose, the geometric mean body-weight-normalized apparent oral clearance was approximately 50% higher in the younger group compared with the older group (0.40 and 0.25 L/h x kg(-1), respectively).","Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213007/),[h·l] / [kg],0.25,182708,DB00338,Omeprazole
,23545593,half-life,"The VRZ half-life, calculated to 58 h in this patient, was by far higher than the values reported in the literature.",A case-report of unpredictable and massive voriconazole intoxication in a patient with extensive CYP2C19 and CYP2C9 polymorphisms. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23545593/),h,58,182752,DB00338,Omeprazole
,26071277,Emax,"The relationship between inhibition of platelet aggregation (IPA, %) and the active metabolite AUC (h*μg/L) was described by a sigmoid function (Emax 56 ± 5%; EAUC50 15.9 ± 0.8 h*μg/L) with a gamma exponent (7.04 ± 2.26).","Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26071277/),%,56,183118,DB00338,Omeprazole
,26071277,EAUC50,"The relationship between inhibition of platelet aggregation (IPA, %) and the active metabolite AUC (h*μg/L) was described by a sigmoid function (Emax 56 ± 5%; EAUC50 15.9 ± 0.8 h*μg/L) with a gamma exponent (7.04 ± 2.26).","Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26071277/),[h·μg] / [l],15.9,183119,DB00338,Omeprazole
,33531903,m/z,OME enantiomers were determined utilizing a triple quadrupole tandem mass spectrometer in positive ion mode (ESI+) monitoring mass transitions: m/z 346.3 ⟶ 198.0 for OME and m/z 369.98 ⟶ 252.0 for internal standard.,Determination and Pharmacokinetics of Omeprazole Enantiomers in Human Plasma and Oral Fluid Utilizing Microextraction by Packed Sorbent and Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33531903/),⟶,346.3,184532,DB00338,Omeprazole
,33531903,m/z,OME enantiomers were determined utilizing a triple quadrupole tandem mass spectrometer in positive ion mode (ESI+) monitoring mass transitions: m/z 346.3 ⟶ 198.0 for OME and m/z 369.98 ⟶ 252.0 for internal standard.,Determination and Pharmacokinetics of Omeprazole Enantiomers in Human Plasma and Oral Fluid Utilizing Microextraction by Packed Sorbent and Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33531903/),⟶,198.0,184533,DB00338,Omeprazole
,33531903,m/z,OME enantiomers were determined utilizing a triple quadrupole tandem mass spectrometer in positive ion mode (ESI+) monitoring mass transitions: m/z 346.3 ⟶ 198.0 for OME and m/z 369.98 ⟶ 252.0 for internal standard.,Determination and Pharmacokinetics of Omeprazole Enantiomers in Human Plasma and Oral Fluid Utilizing Microextraction by Packed Sorbent and Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33531903/),⟶,369.98,184534,DB00338,Omeprazole
,33531903,m/z,OME enantiomers were determined utilizing a triple quadrupole tandem mass spectrometer in positive ion mode (ESI+) monitoring mass transitions: m/z 346.3 ⟶ 198.0 for OME and m/z 369.98 ⟶ 252.0 for internal standard.,Determination and Pharmacokinetics of Omeprazole Enantiomers in Human Plasma and Oral Fluid Utilizing Microextraction by Packed Sorbent and Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33531903/),⟶,252.0,184535,DB00338,Omeprazole
,33531903,limits of detection,"The limits of detection and quantification of the present method for both enantiomers were 0.1 and 0.4 ng/mL, respectively.",Determination and Pharmacokinetics of Omeprazole Enantiomers in Human Plasma and Oral Fluid Utilizing Microextraction by Packed Sorbent and Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33531903/),[ng] / [ml],0.1,184536,DB00338,Omeprazole
,33531903,limits of detection,"The limits of detection and quantification of the present method for both enantiomers were 0.1 and 0.4 ng/mL, respectively.",Determination and Pharmacokinetics of Omeprazole Enantiomers in Human Plasma and Oral Fluid Utilizing Microextraction by Packed Sorbent and Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33531903/),[ng] / [ml],0,184537,DB00338,Omeprazole
,7859807,systemic clearance,"The pharmacokinetic parameters of omeprazole were: systemic clearance, 0.23 l.kg-1.h-1; volume of distribution, 0.45 l.kg-1; elimination half life 0.86 h; but were highly variable between individuals.",Pharmacokinetics of intravenous omeprazole in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859807/),[l] / [h·kg],0.23,185162,DB00338,Omeprazole
,7859807,volume of distribution,"The pharmacokinetic parameters of omeprazole were: systemic clearance, 0.23 l.kg-1.h-1; volume of distribution, 0.45 l.kg-1; elimination half life 0.86 h; but were highly variable between individuals.",Pharmacokinetics of intravenous omeprazole in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859807/),[l] / [kg],0.45,185163,DB00338,Omeprazole
,7859807,elimination half life,"The pharmacokinetic parameters of omeprazole were: systemic clearance, 0.23 l.kg-1.h-1; volume of distribution, 0.45 l.kg-1; elimination half life 0.86 h; but were highly variable between individuals.",Pharmacokinetics of intravenous omeprazole in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859807/),h,0.86,185164,DB00338,Omeprazole
,27734291,terminal plasma half-life,Cabozantinib displays a long terminal plasma half-life (~120 h) and accumulates ~fivefold by day 15 following daily dosing based on area under the plasma concentration-time curve (AUC).,Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27734291/),h,120,185601,DB00338,Omeprazole
,30570132,AUC0-24h,"AUC0-24h for regorafenib alone was 55.9 μg·hour/mL (coefficient of variance (CV): 40%), and for regorafenib with concomitant esomeprazole or with esomeprazole 3 hours prior AUC0-24h was 53.7 μg·hour/mL (CV: 34%) and 53.6 μg·hour/mL (CV: 43%), respectively.",Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30570132/),[h·μg] / [ml],55.9,186198,DB00338,Omeprazole
,30570132,AUC0-24h,"AUC0-24h for regorafenib alone was 55.9 μg·hour/mL (coefficient of variance (CV): 40%), and for regorafenib with concomitant esomeprazole or with esomeprazole 3 hours prior AUC0-24h was 53.7 μg·hour/mL (CV: 34%) and 53.6 μg·hour/mL (CV: 43%), respectively.",Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30570132/),[h·μg] / [ml],53.7,186199,DB00338,Omeprazole
,30570132,AUC0-24h,"AUC0-24h for regorafenib alone was 55.9 μg·hour/mL (coefficient of variance (CV): 40%), and for regorafenib with concomitant esomeprazole or with esomeprazole 3 hours prior AUC0-24h was 53.7 μg·hour/mL (CV: 34%) and 53.6 μg·hour/mL (CV: 43%), respectively.",Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30570132/),[h·μg] / [ml],53.6,186200,DB00338,Omeprazole
,19930799,flow rate,"Chromatographic separation was performed on a Narrow Bore C(18) column using methanol-10 mM ammonium acetate (68:32, v/v) as the mobile phase at the flow rate of 0.2 mL/min.",Simultaneous determination of omeprazole and domperidone in dog plasma by LC-MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19930799/),[ml] / [min],0.2,186280,DB00338,Omeprazole
,21350850,area under the plasma concentration-time curve from time 0 to 12 h (AUC(0-12)),"On day 28, area under the plasma concentration-time curve from time 0 to 12 h (AUC(0-12)) and maximum plasma concentration (C(max)) for sorafenib were 38.1 mg h/l and 4.9 mg/l, respectively.",Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21350850/),[h·mg] / [l],38.1,186875,DB00338,Omeprazole
,21350850,maximum plasma concentration (C(max)),"On day 28, area under the plasma concentration-time curve from time 0 to 12 h (AUC(0-12)) and maximum plasma concentration (C(max)) for sorafenib were 38.1 mg h/l and 4.9 mg/l, respectively.",Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21350850/),[mg] / [l],4.9,186876,DB00338,Omeprazole
,33396585,flow rate,The flow rate was 1.00 mL/min and maximum absorption was measured with UV detector set at 300 nm.,HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33396585/),[ml] / [min],1.00,187464,DB00338,Omeprazole
,33396585,Limits of detection,"Limits of detection were reported to be 0.41, 0.13, 0.18, and 0.15 µg/mL for secnidazole, omeprazole, albendazole, and fenbendazole, respectively, showing a high degree of the method sensitivity.",HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33396585/),[μg] / [ml],0.41,187465,DB00338,Omeprazole
,33396585,Limits of detection,"Limits of detection were reported to be 0.41, 0.13, 0.18, and 0.15 µg/mL for secnidazole, omeprazole, albendazole, and fenbendazole, respectively, showing a high degree of the method sensitivity.",HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33396585/),[μg] / [ml],0.13,187466,DB00338,Omeprazole
,33396585,Limits of detection,"Limits of detection were reported to be 0.41, 0.13, 0.18, and 0.15 µg/mL for secnidazole, omeprazole, albendazole, and fenbendazole, respectively, showing a high degree of the method sensitivity.",HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33396585/),[μg] / [ml],0.18,187467,DB00338,Omeprazole
,33396585,Limits of detection,"Limits of detection were reported to be 0.41, 0.13, 0.18, and 0.15 µg/mL for secnidazole, omeprazole, albendazole, and fenbendazole, respectively, showing a high degree of the method sensitivity.",HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33396585/),[μg] / [ml],0.15,187468,DB00338,Omeprazole
,8617118,concentration area under the curve (AUC),Omeprazole reduced mean pentagastrin-stimulated peak gastric acid secretion by 85.5% +/- 23.7% when delivered orally and by 79.6% +/- 32.1% when delivered by nasogastric tube; the mean plasma omeprazole concentration area under the curve (AUC) was 2.02 +/- 0.79 after oral delivery and 1.74 +/- 1.89 after nasogastric tube delivery.,Bioavailability and efficacy of omeprazole given orally and by nasogastric tube. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8617118/),,2.02,188110,DB00338,Omeprazole
,8617118,concentration area under the curve (AUC),Omeprazole reduced mean pentagastrin-stimulated peak gastric acid secretion by 85.5% +/- 23.7% when delivered orally and by 79.6% +/- 32.1% when delivered by nasogastric tube; the mean plasma omeprazole concentration area under the curve (AUC) was 2.02 +/- 0.79 after oral delivery and 1.74 +/- 1.89 after nasogastric tube delivery.,Bioavailability and efficacy of omeprazole given orally and by nasogastric tube. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8617118/),,1.74,188111,DB00338,Omeprazole
,29403981,flow rate,The flow rate was set at 0.5 mL/min to elute all the analytes and IS within 1.00 min runtime.,"Development and validation of a high throughput UPLC-MS/MS method for simultaneous quantification of esomeprazole, rabeprazole and levosulpiride in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403981/),[ml] / [min],0.5,188171,DB00338,Omeprazole
,33420642,peak plasma concentrations (Cmax),"The peak plasma concentrations (Cmax) after fluzoparib administration was 2395.17 ± 418.27 ng/mL, the area under the curve (AUC) within 72 h (AUC0 - 72 h) was 26669.09 ± 7320.12 h·ng/mL, and AUC0-∞ was 26897.44 ± 7573.61 h·ng/mL.","Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33420642/),[ng] / [ml],2395.17,190027,DB00338,Omeprazole
,33420642,area under the curve (AUC) within 72 h (AUC0 - 72 h),"The peak plasma concentrations (Cmax) after fluzoparib administration was 2395.17 ± 418.27 ng/mL, the area under the curve (AUC) within 72 h (AUC0 - 72 h) was 26669.09 ± 7320.12 h·ng/mL, and AUC0-∞ was 26897.44 ± 7573.61 h·ng/mL.","Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33420642/),[h·ng] / [ml],26669.09,190028,DB00338,Omeprazole
,33420642,AUC0-∞,"The peak plasma concentrations (Cmax) after fluzoparib administration was 2395.17 ± 418.27 ng/mL, the area under the curve (AUC) within 72 h (AUC0 - 72 h) was 26669.09 ± 7320.12 h·ng/mL, and AUC0-∞ was 26897.44 ± 7573.61 h·ng/mL.","Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33420642/),[h·ng] / [ml],26897.44,190029,DB00338,Omeprazole
,33420642,Cmax,"The Cmax after co-administration of fluzoparib and omeprazole was 2489.43 ± 423.72 ng·mL, AUC0 - 72 h was 30300.49 ± 8350.08 h·ng/mL, and AUC0-∞ was 30678.74 ± 8595.55 h·ng/mL.","Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33420642/),ml·ng,2489.43,190030,DB00338,Omeprazole
,33420642,AUC0 - 72 h,"The Cmax after co-administration of fluzoparib and omeprazole was 2489.43 ± 423.72 ng·mL, AUC0 - 72 h was 30300.49 ± 8350.08 h·ng/mL, and AUC0-∞ was 30678.74 ± 8595.55 h·ng/mL.","Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33420642/),[h·ng] / [ml],30300.49,190031,DB00338,Omeprazole
,33420642,AUC0-∞,"The Cmax after co-administration of fluzoparib and omeprazole was 2489.43 ± 423.72 ng·mL, AUC0 - 72 h was 30300.49 ± 8350.08 h·ng/mL, and AUC0-∞ was 30678.74 ± 8595.55 h·ng/mL.","Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33420642/),[h·ng] / [ml],30678.74,190032,DB00338,Omeprazole
,9222077,area under the curve (AUC),"After treatments A and C, mean area under the curve (AUC) was reduced by 66% and 28% (14.2 and 30.2 mg.h/L), respectively, and mean T(1/2) declined by 33% and 31% (8.3 and 8.5 h), respectively, relative to the values after B (42.1 mg.h/L; 12.4 h).",Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),[h·mg] / [l],14.2,190917,DB00338,Omeprazole
,9222077,area under the curve (AUC),"After treatments A and C, mean area under the curve (AUC) was reduced by 66% and 28% (14.2 and 30.2 mg.h/L), respectively, and mean T(1/2) declined by 33% and 31% (8.3 and 8.5 h), respectively, relative to the values after B (42.1 mg.h/L; 12.4 h).",Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),[h·mg] / [l],30.2,190918,DB00338,Omeprazole
,9222077,T(1/2),"After treatments A and C, mean area under the curve (AUC) was reduced by 66% and 28% (14.2 and 30.2 mg.h/L), respectively, and mean T(1/2) declined by 33% and 31% (8.3 and 8.5 h), respectively, relative to the values after B (42.1 mg.h/L; 12.4 h).",Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),h,8.3,190919,DB00338,Omeprazole
,9222077,T(1/2),"After treatments A and C, mean area under the curve (AUC) was reduced by 66% and 28% (14.2 and 30.2 mg.h/L), respectively, and mean T(1/2) declined by 33% and 31% (8.3 and 8.5 h), respectively, relative to the values after B (42.1 mg.h/L; 12.4 h).",Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),h,8.5,190920,DB00338,Omeprazole
,9222077,T(1/2),"After treatments A and C, mean area under the curve (AUC) was reduced by 66% and 28% (14.2 and 30.2 mg.h/L), respectively, and mean T(1/2) declined by 33% and 31% (8.3 and 8.5 h), respectively, relative to the values after B (42.1 mg.h/L; 12.4 h).",Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),[h·mg] / [l],42.1,190921,DB00338,Omeprazole
,9222077,T(1/2),"After treatments A and C, mean area under the curve (AUC) was reduced by 66% and 28% (14.2 and 30.2 mg.h/L), respectively, and mean T(1/2) declined by 33% and 31% (8.3 and 8.5 h), respectively, relative to the values after B (42.1 mg.h/L; 12.4 h).",Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),h,12.4,190922,DB00338,Omeprazole
,9222077,Kel-corrected relative bioavailabilities,"The mean Kel-corrected relative bioavailabilities for A and C were 50% and 104%, respectively, suggesting a large reduction in the initial absorption of trovafloxacin with A.",Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),%,50,190923,DB00338,Omeprazole
,9222077,Kel-corrected relative bioavailabilities,"The mean Kel-corrected relative bioavailabilities for A and C were 50% and 104%, respectively, suggesting a large reduction in the initial absorption of trovafloxacin with A.",Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),%,104,190924,DB00338,Omeprazole
,9222077,relative bioavailability,The mean relative bioavailability after D was 82%.,Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),%,82,190925,DB00338,Omeprazole
,16997515,AUC,"After intravenous administration to cirrhotic rats, the AUC (1180 microg min/ml versus 474 microg min/ml) and CL(NR) (17.4 ml/min/kg versus 42.3 ml/min/kg) of omeprazole were significantly greater and slower, respectively, than the controls.",Pharmacokinetics of omeprazole after intravenous and oral administration to rats with liver cirrhosis induced by dimethylnitrosamine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997515/),[min·μg] / [ml],1180,191852,DB00338,Omeprazole
,16997515,AUC,"After intravenous administration to cirrhotic rats, the AUC (1180 microg min/ml versus 474 microg min/ml) and CL(NR) (17.4 ml/min/kg versus 42.3 ml/min/kg) of omeprazole were significantly greater and slower, respectively, than the controls.",Pharmacokinetics of omeprazole after intravenous and oral administration to rats with liver cirrhosis induced by dimethylnitrosamine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997515/),[min·μg] / [ml],474,191853,DB00338,Omeprazole
,16997515,CL(NR),"After intravenous administration to cirrhotic rats, the AUC (1180 microg min/ml versus 474 microg min/ml) and CL(NR) (17.4 ml/min/kg versus 42.3 ml/min/kg) of omeprazole were significantly greater and slower, respectively, than the controls.",Pharmacokinetics of omeprazole after intravenous and oral administration to rats with liver cirrhosis induced by dimethylnitrosamine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997515/),[ml] / [kg·min],17.4,191854,DB00338,Omeprazole
,16997515,CL(NR),"After intravenous administration to cirrhotic rats, the AUC (1180 microg min/ml versus 474 microg min/ml) and CL(NR) (17.4 ml/min/kg versus 42.3 ml/min/kg) of omeprazole were significantly greater and slower, respectively, than the controls.",Pharmacokinetics of omeprazole after intravenous and oral administration to rats with liver cirrhosis induced by dimethylnitrosamine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997515/),[ml] / [kg·min],42.3,191855,DB00338,Omeprazole
,16997515,CL(int),The significantly slower CL(NR) could be supported by significantly slower in vitro CL(int) for the disappearance of omeprazole from hepatic microsomal study (0.102 ml/min/mg protein versus 0.144 ml/min/mg protein) and slower hepatic blood flow rate in cirrhotic rats.,Pharmacokinetics of omeprazole after intravenous and oral administration to rats with liver cirrhosis induced by dimethylnitrosamine. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997515/),[ml] / [mg·min],0.102,191856,DB00338,Omeprazole
,16997515,CL(int),The significantly slower CL(NR) could be supported by significantly slower in vitro CL(int) for the disappearance of omeprazole from hepatic microsomal study (0.102 ml/min/mg protein versus 0.144 ml/min/mg protein) and slower hepatic blood flow rate in cirrhotic rats.,Pharmacokinetics of omeprazole after intravenous and oral administration to rats with liver cirrhosis induced by dimethylnitrosamine. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997515/),[ml] / [mg·min],0.144,191857,DB00338,Omeprazole
,8927940,gastric emptying time,"The estimated mean (and range) gastric emptying time of the modified-release tablet after drug administration was 0.3 h (0.1-1.0 h) during fasting conditions, 4.3 h (1.7-5.0 h) after a light breakfast, and 4.9 h (1.9-18.0 h) after a heavy breakfast.",Gastrointestinal transit of amoxicillin modified-release tablets and a placebo tablet including pharmacokinetic assessments of amoxicillin. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8927940/),h,0.3,192248,DB00338,Omeprazole
,8927940,gastric emptying time,"The estimated mean (and range) gastric emptying time of the modified-release tablet after drug administration was 0.3 h (0.1-1.0 h) during fasting conditions, 4.3 h (1.7-5.0 h) after a light breakfast, and 4.9 h (1.9-18.0 h) after a heavy breakfast.",Gastrointestinal transit of amoxicillin modified-release tablets and a placebo tablet including pharmacokinetic assessments of amoxicillin. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8927940/),h,4.3,192249,DB00338,Omeprazole
,8927940,gastric emptying time,"The estimated mean (and range) gastric emptying time of the modified-release tablet after drug administration was 0.3 h (0.1-1.0 h) during fasting conditions, 4.3 h (1.7-5.0 h) after a light breakfast, and 4.9 h (1.9-18.0 h) after a heavy breakfast.",Gastrointestinal transit of amoxicillin modified-release tablets and a placebo tablet including pharmacokinetic assessments of amoxicillin. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8927940/),h,4.9,192250,DB00338,Omeprazole
,8927940,small-intestinal transit time,The small-intestinal transit time during fasting conditions was 4.7 h (2.9-6.9 h) and was not significantly changed after light or heavy breakfast intake.,Gastrointestinal transit of amoxicillin modified-release tablets and a placebo tablet including pharmacokinetic assessments of amoxicillin. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8927940/),h,4.7,192251,DB00338,Omeprazole
,8927940,relative bioavailability,"The relative bioavailability of the modified-release tablet was 55%, compared with a commercially available amoxicillin immediate-release tablet.",Gastrointestinal transit of amoxicillin modified-release tablets and a placebo tablet including pharmacokinetic assessments of amoxicillin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8927940/),%,55,192252,DB00338,Omeprazole
,29468684,Cmax,"Cmax of 436-2,432 ng/ml and AUC0-tau of 1,476-4,371 ng hr ml-1 were obtained for plasma and indicated, in conjunction with other published oral omeprazole studies, that an appropriate plasma screening limit would be 500 pg/ml with a detection time of 48 hr.",Re-evaluation of the regulation of omeprazole in racehorses: An evidence-based approach. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29468684/),[ng] / [ml],"436-2,432",192728,DB00338,Omeprazole
,29468684,AUC0-tau,"Cmax of 436-2,432 ng/ml and AUC0-tau of 1,476-4,371 ng hr ml-1 were obtained for plasma and indicated, in conjunction with other published oral omeprazole studies, that an appropriate plasma screening limit would be 500 pg/ml with a detection time of 48 hr.",Re-evaluation of the regulation of omeprazole in racehorses: An evidence-based approach. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29468684/),[h·ng] / [ml],"1,476-4,371",192729,DB00338,Omeprazole
,29468684,detection time,"Cmax of 436-2,432 ng/ml and AUC0-tau of 1,476-4,371 ng hr ml-1 were obtained for plasma and indicated, in conjunction with other published oral omeprazole studies, that an appropriate plasma screening limit would be 500 pg/ml with a detection time of 48 hr.",Re-evaluation of the regulation of omeprazole in racehorses: An evidence-based approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29468684/),h,48,192730,DB00338,Omeprazole
,29468684,detection time advice,Urine analysis showed that omeprazole could be detected for up to 25 hr above the previously established urine screening limit of 500 pg/ml and thus indicated that the detection time advice could be potentially reduced from 72 to 48 hr to allow more comprehensive treatment of gastric lesions.,Re-evaluation of the regulation of omeprazole in racehorses: An evidence-based approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29468684/),h,72,192731,DB00338,Omeprazole
,18261364,CLNR,"After intravenous administration of omeprazole, the CLNR of the drug was significantly faster in DMIA (52.6 versus 67.4 mL/min/kg) and DMIS (50.2 versus 73.0 mL/min/kg) rats than the respective controls.",Changes in omeprazole pharmacokinetics in rats with diabetes induced by alloxan or streptozotocin: faster clearance of omeprazole due to induction of hepatic CYP1A2 and 3A1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261364/),[ml] / [kg·min],52.6,193748,DB00338,Omeprazole
,18261364,CLNR,"After intravenous administration of omeprazole, the CLNR of the drug was significantly faster in DMIA (52.6 versus 67.4 mL/min/kg) and DMIS (50.2 versus 73.0 mL/min/kg) rats than the respective controls.",Changes in omeprazole pharmacokinetics in rats with diabetes induced by alloxan or streptozotocin: faster clearance of omeprazole due to induction of hepatic CYP1A2 and 3A1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261364/),[ml] / [kg·min],67.4,193749,DB00338,Omeprazole
,18261364,CLNR,"After intravenous administration of omeprazole, the CLNR of the drug was significantly faster in DMIA (52.6 versus 67.4 mL/min/kg) and DMIS (50.2 versus 73.0 mL/min/kg) rats than the respective controls.",Changes in omeprazole pharmacokinetics in rats with diabetes induced by alloxan or streptozotocin: faster clearance of omeprazole due to induction of hepatic CYP1A2 and 3A1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261364/),[ml] / [kg·min],50.2,193750,DB00338,Omeprazole
,18261364,CLNR,"After intravenous administration of omeprazole, the CLNR of the drug was significantly faster in DMIA (52.6 versus 67.4 mL/min/kg) and DMIS (50.2 versus 73.0 mL/min/kg) rats than the respective controls.",Changes in omeprazole pharmacokinetics in rats with diabetes induced by alloxan or streptozotocin: faster clearance of omeprazole due to induction of hepatic CYP1A2 and 3A1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261364/),[ml] / [kg·min],73.0,193751,DB00338,Omeprazole
,33176242,m,"The mass transition ion pairs were m/z 231.2 → 185.0, 346.9 → 198.2, 285.1 → 193.1 and 382.2 → 281.2 for NAP, ESOM, diazepam (IS for NAP) and celecoxib (IS for ESOM), respectively.",Simultaneous determination of naproxen and esomeprazole in beagle dog plasma by supercritical fluid chromatography-tandem mass spectrometry coupled with evaporation-free liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176242/),,231.2,193838,DB00338,Omeprazole
,33176242,m,"The mass transition ion pairs were m/z 231.2 → 185.0, 346.9 → 198.2, 285.1 → 193.1 and 382.2 → 281.2 for NAP, ESOM, diazepam (IS for NAP) and celecoxib (IS for ESOM), respectively.",Simultaneous determination of naproxen and esomeprazole in beagle dog plasma by supercritical fluid chromatography-tandem mass spectrometry coupled with evaporation-free liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176242/),,346.9,193839,DB00338,Omeprazole
,33176242,m,"The mass transition ion pairs were m/z 231.2 → 185.0, 346.9 → 198.2, 285.1 → 193.1 and 382.2 → 281.2 for NAP, ESOM, diazepam (IS for NAP) and celecoxib (IS for ESOM), respectively.",Simultaneous determination of naproxen and esomeprazole in beagle dog plasma by supercritical fluid chromatography-tandem mass spectrometry coupled with evaporation-free liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176242/),,285.1,193840,DB00338,Omeprazole
,33176242,m,"The mass transition ion pairs were m/z 231.2 → 185.0, 346.9 → 198.2, 285.1 → 193.1 and 382.2 → 281.2 for NAP, ESOM, diazepam (IS for NAP) and celecoxib (IS for ESOM), respectively.",Simultaneous determination of naproxen and esomeprazole in beagle dog plasma by supercritical fluid chromatography-tandem mass spectrometry coupled with evaporation-free liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176242/),,382.2,193841,DB00338,Omeprazole
,8116940,area under the concentration vs time curve,"Dosage of 0.25 mg/kg induced approximately half-maximal inhibition of basal gastric pH in these ponies and was associated with area under the concentration vs time curve of 0.7 mumol.h/L, which corresponds reasonably with results of other species.",Effects of single intravenously administered doses of omeprazole and ranitidine on intragastric pH and plasma gastrin concentration in nonfed ponies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8116940/),[h·μM] / [l],0.7,193918,DB00338,Omeprazole
,3880557,pH,The pretreatment 24-h median pH was 1.9 (interquartile range 1.4-2.9).,Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3880557/),,1.9,194370,DB00338,Omeprazole
,11046103,Second order association rate constants (k(ome)),"Second order association rate constants (k(ome)) for the covalent binding of omeprazole to H(+),K(+)-ATPase were estimated to 11 and 3.0 l/micromol/h for the i.v. and intraduodenal experiments, respectively.",A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11046103/),[l] / [h·μM],11,195402,DB00338,Omeprazole
,11046103,Second order association rate constants (k(ome)),"Second order association rate constants (k(ome)) for the covalent binding of omeprazole to H(+),K(+)-ATPase were estimated to 11 and 3.0 l/micromol/h for the i.v. and intraduodenal experiments, respectively.",A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11046103/),[l] / [h·μM],3.0,195403,DB00338,Omeprazole
,11046103,apparent turnover rate constant of the enzyme (k(out)),The apparent turnover rate constant of the enzyme (k(out)) was 0.013 h(-1) and the corresponding half-life of inhibition of acid secretory capacity was 54 h.,A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11046103/),1/[h],0.013,195404,DB00338,Omeprazole
,11046103,half-life of inhibition of acid secretory capacity,The apparent turnover rate constant of the enzyme (k(out)) was 0.013 h(-1) and the corresponding half-life of inhibition of acid secretory capacity was 54 h.,A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11046103/),h,54,195405,DB00338,Omeprazole
,11046103,k(out),"The potency, calculated as k(out) over k(ome), was 4.3 and 1.2 nM for the intraduodenal and i.v. doses, respectively.",A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11046103/),nM,4.3,195406,DB00338,Omeprazole
,11046103,k(ome),"The potency, calculated as k(out) over k(ome), was 4.3 and 1.2 nM for the intraduodenal and i.v. doses, respectively.",A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11046103/),nM,4.3,195407,DB00338,Omeprazole
,11046103,k(ome),"The potency, calculated as k(out) over k(ome), was 4.3 and 1.2 nM for the intraduodenal and i.v. doses, respectively.",A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11046103/),nM,1.2,195408,DB00338,Omeprazole
,18401017,clearance (CL,"Population estimates (typical value +/- standard error) were obtained from the final covariate model: clearance (CL: 0.273 +/- 0.007 L/day), volume of distribution in the central compartment (V(1): 3.06 +/- 0.057 L), intercompartment clearance (Q: 1.72 +/- 0.48 L/day), and volume of distribution in the peripheral compartment (V(2): 2.94 +/- 0.17 L).",Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18401017/),[l] / [d],0.273,196260,DB00338,Omeprazole
,18401017,volume of distribution in the central compartment (V(1),"Population estimates (typical value +/- standard error) were obtained from the final covariate model: clearance (CL: 0.273 +/- 0.007 L/day), volume of distribution in the central compartment (V(1): 3.06 +/- 0.057 L), intercompartment clearance (Q: 1.72 +/- 0.48 L/day), and volume of distribution in the peripheral compartment (V(2): 2.94 +/- 0.17 L).",Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18401017/),l,3.06,196261,DB00338,Omeprazole
,18401017,intercompartment clearance (Q,"Population estimates (typical value +/- standard error) were obtained from the final covariate model: clearance (CL: 0.273 +/- 0.007 L/day), volume of distribution in the central compartment (V(1): 3.06 +/- 0.057 L), intercompartment clearance (Q: 1.72 +/- 0.48 L/day), and volume of distribution in the peripheral compartment (V(2): 2.94 +/- 0.17 L).",Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18401017/),[l] / [d],1.72,196262,DB00338,Omeprazole
,18401017,volume of distribution in the peripheral compartment (V(2),"Population estimates (typical value +/- standard error) were obtained from the final covariate model: clearance (CL: 0.273 +/- 0.007 L/day), volume of distribution in the central compartment (V(1): 3.06 +/- 0.057 L), intercompartment clearance (Q: 1.72 +/- 0.48 L/day), and volume of distribution in the peripheral compartment (V(2): 2.94 +/- 0.17 L).",Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18401017/),l,2.94,196263,DB00338,Omeprazole
,12222750,hydroxylation index,Four PMs were identified with the omeprazole phenotype probe and had a mean +/- SD hydroxylation index of 1.335 +/- 0.271.,Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12222750/),,1.335,196426,DB00338,Omeprazole
,15871633,time to reach maximum plasma concentration,"Like adults, PPIs are rapidly absorbed in children following oral administration; the mean time to reach maximum plasma concentration varies from 1 to 3 hours.",Pharmacokinetics of proton pump inhibitors in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871633/),h,1 to 3,196990,DB00338,Omeprazole
,15871633,elimination half-lives,"PPIs are rapidly metabolised in children, with short elimination half-lives of around 1 hour, similar to that reported for adults.",Pharmacokinetics of proton pump inhibitors in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871633/),h,1,196991,DB00338,Omeprazole
,8181192,half-life,"As expected, control mean pH values (2.1) were evaluated to 4.7 by omeprazole (p = 0.001), which was eliminated with a half-life of 1.3 +/- 0.7 hours (mean +/- SD) and an oral clearance of 387 +/- 221 ml/min.",Omeprazole-induced increase in the absorption of bismuth from tripotassium dicitrato bismuthate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181192/),h,1.3,198093,DB00338,Omeprazole
,8181192,oral clearance,"As expected, control mean pH values (2.1) were evaluated to 4.7 by omeprazole (p = 0.001), which was eliminated with a half-life of 1.3 +/- 0.7 hours (mean +/- SD) and an oral clearance of 387 +/- 221 ml/min.",Omeprazole-induced increase in the absorption of bismuth from tripotassium dicitrato bismuthate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181192/),[ml] / [min],387,198094,DB00338,Omeprazole
,8181192,AUC,"Omeprazole increased absorption of bismuth because AUC and Ae were higher (p < or = 0.05) during omeprazole treatment (172 +/- 158 micrograms/L.hr and 1.9 +/- 2.0 mg/8 hr, respectively) compared with placebo (46 +/- 33 micrograms/L.hr and 0.27 +/- 0.28 mg/8 hr, respectively).",Omeprazole-induced increase in the absorption of bismuth from tripotassium dicitrato bismuthate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181192/),[μg] / [h·l],172,198095,DB00338,Omeprazole
,8181192,AUC,"Omeprazole increased absorption of bismuth because AUC and Ae were higher (p < or = 0.05) during omeprazole treatment (172 +/- 158 micrograms/L.hr and 1.9 +/- 2.0 mg/8 hr, respectively) compared with placebo (46 +/- 33 micrograms/L.hr and 0.27 +/- 0.28 mg/8 hr, respectively).",Omeprazole-induced increase in the absorption of bismuth from tripotassium dicitrato bismuthate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181192/),[μg] / [h·l],46,198096,DB00338,Omeprazole
,8181192,Ae,"Omeprazole increased absorption of bismuth because AUC and Ae were higher (p < or = 0.05) during omeprazole treatment (172 +/- 158 micrograms/L.hr and 1.9 +/- 2.0 mg/8 hr, respectively) compared with placebo (46 +/- 33 micrograms/L.hr and 0.27 +/- 0.28 mg/8 hr, respectively).",Omeprazole-induced increase in the absorption of bismuth from tripotassium dicitrato bismuthate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181192/),-1·mg,1.9,198097,DB00338,Omeprazole
,8181192,Ae,"Omeprazole increased absorption of bismuth because AUC and Ae were higher (p < or = 0.05) during omeprazole treatment (172 +/- 158 micrograms/L.hr and 1.9 +/- 2.0 mg/8 hr, respectively) compared with placebo (46 +/- 33 micrograms/L.hr and 0.27 +/- 0.28 mg/8 hr, respectively).",Omeprazole-induced increase in the absorption of bismuth from tripotassium dicitrato bismuthate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181192/),[mg] / [8·h],0.27,198098,DB00338,Omeprazole
,23512128,half-life,"After irreversible chemical inhibition of the proton pump, such as occurs with pantoprazole, the recovery of the protein of the pump has a half-life of around 50 h.","Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23512128/),h,50,198226,DB00338,Omeprazole
,27292271,serum elimination half-life,"The serum elimination half-life was 7.05 ± 1.02, 7.43 ± 0.851 and 3.94 ± 1.04 h for cimetidine, ranitidine, and omeprazole, respectively.","Disposition of the anti-ulcer medications ranitidine, cimetidine, and omeprazole following administration of multiple doses to exercised Thoroughbred horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27292271/),h,7.05,198297,DB00338,Omeprazole
,27292271,serum elimination half-life,"The serum elimination half-life was 7.05 ± 1.02, 7.43 ± 0.851 and 3.94 ± 1.04 h for cimetidine, ranitidine, and omeprazole, respectively.","Disposition of the anti-ulcer medications ranitidine, cimetidine, and omeprazole following administration of multiple doses to exercised Thoroughbred horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27292271/),h,7.43,198298,DB00338,Omeprazole
,27292271,serum elimination half-life,"The serum elimination half-life was 7.05 ± 1.02, 7.43 ± 0.851 and 3.94 ± 1.04 h for cimetidine, ranitidine, and omeprazole, respectively.","Disposition of the anti-ulcer medications ranitidine, cimetidine, and omeprazole following administration of multiple doses to exercised Thoroughbred horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27292271/),h,3.94,198299,DB00338,Omeprazole
,15285851,area under the blood concentration-time curve (AUC0-8),"Coadministration of lansoprazole significantly decreased the oral tacrolimus clearance, resulting in an increase in the area under the blood concentration-time curve (AUC0-8) (control vs with lansoprazole: 29.7 +/- 3.5 vs 44.1 +/- 5.0 ng h mL(-1), P < 0.05).",Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15285851/),[h·ng] / [ml],29.7,198748,DB00338,Omeprazole
,15285851,area under the blood concentration-time curve (AUC0-8),"Coadministration of lansoprazole significantly decreased the oral tacrolimus clearance, resulting in an increase in the area under the blood concentration-time curve (AUC0-8) (control vs with lansoprazole: 29.7 +/- 3.5 vs 44.1 +/- 5.0 ng h mL(-1), P < 0.05).",Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15285851/),[h·ng] / [ml],44.1,198749,DB00338,Omeprazole
,16719541,peak plasma concentration (Cmax),"The mean pharmacokinetic parameters and their corresponding coefficient of variation (CV%) for peak plasma concentration (Cmax), AUC from time zero to infinity (AUCinfinity), time to reach Cmax (tmax), apparent oral clearance (CL/F) and elimination half-life (t(1/2)) were 314.96 ng/mL (56%), 923.2 ng . h/mL (108.6%), 2.1h (44%), 0.66 L/h/kg (92%) and 1.5 h (56.6%), respectively.",Possible interethnic differences in omeprazole pharmacokinetics : comparison of Jordanian Arabs with other populations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16719541/),[ng] / [ml],314.96,198921,DB00338,Omeprazole
,16719541,elimination half-life (t(1/2)),"The mean pharmacokinetic parameters and their corresponding coefficient of variation (CV%) for peak plasma concentration (Cmax), AUC from time zero to infinity (AUCinfinity), time to reach Cmax (tmax), apparent oral clearance (CL/F) and elimination half-life (t(1/2)) were 314.96 ng/mL (56%), 923.2 ng . h/mL (108.6%), 2.1h (44%), 0.66 L/h/kg (92%) and 1.5 h (56.6%), respectively.",Possible interethnic differences in omeprazole pharmacokinetics : comparison of Jordanian Arabs with other populations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16719541/),h,1.5,198922,DB00338,Omeprazole
,11798692,latent time,"It also showed the shortest latent time in elevating intragastric pH (2.53 hours), the largest net increment in mean gastric pH (3.37), and the greatest prolongation of time with pH > 4 (15.3 hours) among the three products.",[Bioavailability of three brands of omeprazole capsule and their effects on 24 hour intragastric pH in healthy volunteers]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11798692/),h,2.53,199385,DB00338,Omeprazole
,11568514,area under the curve,The median area under the curve of omeprazole was 0.78 microg.,Intravenous omeprazole in children: pharmacokinetics and effect on 24-hour intragastric pH. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11568514/),μg,0.78,199857,DB00338,Omeprazole
,11568514,Systemic clearance,Systemic clearance was not different between the two groups: median values were 0.68 and 0.42 L. kg-1. h-1 (P = 0.22).,Intravenous omeprazole in children: pharmacokinetics and effect on 24-hour intragastric pH. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11568514/),[l] / [h·kg],0.68,199858,DB00338,Omeprazole
,11568514,Systemic clearance,Systemic clearance was not different between the two groups: median values were 0.68 and 0.42 L. kg-1. h-1 (P = 0.22).,Intravenous omeprazole in children: pharmacokinetics and effect on 24-hour intragastric pH. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11568514/),[l] / [h·kg],0.42,199859,DB00338,Omeprazole
,26121346,AUC0-t,"The geometric mean AUC0-t of esomeprazole were 0.24 and 1.79 μmol · h/L for the 0.25 mg/kg and 1 mg/kg dosages of esomeprazole, respectively.",Pharmacokinetics and Acid-suppressive Effects of Esomeprazole in Infants 1-24 Months Old With Symptoms of Gastroesophageal Reflux Disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26121346/),[h·μM] / [l],0.24,200305,DB00338,Omeprazole
,26121346,AUC0-t,"The geometric mean AUC0-t of esomeprazole were 0.24 and 1.79 μmol · h/L for the 0.25 mg/kg and 1 mg/kg dosages of esomeprazole, respectively.",Pharmacokinetics and Acid-suppressive Effects of Esomeprazole in Infants 1-24 Months Old With Symptoms of Gastroesophageal Reflux Disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26121346/),[h·μM] / [l],1.79,200306,DB00338,Omeprazole
,27810562,absolute bioavailability (BA),"Although the oral absorption of crystalline ITZ was negligible, SMSD/ITZ showed an improved pharmacokinetic profile in normal rats, with an absolute bioavailability (BA) of 2.9%, and even 6.3% in the hypochlorhydric model.",Improved oral absorption profile of itraconazole in hypochlorhydria by self-micellizing solid dispersion approach. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27810562/),%,2.9,200449,DB00338,Omeprazole
,27810562,absolute bioavailability (BA),"Although the oral absorption of crystalline ITZ was negligible, SMSD/ITZ showed an improved pharmacokinetic profile in normal rats, with an absolute bioavailability (BA) of 2.9%, and even 6.3% in the hypochlorhydric model.",Improved oral absorption profile of itraconazole in hypochlorhydria by self-micellizing solid dispersion approach. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27810562/),%,6.3,200450,DB00338,Omeprazole
,3742939,systemic availability,The mean systemic availability was 70%.,Pharmacokinetics of [14C]omeprazole in patients with impaired renal function. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3742939/),%,70,201160,DB00338,Omeprazole
,3742939,plasma t1/2,The mean plasma t1/2 of omeprazole was 0.6 hours.,Pharmacokinetics of [14C]omeprazole in patients with impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3742939/),h,0.6,201161,DB00338,Omeprazole
,3742939,cumulative excretion,The cumulative excretion of total radioactivity in urine over 96 hours in percent of given dose varied between 25% and 83%.,Pharmacokinetics of [14C]omeprazole in patients with impaired renal function. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3742939/),%,25,201162,DB00338,Omeprazole
,3742939,cumulative excretion,The cumulative excretion of total radioactivity in urine over 96 hours in percent of given dose varied between 25% and 83%.,Pharmacokinetics of [14C]omeprazole in patients with impaired renal function. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3742939/),%,83,201163,DB00338,Omeprazole
,24292311,maximum plasma concentration,But most of the studies in western population showed that the maximum plasma concentration was within 0.5 to 2.0hours indicating a difference from that of western studies.,Bioavailability and plasma concentration of omeprazole in healthy bangladeshi population after ingestion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24292311/),h,0.5 to 2.0,201485,DB00338,Omeprazole
,25250612,AUC(0-∞),"Children weighing 8 - < 20 kg had a 1.8-fold higher exposure with the 10-mg vs. 5-mg dose (AUC(0-∞), 1.32 vs.","Single-dose pharmacokinetic properties of esomeprazole in children aged 1 - 11 years with endoscopically proven GERD: a randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25250612/),,1.32,206504,DB00338,Omeprazole
,25250612,AUC(0-∞),"0.73 μmol·h/L, respectively); children weighing ≥ 20 kg had a 4.4-fold higher exposure with the 20-mg vs. 10-mg dose (AUC(0-∞), 3.06 vs. 0.69 μmol·h/L).","Single-dose pharmacokinetic properties of esomeprazole in children aged 1 - 11 years with endoscopically proven GERD: a randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25250612/),[h·μM] / [l],3.06,206505,DB00338,Omeprazole
,25250612,AUC(0-∞),"0.73 μmol·h/L, respectively); children weighing ≥ 20 kg had a 4.4-fold higher exposure with the 20-mg vs. 10-mg dose (AUC(0-∞), 3.06 vs. 0.69 μmol·h/L).","Single-dose pharmacokinetic properties of esomeprazole in children aged 1 - 11 years with endoscopically proven GERD: a randomized, open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25250612/),[h·μM] / [l],0.69,206506,DB00338,Omeprazole
,16487224,"AUCs(0,infinity)","During placebo administration, the mean AUCs(0,infinity) of rabeprazole in homozygous EMs, heterozygous EMs and PMs were 882 (95% CI, 602, 1162) ng ml-1h , 1214 (975, 1453) ng ml-1 h and 2762 (2482, 3042) ng ml-1 h (P<0.001), respectively.",Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487224/),[ng] / [ml],882,206585,DB00338,Omeprazole
,16487224,"AUCs(0,infinity)","During placebo administration, the mean AUCs(0,infinity) of rabeprazole in homozygous EMs, heterozygous EMs and PMs were 882 (95% CI, 602, 1162) ng ml-1h , 1214 (975, 1453) ng ml-1 h and 2762 (2482, 3042) ng ml-1 h (P<0.001), respectively.",Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487224/),[h·ng] / [ml],1214,206586,DB00338,Omeprazole
,16487224,"AUCs(0,infinity)","During placebo administration, the mean AUCs(0,infinity) of rabeprazole in homozygous EMs, heterozygous EMs and PMs were 882 (95% CI, 602, 1162) ng ml-1h , 1214 (975, 1453) ng ml-1 h and 2762 (2482, 3042) ng ml-1 h (P<0.001), respectively.",Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487224/),[h·ng] / [ml],2762,206587,DB00338,Omeprazole
,23692061,AUC0-24,"On Day 7, mean per cent time intragastric pH >4 was 50.6% for PA32540 and 57.6% for EC-omeprazole 40 mg (P = 0.004) and geometric least squares mean AUC0-24 for omeprazole was 1446 h*ng/mL for PA32540 and 2558 h*ng/mL for EC-omeprazole 40 mg.","Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23692061/),[h·ng] / [ml],1446,207416,DB00338,Omeprazole
,23692061,AUC0-24,"On Day 7, mean per cent time intragastric pH >4 was 50.6% for PA32540 and 57.6% for EC-omeprazole 40 mg (P = 0.004) and geometric least squares mean AUC0-24 for omeprazole was 1446 h*ng/mL for PA32540 and 2558 h*ng/mL for EC-omeprazole 40 mg.","Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23692061/),[h·ng] / [ml],2558,207417,DB00338,Omeprazole
,23692061,Tmax,Day 7 median Tmax of omeprazole was 0.5 h for PA32540 and 1.25 h for EC-omeprazole 40 mg.,"Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23692061/),h,0.5,207418,DB00338,Omeprazole
,23692061,Tmax,Day 7 median Tmax of omeprazole was 0.5 h for PA32540 and 1.25 h for EC-omeprazole 40 mg.,"Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23692061/),h,1.25,207419,DB00338,Omeprazole
,7628184,oral clearance,"In the absence of omeprazole, diazepam oral clearance was marginally greater (mean +/- SEM) (34.4 +/- 2.8 ml/min versus 25.2 +/- 3.5 ml/min, p = 0.057, respectively) and the AUC of desmethyldiazepam was significantly lower (8794 +/- 538 micrograms/L.hr versus 16,358 +/- 2985 mg/L.hr, p = 0.04, respectively) in the white subjects compared with the Chinese subjects.",Interethnic difference in omeprazole's inhibition of diazepam metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628184/),[ml] / [min],34.4,207703,DB00338,Omeprazole
,7628184,oral clearance,"In the absence of omeprazole, diazepam oral clearance was marginally greater (mean +/- SEM) (34.4 +/- 2.8 ml/min versus 25.2 +/- 3.5 ml/min, p = 0.057, respectively) and the AUC of desmethyldiazepam was significantly lower (8794 +/- 538 micrograms/L.hr versus 16,358 +/- 2985 mg/L.hr, p = 0.04, respectively) in the white subjects compared with the Chinese subjects.",Interethnic difference in omeprazole's inhibition of diazepam metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628184/),[ml] / [min],25.2,207704,DB00338,Omeprazole
,7628184,AUC,"In the absence of omeprazole, diazepam oral clearance was marginally greater (mean +/- SEM) (34.4 +/- 2.8 ml/min versus 25.2 +/- 3.5 ml/min, p = 0.057, respectively) and the AUC of desmethyldiazepam was significantly lower (8794 +/- 538 micrograms/L.hr versus 16,358 +/- 2985 mg/L.hr, p = 0.04, respectively) in the white subjects compared with the Chinese subjects.",Interethnic difference in omeprazole's inhibition of diazepam metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628184/),[μg] / [h·l],8794,207705,DB00338,Omeprazole
,7628184,AUC,"In the absence of omeprazole, diazepam oral clearance was marginally greater (mean +/- SEM) (34.4 +/- 2.8 ml/min versus 25.2 +/- 3.5 ml/min, p = 0.057, respectively) and the AUC of desmethyldiazepam was significantly lower (8794 +/- 538 micrograms/L.hr versus 16,358 +/- 2985 mg/L.hr, p = 0.04, respectively) in the white subjects compared with the Chinese subjects.",Interethnic difference in omeprazole's inhibition of diazepam metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628184/),[mg] / [h·l],"16,358",207706,DB00338,Omeprazole
,10468704,Cmax,"On day 7, Cmax was 1343 ng/mL in patients compared with 765 ng/mL in healthy volunteers, AUC was 3458 ng.h/mL vs. 1350 ng.h/mL and t(1/2) was 1.62 h vs. 0.90 h.",Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10468704/),[ng] / [ml],1343,210072,DB00338,Omeprazole
,10468704,Cmax,"On day 7, Cmax was 1343 ng/mL in patients compared with 765 ng/mL in healthy volunteers, AUC was 3458 ng.h/mL vs. 1350 ng.h/mL and t(1/2) was 1.62 h vs. 0.90 h.",Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10468704/),[ng] / [ml],765,210073,DB00338,Omeprazole
,10468704,AUC,"On day 7, Cmax was 1343 ng/mL in patients compared with 765 ng/mL in healthy volunteers, AUC was 3458 ng.h/mL vs. 1350 ng.h/mL and t(1/2) was 1.62 h vs. 0.90 h.",Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10468704/),[h·ng] / [ml],3458,210074,DB00338,Omeprazole
,10468704,AUC,"On day 7, Cmax was 1343 ng/mL in patients compared with 765 ng/mL in healthy volunteers, AUC was 3458 ng.h/mL vs. 1350 ng.h/mL and t(1/2) was 1.62 h vs. 0.90 h.",Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10468704/),[h·ng] / [ml],1350,210075,DB00338,Omeprazole
,10468704,t(1/2),"On day 7, Cmax was 1343 ng/mL in patients compared with 765 ng/mL in healthy volunteers, AUC was 3458 ng.h/mL vs. 1350 ng.h/mL and t(1/2) was 1.62 h vs. 0.90 h.",Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10468704/),h,1.62,210076,DB00338,Omeprazole
,10468704,t(1/2),"On day 7, Cmax was 1343 ng/mL in patients compared with 765 ng/mL in healthy volunteers, AUC was 3458 ng.h/mL vs. 1350 ng.h/mL and t(1/2) was 1.62 h vs. 0.90 h.",Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10468704/),h,0.90,210077,DB00338,Omeprazole
,16988209,C(max),"Pharmacokinetic parameters for ivabradine did not vary significantly after omeprazole (C(max): 45.0 +/- 36.6 vs 42.7 +/- 27.6 ng/mL, P = .98; AUC: 128 +/- 87 vs 126 +/- 63 ng/mL, P = .82) or lansoprazole administration (C(max): 45.0 +/- 36.6 vs 41.3 +/- 29.4 ng/mL, P = .70; AUC: 128 +/- 87 vs 123 +/- 50, P = .73).","Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988209/),[ng] / [ml],45.0,210682,DB00338,Omeprazole
,16988209,C(max),"Pharmacokinetic parameters for ivabradine did not vary significantly after omeprazole (C(max): 45.0 +/- 36.6 vs 42.7 +/- 27.6 ng/mL, P = .98; AUC: 128 +/- 87 vs 126 +/- 63 ng/mL, P = .82) or lansoprazole administration (C(max): 45.0 +/- 36.6 vs 41.3 +/- 29.4 ng/mL, P = .70; AUC: 128 +/- 87 vs 123 +/- 50, P = .73).","Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988209/),[ng] / [ml],42.7,210683,DB00338,Omeprazole
,16988209,AUC,"Pharmacokinetic parameters for ivabradine did not vary significantly after omeprazole (C(max): 45.0 +/- 36.6 vs 42.7 +/- 27.6 ng/mL, P = .98; AUC: 128 +/- 87 vs 126 +/- 63 ng/mL, P = .82) or lansoprazole administration (C(max): 45.0 +/- 36.6 vs 41.3 +/- 29.4 ng/mL, P = .70; AUC: 128 +/- 87 vs 123 +/- 50, P = .73).","Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988209/),[ng] / [ml],128,210684,DB00338,Omeprazole
,16988209,AUC,"Pharmacokinetic parameters for ivabradine did not vary significantly after omeprazole (C(max): 45.0 +/- 36.6 vs 42.7 +/- 27.6 ng/mL, P = .98; AUC: 128 +/- 87 vs 126 +/- 63 ng/mL, P = .82) or lansoprazole administration (C(max): 45.0 +/- 36.6 vs 41.3 +/- 29.4 ng/mL, P = .70; AUC: 128 +/- 87 vs 123 +/- 50, P = .73).","Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988209/),[ng] / [ml],126,210685,DB00338,Omeprazole
,16988209,C(max),"Pharmacokinetic parameters for ivabradine did not vary significantly after omeprazole (C(max): 45.0 +/- 36.6 vs 42.7 +/- 27.6 ng/mL, P = .98; AUC: 128 +/- 87 vs 126 +/- 63 ng/mL, P = .82) or lansoprazole administration (C(max): 45.0 +/- 36.6 vs 41.3 +/- 29.4 ng/mL, P = .70; AUC: 128 +/- 87 vs 123 +/- 50, P = .73).","Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988209/),[ng] / [ml],41.3,210686,DB00338,Omeprazole
,16988209,AUC,"Pharmacokinetic parameters for ivabradine did not vary significantly after omeprazole (C(max): 45.0 +/- 36.6 vs 42.7 +/- 27.6 ng/mL, P = .98; AUC: 128 +/- 87 vs 126 +/- 63 ng/mL, P = .82) or lansoprazole administration (C(max): 45.0 +/- 36.6 vs 41.3 +/- 29.4 ng/mL, P = .70; AUC: 128 +/- 87 vs 123 +/- 50, P = .73).","Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988209/),,128,210687,DB00338,Omeprazole
,16988209,AUC,"Pharmacokinetic parameters for ivabradine did not vary significantly after omeprazole (C(max): 45.0 +/- 36.6 vs 42.7 +/- 27.6 ng/mL, P = .98; AUC: 128 +/- 87 vs 126 +/- 63 ng/mL, P = .82) or lansoprazole administration (C(max): 45.0 +/- 36.6 vs 41.3 +/- 29.4 ng/mL, P = .70; AUC: 128 +/- 87 vs 123 +/- 50, P = .73).","Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988209/),,123,210688,DB00338,Omeprazole
<,18171251,trough blood levels,"A large variability in voriconazole trough blood levels was observed, ranging from <or=1 mg/L (the minimum inhibitory concentration at which, for most fungal pathogens, 90% of isolates are susceptible) in 25% of cases to >5.5 mg/L (a level possibly associated with toxicity) in 31% of cases.",Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18171251/),[mg] / [l],1,211929,DB00338,Omeprazole
>,18171251,trough blood levels,"A large variability in voriconazole trough blood levels was observed, ranging from <or=1 mg/L (the minimum inhibitory concentration at which, for most fungal pathogens, 90% of isolates are susceptible) in 25% of cases to >5.5 mg/L (a level possibly associated with toxicity) in 31% of cases.",Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18171251/),[mg] / [l],5.5,211930,DB00338,Omeprazole
>,18171251,trough blood levels,"Among 16 patients with voriconazole trough blood levels >5.5 mg/L, 5 patients (31%) presented with an encephalopathy, including 4 patients who were treated intravenously with a median voriconazole dosage of 8 mg/kg per day, whereas none of the patients with levels <or=5.5 mg/L presented with neurological toxicity (P=.002).",Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18171251/),[mg] / [l],5.5,211931,DB00338,Omeprazole
,11419747,extraction recovery,The mean extraction recovery of the drug from plasma was found to be 94.9%.,Determination of sulfadoxine in human blood plasma using packed-column supercritical fluid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11419747/),%,94.9,212165,DB00338,Omeprazole
,15578172,total area under the plasma concentration-time curve (AUC),"Following the 20-mg dose of each compound, values of the total area under the plasma concentration-time curve (AUC) were 1.52, 0.62 and 1.04 micromol h/l for S-omeprazole, R-omeprazole and racemic omeprazole, respectively, on day 1.","A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15578172/),[h·μM] / [l],1.52,214276,DB00338,Omeprazole
,15578172,total area under the plasma concentration-time curve (AUC),"Following the 20-mg dose of each compound, values of the total area under the plasma concentration-time curve (AUC) were 1.52, 0.62 and 1.04 micromol h/l for S-omeprazole, R-omeprazole and racemic omeprazole, respectively, on day 1.","A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15578172/),[h·μM] / [l],0.62,214277,DB00338,Omeprazole
,15578172,total area under the plasma concentration-time curve (AUC),"Following the 20-mg dose of each compound, values of the total area under the plasma concentration-time curve (AUC) were 1.52, 0.62 and 1.04 micromol h/l for S-omeprazole, R-omeprazole and racemic omeprazole, respectively, on day 1.","A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15578172/),[h·μM] / [l],1.04,214278,DB00338,Omeprazole
,15578172,AUC,"Respectively, AUC values on day 5 were 2.84, 0.68 and 1.63 micromol h/l.","A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15578172/),[h·μM] / [l],2.84,214279,DB00338,Omeprazole
,15578172,AUC,"Respectively, AUC values on day 5 were 2.84, 0.68 and 1.63 micromol h/l.","A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15578172/),[h·μM] / [l],0.68,214280,DB00338,Omeprazole
,15578172,AUC,"Respectively, AUC values on day 5 were 2.84, 0.68 and 1.63 micromol h/l.","A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15578172/),[h·μM] / [l],1.63,214281,DB00338,Omeprazole
,10363734,maximum rabeprazole concentration,"The maximum rabeprazole concentration (+/- SD) in subjects with cirrhosis (635+/-199 ng/mL) was approximately 50% higher than that in the healthy volunteers (401+/-246 ng/mL), and both area under the curve and elimination half-life were increased by approximately 100%.","Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363734/),[ng] / [ml],635,215150,DB00338,Omeprazole
,10363734,maximum rabeprazole concentration,"The maximum rabeprazole concentration (+/- SD) in subjects with cirrhosis (635+/-199 ng/mL) was approximately 50% higher than that in the healthy volunteers (401+/-246 ng/mL), and both area under the curve and elimination half-life were increased by approximately 100%.","Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363734/),[ng] / [ml],401,215151,DB00338,Omeprazole
,30548689,MPTs,"The MPTs for which intragastric pH was ≥3 and ≥4 for 48 hours were 88% ± 7% and 81% ± 9% for the 0.5 mg/kg group and 90% ± 9% and 85% ± 11% for the 1 mg/kg group, respectively, with no significant intergroup differences.",Pharmacokinetics and pharmacodynamics of intravenous esomeprazole at 2 different dosages in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30548689/),%,88,215518,DB00338,Omeprazole
,30548689,MPTs,"The MPTs for which intragastric pH was ≥3 and ≥4 for 48 hours were 88% ± 7% and 81% ± 9% for the 0.5 mg/kg group and 90% ± 9% and 85% ± 11% for the 1 mg/kg group, respectively, with no significant intergroup differences.",Pharmacokinetics and pharmacodynamics of intravenous esomeprazole at 2 different dosages in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30548689/),%,81,215519,DB00338,Omeprazole
,30548689,MPTs,"The MPTs for which intragastric pH was ≥3 and ≥4 for 48 hours were 88% ± 7% and 81% ± 9% for the 0.5 mg/kg group and 90% ± 9% and 85% ± 11% for the 1 mg/kg group, respectively, with no significant intergroup differences.",Pharmacokinetics and pharmacodynamics of intravenous esomeprazole at 2 different dosages in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30548689/),%,90,215520,DB00338,Omeprazole
,30548689,MPTs,"The MPTs for which intragastric pH was ≥3 and ≥4 for 48 hours were 88% ± 7% and 81% ± 9% for the 0.5 mg/kg group and 90% ± 9% and 85% ± 11% for the 1 mg/kg group, respectively, with no significant intergroup differences.",Pharmacokinetics and pharmacodynamics of intravenous esomeprazole at 2 different dosages in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30548689/),%,85,215521,DB00338,Omeprazole
,12793947,onset of action,"MEASUREMENTS AND MAIN RESULTS: Mean onset of action of omeprazole in a sodium bicarbonate vehicle was 62 +/- 82 mins (range, 2-226 mins).",Omeprazole pharmacodynamics and gastric acid suppression in critically ill pediatric transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793947/),min,62,215592,DB00338,Omeprazole
,12793947,onset of action,"Subjects <4 yrs of age exhibited a more variable onset of omeprazole action (range, 3-226 mins) when compared with older subjects (onset of action, 2-40 min).",Omeprazole pharmacodynamics and gastric acid suppression in critically ill pediatric transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793947/),min,2-40,215593,DB00338,Omeprazole
,12793947,gastric,Mean baseline gastric pH in this study population was 1.0 +/- 0.8.,Omeprazole pharmacodynamics and gastric acid suppression in critically ill pediatric transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793947/),,1.0,215594,DB00338,Omeprazole
,16791014,trough plasma concentration (C trough,"The geometric mean and 95% confidence interval (CI), for the area under time-concentration curve (AUC; ng h/ml), trough plasma concentration (C trough; ng/ml) and maximum observed plasma concentration (Cmax; ng/ml) of saquinavir were 20599 (14396-29360) and 37511 (28733-48970); 737 (482-1127) and 1521 (1039-2227); 3227 (2370-4393) and 5611 (4507-7710) on days 10 and 15, respectively, with geometric mean ratios of 1.82, 2.06 and 1.75.",Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791014/),[ng] / [ml],20599,216628,DB00338,Omeprazole
,16791014,trough plasma concentration (C trough,"The geometric mean and 95% confidence interval (CI), for the area under time-concentration curve (AUC; ng h/ml), trough plasma concentration (C trough; ng/ml) and maximum observed plasma concentration (Cmax; ng/ml) of saquinavir were 20599 (14396-29360) and 37511 (28733-48970); 737 (482-1127) and 1521 (1039-2227); 3227 (2370-4393) and 5611 (4507-7710) on days 10 and 15, respectively, with geometric mean ratios of 1.82, 2.06 and 1.75.",Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791014/),[ng] / [ml],37511,216629,DB00338,Omeprazole
,16791014,trough plasma concentration (C trough,"The geometric mean and 95% confidence interval (CI), for the area under time-concentration curve (AUC; ng h/ml), trough plasma concentration (C trough; ng/ml) and maximum observed plasma concentration (Cmax; ng/ml) of saquinavir were 20599 (14396-29360) and 37511 (28733-48970); 737 (482-1127) and 1521 (1039-2227); 3227 (2370-4393) and 5611 (4507-7710) on days 10 and 15, respectively, with geometric mean ratios of 1.82, 2.06 and 1.75.",Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791014/),[ng] / [ml],737,216630,DB00338,Omeprazole
,16791014,trough plasma concentration (C trough,"The geometric mean and 95% confidence interval (CI), for the area under time-concentration curve (AUC; ng h/ml), trough plasma concentration (C trough; ng/ml) and maximum observed plasma concentration (Cmax; ng/ml) of saquinavir were 20599 (14396-29360) and 37511 (28733-48970); 737 (482-1127) and 1521 (1039-2227); 3227 (2370-4393) and 5611 (4507-7710) on days 10 and 15, respectively, with geometric mean ratios of 1.82, 2.06 and 1.75.",Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791014/),[ng] / [ml],1521,216631,DB00338,Omeprazole
,16791014,trough plasma concentration (C trough,"The geometric mean and 95% confidence interval (CI), for the area under time-concentration curve (AUC; ng h/ml), trough plasma concentration (C trough; ng/ml) and maximum observed plasma concentration (Cmax; ng/ml) of saquinavir were 20599 (14396-29360) and 37511 (28733-48970); 737 (482-1127) and 1521 (1039-2227); 3227 (2370-4393) and 5611 (4507-7710) on days 10 and 15, respectively, with geometric mean ratios of 1.82, 2.06 and 1.75.",Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791014/),[ng] / [ml],3227,216632,DB00338,Omeprazole
,16791014,maximum observed plasma concentration (Cmax,"The geometric mean and 95% confidence interval (CI), for the area under time-concentration curve (AUC; ng h/ml), trough plasma concentration (C trough; ng/ml) and maximum observed plasma concentration (Cmax; ng/ml) of saquinavir were 20599 (14396-29360) and 37511 (28733-48970); 737 (482-1127) and 1521 (1039-2227); 3227 (2370-4393) and 5611 (4507-7710) on days 10 and 15, respectively, with geometric mean ratios of 1.82, 2.06 and 1.75.",Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791014/),[ng] / [ml],37511,216633,DB00338,Omeprazole
,16791014,maximum observed plasma concentration (Cmax,"The geometric mean and 95% confidence interval (CI), for the area under time-concentration curve (AUC; ng h/ml), trough plasma concentration (C trough; ng/ml) and maximum observed plasma concentration (Cmax; ng/ml) of saquinavir were 20599 (14396-29360) and 37511 (28733-48970); 737 (482-1127) and 1521 (1039-2227); 3227 (2370-4393) and 5611 (4507-7710) on days 10 and 15, respectively, with geometric mean ratios of 1.82, 2.06 and 1.75.",Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791014/),[ng] / [ml],737,216634,DB00338,Omeprazole
,16791014,maximum observed plasma concentration (Cmax,"The geometric mean and 95% confidence interval (CI), for the area under time-concentration curve (AUC; ng h/ml), trough plasma concentration (C trough; ng/ml) and maximum observed plasma concentration (Cmax; ng/ml) of saquinavir were 20599 (14396-29360) and 37511 (28733-48970); 737 (482-1127) and 1521 (1039-2227); 3227 (2370-4393) and 5611 (4507-7710) on days 10 and 15, respectively, with geometric mean ratios of 1.82, 2.06 and 1.75.",Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791014/),[ng] / [ml],1521,216635,DB00338,Omeprazole
,16791014,maximum observed plasma concentration (Cmax,"The geometric mean and 95% confidence interval (CI), for the area under time-concentration curve (AUC; ng h/ml), trough plasma concentration (C trough; ng/ml) and maximum observed plasma concentration (Cmax; ng/ml) of saquinavir were 20599 (14396-29360) and 37511 (28733-48970); 737 (482-1127) and 1521 (1039-2227); 3227 (2370-4393) and 5611 (4507-7710) on days 10 and 15, respectively, with geometric mean ratios of 1.82, 2.06 and 1.75.",Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791014/),[ng] / [ml],3227,216636,DB00338,Omeprazole
,16791014,maximum observed plasma concentration (Cmax,"The geometric mean and 95% confidence interval (CI), for the area under time-concentration curve (AUC; ng h/ml), trough plasma concentration (C trough; ng/ml) and maximum observed plasma concentration (Cmax; ng/ml) of saquinavir were 20599 (14396-29360) and 37511 (28733-48970); 737 (482-1127) and 1521 (1039-2227); 3227 (2370-4393) and 5611 (4507-7710) on days 10 and 15, respectively, with geometric mean ratios of 1.82, 2.06 and 1.75.",Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791014/),[ng] / [ml],5611,216637,DB00338,Omeprazole
,17173278,Tmax,No significant differences in Tmax (regimen A: 2.9 h vs regimen B: 2.6 h) or t1/2 (6.83 h vs 6.6 h) between the regimens were observed.,Effect of omeprazole on the pharmacokinetics of paricalcitol in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17173278/),h,2.9,218782,DB00338,Omeprazole
,17173278,Tmax,No significant differences in Tmax (regimen A: 2.9 h vs regimen B: 2.6 h) or t1/2 (6.83 h vs 6.6 h) between the regimens were observed.,Effect of omeprazole on the pharmacokinetics of paricalcitol in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17173278/),h,2.6,218783,DB00338,Omeprazole
,17173278,t1/2,No significant differences in Tmax (regimen A: 2.9 h vs regimen B: 2.6 h) or t1/2 (6.83 h vs 6.6 h) between the regimens were observed.,Effect of omeprazole on the pharmacokinetics of paricalcitol in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17173278/),h,6.83,218784,DB00338,Omeprazole
,17173278,t1/2,No significant differences in Tmax (regimen A: 2.9 h vs regimen B: 2.6 h) or t1/2 (6.83 h vs 6.6 h) between the regimens were observed.,Effect of omeprazole on the pharmacokinetics of paricalcitol in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17173278/),h,6.6,218785,DB00338,Omeprazole
,10743982,time to maximum concentration,"A statistically significant difference was detected in the time to maximum concentration between regimens C and D at 2.1 and 1.5 hours, respectively (P < or = 0.05).",Effect on bioavailability of admixing the contents of lansoprazole capsules with selected soft foods. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10743982/),h,2.1,218903,DB00338,Omeprazole
,10743982,time to maximum concentration,"A statistically significant difference was detected in the time to maximum concentration between regimens C and D at 2.1 and 1.5 hours, respectively (P < or = 0.05).",Effect on bioavailability of admixing the contents of lansoprazole capsules with selected soft foods. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10743982/),h,1.5,218904,DB00338,Omeprazole
,34152812,maximum velocity of elimination (Vmax),"Body weight, CYP2C19 phenotype, and omeprazole were significant covariates on the maximum velocity of elimination (Vmax), which had an estimated typical value of 18.13 mg · h-1.",Model-Oriented Dose Optimization of Voriconazole in Critically Ill Children. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34152812/),[mg] / [h],18.13,222044,DB00338,Omeprazole
,20646199,peak plasma concentrations (C(max)),"Pharmacokinetic results demonstrated median peak plasma concentrations (C(max)) of 7.35 (3.2-15.2), 7.30 (1.7-10.9) and 8.65 (1.8-19.3) ng/mL and median area under the concentration curve (AUC((0-180))) of 747 (237-1681) min x ng/mL, 552.9 (39-1063) min x ng/mL, and 972 (107-1841) min x ng/mL for treatments A, B and C, respectively.",Pharmacokinetics of intrarectal omeprazole in alpacas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20646199/),[ng] / [ml],7.35,223052,DB00338,Omeprazole
,20646199,peak plasma concentrations (C(max)),"Pharmacokinetic results demonstrated median peak plasma concentrations (C(max)) of 7.35 (3.2-15.2), 7.30 (1.7-10.9) and 8.65 (1.8-19.3) ng/mL and median area under the concentration curve (AUC((0-180))) of 747 (237-1681) min x ng/mL, 552.9 (39-1063) min x ng/mL, and 972 (107-1841) min x ng/mL for treatments A, B and C, respectively.",Pharmacokinetics of intrarectal omeprazole in alpacas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20646199/),[ng] / [ml],7.30,223053,DB00338,Omeprazole
,20646199,peak plasma concentrations (C(max)),"Pharmacokinetic results demonstrated median peak plasma concentrations (C(max)) of 7.35 (3.2-15.2), 7.30 (1.7-10.9) and 8.65 (1.8-19.3) ng/mL and median area under the concentration curve (AUC((0-180))) of 747 (237-1681) min x ng/mL, 552.9 (39-1063) min x ng/mL, and 972 (107-1841) min x ng/mL for treatments A, B and C, respectively.",Pharmacokinetics of intrarectal omeprazole in alpacas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20646199/),[ng] / [ml],8.65,223054,DB00338,Omeprazole
,20646199,area under the concentration curve (AUC((0-180))),"Pharmacokinetic results demonstrated median peak plasma concentrations (C(max)) of 7.35 (3.2-15.2), 7.30 (1.7-10.9) and 8.65 (1.8-19.3) ng/mL and median area under the concentration curve (AUC((0-180))) of 747 (237-1681) min x ng/mL, 552.9 (39-1063) min x ng/mL, and 972 (107-1841) min x ng/mL for treatments A, B and C, respectively.",Pharmacokinetics of intrarectal omeprazole in alpacas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20646199/),[min·ng] / [ml],747,223055,DB00338,Omeprazole
,20646199,area under the concentration curve (AUC((0-180))),"Pharmacokinetic results demonstrated median peak plasma concentrations (C(max)) of 7.35 (3.2-15.2), 7.30 (1.7-10.9) and 8.65 (1.8-19.3) ng/mL and median area under the concentration curve (AUC((0-180))) of 747 (237-1681) min x ng/mL, 552.9 (39-1063) min x ng/mL, and 972 (107-1841) min x ng/mL for treatments A, B and C, respectively.",Pharmacokinetics of intrarectal omeprazole in alpacas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20646199/),[min·ng] / [ml],552.9,223056,DB00338,Omeprazole
,20646199,area under the concentration curve (AUC((0-180))),"Pharmacokinetic results demonstrated median peak plasma concentrations (C(max)) of 7.35 (3.2-15.2), 7.30 (1.7-10.9) and 8.65 (1.8-19.3) ng/mL and median area under the concentration curve (AUC((0-180))) of 747 (237-1681) min x ng/mL, 552.9 (39-1063) min x ng/mL, and 972 (107-1841) min x ng/mL for treatments A, B and C, respectively.",Pharmacokinetics of intrarectal omeprazole in alpacas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20646199/),[min·ng] / [ml],972,223057,DB00338,Omeprazole
,20646199,half-lives,"The median half-lives were similar between groups: 38, 50, and 53 min.",Pharmacokinetics of intrarectal omeprazole in alpacas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20646199/),min,38,223058,DB00338,Omeprazole
,20646199,half-lives,"The median half-lives were similar between groups: 38, 50, and 53 min.",Pharmacokinetics of intrarectal omeprazole in alpacas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20646199/),min,50,223059,DB00338,Omeprazole
,20646199,half-lives,"The median half-lives were similar between groups: 38, 50, and 53 min.",Pharmacokinetics of intrarectal omeprazole in alpacas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20646199/),min,53,223060,DB00338,Omeprazole
,23750331,Cmax,"Cmax reduced from 2.94 to 1.88 ng/mL (-36%), 1.03 to 0.50 ng/mL (-52%) and 3.38 to 0.45 ng/mL (-87%) for THC, CBD and 11-OH-THC, respectively compared to single dose administration of THC/CBD spray alone.","A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23750331/),[ng] / [ml],2.94 to,224410,DB00338,Omeprazole
,23750331,Cmax,"Cmax reduced from 2.94 to 1.88 ng/mL (-36%), 1.03 to 0.50 ng/mL (-52%) and 3.38 to 0.45 ng/mL (-87%) for THC, CBD and 11-OH-THC, respectively compared to single dose administration of THC/CBD spray alone.","A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23750331/),[ng] / [ml],1,224411,DB00338,Omeprazole
,23750331,Cmax,"Cmax reduced from 2.94 to 1.88 ng/mL (-36%), 1.03 to 0.50 ng/mL (-52%) and 3.38 to 0.45 ng/mL (-87%) for THC, CBD and 11-OH-THC, respectively compared to single dose administration of THC/CBD spray alone.","A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23750331/),[ng] / [ml],1.03 to 0.50,224412,DB00338,Omeprazole
,23750331,Cmax,"Cmax reduced from 2.94 to 1.88 ng/mL (-36%), 1.03 to 0.50 ng/mL (-52%) and 3.38 to 0.45 ng/mL (-87%) for THC, CBD and 11-OH-THC, respectively compared to single dose administration of THC/CBD spray alone.","A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23750331/),[ng] / [ml],3.38 to 0.45,224413,DB00338,Omeprazole
,23750331,Cmax,"Ketoconazole co-administration with THC/CBD spray had the opposite effect, increasing the Cmax of the respective analytes from 2.65 to 3.36 ng/mL (+27%), 0.66 to 1.25 ng/mL (+89%) and 3.59 to 10.92 ng/mL (+204%).","A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23750331/),[ng] / [ml],2.65 to 3.36,224414,DB00338,Omeprazole
,23750331,Cmax,"Ketoconazole co-administration with THC/CBD spray had the opposite effect, increasing the Cmax of the respective analytes from 2.65 to 3.36 ng/mL (+27%), 0.66 to 1.25 ng/mL (+89%) and 3.59 to 10.92 ng/mL (+204%).","A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23750331/),[ng] / [ml],0.66 to 1.25,224415,DB00338,Omeprazole
,23750331,Cmax,"Ketoconazole co-administration with THC/CBD spray had the opposite effect, increasing the Cmax of the respective analytes from 2.65 to 3.36 ng/mL (+27%), 0.66 to 1.25 ng/mL (+89%) and 3.59 to 10.92 ng/mL (+204%).","A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23750331/),[ng] / [ml],3.59 to 10.92,224416,DB00338,Omeprazole
,16402242,t(1/2 ke),"In the homEMs, hetEMs and PMs, the relative AUC(0-infinity) values were 1:2.8:7.5 for omeprazole, 1:1.7:4.0 for lansoprazole and 1:1.6:3.7 for rabeprazole, respectively; the relative t(1/2 ke) values were 1:1.02:1.65 for omeprazole, 1:1.08:2.39 for lansoprazole and 1:1.37:1.85 for rabeprazole, respectively; the relative c(max) values were 1:2.09:4.39 for omeprazole, 1:1.34:1.72 for lansoprazole, and 1:1.24:2.04 for rabeprazole, respectively.",Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16402242/),,1,224766,DB00338,Omeprazole
,16402242,t(1/2 ke),"In the homEMs, hetEMs and PMs, the relative AUC(0-infinity) values were 1:2.8:7.5 for omeprazole, 1:1.7:4.0 for lansoprazole and 1:1.6:3.7 for rabeprazole, respectively; the relative t(1/2 ke) values were 1:1.02:1.65 for omeprazole, 1:1.08:2.39 for lansoprazole and 1:1.37:1.85 for rabeprazole, respectively; the relative c(max) values were 1:2.09:4.39 for omeprazole, 1:1.34:1.72 for lansoprazole, and 1:1.24:2.04 for rabeprazole, respectively.",Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16402242/),,1.02,224767,DB00338,Omeprazole
,16402242,t(1/2 ke),"In the homEMs, hetEMs and PMs, the relative AUC(0-infinity) values were 1:2.8:7.5 for omeprazole, 1:1.7:4.0 for lansoprazole and 1:1.6:3.7 for rabeprazole, respectively; the relative t(1/2 ke) values were 1:1.02:1.65 for omeprazole, 1:1.08:2.39 for lansoprazole and 1:1.37:1.85 for rabeprazole, respectively; the relative c(max) values were 1:2.09:4.39 for omeprazole, 1:1.34:1.72 for lansoprazole, and 1:1.24:2.04 for rabeprazole, respectively.",Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16402242/),,1,224768,DB00338,Omeprazole
,16402242,t(1/2 ke),"In the homEMs, hetEMs and PMs, the relative AUC(0-infinity) values were 1:2.8:7.5 for omeprazole, 1:1.7:4.0 for lansoprazole and 1:1.6:3.7 for rabeprazole, respectively; the relative t(1/2 ke) values were 1:1.02:1.65 for omeprazole, 1:1.08:2.39 for lansoprazole and 1:1.37:1.85 for rabeprazole, respectively; the relative c(max) values were 1:2.09:4.39 for omeprazole, 1:1.34:1.72 for lansoprazole, and 1:1.24:2.04 for rabeprazole, respectively.",Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16402242/),,1,224769,DB00338,Omeprazole
,16402242,t(1/2 ke),"In the homEMs, hetEMs and PMs, the relative AUC(0-infinity) values were 1:2.8:7.5 for omeprazole, 1:1.7:4.0 for lansoprazole and 1:1.6:3.7 for rabeprazole, respectively; the relative t(1/2 ke) values were 1:1.02:1.65 for omeprazole, 1:1.08:2.39 for lansoprazole and 1:1.37:1.85 for rabeprazole, respectively; the relative c(max) values were 1:2.09:4.39 for omeprazole, 1:1.34:1.72 for lansoprazole, and 1:1.24:2.04 for rabeprazole, respectively.",Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16402242/),,1.08,224770,DB00338,Omeprazole
,32227647,apparent clearance,"The apparent clearance at 10-mg dose was 17.32, 9.77 and 7.37 (L/h) for homozygous extensive metabolizer, heterozygous extensive metabolizer and poor metabolizer subjects, respectively.",Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32227647/),[l] / [h],17.32,225083,DB00338,Omeprazole
,32227647,apparent clearance,"The apparent clearance at 10-mg dose was 17.32, 9.77 and 7.37 (L/h) for homozygous extensive metabolizer, heterozygous extensive metabolizer and poor metabolizer subjects, respectively.",Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32227647/),[l] / [h],9.77,225084,DB00338,Omeprazole
,32227647,apparent clearance,"The apparent clearance at 10-mg dose was 17.32, 9.77 and 7.37 (L/h) for homozygous extensive metabolizer, heterozygous extensive metabolizer and poor metabolizer subjects, respectively.",Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32227647/),[l] / [h],7.37,225085,DB00338,Omeprazole
,15355126,systemic availability,A low systemic availability of 9-21% indicates extensive first-pass elimination.,Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355126/),%,9-21,227652,DB00338,Omeprazole
,18294333,AUC(infinity),"The mean omeprazole AUC(infinity) of 1973 h nmol l(-1) in CYP2C19*17/*17 subjects was 2.1-fold lower [95% confidence interval (CI) 1.1, 3.3] than in CYP2C19*1/*1 subjects (4151 h nmol l(-1), P = 0.04).",Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294333/),[h·nM] / [l],1973,227672,DB00338,Omeprazole
,18294333,AUC(infinity),"The mean omeprazole AUC(infinity) of 1973 h nmol l(-1) in CYP2C19*17/*17 subjects was 2.1-fold lower [95% confidence interval (CI) 1.1, 3.3] than in CYP2C19*1/*1 subjects (4151 h nmol l(-1), P = 0.04).",Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294333/),[h·nM] / [l],4151,227673,DB00338,Omeprazole
,18294333,AUC(infinity),"A similar trend was observed for the sulphone metabolite with the CYP2C19*17/*17 group having a mean AUC(infinity) of 1083 h nmol l(-1), 3.1-fold lower (95% CI 1.2, 5.5) than the CYP2C19*1/*1 group (3343 h nmol l(-1), P = 0.03).",Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294333/),[h·nM] / [l],1083,227674,DB00338,Omeprazole
,18294333,AUC(infinity),"A similar trend was observed for the sulphone metabolite with the CYP2C19*17/*17 group having a mean AUC(infinity) of 1083 h nmol l(-1), 3.1-fold lower (95% CI 1.2, 5.5) than the CYP2C19*1/*1 group (3343 h nmol l(-1), P = 0.03).",Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294333/),[h·nM] / [l],3343,227675,DB00338,Omeprazole
,30050845,dose-normalized peak plasma concentration (Cmax),"Median (range) dose-normalized peak plasma concentration (Cmax) values for the IV and po formulations were 4.06 µg/mL (2.47-4.57 µg/mL) and 1.04 µg/mL (0.31-1.91 µg/mL), respectively.",Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30050845/),[μg] / [ml],4.06,228203,DB00338,Omeprazole
,30050845,dose-normalized peak plasma concentration (Cmax),"Median (range) dose-normalized peak plasma concentration (Cmax) values for the IV and po formulations were 4.06 µg/mL (2.47-4.57 µg/mL) and 1.04 µg/mL (0.31-1.91 µg/mL), respectively.",Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30050845/),[μg] / [ml],1.04,228204,DB00338,Omeprazole
,30050845,time-to-peak concentration (Tmax),The median (range) time-to-peak concentration (Tmax) for the po formulation was 105 minutes (45-360 minutes).,Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30050845/),min,105,228205,DB00338,Omeprazole
,30050845,plasma terminal half-life (t½),Median (range) plasma terminal half-life (t½) was 45.56 minutes (39.43-64.20 minutes) for the IV formulation and 63.97 minutes (44.02-109.94 minutes) for the enteric-coated po formulation.,Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30050845/),min,45.56,228206,DB00338,Omeprazole
,30050845,plasma terminal half-life (t½),Median (range) plasma terminal half-life (t½) was 45.56 minutes (39.43-64.20 minutes) for the IV formulation and 63.97 minutes (44.02-109.94 minutes) for the enteric-coated po formulation.,Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30050845/),min,63.97,228207,DB00338,Omeprazole
,30050845,bioavailability,The median (range) po bioavailability was 63.33% (32.26%-79.77%).,Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30050845/),%,63.33,228208,DB00338,Omeprazole
,20015104,pH,"On day 5, median pH (5.34 +/- 0.45 and 5.19 +/- 0.52 vs.","The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015104/),,5.34,229709,DB00338,Omeprazole
,20015104,pH,"On day 5, median pH (5.34 +/- 0.45 and 5.19 +/- 0.52 vs.","The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015104/),,5.19,229710,DB00338,Omeprazole
,20015104,percentage time,"4.76 +/- 0.82, respectively, P < 0.002) and percentage time with pH > 4 (80 +/- 11 and 77 +/- 12, vs. 63 +/- 11 respectively, P < 0.0001) for 24-h were higher with S-tenatoprazole-Na 90 mg and 60 mg than esomeprazole.","The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015104/),,80,229711,DB00338,Omeprazole
,20015104,percentage time,"4.76 +/- 0.82, respectively, P < 0.002) and percentage time with pH > 4 (80 +/- 11 and 77 +/- 12, vs. 63 +/- 11 respectively, P < 0.0001) for 24-h were higher with S-tenatoprazole-Na 90 mg and 60 mg than esomeprazole.","The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015104/),,77,229712,DB00338,Omeprazole
,20015104,percentage time,"4.76 +/- 0.82, respectively, P < 0.002) and percentage time with pH > 4 (80 +/- 11 and 77 +/- 12, vs. 63 +/- 11 respectively, P < 0.0001) for 24-h were higher with S-tenatoprazole-Na 90 mg and 60 mg than esomeprazole.","The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015104/),,63,229713,DB00338,Omeprazole
,20015104,percentage,"In nocturnal periods, S-tenatoprazole-Na 90 mg, 60 mg and 30 mg were superior to esomeprazole with regard to median pH (5.14 +/- 0.64, 4.94 +/- 0.65, 4.65 +/- 0.86 and 3.69 +/- 1.18 respectively, P < 0.0001) and percentage time with pH > 4 (77 +/- 12, 73 +/- 17, 64 +/- 17 and 46 +/- 17 respectively, P < 0.0001).","The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015104/),,77,229714,DB00338,Omeprazole
,20015104,percentage,"In nocturnal periods, S-tenatoprazole-Na 90 mg, 60 mg and 30 mg were superior to esomeprazole with regard to median pH (5.14 +/- 0.64, 4.94 +/- 0.65, 4.65 +/- 0.86 and 3.69 +/- 1.18 respectively, P < 0.0001) and percentage time with pH > 4 (77 +/- 12, 73 +/- 17, 64 +/- 17 and 46 +/- 17 respectively, P < 0.0001).","The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015104/),,73,229715,DB00338,Omeprazole
,20015104,percentage,"In nocturnal periods, S-tenatoprazole-Na 90 mg, 60 mg and 30 mg were superior to esomeprazole with regard to median pH (5.14 +/- 0.64, 4.94 +/- 0.65, 4.65 +/- 0.86 and 3.69 +/- 1.18 respectively, P < 0.0001) and percentage time with pH > 4 (77 +/- 12, 73 +/- 17, 64 +/- 17 and 46 +/- 17 respectively, P < 0.0001).","The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015104/),,64,229716,DB00338,Omeprazole
,20015104,percentage,"In nocturnal periods, S-tenatoprazole-Na 90 mg, 60 mg and 30 mg were superior to esomeprazole with regard to median pH (5.14 +/- 0.64, 4.94 +/- 0.65, 4.65 +/- 0.86 and 3.69 +/- 1.18 respectively, P < 0.0001) and percentage time with pH > 4 (77 +/- 12, 73 +/- 17, 64 +/- 17 and 46 +/- 17 respectively, P < 0.0001).","The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015104/),,46,229717,DB00338,Omeprazole
,28452843,trough level,"There were significant differences in dabigatran trough level comparing patients treated with PPI and patients without PPI (58.86 ± 36.76 ng/mL vs. 110.72 ± 88.47 ng/mL, P < 0.05).",The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28452843/),[ng] / [ml],58.86,229739,DB00338,Omeprazole
,28452843,trough level,"There were significant differences in dabigatran trough level comparing patients treated with PPI and patients without PPI (58.86 ± 36.76 ng/mL vs. 110.72 ± 88.47 ng/mL, P < 0.05).",The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28452843/),[ng] / [ml],110.72,229740,DB00338,Omeprazole
,28452843,peak level,"Similarly, there were significant differences in dabigatran peak level between compared groups (88.0 ± 20.5 ng/mL vs. 174.4 ± 139.64 ng/mL, P < 0.05).",The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28452843/),[ng] / [ml],88.0,229741,DB00338,Omeprazole
,28452843,peak level,"Similarly, there were significant differences in dabigatran peak level between compared groups (88.0 ± 20.5 ng/mL vs. 174.4 ± 139.64 ng/mL, P < 0.05).",The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28452843/),[ng] / [ml],174.4,229742,DB00338,Omeprazole
>,16207309,oral bioavailability,"Methadone is an opioid, which has a high oral bioavailability (>70%) and a long elimination half-life (>20 h) in human beings.","The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207309/),%,70,230489,DB00338,Omeprazole
>,16207309,elimination half-life,"Methadone is an opioid, which has a high oral bioavailability (>70%) and a long elimination half-life (>20 h) in human beings.","The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207309/),h,20,230490,DB00338,Omeprazole
,16207309,elimination half-life,"The mean +/- SD for the elimination half-life, volume of distribution, and clearance were 1.75 +/- 0.25 h, 3.46 +/- 1.09 L/kg, and 25.14 +/- 9.79 mL/min.","The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207309/),h,1.75,230491,DB00338,Omeprazole
,16207309,volume of distribution,"The mean +/- SD for the elimination half-life, volume of distribution, and clearance were 1.75 +/- 0.25 h, 3.46 +/- 1.09 L/kg, and 25.14 +/- 9.79 mL/min.","The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207309/),[l] / [kg],3.46,230492,DB00338,Omeprazole
,16207309,clearance,"The mean +/- SD for the elimination half-life, volume of distribution, and clearance were 1.75 +/- 0.25 h, 3.46 +/- 1.09 L/kg, and 25.14 +/- 9.79 mL/min.","The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207309/),[ml] / [min],25.14,230493,DB00338,Omeprazole
,16207309,bioavailability,"Following administration with ketoconazole, detectable concentrations of methadone were present in one dog with a 29% bioavailability.","The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207309/),%,29,230494,DB00338,Omeprazole
,11563995,inhibition,"The mean inhibition values of the pentagastrin-stimulated peak acid output on day 1 for 5, 10 and 20 mg of esomeprazole were 15%, 29% and 46%, respectively; the corresponding day 5 values were 28%, 62% and 90%.","Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563995/),%,15,231478,DB00338,Omeprazole
,11563995,inhibition,"The mean inhibition values of the pentagastrin-stimulated peak acid output on day 1 for 5, 10 and 20 mg of esomeprazole were 15%, 29% and 46%, respectively; the corresponding day 5 values were 28%, 62% and 90%.","Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563995/),%,29,231479,DB00338,Omeprazole
,11563995,inhibition,"The mean inhibition values of the pentagastrin-stimulated peak acid output on day 1 for 5, 10 and 20 mg of esomeprazole were 15%, 29% and 46%, respectively; the corresponding day 5 values were 28%, 62% and 90%.","Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563995/),%,46,231480,DB00338,Omeprazole
,11563995,inhibition,"The mean inhibition values of the pentagastrin-stimulated peak acid output on day 1 for 5, 10 and 20 mg of esomeprazole were 15%, 29% and 46%, respectively; the corresponding day 5 values were 28%, 62% and 90%.","Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563995/),%,28,231481,DB00338,Omeprazole
,11563995,inhibition,"The mean inhibition values of the pentagastrin-stimulated peak acid output on day 1 for 5, 10 and 20 mg of esomeprazole were 15%, 29% and 46%, respectively; the corresponding day 5 values were 28%, 62% and 90%.","Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563995/),%,62,231482,DB00338,Omeprazole
,11563995,inhibition,"The mean inhibition values of the pentagastrin-stimulated peak acid output on day 1 for 5, 10 and 20 mg of esomeprazole were 15%, 29% and 46%, respectively; the corresponding day 5 values were 28%, 62% and 90%.","Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563995/),%,90,231483,DB00338,Omeprazole
,11563995,inhibition,The mean inhibition values of the pentagastrin-stimulated peak acid output for omeprazole were 35% (day 1) to 79% (day 5).,"Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563995/),,35,231484,DB00338,Omeprazole
,11563995,inhibition,The mean inhibition values of the pentagastrin-stimulated peak acid output for omeprazole were 35% (day 1) to 79% (day 5).,"Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563995/),,79,231485,DB00338,Omeprazole
,22122821,Cmax,"After administering a single dose of 20 mg of each omeprazole formulation, the obtained mean (SD) values for the test and reference products were 608.40 (116.37) and 588.56 (98.36) ng/ml for Cmax; 1.83 (0.25) and 2.00 (0.30) h for tmax; 1,635.77 (581.25) and 1,639.58 (652.54) h-ng/ml for AUC0-12; and 1,721.12 (572.07) and 1,805.58 (856.39) h-ng/ml for AUC(0-∞) respectively.","Bioavailability of omeprazole 20 mg capsules containing omeprazole 22.5% enteric coated pellets versus a reference product in healthy Bangladeshi male subjects: an open-label, single-dose, randomized-sequence, two-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122821/),[ng] / [ml],608.40,232663,DB00338,Omeprazole
,22122821,Cmax,"After administering a single dose of 20 mg of each omeprazole formulation, the obtained mean (SD) values for the test and reference products were 608.40 (116.37) and 588.56 (98.36) ng/ml for Cmax; 1.83 (0.25) and 2.00 (0.30) h for tmax; 1,635.77 (581.25) and 1,639.58 (652.54) h-ng/ml for AUC0-12; and 1,721.12 (572.07) and 1,805.58 (856.39) h-ng/ml for AUC(0-∞) respectively.","Bioavailability of omeprazole 20 mg capsules containing omeprazole 22.5% enteric coated pellets versus a reference product in healthy Bangladeshi male subjects: an open-label, single-dose, randomized-sequence, two-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122821/),[ng] / [ml],588.56,232664,DB00338,Omeprazole
,22122821,tmax,"After administering a single dose of 20 mg of each omeprazole formulation, the obtained mean (SD) values for the test and reference products were 608.40 (116.37) and 588.56 (98.36) ng/ml for Cmax; 1.83 (0.25) and 2.00 (0.30) h for tmax; 1,635.77 (581.25) and 1,639.58 (652.54) h-ng/ml for AUC0-12; and 1,721.12 (572.07) and 1,805.58 (856.39) h-ng/ml for AUC(0-∞) respectively.","Bioavailability of omeprazole 20 mg capsules containing omeprazole 22.5% enteric coated pellets versus a reference product in healthy Bangladeshi male subjects: an open-label, single-dose, randomized-sequence, two-way crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122821/),h,1.83,232665,DB00338,Omeprazole
,22122821,tmax,"After administering a single dose of 20 mg of each omeprazole formulation, the obtained mean (SD) values for the test and reference products were 608.40 (116.37) and 588.56 (98.36) ng/ml for Cmax; 1.83 (0.25) and 2.00 (0.30) h for tmax; 1,635.77 (581.25) and 1,639.58 (652.54) h-ng/ml for AUC0-12; and 1,721.12 (572.07) and 1,805.58 (856.39) h-ng/ml for AUC(0-∞) respectively.","Bioavailability of omeprazole 20 mg capsules containing omeprazole 22.5% enteric coated pellets versus a reference product in healthy Bangladeshi male subjects: an open-label, single-dose, randomized-sequence, two-way crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122821/),h,2.00,232666,DB00338,Omeprazole
,22122821,AUC0-12,"After administering a single dose of 20 mg of each omeprazole formulation, the obtained mean (SD) values for the test and reference products were 608.40 (116.37) and 588.56 (98.36) ng/ml for Cmax; 1.83 (0.25) and 2.00 (0.30) h for tmax; 1,635.77 (581.25) and 1,639.58 (652.54) h-ng/ml for AUC0-12; and 1,721.12 (572.07) and 1,805.58 (856.39) h-ng/ml for AUC(0-∞) respectively.","Bioavailability of omeprazole 20 mg capsules containing omeprazole 22.5% enteric coated pellets versus a reference product in healthy Bangladeshi male subjects: an open-label, single-dose, randomized-sequence, two-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122821/),[h-ng] / [ml],"1,635.77",232667,DB00338,Omeprazole
,22122821,AUC0-12,"After administering a single dose of 20 mg of each omeprazole formulation, the obtained mean (SD) values for the test and reference products were 608.40 (116.37) and 588.56 (98.36) ng/ml for Cmax; 1.83 (0.25) and 2.00 (0.30) h for tmax; 1,635.77 (581.25) and 1,639.58 (652.54) h-ng/ml for AUC0-12; and 1,721.12 (572.07) and 1,805.58 (856.39) h-ng/ml for AUC(0-∞) respectively.","Bioavailability of omeprazole 20 mg capsules containing omeprazole 22.5% enteric coated pellets versus a reference product in healthy Bangladeshi male subjects: an open-label, single-dose, randomized-sequence, two-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122821/),[h-ng] / [ml],"1,639.58",232668,DB00338,Omeprazole
,22122821,AUC(0-∞),"After administering a single dose of 20 mg of each omeprazole formulation, the obtained mean (SD) values for the test and reference products were 608.40 (116.37) and 588.56 (98.36) ng/ml for Cmax; 1.83 (0.25) and 2.00 (0.30) h for tmax; 1,635.77 (581.25) and 1,639.58 (652.54) h-ng/ml for AUC0-12; and 1,721.12 (572.07) and 1,805.58 (856.39) h-ng/ml for AUC(0-∞) respectively.","Bioavailability of omeprazole 20 mg capsules containing omeprazole 22.5% enteric coated pellets versus a reference product in healthy Bangladeshi male subjects: an open-label, single-dose, randomized-sequence, two-way crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122821/),[h-ng] / [ml],"1,721.12",232669,DB00338,Omeprazole
,22122821,AUC(0-∞),"After administering a single dose of 20 mg of each omeprazole formulation, the obtained mean (SD) values for the test and reference products were 608.40 (116.37) and 588.56 (98.36) ng/ml for Cmax; 1.83 (0.25) and 2.00 (0.30) h for tmax; 1,635.77 (581.25) and 1,639.58 (652.54) h-ng/ml for AUC0-12; and 1,721.12 (572.07) and 1,805.58 (856.39) h-ng/ml for AUC(0-∞) respectively.","Bioavailability of omeprazole 20 mg capsules containing omeprazole 22.5% enteric coated pellets versus a reference product in healthy Bangladeshi male subjects: an open-label, single-dose, randomized-sequence, two-way crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122821/),[h-ng] / [ml],"1,805.58",232670,DB00338,Omeprazole
,22122821,t(1/2),The mean t(1/2) was 3.33 (1.61) and 3.57 (1.24) h for test and reference product respectively.,"Bioavailability of omeprazole 20 mg capsules containing omeprazole 22.5% enteric coated pellets versus a reference product in healthy Bangladeshi male subjects: an open-label, single-dose, randomized-sequence, two-way crossover study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122821/),h,3.33,232671,DB00338,Omeprazole
,22122821,t(1/2),The mean t(1/2) was 3.33 (1.61) and 3.57 (1.24) h for test and reference product respectively.,"Bioavailability of omeprazole 20 mg capsules containing omeprazole 22.5% enteric coated pellets versus a reference product in healthy Bangladeshi male subjects: an open-label, single-dose, randomized-sequence, two-way crossover study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122821/),h,3.57,232672,DB00338,Omeprazole
less,7585848,time elapsed to peak concentration (Tmax),Mean time elapsed to peak concentration (Tmax) was less than 2 hours for each regimen.,Lansoprazole: an alternative method of administration of a capsule dosage formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7585848/),h,2,234243,DB00338,Omeprazole
,11448052,buccal bioavailability,The buccal bioavailability of omeprazole in hamsters was 13.7% +/- 3.2%.,Physicochemical characterization and evaluation of buccal adhesive tablets containing omeprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448052/),%,13.7,237256,DB00338,Omeprazole
,23110788,tmax,"Co-administration of esomeprazole decreased geometric mean Cmax of ulipristal acetate by 65% (geometric mean ratio point estimate (90% CI): 0.35 (0.28 - 0.42)), and delayed median tmax from 0.75 to 1.00 h (Hodges-Lehmann estimate of difference (90% CI): tmax 0.63 (0.25 - 1.25)) but had minor effects on AUCs of +15% and +11% (geometric mean ratio point estimates (90% CI): AUC0-t 1.15 (1.02 - 1.31) and AUC0-∞ (1.11 (0.98 - 1.27)), respectively.",Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23110788/),h,0.75,238667,DB00338,Omeprazole
,23110788,tmax,"Co-administration of esomeprazole decreased geometric mean Cmax of ulipristal acetate by 65% (geometric mean ratio point estimate (90% CI): 0.35 (0.28 - 0.42)), and delayed median tmax from 0.75 to 1.00 h (Hodges-Lehmann estimate of difference (90% CI): tmax 0.63 (0.25 - 1.25)) but had minor effects on AUCs of +15% and +11% (geometric mean ratio point estimates (90% CI): AUC0-t 1.15 (1.02 - 1.31) and AUC0-∞ (1.11 (0.98 - 1.27)), respectively.",Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23110788/),h,1.00,238668,DB00338,Omeprazole
,16497565,total time for,"The peak was detected with an ultraviolet detector set at a wavelength of 302 nm, and total time for chromatographic separation was approximately 25 min.",Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography: application to pharmacokinetic study in relation to CYP2C19 genotypes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16497565/),min,25,239164,DB00338,Omeprazole
,16497565,recoveries,"Mean recoveries were 84.3% for omeprazole, 64.3% for 5-hydroxyomeprazole and 86.1% for omeprazole sulfone.",Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography: application to pharmacokinetic study in relation to CYP2C19 genotypes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16497565/),%,84.3,239165,DB00338,Omeprazole
,16497565,recoveries,"Mean recoveries were 84.3% for omeprazole, 64.3% for 5-hydroxyomeprazole and 86.1% for omeprazole sulfone.",Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography: application to pharmacokinetic study in relation to CYP2C19 genotypes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16497565/),%,64.3,239166,DB00338,Omeprazole
,16497565,recoveries,"Mean recoveries were 84.3% for omeprazole, 64.3% for 5-hydroxyomeprazole and 86.1% for omeprazole sulfone.",Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography: application to pharmacokinetic study in relation to CYP2C19 genotypes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16497565/),%,86.1,239167,DB00338,Omeprazole
,11515348,maximum observed plasma concentration (Cmax),The mean maximum observed plasma concentration (Cmax) of the suspension was significantly higher and the mean area under the concentration-time curve from time zero to infinity (AUC infinity) was significantly lower than those of the intact capsule (879 versus 810 ng/mL and 1825 versus 2229 ng.hr/mL).,Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11515348/),[ng] / [ml],879,240307,DB00338,Omeprazole
,11515348,maximum observed plasma concentration (Cmax),The mean maximum observed plasma concentration (Cmax) of the suspension was significantly higher and the mean area under the concentration-time curve from time zero to infinity (AUC infinity) was significantly lower than those of the intact capsule (879 versus 810 ng/mL and 1825 versus 2229 ng.hr/mL).,Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11515348/),[ng] / [ml],810,240308,DB00338,Omeprazole
,11515348,area under the concentration-time curve from time zero to infinity (AUC infinity),The mean maximum observed plasma concentration (Cmax) of the suspension was significantly higher and the mean area under the concentration-time curve from time zero to infinity (AUC infinity) was significantly lower than those of the intact capsule (879 versus 810 ng/mL and 1825 versus 2229 ng.hr/mL).,Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11515348/),[h·ng] / [ml],1825,240309,DB00338,Omeprazole
,11515348,area under the concentration-time curve from time zero to infinity (AUC infinity),The mean maximum observed plasma concentration (Cmax) of the suspension was significantly higher and the mean area under the concentration-time curve from time zero to infinity (AUC infinity) was significantly lower than those of the intact capsule (879 versus 810 ng/mL and 1825 versus 2229 ng.hr/mL).,Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11515348/),[h·ng] / [ml],2229,240310,DB00338,Omeprazole
,11683127,maximal serum concentrations,"No statistically significant differences, at the probability level of 90%, were observed neither for the maximal serum concentrations (1.12:1.22 micrograms/ml) nor for the area under the concentration-time curves (5.01:5.77 micrograms/ml.h), the parameter to which the inhibition of acid secretion induced by lansoprazole is directly related.",A bioavailability/bioequivalence study of two oral lansoprazole formulations after single administration to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11683127/),[μg] / [ml],1.12,240583,DB00338,Omeprazole
,11683127,maximal serum concentrations,"No statistically significant differences, at the probability level of 90%, were observed neither for the maximal serum concentrations (1.12:1.22 micrograms/ml) nor for the area under the concentration-time curves (5.01:5.77 micrograms/ml.h), the parameter to which the inhibition of acid secretion induced by lansoprazole is directly related.",A bioavailability/bioequivalence study of two oral lansoprazole formulations after single administration to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11683127/),[μg] / [ml],1.22,240584,DB00338,Omeprazole
,11683127,area under the concentration-time curves,"No statistically significant differences, at the probability level of 90%, were observed neither for the maximal serum concentrations (1.12:1.22 micrograms/ml) nor for the area under the concentration-time curves (5.01:5.77 micrograms/ml.h), the parameter to which the inhibition of acid secretion induced by lansoprazole is directly related.",A bioavailability/bioequivalence study of two oral lansoprazole formulations after single administration to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11683127/),[μg] / [h·ml],5.01,240585,DB00338,Omeprazole
,11683127,area under the concentration-time curves,"No statistically significant differences, at the probability level of 90%, were observed neither for the maximal serum concentrations (1.12:1.22 micrograms/ml) nor for the area under the concentration-time curves (5.01:5.77 micrograms/ml.h), the parameter to which the inhibition of acid secretion induced by lansoprazole is directly related.",A bioavailability/bioequivalence study of two oral lansoprazole formulations after single administration to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11683127/),[μg] / [h·ml],5.77,240586,DB00338,Omeprazole
,11683127,terminal elimination half-lives,The terminal elimination half-lives were 4.56 h for Lasoprol and 4.57 h for the reference formulation.,A bioavailability/bioequivalence study of two oral lansoprazole formulations after single administration to healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11683127/),h,4.56,240587,DB00338,Omeprazole
,11683127,terminal elimination half-lives,The terminal elimination half-lives were 4.56 h for Lasoprol and 4.57 h for the reference formulation.,A bioavailability/bioequivalence study of two oral lansoprazole formulations after single administration to healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11683127/),h,4.57,240588,DB00338,Omeprazole
,12407126,elimination half-life (t(1/2)),"For lansoprazole, the elimination half-life (t(1/2)) was significantly prolonged (1.46 versus 1.7 h, P < 0.05) and the area under the concentration-time curve from 0 to 8 h (AUC(0-8)) was significantly increased (3.65 versus 4.59 mg.h/L, P < 0.05) by combination of the drugs.","Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407126/),h,1.46,243228,DB00338,Omeprazole
,12407126,elimination half-life (t(1/2)),"For lansoprazole, the elimination half-life (t(1/2)) was significantly prolonged (1.46 versus 1.7 h, P < 0.05) and the area under the concentration-time curve from 0 to 8 h (AUC(0-8)) was significantly increased (3.65 versus 4.59 mg.h/L, P < 0.05) by combination of the drugs.","Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407126/),h,1.7,243229,DB00338,Omeprazole
,12407126,area under the concentration-time curve from 0 to 8 h (AUC(0-8)),"For lansoprazole, the elimination half-life (t(1/2)) was significantly prolonged (1.46 versus 1.7 h, P < 0.05) and the area under the concentration-time curve from 0 to 8 h (AUC(0-8)) was significantly increased (3.65 versus 4.59 mg.h/L, P < 0.05) by combination of the drugs.","Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407126/),[h·mg] / [l],3.65,243230,DB00338,Omeprazole
,12407126,area under the concentration-time curve from 0 to 8 h (AUC(0-8)),"For lansoprazole, the elimination half-life (t(1/2)) was significantly prolonged (1.46 versus 1.7 h, P < 0.05) and the area under the concentration-time curve from 0 to 8 h (AUC(0-8)) was significantly increased (3.65 versus 4.59 mg.h/L, P < 0.05) by combination of the drugs.","Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407126/),[h·mg] / [l],4.59,243231,DB00338,Omeprazole
,12407126,peak concentration (C(max)),"For 14-OH-clarithromycin, the peak concentration (C(max)) was 0.95 versus 1.18 mg/L and the AUC from 0 to 12 h (AUC(0-12)) was 8.3 versus 10.5 mg.h/L (augmented significantly, P < 0.05).","Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407126/),[mg] / [l],0.95,243232,DB00338,Omeprazole
,12407126,peak concentration (C(max)),"For 14-OH-clarithromycin, the peak concentration (C(max)) was 0.95 versus 1.18 mg/L and the AUC from 0 to 12 h (AUC(0-12)) was 8.3 versus 10.5 mg.h/L (augmented significantly, P < 0.05).","Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407126/),[mg] / [l],1.18,243233,DB00338,Omeprazole
,12407126,AUC from 0 to 12 h (AUC(0-12)),"For 14-OH-clarithromycin, the peak concentration (C(max)) was 0.95 versus 1.18 mg/L and the AUC from 0 to 12 h (AUC(0-12)) was 8.3 versus 10.5 mg.h/L (augmented significantly, P < 0.05).","Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407126/),[h·mg] / [l],8.3,243234,DB00338,Omeprazole
,12407126,AUC from 0 to 12 h (AUC(0-12)),"For 14-OH-clarithromycin, the peak concentration (C(max)) was 0.95 versus 1.18 mg/L and the AUC from 0 to 12 h (AUC(0-12)) was 8.3 versus 10.5 mg.h/L (augmented significantly, P < 0.05).","Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407126/),[h·mg] / [l],10.5,243235,DB00338,Omeprazole
,12407126,time to maximum concentration of drug in serum (T(max)),"For clarithromycin, the time to maximum concentration of drug in serum (T(max)) was increased (2.73 versus 3.31 h, P < 0.05), whereas AUC and C(max) remained unchanged.","Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407126/),h,2.73,243236,DB00338,Omeprazole
,12407126,time to maximum concentration of drug in serum (T(max)),"For clarithromycin, the time to maximum concentration of drug in serum (T(max)) was increased (2.73 versus 3.31 h, P < 0.05), whereas AUC and C(max) remained unchanged.","Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407126/),h,3.31,243237,DB00338,Omeprazole
,29348104,Peak plasma concentration was (Cmax),Peak plasma concentration was (Cmax) 0.38±0.04 μg/ml achieved at 2.07±0.22 hrs.,Disposition kinetics of omeprazole in healthy female volunteers in Faisalabad. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29348104/),[μg] / [ml],0.38,243757,DB00338,Omeprazole
,29348104,elimination half-life (t1/2 β),The elimination half-life (t1/2 β) was1.82 ± 0.42 hrs.,Disposition kinetics of omeprazole in healthy female volunteers in Faisalabad. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29348104/),h,1.82,243758,DB00338,Omeprazole
,29348104,Volume of distribution (Vd),Volume of distribution (Vd) in the present study was 0.40 ± 0.07 l/kg with total body clearance (ClB) 0.19 ± 0.02 l/hr/kg and area under the curve (AUC) 1.89 ± 0.23 μg.hr/ml.,Disposition kinetics of omeprazole in healthy female volunteers in Faisalabad. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29348104/),[l] / [kg],0.40,243759,DB00338,Omeprazole
,29348104,total body clearance (ClB),Volume of distribution (Vd) in the present study was 0.40 ± 0.07 l/kg with total body clearance (ClB) 0.19 ± 0.02 l/hr/kg and area under the curve (AUC) 1.89 ± 0.23 μg.hr/ml.,Disposition kinetics of omeprazole in healthy female volunteers in Faisalabad. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29348104/),[l] / [h·kg],0.19,243760,DB00338,Omeprazole
,29348104,area under the curve (AUC),Volume of distribution (Vd) in the present study was 0.40 ± 0.07 l/kg with total body clearance (ClB) 0.19 ± 0.02 l/hr/kg and area under the curve (AUC) 1.89 ± 0.23 μg.hr/ml.,Disposition kinetics of omeprazole in healthy female volunteers in Faisalabad. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29348104/),[h·μg] / [ml],1.89,243761,DB00338,Omeprazole
,15663296,peak plasma concentrations Cmax,"In the two periods of treatments, the mean peak plasma concentrations Cmax were 730.8 ng/ml for omeprazole alone and 802.1 ng/ml for omeprazole co-administered with ranitidine (not significant).",A pharmacokinetic interaction study between omeprazole and the H2-receptor antagonist ranitidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663296/),[ng] / [ml],730.8,245645,DB00338,Omeprazole
,15663296,peak plasma concentrations Cmax,"In the two periods of treatments, the mean peak plasma concentrations Cmax were 730.8 ng/ml for omeprazole alone and 802.1 ng/ml for omeprazole co-administered with ranitidine (not significant).",A pharmacokinetic interaction study between omeprazole and the H2-receptor antagonist ranitidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663296/),[ng] / [ml],802.1,245646,DB00338,Omeprazole
,15663296,"time taken to reach the peak, Tmax","The time taken to reach the peak, Tmax, was 1.29 h and 1.42 h, respectively (not significant).",A pharmacokinetic interaction study between omeprazole and the H2-receptor antagonist ranitidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663296/),h,1.29,245647,DB00338,Omeprazole
,15663296,"time taken to reach the peak, Tmax","The time taken to reach the peak, Tmax, was 1.29 h and 1.42 h, respectively (not significant).",A pharmacokinetic interaction study between omeprazole and the H2-receptor antagonist ranitidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663296/),h,1.42,245648,DB00338,Omeprazole
,15663296,areas under the curve (AUC0-10),"The areas under the curve (AUC0-10) were 1,453.3 ng.h/ml and 1,736.8 ng.h/ml for the two periods of treatment; thus a greater AUC was obtained after pretreatment with multiple doses of ranitidine.",A pharmacokinetic interaction study between omeprazole and the H2-receptor antagonist ranitidine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663296/),[h·ng] / [ml],"1,453.3",245649,DB00338,Omeprazole
,15663296,areas under the curve (AUC0-10),"The areas under the curve (AUC0-10) were 1,453.3 ng.h/ml and 1,736.8 ng.h/ml for the two periods of treatment; thus a greater AUC was obtained after pretreatment with multiple doses of ranitidine.",A pharmacokinetic interaction study between omeprazole and the H2-receptor antagonist ranitidine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663296/),[h·ng] / [ml],"1,736.8",245650,DB00338,Omeprazole
,12959297,AUC,Mean values of AUC after single dose were 2668 ng ml(-1) h in the young subjects and 5216 ng ml(-1) h in the elderly (P < 0.05).,Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959297/),[h·ng] / [ml],2668,246646,DB00338,Omeprazole
,12959297,AUC,Mean values of AUC after single dose were 2668 ng ml(-1) h in the young subjects and 5216 ng ml(-1) h in the elderly (P < 0.05).,Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959297/),[h·ng] / [ml],5216,246647,DB00338,Omeprazole
,12959297,t 1/2z,"Mean t 1/2z values in young and elderly subjects were 1.4 h and 2.9 h, respectively (P < 0.001).",Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959297/),h,1.4,246648,DB00338,Omeprazole
,12959297,t 1/2z,"Mean t 1/2z values in young and elderly subjects were 1.4 h and 2.9 h, respectively (P < 0.001).",Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959297/),h,2.9,246649,DB00338,Omeprazole
,12959297,accumulation ratio,The accumulation ratio was 1.31 in the elderly subjects.,Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959297/),,1.31,246650,DB00338,Omeprazole
,11413863,Tmax,Tmax of crushed pantoprazole was earlier as compared to the intact tablet (0.5 h vs. 3 h) and Cmax was approximately 10% higher due to faster absorption.,Bioavailability of a crushed pantoprazole tablet after buffering with sodium hydrogencarbonate or magaldrate relative to the intact enteric coated pantoprazole tablet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11413863/),h,0.5,247800,DB00338,Omeprazole
,11413863,Tmax,Tmax of crushed pantoprazole was earlier as compared to the intact tablet (0.5 h vs. 3 h) and Cmax was approximately 10% higher due to faster absorption.,Bioavailability of a crushed pantoprazole tablet after buffering with sodium hydrogencarbonate or magaldrate relative to the intact enteric coated pantoprazole tablet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11413863/),h,3,247801,DB00338,Omeprazole
,11413863,bioavailability,"The bioavailability of the crushed pantoprazole tablet relative to the intact pantoprazole tablet was 93% when using sodium hydrogencarbonate as the buffering agent, and 88% when using magaldrate.",Bioavailability of a crushed pantoprazole tablet after buffering with sodium hydrogencarbonate or magaldrate relative to the intact enteric coated pantoprazole tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11413863/),%,93,247802,DB00338,Omeprazole
,11413863,bioavailability,"The bioavailability of the crushed pantoprazole tablet relative to the intact pantoprazole tablet was 93% when using sodium hydrogencarbonate as the buffering agent, and 88% when using magaldrate.",Bioavailability of a crushed pantoprazole tablet after buffering with sodium hydrogencarbonate or magaldrate relative to the intact enteric coated pantoprazole tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11413863/),%,88,247803,DB00338,Omeprazole
,8690200,maximum antibiotic gastric juice concentrations,"In the omeprazole group compared with the placebo group, mean maximum antibiotic gastric juice concentrations (in milligram per liter) of metronidazole decreased from 33.6 to 8.3 (P = 0.0001), whereas those of clarithromycin were unchanged, and those of amoxicillin increased from 0.13 to 0.68 (P = 0.02).","Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690200/),[milligram] / [l],33.6,248225,DB00338,Omeprazole
,8690200,maximum antibiotic gastric juice concentrations,"In the omeprazole group compared with the placebo group, mean maximum antibiotic gastric juice concentrations (in milligram per liter) of metronidazole decreased from 33.6 to 8.3 (P = 0.0001), whereas those of clarithromycin were unchanged, and those of amoxicillin increased from 0.13 to 0.68 (P = 0.02).","Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690200/),[milligram] / [l],8.3,248226,DB00338,Omeprazole
,8690200,maximum antibiotic gastric juice concentrations,"In the omeprazole group compared with the placebo group, mean maximum antibiotic gastric juice concentrations (in milligram per liter) of metronidazole decreased from 33.6 to 8.3 (P = 0.0001), whereas those of clarithromycin were unchanged, and those of amoxicillin increased from 0.13 to 0.68 (P = 0.02).","Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690200/),[milligram] / [l],0,248227,DB00338,Omeprazole
,8690200,maximum antibiotic gastric juice concentrations,"In the omeprazole group compared with the placebo group, mean maximum antibiotic gastric juice concentrations (in milligram per liter) of metronidazole decreased from 33.6 to 8.3 (P = 0.0001), whereas those of clarithromycin were unchanged, and those of amoxicillin increased from 0.13 to 0.68 (P = 0.02).","Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690200/),[milligram] / [l],0.,248228,DB00338,Omeprazole
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),,98.,248833,DB00338,Omeprazole
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),%,53.1,248834,DB00338,Omeprazole
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),%,45.2,248835,DB00338,Omeprazole
,29310119,Eradication rates,"Eradication rates of group B (reduced amoxicillin-regimen) were 84.2% in intention-to-treat analysis and 88.9% in per-protocol analysis, which were similar with group A (77.8 and 77.8%) and group C (74.6 and 81.0%).",Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis: A Randomized Controlled Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29310119/),%,84.2,249470,DB00338,Omeprazole
,29310119,Eradication rates,"Eradication rates of group B (reduced amoxicillin-regimen) were 84.2% in intention-to-treat analysis and 88.9% in per-protocol analysis, which were similar with group A (77.8 and 77.8%) and group C (74.6 and 81.0%).",Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis: A Randomized Controlled Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29310119/),%,88.9,249471,DB00338,Omeprazole
,29310119,Eradication rates,"Eradication rates of group B (reduced amoxicillin-regimen) were 84.2% in intention-to-treat analysis and 88.9% in per-protocol analysis, which were similar with group A (77.8 and 77.8%) and group C (74.6 and 81.0%).",Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis: A Randomized Controlled Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29310119/),%,77.8,249472,DB00338,Omeprazole
,29310119,Eradication rates,"Eradication rates of group B (reduced amoxicillin-regimen) were 84.2% in intention-to-treat analysis and 88.9% in per-protocol analysis, which were similar with group A (77.8 and 77.8%) and group C (74.6 and 81.0%).",Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis: A Randomized Controlled Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29310119/),%,74.6,249473,DB00338,Omeprazole
,29310119,Eradication rates,"Eradication rates of group B (reduced amoxicillin-regimen) were 84.2% in intention-to-treat analysis and 88.9% in per-protocol analysis, which were similar with group A (77.8 and 77.8%) and group C (74.6 and 81.0%).",Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis: A Randomized Controlled Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29310119/),%,81.0,249474,DB00338,Omeprazole
,19288444,Cl(nr),"After intravenous administration of omeprazole to NARs, the Cl(nr) was significantly faster than in the controls (110 versus 46.6 ml/min/kg), and this could be due to an increase in hepatic metabolism caused by a greater hepatic CYP1A2 level in addition to greater free fractions of the drug in NARs.",Faster clearance of omeprazole in mutant Nagase analbuminemic rats: possible roles of increased protein expression of hepatic CYP1A2 and lower plasma protein binding. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19288444/),[ml] / [kg·min],110,249900,DB00338,Omeprazole
,19288444,Cl(nr),"After intravenous administration of omeprazole to NARs, the Cl(nr) was significantly faster than in the controls (110 versus 46.6 ml/min/kg), and this could be due to an increase in hepatic metabolism caused by a greater hepatic CYP1A2 level in addition to greater free fractions of the drug in NARs.",Faster clearance of omeprazole in mutant Nagase analbuminemic rats: possible roles of increased protein expression of hepatic CYP1A2 and lower plasma protein binding. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19288444/),[ml] / [kg·min],46.6,249901,DB00338,Omeprazole
,33340169,Cmax,"Consistent with the larger dose administered, Cmax (median, 1032 ng/mL; range, 576-1766) and AUC0-24 (median, 63.9 μg/mL*min; range, 42.4-152.4) were greater after single oral administration of NOV than REF (282.7 ng/mL; range, 94.8-390.2, and 319 23.8 μg/mL*min; range, 8.2-42.3, respectively; both P = .004).",Pharmacokinetic and pharmacodynamic effects of 2 registered omeprazole preparations and varying dose rates in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33340169/),[ng] / [ml],1032,250009,DB00338,Omeprazole
,33340169,AUC0-24,"Consistent with the larger dose administered, Cmax (median, 1032 ng/mL; range, 576-1766) and AUC0-24 (median, 63.9 μg/mL*min; range, 42.4-152.4) were greater after single oral administration of NOV than REF (282.7 ng/mL; range, 94.8-390.2, and 319 23.8 μg/mL*min; range, 8.2-42.3, respectively; both P = .004).",Pharmacokinetic and pharmacodynamic effects of 2 registered omeprazole preparations and varying dose rates in horses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33340169/),[μg] / [min·ml],63.9,250010,DB00338,Omeprazole
,33340169,AUC0-24,"Consistent with the larger dose administered, Cmax (median, 1032 ng/mL; range, 576-1766) and AUC0-24 (median, 63.9 μg/mL*min; range, 42.4-152.4) were greater after single oral administration of NOV than REF (282.7 ng/mL; range, 94.8-390.2, and 319 23.8 μg/mL*min; range, 8.2-42.3, respectively; both P = .004).",Pharmacokinetic and pharmacodynamic effects of 2 registered omeprazole preparations and varying dose rates in horses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33340169/),[ng] / [ml],282.7,250011,DB00338,Omeprazole
,33340169,AUC0-24,"Consistent with the larger dose administered, Cmax (median, 1032 ng/mL; range, 576-1766) and AUC0-24 (median, 63.9 μg/mL*min; range, 42.4-152.4) were greater after single oral administration of NOV than REF (282.7 ng/mL; range, 94.8-390.2, and 319 23.8 μg/mL*min; range, 8.2-42.3, respectively; both P = .004).",Pharmacokinetic and pharmacodynamic effects of 2 registered omeprazole preparations and varying dose rates in horses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33340169/),[μg] / [min·ml],319,250012,DB00338,Omeprazole
,33340169,AUC0-24,"Consistent with the larger dose administered, Cmax (median, 1032 ng/mL; range, 576-1766) and AUC0-24 (median, 63.9 μg/mL*min; range, 42.4-152.4) were greater after single oral administration of NOV than REF (282.7 ng/mL; range, 94.8-390.2, and 319 23.8 μg/mL*min; range, 8.2-42.3, respectively; both P = .004).",Pharmacokinetic and pharmacodynamic effects of 2 registered omeprazole preparations and varying dose rates in horses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33340169/),[μg] / [min·ml],23.8,250013,DB00338,Omeprazole
,9701531,t1/2,The pharmacokinetics of rabeprazole were similar to those of other proton pump inhibitors with a t1/2 of between 0.7 and 1.0 h.,An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9701531/),h,0.7 and 1.0,250659,DB00338,Omeprazole
,8793599,absolute bioavailability,Its absolute bioavailability is 77% and does not change upon multiple dosing.,Pharmacokinetics of pantoprazole in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),%,77,251776,DB00338,Omeprazole
,8793599,Cmax,"Following a single oral dose of 40 mg, Cmax is approximately 2.5 mg/l, with a tmax of 2-3 h.",Pharmacokinetics of pantoprazole in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),[mg] / [l],2.5,251777,DB00338,Omeprazole
,8793599,tmax,"Following a single oral dose of 40 mg, Cmax is approximately 2.5 mg/l, with a tmax of 2-3 h.",Pharmacokinetics of pantoprazole in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),h,2-3,251778,DB00338,Omeprazole
,8793599,AUC(0,"The AUC(0,inf.) is approximately 5 mgxh/l.",Pharmacokinetics of pantoprazole in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),[h·mg] / [l],5,251779,DB00338,Omeprazole
,8793599,total serum clearance,"Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination half-life of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins.",Pharmacokinetics of pantoprazole in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),[l] / [h·kg],0.1,251780,DB00338,Omeprazole
,8793599,serum elimination half-life,"Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination half-life of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins.",Pharmacokinetics of pantoprazole in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),h,1.1,251781,DB00338,Omeprazole
,8793599,apparent volume of distribution,"Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination half-life of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins.",Pharmacokinetics of pantoprazole in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),[l] / [kg],0.15,251782,DB00338,Omeprazole
,8793599,half-life,"In patients with severe liver cirrhosis, the decreased rate of metabolism results in a half-life of 7-9 h.",Pharmacokinetics of pantoprazole in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),h,7-9,251783,DB00338,Omeprazole
,8793599,half-life,"The clearance of pantoprazole is only slightly affected by age, its half-life being approximately 1.25 h in the elderly.",Pharmacokinetics of pantoprazole in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),h,1.25,251784,DB00338,Omeprazole
,1400730,quantification,The quantification limit was 2 ng/ml for lansoprazole and 3 or 5 ng/ml for the metabolites.,Determination of lansoprazole and its metabolites in plasma by high-performance liquid chromatography using a loop column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400730/),[ng] / [ml],2,252285,DB00338,Omeprazole
,1400730,quantification,The quantification limit was 2 ng/ml for lansoprazole and 3 or 5 ng/ml for the metabolites.,Determination of lansoprazole and its metabolites in plasma by high-performance liquid chromatography using a loop column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400730/),[ng] / [ml],3,252286,DB00338,Omeprazole
,1400730,quantification,The quantification limit was 2 ng/ml for lansoprazole and 3 or 5 ng/ml for the metabolites.,Determination of lansoprazole and its metabolites in plasma by high-performance liquid chromatography using a loop column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400730/),[ng] / [ml],5,252287,DB00338,Omeprazole
,1400730,overall recovery,The mean overall recovery was between 75 and 95% for lansoprazole and its metabolites.,Determination of lansoprazole and its metabolites in plasma by high-performance liquid chromatography using a loop column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400730/),%,75 and 95,252288,DB00338,Omeprazole
,20456825,flow rate,"Following a single step liquid-liquid extraction analytes along with an internal standard (IS) were separated using an isocratic mobile phase of phosphate buffer (10 mM)/acetonitrile (53/47, v/v adjusted pH to 7.3 with triethylamine) at flow rate of 1 mL/min on reverse phase TRACER EXCEL 120 ODS-A column at room temperature.","Improved HPLC method for determination of four PPIs, omeprazole, pantoprazole, lansoprazole and rabeprazole in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20456825/),[ml] / [min],1,253824,DB00338,Omeprazole
,20456825,Total analytical run time,Total analytical run time for selected PPIs was 10 min.,"Improved HPLC method for determination of four PPIs, omeprazole, pantoprazole, lansoprazole and rabeprazole in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20456825/),min,10,253825,DB00338,Omeprazole
greater,20456825,recovery of,The recovery of method was equal or greater than 80% and lower limit of quantification (LLOQ) was 20 ng/mL for four PPIs.,"Improved HPLC method for determination of four PPIs, omeprazole, pantoprazole, lansoprazole and rabeprazole in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20456825/),%,80,253826,DB00338,Omeprazole
,16550734,area under the plasma concentration-time curve during the dosing interval (AUCtau),Triple therapy with esomeprazole 40 mg increased the area under the plasma concentration-time curve during the dosing interval (AUCtau) from 13.31 micromol x h/l (11.12-15.93) for esomeprazole alone to 22.69 micromol x h/l (18.94-27.17) for triple treatment.,"Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16550734/),[h·μM] / [l],13.31,254558,DB00338,Omeprazole
,16550734,area under the plasma concentration-time curve during the dosing interval (AUCtau),Triple therapy with esomeprazole 40 mg increased the area under the plasma concentration-time curve during the dosing interval (AUCtau) from 13.31 micromol x h/l (11.12-15.93) for esomeprazole alone to 22.69 micromol x h/l (18.94-27.17) for triple treatment.,"Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16550734/),[h·μM] / [l],22.69,254559,DB00338,Omeprazole
,16550734,AUCtau,Respective AUCtau values with esomeprazole 20 mg b.i.d. were 4.97 micromol.h/l (3.97-6.21) and 11.29 micromol x h/l (9.03-14.12).,"Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16550734/),[h·μM] / [l],4.97,254560,DB00338,Omeprazole
,16550734,AUCtau,Respective AUCtau values with esomeprazole 20 mg b.i.d. were 4.97 micromol.h/l (3.97-6.21) and 11.29 micromol x h/l (9.03-14.12).,"Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16550734/),[h·μM] / [l],11.29,254561,DB00338,Omeprazole
,9496401,AUCs,"The mean AUCs after administration of mexiletine alone and in combination with omeprazole 40 mg/d were 6.26 and 6.20 ng.h/L, respectively.",Lack of pharmacokinetic interaction between mexiletine and omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496401/),[h·ng] / [l],6.26,254935,DB00338,Omeprazole
,9496401,AUCs,"The mean AUCs after administration of mexiletine alone and in combination with omeprazole 40 mg/d were 6.26 and 6.20 ng.h/L, respectively.",Lack of pharmacokinetic interaction between mexiletine and omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496401/),[h·ng] / [l],6.20,254936,DB00338,Omeprazole
,1618254,peak blood ethanol concentration,The peak blood ethanol concentration of 21.9 to 22.8 mmol.l-1 occurred at 64 to 70 min after the end of drinking.,"Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618254/),[mM] / [l],21.9 to 22.8,255086,DB00338,Omeprazole
,1618254,rate of disappearance,The rate of disappearance of ethanol from the blood ranged from 3.0 to 3.3 mmol.l-1.h-1 and the rate of removal from the whole body ranged from 8.0 to 8.5 g.h-1.,"Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. ",km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618254/),[mM] / [h·l],3.0 to 3.3,255087,DB00338,Omeprazole
,1618254,rate of removal,The rate of disappearance of ethanol from the blood ranged from 3.0 to 3.3 mmol.l-1.h-1 and the rate of removal from the whole body ranged from 8.0 to 8.5 g.h-1.,"Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618254/),[g] / [h],8.0 to 8.5,255088,DB00338,Omeprazole
,1618254,apparent volume of distribution,"The apparent volume of distribution of ethanol was almost the same for all four treatments: mean 0.68 l.kg-1, corresponding to a mean total body water of 44 l (59% body weight).","Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618254/),[l] / [kg],0.68,255089,DB00338,Omeprazole
,1618254,areas under the concentration-time profiles,Mean areas under the concentration-time profiles of ethanol ranged from 83 to 87 mmol.l-1.h for the four treatments.,"Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618254/),[h·mM] / [l],83 to 87,255090,DB00338,Omeprazole
,15548851,AUC(0-24s),The mean AUC(0-24s) were 2004.4+/-973.6 ng.h/mL in without-water experiment and 2018.5+/-1159.6 ng.h/mL in the case of with-water experiment.,Effect of water intake on pharmacokinetics of lansoprazole from fast disintegrating tablet in human subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15548851/),[h·ng] / [ml],2004.4,255420,DB00338,Omeprazole
,15548851,AUC(0-24s),The mean AUC(0-24s) were 2004.4+/-973.6 ng.h/mL in without-water experiment and 2018.5+/-1159.6 ng.h/mL in the case of with-water experiment.,Effect of water intake on pharmacokinetics of lansoprazole from fast disintegrating tablet in human subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15548851/),[h·ng] / [ml],2018.5,255421,DB00338,Omeprazole
,15548851,C(maxs),"Mean C(maxs) were 851.9+/-450.8 ng/mL in without-water experiment and 830.8+/-456.8 ng/mL in with-water experiment, respectively.",Effect of water intake on pharmacokinetics of lansoprazole from fast disintegrating tablet in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15548851/),[ng] / [ml],851.9,255422,DB00338,Omeprazole
,15548851,C(maxs),"Mean C(maxs) were 851.9+/-450.8 ng/mL in without-water experiment and 830.8+/-456.8 ng/mL in with-water experiment, respectively.",Effect of water intake on pharmacokinetics of lansoprazole from fast disintegrating tablet in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15548851/),[ng] / [ml],830.8,255423,DB00338,Omeprazole
,16387482,F-value,The low F-value (approximately 0.136%) of DA-6034 at a dose of 50mg/kg in rats could be due to considerable intestinal first-pass effect (approximately 69% of oral dose) and unabsorbed fraction from the gastrointestinal tract (approximately 30.5%).,"Pharmacokinetics of DA-6034, an agent for inflammatory bowel disease, in rats and dogs: Contribution of intestinal first-pass effect to low bioavailability in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16387482/),%,0.136,255561,DB00338,Omeprazole
,32671657,IC50,"In vitro studies demonstrated that PPIs inhibited rOAT3-mediated uptake of MTX, with estimated IC50 values of 2.1-5.2 μM, and a rank order of esomeprazole ≈ lansoprazole ≈ omeprazole > rabeprazole.",Evaluation of possible pharmacokinetic interaction between methotrexate and proton pump inhibitors in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32671657/),μM,2.1-5.2,258778,DB00338,Omeprazole
,20642546,oral midazolam clearance,"In a cross-over study, healthy volunteers (n = 9) phenotyped as extensive metabolizers of CYP2C19 and CYP2D6 and with an oral midazolam clearance ranging from 10.9 to 149.3 ml min(-1) kg(-1) received a single dose of racemic CITA (20 mg orally) in combination or not with omeprazole (20 mg day(-1) for 18 days).",Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20642546/),[ml] / [kg·min],10.9 to 149.3,259312,DB00338,Omeprazole
,16231968,CL,"There were significant age- and genotype-related differences and a significant age x genotype interaction in CL (20.6+/-11.0/12.7+/-4.0/3.2+/-1.0 and 5.4+/-4.0/3.7+/-1.4/2.1+/-0.7 L/h for homozygous extensive metabolisers [EMs]/heterozygous EMs/poor metabolisers [PMs] of the young and the elderly groups, respectively).",The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231968/),[l] / [h],20.6,259424,DB00338,Omeprazole
,16231968,CL,"There were significant age- and genotype-related differences and a significant age x genotype interaction in CL (20.6+/-11.0/12.7+/-4.0/3.2+/-1.0 and 5.4+/-4.0/3.7+/-1.4/2.1+/-0.7 L/h for homozygous extensive metabolisers [EMs]/heterozygous EMs/poor metabolisers [PMs] of the young and the elderly groups, respectively).",The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231968/),[l] / [h],12.7,259425,DB00338,Omeprazole
,16231968,CL,"There were significant age- and genotype-related differences and a significant age x genotype interaction in CL (20.6+/-11.0/12.7+/-4.0/3.2+/-1.0 and 5.4+/-4.0/3.7+/-1.4/2.1+/-0.7 L/h for homozygous extensive metabolisers [EMs]/heterozygous EMs/poor metabolisers [PMs] of the young and the elderly groups, respectively).",The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231968/),[l] / [h],3.2,259426,DB00338,Omeprazole
,16231968,CL,"There were significant age- and genotype-related differences and a significant age x genotype interaction in CL (20.6+/-11.0/12.7+/-4.0/3.2+/-1.0 and 5.4+/-4.0/3.7+/-1.4/2.1+/-0.7 L/h for homozygous extensive metabolisers [EMs]/heterozygous EMs/poor metabolisers [PMs] of the young and the elderly groups, respectively).",The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231968/),[l] / [h],5.4,259427,DB00338,Omeprazole
,16231968,CL,"There were significant age- and genotype-related differences and a significant age x genotype interaction in CL (20.6+/-11.0/12.7+/-4.0/3.2+/-1.0 and 5.4+/-4.0/3.7+/-1.4/2.1+/-0.7 L/h for homozygous extensive metabolisers [EMs]/heterozygous EMs/poor metabolisers [PMs] of the young and the elderly groups, respectively).",The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231968/),[l] / [h],3.7,259428,DB00338,Omeprazole
,16231968,CL,"There were significant age- and genotype-related differences and a significant age x genotype interaction in CL (20.6+/-11.0/12.7+/-4.0/3.2+/-1.0 and 5.4+/-4.0/3.7+/-1.4/2.1+/-0.7 L/h for homozygous extensive metabolisers [EMs]/heterozygous EMs/poor metabolisers [PMs] of the young and the elderly groups, respectively).",The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231968/),[l] / [h],2.1,259429,DB00338,Omeprazole
,16231968,Vss,"In Vss, a significant difference was found between the young and the elderly groups (219+/-115 and 107+/-44.5 mL/kg, respectively), but not between three genotypes (178+/-142, 173+/-79 and 110+/-51 mL/kg for homozygous EMs, heterozygous EMs and PMs, respectively).",The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231968/),[ml] / [kg],219,259430,DB00338,Omeprazole
,16231968,Vss,"In Vss, a significant difference was found between the young and the elderly groups (219+/-115 and 107+/-44.5 mL/kg, respectively), but not between three genotypes (178+/-142, 173+/-79 and 110+/-51 mL/kg for homozygous EMs, heterozygous EMs and PMs, respectively).",The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231968/),[ml] / [kg],107,259431,DB00338,Omeprazole
,16231968,Vss,"In Vss, a significant difference was found between the young and the elderly groups (219+/-115 and 107+/-44.5 mL/kg, respectively), but not between three genotypes (178+/-142, 173+/-79 and 110+/-51 mL/kg for homozygous EMs, heterozygous EMs and PMs, respectively).",The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231968/),[ml] / [kg],178,259432,DB00338,Omeprazole
,16231968,Vss,"In Vss, a significant difference was found between the young and the elderly groups (219+/-115 and 107+/-44.5 mL/kg, respectively), but not between three genotypes (178+/-142, 173+/-79 and 110+/-51 mL/kg for homozygous EMs, heterozygous EMs and PMs, respectively).",The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231968/),[ml] / [kg],173,259433,DB00338,Omeprazole
,16231968,Vss,"In Vss, a significant difference was found between the young and the elderly groups (219+/-115 and 107+/-44.5 mL/kg, respectively), but not between three genotypes (178+/-142, 173+/-79 and 110+/-51 mL/kg for homozygous EMs, heterozygous EMs and PMs, respectively).",The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231968/),[ml] / [kg],110,259434,DB00338,Omeprazole
,21870106,T(max),"Compared with the placebo period, the T(max) and T(1/2) of midazolam during BBR administration were prolonged from 3.03 ± 0.27 to 3.66 ± 0.37 h and 0.66 ± 0.08 to 0.99 ± 0.09 h, respectively; the oral clearance of midazolam was decreased 27% (P < 0.05); and the phenotypic indices of 1 h midazolam/1'-hydroxymidazolam increased 59% (P < 0.01).",Repeated administration of berberine inhibits cytochromes P450 in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21870106/),h,3.03,259984,DB00338,Omeprazole
,21870106,T(1/2),"Compared with the placebo period, the T(max) and T(1/2) of midazolam during BBR administration were prolonged from 3.03 ± 0.27 to 3.66 ± 0.37 h and 0.66 ± 0.08 to 0.99 ± 0.09 h, respectively; the oral clearance of midazolam was decreased 27% (P < 0.05); and the phenotypic indices of 1 h midazolam/1'-hydroxymidazolam increased 59% (P < 0.01).",Repeated administration of berberine inhibits cytochromes P450 in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21870106/),h,3.66,259985,DB00338,Omeprazole
,21870106,T(1/2),"Compared with the placebo period, the T(max) and T(1/2) of midazolam during BBR administration were prolonged from 3.03 ± 0.27 to 3.66 ± 0.37 h and 0.66 ± 0.08 to 0.99 ± 0.09 h, respectively; the oral clearance of midazolam was decreased 27% (P < 0.05); and the phenotypic indices of 1 h midazolam/1'-hydroxymidazolam increased 59% (P < 0.01).",Repeated administration of berberine inhibits cytochromes P450 in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21870106/),h,0.66,259986,DB00338,Omeprazole
,21870106,T(1/2),"Compared with the placebo period, the T(max) and T(1/2) of midazolam during BBR administration were prolonged from 3.03 ± 0.27 to 3.66 ± 0.37 h and 0.66 ± 0.08 to 0.99 ± 0.09 h, respectively; the oral clearance of midazolam was decreased 27% (P < 0.05); and the phenotypic indices of 1 h midazolam/1'-hydroxymidazolam increased 59% (P < 0.01).",Repeated administration of berberine inhibits cytochromes P450 in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21870106/),h,0.99,259987,DB00338,Omeprazole
,16354407,ED50,"The value of the 50% effective dose for the anti-inflammatory effect of diclofenac sodium (ED50 = 1.14 +/- 0.23 mg kg(-1)) using carrageenan-induced rat paw oedema model, was not modified by the concomitant administration of 30 or 100 mg kg(-1) of CME.",Gastroprotection and effect of the simultaneous administration of Cuachalalate (Amphipterygium adstringens) on the pharmacokinetics and anti-inflammatory activity of diclofenac in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16354407/),[mg] / [kg],1.14,260480,DB00338,Omeprazole
,16354407,Cmax,"It was observed that the simultaneous administration of diclofenac sodium and 300 mg kg(-1) of CME decreased significantly the values of Cmax (7.08 +/- 1.42 microg mL(-1)) and AUC (12.67 +/- 2.97 microg h mL(-1)), but not the value of tmax (0.13 (0.1-0.25)h) obtained with the administration of diclofenac alone.",Gastroprotection and effect of the simultaneous administration of Cuachalalate (Amphipterygium adstringens) on the pharmacokinetics and anti-inflammatory activity of diclofenac in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16354407/),[μg] / [ml],7.08,260481,DB00338,Omeprazole
,16354407,AUC,"It was observed that the simultaneous administration of diclofenac sodium and 300 mg kg(-1) of CME decreased significantly the values of Cmax (7.08 +/- 1.42 microg mL(-1)) and AUC (12.67 +/- 2.97 microg h mL(-1)), but not the value of tmax (0.13 (0.1-0.25)h) obtained with the administration of diclofenac alone.",Gastroprotection and effect of the simultaneous administration of Cuachalalate (Amphipterygium adstringens) on the pharmacokinetics and anti-inflammatory activity of diclofenac in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16354407/),[h·μg] / [ml],12.67,260482,DB00338,Omeprazole
,16354407,tmax,"It was observed that the simultaneous administration of diclofenac sodium and 300 mg kg(-1) of CME decreased significantly the values of Cmax (7.08 +/- 1.42 microg mL(-1)) and AUC (12.67 +/- 2.97 microg h mL(-1)), but not the value of tmax (0.13 (0.1-0.25)h) obtained with the administration of diclofenac alone.",Gastroprotection and effect of the simultaneous administration of Cuachalalate (Amphipterygium adstringens) on the pharmacokinetics and anti-inflammatory activity of diclofenac in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16354407/),h,0.13,260483,DB00338,Omeprazole
,19360758,flow rate,"The baseline separation of all the peaks was achieved with 0.1% triethylamine (pH 6.0):acetonitrile (72:28, v/v) at a flow rate of 1 mL/min on a Zorbax C(8) column.","Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19360758/),[ml] / [min],1,262031,DB00338,Omeprazole
,19360758,total chromatographic run time,"The total chromatographic run time was 11.0 min and the simultaneous elution of IS, OPZ, RPZ, PPZ and LPZ occurred at approximately 2.42, 4.45, 5.02 and 9.37 min, respectively.","Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19360758/),min,11.0,262032,DB00338,Omeprazole
,19360758,total chromatographic run time,"The total chromatographic run time was 11.0 min and the simultaneous elution of IS, OPZ, RPZ, PPZ and LPZ occurred at approximately 2.42, 4.45, 5.02 and 9.37 min, respectively.","Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19360758/),min,2.42,262033,DB00338,Omeprazole
,19360758,total chromatographic run time,"The total chromatographic run time was 11.0 min and the simultaneous elution of IS, OPZ, RPZ, PPZ and LPZ occurred at approximately 2.42, 4.45, 5.02 and 9.37 min, respectively.","Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19360758/),min,5.02,262034,DB00338,Omeprazole
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],5370,262206,DB00338,Omeprazole
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],5246,262207,DB00338,Omeprazole
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],2.43,262208,DB00338,Omeprazole
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],2.87,262209,DB00338,Omeprazole
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],35.23,262210,DB00338,Omeprazole
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],35.11,262211,DB00338,Omeprazole
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],677.9,262212,DB00338,Omeprazole
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],466.9,262213,DB00338,Omeprazole
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],"56,207",262214,DB00338,Omeprazole
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],"56,688",262215,DB00338,Omeprazole
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],34.85,262216,DB00338,Omeprazole
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],37.27,262217,DB00338,Omeprazole
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],92.07,262218,DB00338,Omeprazole
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],93.04,262219,DB00338,Omeprazole
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],1428,262220,DB00338,Omeprazole
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],1499,262221,DB00338,Omeprazole
,19820718,hepatic,"After id administration of 3 mg/kg omeprazole, the hepatic and intestinal extraction ratio was 57.18%+/-2.73% and 54.94%+/-1.85%, while the value was 59.29%+/-3.14% and 54.20%+/-1.53% after given 6 mg/kg, respectively.",Involvement of cytochrome P450 3A4 and P-glycoprotein in first-pass intestinal extraction of omeprazole in rabbits. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820718/),%,57.18,263616,DB00338,Omeprazole
,19820718,hepatic,"After id administration of 3 mg/kg omeprazole, the hepatic and intestinal extraction ratio was 57.18%+/-2.73% and 54.94%+/-1.85%, while the value was 59.29%+/-3.14% and 54.20%+/-1.53% after given 6 mg/kg, respectively.",Involvement of cytochrome P450 3A4 and P-glycoprotein in first-pass intestinal extraction of omeprazole in rabbits. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820718/),%,59.29,263617,DB00338,Omeprazole
,19820718,intestinal extraction ratio,"After id administration of 3 mg/kg omeprazole, the hepatic and intestinal extraction ratio was 57.18%+/-2.73% and 54.94%+/-1.85%, while the value was 59.29%+/-3.14% and 54.20%+/-1.53% after given 6 mg/kg, respectively.",Involvement of cytochrome P450 3A4 and P-glycoprotein in first-pass intestinal extraction of omeprazole in rabbits. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820718/),%,54.94,263618,DB00338,Omeprazole
,19820718,intestinal extraction ratio,"After id administration of 3 mg/kg omeprazole, the hepatic and intestinal extraction ratio was 57.18%+/-2.73% and 54.94%+/-1.85%, while the value was 59.29%+/-3.14% and 54.20%+/-1.53% after given 6 mg/kg, respectively.",Involvement of cytochrome P450 3A4 and P-glycoprotein in first-pass intestinal extraction of omeprazole in rabbits. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820718/),%,54.20,263619,DB00338,Omeprazole
no more,29128277,recovery,"The recovery was no more than 77.06%, and the matrix effect, stability, dilution integrity tests were all satisfied the currently criterion.","A fast, sensitive, and high throughput method for the determination of esomeprazole in dog plasma by UHPLC-MS/MS: Application to formulation development of the compound preparation of esomeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128277/),%,77.06,264504,DB00338,Omeprazole
,15025747,peak concentration (C(max)),"During placebo administration, geometric means of peak concentration (C(max)), under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h)) and elimination half-life (t(1/2)) of omeprazole were 900 ng ml(-1), 1481 ng ml(-1) h, and 0.6 h in homozygous EMs, 1648 ng ml(-1), 4225 ng ml(-1) h, and 1.1 h in heterozygous EMs, and 2991 ng ml(-1), 11537 ng ml(-1) h, and 2.8 h in PMs, respectively.",Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025747/),[ng] / [ml],900,265619,DB00338,Omeprazole
,15025747,"under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h))","During placebo administration, geometric means of peak concentration (C(max)), under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h)) and elimination half-life (t(1/2)) of omeprazole were 900 ng ml(-1), 1481 ng ml(-1) h, and 0.6 h in homozygous EMs, 1648 ng ml(-1), 4225 ng ml(-1) h, and 1.1 h in heterozygous EMs, and 2991 ng ml(-1), 11537 ng ml(-1) h, and 2.8 h in PMs, respectively.",Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025747/),[h·ng] / [ml],1481,265620,DB00338,Omeprazole
,15025747,"under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h))","During placebo administration, geometric means of peak concentration (C(max)), under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h)) and elimination half-life (t(1/2)) of omeprazole were 900 ng ml(-1), 1481 ng ml(-1) h, and 0.6 h in homozygous EMs, 1648 ng ml(-1), 4225 ng ml(-1) h, and 1.1 h in heterozygous EMs, and 2991 ng ml(-1), 11537 ng ml(-1) h, and 2.8 h in PMs, respectively.",Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025747/),h,0.6,265621,DB00338,Omeprazole
,15025747,"under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h))","During placebo administration, geometric means of peak concentration (C(max)), under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h)) and elimination half-life (t(1/2)) of omeprazole were 900 ng ml(-1), 1481 ng ml(-1) h, and 0.6 h in homozygous EMs, 1648 ng ml(-1), 4225 ng ml(-1) h, and 1.1 h in heterozygous EMs, and 2991 ng ml(-1), 11537 ng ml(-1) h, and 2.8 h in PMs, respectively.",Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025747/),[ng] / [ml],1648,265622,DB00338,Omeprazole
,15025747,"under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h))","During placebo administration, geometric means of peak concentration (C(max)), under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h)) and elimination half-life (t(1/2)) of omeprazole were 900 ng ml(-1), 1481 ng ml(-1) h, and 0.6 h in homozygous EMs, 1648 ng ml(-1), 4225 ng ml(-1) h, and 1.1 h in heterozygous EMs, and 2991 ng ml(-1), 11537 ng ml(-1) h, and 2.8 h in PMs, respectively.",Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025747/),[h·ng] / [ml],4225,265623,DB00338,Omeprazole
,15025747,"under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h))","During placebo administration, geometric means of peak concentration (C(max)), under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h)) and elimination half-life (t(1/2)) of omeprazole were 900 ng ml(-1), 1481 ng ml(-1) h, and 0.6 h in homozygous EMs, 1648 ng ml(-1), 4225 ng ml(-1) h, and 1.1 h in heterozygous EMs, and 2991 ng ml(-1), 11537 ng ml(-1) h, and 2.8 h in PMs, respectively.",Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025747/),[ng] / [ml],2991,265624,DB00338,Omeprazole
,15025747,"under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h))","During placebo administration, geometric means of peak concentration (C(max)), under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h)) and elimination half-life (t(1/2)) of omeprazole were 900 ng ml(-1), 1481 ng ml(-1) h, and 0.6 h in homozygous EMs, 1648 ng ml(-1), 4225 ng ml(-1) h, and 1.1 h in heterozygous EMs, and 2991 ng ml(-1), 11537 ng ml(-1) h, and 2.8 h in PMs, respectively.",Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025747/),[h·ng] / [ml],11537,265625,DB00338,Omeprazole
,15025747,"under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h))","During placebo administration, geometric means of peak concentration (C(max)), under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h)) and elimination half-life (t(1/2)) of omeprazole were 900 ng ml(-1), 1481 ng ml(-1) h, and 0.6 h in homozygous EMs, 1648 ng ml(-1), 4225 ng ml(-1) h, and 1.1 h in heterozygous EMs, and 2991 ng ml(-1), 11537 ng ml(-1) h, and 2.8 h in PMs, respectively.",Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025747/),h,2.8,265626,DB00338,Omeprazole
,15025747,elimination half-life (t(1/2)),"During placebo administration, geometric means of peak concentration (C(max)), under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h)) and elimination half-life (t(1/2)) of omeprazole were 900 ng ml(-1), 1481 ng ml(-1) h, and 0.6 h in homozygous EMs, 1648 ng ml(-1), 4225 ng ml(-1) h, and 1.1 h in heterozygous EMs, and 2991 ng ml(-1), 11537 ng ml(-1) h, and 2.8 h in PMs, respectively.",Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025747/),h,0.6,265627,DB00338,Omeprazole
,15025747,elimination half-life (t(1/2)),"During placebo administration, geometric means of peak concentration (C(max)), under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h)) and elimination half-life (t(1/2)) of omeprazole were 900 ng ml(-1), 1481 ng ml(-1) h, and 0.6 h in homozygous EMs, 1648 ng ml(-1), 4225 ng ml(-1) h, and 1.1 h in heterozygous EMs, and 2991 ng ml(-1), 11537 ng ml(-1) h, and 2.8 h in PMs, respectively.",Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025747/),h,2.8,265628,DB00338,Omeprazole
,32369392,inhibitor constant Ki,"The average inhibitor constant Ki, assuming competitive inhibition, was 15.4 ± 5 µM.",Prediction of pharmacokinetic clearance and potential Drug-Drug interactions for omeprazole in the horse using in vitro systems. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32369392/),μM,15.4,266914,DB00338,Omeprazole
,9014204,hydroxylation ratio,Thirteen subjects (12.6%) were identified as poor metabolizers (PMs) with an omeprazole hydroxylation ratio of 6.95 or higher.,CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9014204/),,6,267271,DB00338,Omeprazole
,12132671,era,"In anti-Helicobacter pylori therapy using omeprazole and antimicrobials, the efficacy can be related to the CYP2C19 genotype groups; the eradication rates were 83% in extensive metabolizers and 100% in poor metabolizers.",Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12132671/),%,83,267471,DB00338,Omeprazole
,12132671,era,"In anti-Helicobacter pylori therapy using omeprazole and antimicrobials, the efficacy can be related to the CYP2C19 genotype groups; the eradication rates were 83% in extensive metabolizers and 100% in poor metabolizers.",Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12132671/),,100,267472,DB00338,Omeprazole
,25264242,IC50,"Human liver microsomal studies indicated that orteronel weakly inhibits CYP1A2, 2C8, 2C9 and 2C19, with IC50 values of 17.8, 27.7, 30.8 and 38.8 µm, respectively, whereas orteronel does not inhibit CYP2B6, 2D6 or 3A4/5 (IC50 > 100 µm).",Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),µm,17.8,268318,DB00338,Omeprazole
,25264242,IC50,"Human liver microsomal studies indicated that orteronel weakly inhibits CYP1A2, 2C8, 2C9 and 2C19, with IC50 values of 17.8, 27.7, 30.8 and 38.8 µm, respectively, whereas orteronel does not inhibit CYP2B6, 2D6 or 3A4/5 (IC50 > 100 µm).",Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),µm,27.7,268319,DB00338,Omeprazole
,25264242,IC50,"Human liver microsomal studies indicated that orteronel weakly inhibits CYP1A2, 2C8, 2C9 and 2C19, with IC50 values of 17.8, 27.7, 30.8 and 38.8 µm, respectively, whereas orteronel does not inhibit CYP2B6, 2D6 or 3A4/5 (IC50 > 100 µm).",Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),µm,30.8,268320,DB00338,Omeprazole
,25264242,IC50,"Human liver microsomal studies indicated that orteronel weakly inhibits CYP1A2, 2C8, 2C9 and 2C19, with IC50 values of 17.8, 27.7, 30.8 and 38.8 µm, respectively, whereas orteronel does not inhibit CYP2B6, 2D6 or 3A4/5 (IC50 > 100 µm).",Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),µm,38.8,268321,DB00338,Omeprazole
>,25264242,IC50,"Human liver microsomal studies indicated that orteronel weakly inhibits CYP1A2, 2C8, 2C9 and 2C19, with IC50 values of 17.8, 27.7, 30.8 and 38.8 µm, respectively, whereas orteronel does not inhibit CYP2B6, 2D6 or 3A4/5 (IC50 > 100 µm).",Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),µm,100,268322,DB00338,Omeprazole
>,25264242,[I]/Ki ratio,"The results of a static model indicated an [I]/Ki ratio >0.1 for CYP1A2, 2C8, 2C9 and 2C19.",Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),,0.1,268323,DB00338,Omeprazole
<,25264242,AUC ratios,Simulation of the area under the plasma concentration-time curve (AUC) of these four CYP substrates in the presence and absence of orteronel revealed geometric mean AUC ratios <1.25.,Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),,1.25,268324,DB00338,Omeprazole
,1424419,plasma elimination half-life,"During the placebo session, the plasma elimination half-life, clearance, and volume of distribution of diazepam were 26.0 +/- 1.6 hours, 22.5 +/- 1.1 ml/hr/kg, and 0.82 +/- 0.04 L/kg, respectively.",Influence of lansoprazole treatment on diazepam plasma concentrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424419/),h,26.0,268808,DB00338,Omeprazole
,1424419,clearance,"During the placebo session, the plasma elimination half-life, clearance, and volume of distribution of diazepam were 26.0 +/- 1.6 hours, 22.5 +/- 1.1 ml/hr/kg, and 0.82 +/- 0.04 L/kg, respectively.",Influence of lansoprazole treatment on diazepam plasma concentrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424419/),[ml] / [h·kg],22.5,268809,DB00338,Omeprazole
,1424419,volume of distribution,"During the placebo session, the plasma elimination half-life, clearance, and volume of distribution of diazepam were 26.0 +/- 1.6 hours, 22.5 +/- 1.1 ml/hr/kg, and 0.82 +/- 0.04 L/kg, respectively.",Influence of lansoprazole treatment on diazepam plasma concentrations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424419/),[l] / [kg],0.82,268810,DB00338,Omeprazole
greater,1810958,recoveries,"The recoveries of authentic analytes added to serum at 0.05-2 micrograms/ml or to urine at 1-20 micrograms/ml were greater than 88%, with the coefficients of variation less than 7.1%.",High-performance liquid chromatographic determination of lansoprazole and its metabolites in human serum and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810958/),,88,269128,DB00338,Omeprazole
,1810958,minimum determinable concentrations,The minimum determinable concentrations of all analytes were 5 ng/ml in serum and 50 ng/ml in urine.,High-performance liquid chromatographic determination of lansoprazole and its metabolites in human serum and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810958/),[ng] / [ml],5,269129,DB00338,Omeprazole
,1810958,minimum determinable concentrations,The minimum determinable concentrations of all analytes were 5 ng/ml in serum and 50 ng/ml in urine.,High-performance liquid chromatographic determination of lansoprazole and its metabolites in human serum and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810958/),[ng] / [ml],50,269130,DB00338,Omeprazole
,18581106,hydroxylation index,"The volunteers genotyped as CYP2C19*1*17, CYP2C19*17*17, CYP2C19*1*1 (n = 8), or CYP2C19*17*2 (n = 1) presented a median hydroxylation index (omeprazole/hydroxyomeprazole) of 1.35, indicating that all of them were extensive metabolizers of CYP2C19.",Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18581106/),,1.35,270175,DB00338,Omeprazole
,18581106,oral clearance of midazolam,"The volunteers (n = 9) presented a 0.12 log of the omeprazole/sulfone ratio and a median oral clearance of midazolam of 17.89 ml min(-1) kg(-1), suggesting normal CYP3A activity.",Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18581106/),[ml] / [kg·min],17.89,270176,DB00338,Omeprazole
,7983597,hepatic,"Assuming that the drug was absorbed from the gastrointestinal tract completely, the hepatic and intestinal extraction ratios were 0.80, 0.63, and 0.59 at doses of 2.5, 5, and 10 mg/kg and 0.70 and 0.73 at doses of 5 and 10 mg/kg, respectively.",First-pass metabolism of omeprazole in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983597/),,0.80,270377,DB00338,Omeprazole
,7983597,hepatic,"Assuming that the drug was absorbed from the gastrointestinal tract completely, the hepatic and intestinal extraction ratios were 0.80, 0.63, and 0.59 at doses of 2.5, 5, and 10 mg/kg and 0.70 and 0.73 at doses of 5 and 10 mg/kg, respectively.",First-pass metabolism of omeprazole in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983597/),,0.63,270378,DB00338,Omeprazole
,7983597,hepatic,"Assuming that the drug was absorbed from the gastrointestinal tract completely, the hepatic and intestinal extraction ratios were 0.80, 0.63, and 0.59 at doses of 2.5, 5, and 10 mg/kg and 0.70 and 0.73 at doses of 5 and 10 mg/kg, respectively.",First-pass metabolism of omeprazole in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983597/),,0.70,270379,DB00338,Omeprazole
,7983597,intestinal extraction ratios,"Assuming that the drug was absorbed from the gastrointestinal tract completely, the hepatic and intestinal extraction ratios were 0.80, 0.63, and 0.59 at doses of 2.5, 5, and 10 mg/kg and 0.70 and 0.73 at doses of 5 and 10 mg/kg, respectively.",First-pass metabolism of omeprazole in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983597/),,0.63,270380,DB00338,Omeprazole
,7983597,intestinal extraction ratios,"Assuming that the drug was absorbed from the gastrointestinal tract completely, the hepatic and intestinal extraction ratios were 0.80, 0.63, and 0.59 at doses of 2.5, 5, and 10 mg/kg and 0.70 and 0.73 at doses of 5 and 10 mg/kg, respectively.",First-pass metabolism of omeprazole in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983597/),,0.59,270381,DB00338,Omeprazole
,7983597,intestinal extraction ratios,"Assuming that the drug was absorbed from the gastrointestinal tract completely, the hepatic and intestinal extraction ratios were 0.80, 0.63, and 0.59 at doses of 2.5, 5, and 10 mg/kg and 0.70 and 0.73 at doses of 5 and 10 mg/kg, respectively.",First-pass metabolism of omeprazole in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983597/),,0.70,270382,DB00338,Omeprazole
,7983597,intestinal extraction ratios,"Assuming that the drug was absorbed from the gastrointestinal tract completely, the hepatic and intestinal extraction ratios were 0.80, 0.63, and 0.59 at doses of 2.5, 5, and 10 mg/kg and 0.70 and 0.73 at doses of 5 and 10 mg/kg, respectively.",First-pass metabolism of omeprazole in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983597/),,0.73,270383,DB00338,Omeprazole
,7983597,bioavailability,"The bioavailability of orally administered omeprazole was 6.4, 9.6, and 12.6% at the doses of 10, 20, and 40 mg/kg, respectively.",First-pass metabolism of omeprazole in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983597/),%,6.4,270384,DB00338,Omeprazole
,7983597,bioavailability,"The bioavailability of orally administered omeprazole was 6.4, 9.6, and 12.6% at the doses of 10, 20, and 40 mg/kg, respectively.",First-pass metabolism of omeprazole in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983597/),%,9.6,270385,DB00338,Omeprazole
,7983597,bioavailability,"The bioavailability of orally administered omeprazole was 6.4, 9.6, and 12.6% at the doses of 10, 20, and 40 mg/kg, respectively.",First-pass metabolism of omeprazole in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983597/),%,12.6,270386,DB00338,Omeprazole
,16783042,C(max),"Geometric means and ratios were as follows: C(max) was 555 for omeprazole/alginate and 558 for omeprazole alone (ratio 99.55%, 90% confidence interval 82.75-119.75%; AUC(0-t) was 2050 for omeprazole/alginate and 2094 for omeprazole alone (ratio 97.90%, 90% confidence interval 87.83-109.12%); AUC(0-a) was 2247 for omeprazole/alginate and 2231 for omeprazole alone (ratio 100.74%, 90% confidence interval 90.05-112.70%).",Administration of an alginate based gastric reflux suppressant on the bioavailability of omeprazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16783042/),,555,270537,DB00338,Omeprazole
,16783042,C(max),"Geometric means and ratios were as follows: C(max) was 555 for omeprazole/alginate and 558 for omeprazole alone (ratio 99.55%, 90% confidence interval 82.75-119.75%; AUC(0-t) was 2050 for omeprazole/alginate and 2094 for omeprazole alone (ratio 97.90%, 90% confidence interval 87.83-109.12%); AUC(0-a) was 2247 for omeprazole/alginate and 2231 for omeprazole alone (ratio 100.74%, 90% confidence interval 90.05-112.70%).",Administration of an alginate based gastric reflux suppressant on the bioavailability of omeprazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16783042/),,558,270538,DB00338,Omeprazole
,16783042,AUC(0-t),"Geometric means and ratios were as follows: C(max) was 555 for omeprazole/alginate and 558 for omeprazole alone (ratio 99.55%, 90% confidence interval 82.75-119.75%; AUC(0-t) was 2050 for omeprazole/alginate and 2094 for omeprazole alone (ratio 97.90%, 90% confidence interval 87.83-109.12%); AUC(0-a) was 2247 for omeprazole/alginate and 2231 for omeprazole alone (ratio 100.74%, 90% confidence interval 90.05-112.70%).",Administration of an alginate based gastric reflux suppressant on the bioavailability of omeprazole. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16783042/),,2050,270539,DB00338,Omeprazole
,16783042,AUC(0-t),"Geometric means and ratios were as follows: C(max) was 555 for omeprazole/alginate and 558 for omeprazole alone (ratio 99.55%, 90% confidence interval 82.75-119.75%; AUC(0-t) was 2050 for omeprazole/alginate and 2094 for omeprazole alone (ratio 97.90%, 90% confidence interval 87.83-109.12%); AUC(0-a) was 2247 for omeprazole/alginate and 2231 for omeprazole alone (ratio 100.74%, 90% confidence interval 90.05-112.70%).",Administration of an alginate based gastric reflux suppressant on the bioavailability of omeprazole. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16783042/),,2094,270540,DB00338,Omeprazole
,16783042,AUC(0-a),"Geometric means and ratios were as follows: C(max) was 555 for omeprazole/alginate and 558 for omeprazole alone (ratio 99.55%, 90% confidence interval 82.75-119.75%; AUC(0-t) was 2050 for omeprazole/alginate and 2094 for omeprazole alone (ratio 97.90%, 90% confidence interval 87.83-109.12%); AUC(0-a) was 2247 for omeprazole/alginate and 2231 for omeprazole alone (ratio 100.74%, 90% confidence interval 90.05-112.70%).",Administration of an alginate based gastric reflux suppressant on the bioavailability of omeprazole. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16783042/),,2247,270541,DB00338,Omeprazole
,16783042,AUC(0-a),"Geometric means and ratios were as follows: C(max) was 555 for omeprazole/alginate and 558 for omeprazole alone (ratio 99.55%, 90% confidence interval 82.75-119.75%; AUC(0-t) was 2050 for omeprazole/alginate and 2094 for omeprazole alone (ratio 97.90%, 90% confidence interval 87.83-109.12%); AUC(0-a) was 2247 for omeprazole/alginate and 2231 for omeprazole alone (ratio 100.74%, 90% confidence interval 90.05-112.70%).",Administration of an alginate based gastric reflux suppressant on the bioavailability of omeprazole. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16783042/),,2231,270542,DB00338,Omeprazole
,23350044,elimination half-life,PPIs have about 1hour of elimination half-life.,Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23350044/),h,1,271438,DB00338,Omeprazole
,15499190,C(max),The mean C(max) and AUC(0-24) were 474.1+/-254.0 ng/mL and 1105.3+/-1101.4 ng.h/mL (15 mg) and 992.8+/-384.3 ng/mL and 2216.5+/-1270.1 ng.h/mL (30 mg).,Evaluation of fast disintegrating lansoprazole tablet in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15499190/),[ng] / [ml],474.1,271451,DB00338,Omeprazole
,15499190,C(max),The mean C(max) and AUC(0-24) were 474.1+/-254.0 ng/mL and 1105.3+/-1101.4 ng.h/mL (15 mg) and 992.8+/-384.3 ng/mL and 2216.5+/-1270.1 ng.h/mL (30 mg).,Evaluation of fast disintegrating lansoprazole tablet in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15499190/),[ng] / [ml],992.8,271452,DB00338,Omeprazole
,15499190,AUC(0-24),The mean C(max) and AUC(0-24) were 474.1+/-254.0 ng/mL and 1105.3+/-1101.4 ng.h/mL (15 mg) and 992.8+/-384.3 ng/mL and 2216.5+/-1270.1 ng.h/mL (30 mg).,Evaluation of fast disintegrating lansoprazole tablet in human subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15499190/),[h·ng] / [ml],1105.3,271453,DB00338,Omeprazole
,15499190,AUC(0-24),The mean C(max) and AUC(0-24) were 474.1+/-254.0 ng/mL and 1105.3+/-1101.4 ng.h/mL (15 mg) and 992.8+/-384.3 ng/mL and 2216.5+/-1270.1 ng.h/mL (30 mg).,Evaluation of fast disintegrating lansoprazole tablet in human subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15499190/),[h·ng] / [ml],2216.5,271454,DB00338,Omeprazole
,12115824,k(01),"RS-Methadone rate of absorption (mean +/- SE) was faster in OP(oral) (k(01) = 0.31 +/- 0.04 min(-1)) than in CO(oral) (k(01) = 0.05 +/- 0.007 min(-1)), consequently plasma peak concentrations (C(max)) were greater (197.41 +/- 33.70 ng/mL versus 83.54 +/- 7.97 ng/mL) and the time to reach C(max) (t(max)) was shorter (11.23 +/- 1.32 min versus 39.18 +/- 1.74 min).",Effect of omeprazole on oral and intravenous RS-methadone pharmacokinetics and pharmacodynamics in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115824/),1/[min],0.31,272820,DB00338,Omeprazole
,12115824,k(01),"RS-Methadone rate of absorption (mean +/- SE) was faster in OP(oral) (k(01) = 0.31 +/- 0.04 min(-1)) than in CO(oral) (k(01) = 0.05 +/- 0.007 min(-1)), consequently plasma peak concentrations (C(max)) were greater (197.41 +/- 33.70 ng/mL versus 83.54 +/- 7.97 ng/mL) and the time to reach C(max) (t(max)) was shorter (11.23 +/- 1.32 min versus 39.18 +/- 1.74 min).",Effect of omeprazole on oral and intravenous RS-methadone pharmacokinetics and pharmacodynamics in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115824/),1/[min],0.05,272821,DB00338,Omeprazole
,12115824,plasma peak concentrations (C(max)),"RS-Methadone rate of absorption (mean +/- SE) was faster in OP(oral) (k(01) = 0.31 +/- 0.04 min(-1)) than in CO(oral) (k(01) = 0.05 +/- 0.007 min(-1)), consequently plasma peak concentrations (C(max)) were greater (197.41 +/- 33.70 ng/mL versus 83.54 +/- 7.97 ng/mL) and the time to reach C(max) (t(max)) was shorter (11.23 +/- 1.32 min versus 39.18 +/- 1.74 min).",Effect of omeprazole on oral and intravenous RS-methadone pharmacokinetics and pharmacodynamics in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115824/),[ng] / [ml],197.41,272822,DB00338,Omeprazole
,12115824,plasma peak concentrations (C(max)),"RS-Methadone rate of absorption (mean +/- SE) was faster in OP(oral) (k(01) = 0.31 +/- 0.04 min(-1)) than in CO(oral) (k(01) = 0.05 +/- 0.007 min(-1)), consequently plasma peak concentrations (C(max)) were greater (197.41 +/- 33.70 ng/mL versus 83.54 +/- 7.97 ng/mL) and the time to reach C(max) (t(max)) was shorter (11.23 +/- 1.32 min versus 39.18 +/- 1.74 min).",Effect of omeprazole on oral and intravenous RS-methadone pharmacokinetics and pharmacodynamics in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115824/),[ng] / [ml],83.54,272823,DB00338,Omeprazole
,12115824,time to reach C(max) (t(max)),"RS-Methadone rate of absorption (mean +/- SE) was faster in OP(oral) (k(01) = 0.31 +/- 0.04 min(-1)) than in CO(oral) (k(01) = 0.05 +/- 0.007 min(-1)), consequently plasma peak concentrations (C(max)) were greater (197.41 +/- 33.70 ng/mL versus 83.54 +/- 7.97 ng/mL) and the time to reach C(max) (t(max)) was shorter (11.23 +/- 1.32 min versus 39.18 +/- 1.74 min).",Effect of omeprazole on oral and intravenous RS-methadone pharmacokinetics and pharmacodynamics in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115824/),min,11.23,272824,DB00338,Omeprazole
,12115824,time to reach C(max) (t(max)),"RS-Methadone rate of absorption (mean +/- SE) was faster in OP(oral) (k(01) = 0.31 +/- 0.04 min(-1)) than in CO(oral) (k(01) = 0.05 +/- 0.007 min(-1)), consequently plasma peak concentrations (C(max)) were greater (197.41 +/- 33.70 ng/mL versus 83.54 +/- 7.97 ng/mL) and the time to reach C(max) (t(max)) was shorter (11.23 +/- 1.32 min versus 39.18 +/- 1.74 min).",Effect of omeprazole on oral and intravenous RS-methadone pharmacokinetics and pharmacodynamics in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115824/),min,39.18,272825,DB00338,Omeprazole
,12115824,k(e0),The relationship between Cp and drug effect in the OP(oral) group showed a counterclockwise hysteresis (k(e0) of 0.018 +/- 0.006 min(-1)).,Effect of omeprazole on oral and intravenous RS-methadone pharmacokinetics and pharmacodynamics in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12115824/),1/[min],0.018,272826,DB00338,Omeprazole
,9354316,AUC,"The pharmacokinetics of R- and S-acenocoumarol (AUC 3016 +/- 221 and 233 +/- 14 ng ml(-1) h, respectively) did not change after omeprazole (AUC 2929 +/- 256 and 220 +/- 18 ng ml(-1) h, respectively).",No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354316/),[h·ng] / [ml],3016,274191,DB00338,Omeprazole
,9354316,AUC,"The pharmacokinetics of R- and S-acenocoumarol (AUC 3016 +/- 221 and 233 +/- 14 ng ml(-1) h, respectively) did not change after omeprazole (AUC 2929 +/- 256 and 220 +/- 18 ng ml(-1) h, respectively).",No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354316/),[h·ng] / [ml],233,274192,DB00338,Omeprazole
,9354316,AUC,"The pharmacokinetics of R- and S-acenocoumarol (AUC 3016 +/- 221 and 233 +/- 14 ng ml(-1) h, respectively) did not change after omeprazole (AUC 2929 +/- 256 and 220 +/- 18 ng ml(-1) h, respectively).",No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354316/),[h·ng] / [ml],2929,274193,DB00338,Omeprazole
,9354316,AUC,"The pharmacokinetics of R- and S-acenocoumarol (AUC 3016 +/- 221 and 233 +/- 14 ng ml(-1) h, respectively) did not change after omeprazole (AUC 2929 +/- 256 and 220 +/- 18 ng ml(-1) h, respectively).",No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354316/),[h·ng] / [ml],220,274194,DB00338,Omeprazole
